## Cancer Statistics, 2003

Ca-A Cancer Journal for Clinicians 53, 5-26 DOI: 10.3322/canjclin.53.1.5

Citation Report

Сітат	ION REPORT	
Article	IF	CITATIONS
A HEARTRENDING BURDEN OF GYNAECOLOGICAL CANCERS IN ADVANCE STAGE AT NUCLEAR INSTITUTE MEDICINE AND RADIOTHERAPY JAMSHORO SINDH Pakistan Journal of Medical Sciences, 1969, 32, 120-		3
The Challenge of Pancreatic Cancer. International Journal of Gastrointestinal Cancer, 2003, 33, 1-2.	0.4	6
Stratification by Risk Factors Predicts Survival on the Active Treatment Arm in a Randomized Phase II Study of Interferon-Gamma Plus/Minus Interferon-Alpha in Advanced Renal Cell Carcinoma (E6890). Medical Oncology, 2003, 20, 271-282.	1.2	15
Diet and breast cancer: can dietary factors influence survival?. Journal of Mammary Gland Biology and Neoplasia, 2003, 8, 119-132.	1.0	22
Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype. Clinical and Experimental Metastasis, 2003, 20, 723-731.	1.7	84
Perspectives and Risks of Breast-Conservation Therapy for Breast Cancer. Annals of Surgical Oncology, 2003, 10, 718-721.	0.7	75
Revised American Joint Committee on Cancer Staging Criteria Accurately Predict Sentinel Lymph Node Positivity in Clinically Node-Negative Melanoma Patients. Annals of Surgical Oncology, 2003, 10, 569-574.	0.7	186
Where are the â€~poster boys' for bladder cancer?. BJU International, 2003, 91, 769-770.	1.3	3
Epirubicin Versus Doxorubicin: Which Is the Anthracycline of Choice for the Treatment of Breast Cancer, 2003, 4, S26-S33.	1.1	76
Advances in Brachytherapy: New Approaches to Target Breast Cancer. Clinical Journal of Oncology Nursing, 2003, 7, 324-328.	0.3	5
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 844-850.	3.3	358
Pancreatic cancer - a continuing challenge in oncology. Pathology and Oncology Research, 2003, 9, 252-263.	0.9	14
International Collaboration on Childhood Leukemia. International Journal of Hematology, 2003, 78, 383-389.	0.7	48

14	Butyrate inhibits pancreatic cancer invasion. Journal of Gastrointestinal Surgery, 2003, 7, 864-870.	0.9	34
15	Surgical treatment of small bowel cancer: A 20-year single institution experience. Journal of Gastrointestinal Surgery, 2003, 7, 925-930.	0.9	41
16	Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer. Current Treatment Options in Oncology, 2003, 4, 351-362.	1.3	6
17	Gastric cancer: Advances in adjuvant and adjunct therapy. Current Treatment Options in Oncology, 2003, 4, 413-419.	1.3	3
18	Advances in neoadjuvant chemotherapy in soft tissue sarcomas. Current Treatment Options in Oncology, 2003, 4, 433-439.	1.3	11

#

1

3

5

7

9

11

13

	CHAIL	ON REPORT	
#	Article	IF	CITATIONS
19	Intraperitoneal chemotherapy for ovarian cancer. Current Oncology Reports, 2003, 5, 447-453.	1.8	5
20	New strategies in radioimmunotherapy for lymphoma. Current Oncology Reports, 2003, 5, 364-371.	1.8	7
21	Vaccination strategies for lymphomas. Current Oncology Reports, 2003, 5, 380-386.	1.8	5
22	Immunity against soft-tissue sarcomas. Current Oncology Reports, 2003, 5, 282-287.	1.8	11
23	Quality of life after treatment for prostate cancer. Current Prostate Reports, 2003, 1, 55-65.	0.1	1
24	Quality of life after treatment for prostate cancer. Current Urology Reports, 2003, 4, 185-195.	1.0	61
25	Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 443, 508-517.	1.4	103
26	Interaction effect of PTEN and CDKN1B chromosomal regions on prostate cancer linkage. Human Genetics, 2003, -1, 1-1.	1.8	17
27	Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. Seminars in Radiation Oncology, 2003, 13, 454-468.	1.0	41
28	Spiral Computed Tomography Screening for the Diagnosis of Early-Stage Lung Cancer. Clinical Lung Cancer, 2003, 4, 277-278.	1.1	0
29	Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell, 2003, 4, 437-450.	7.7	2,150
30	Abdominoperineal resection. Operative Techniques in General Surgery, 2003, 5, 240-256.	0.0	1
31	Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Seminars in Oncology, 2003, 30, 93-104.	0.8	39
32	Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. Seminars in Oncology, 2003, 30, 776-788.	0.8	25
33	Follow-up care of breast cancer survivors. Seminars in Oncology, 2003, 30, 817-825.	0.8	16
34	Introduction: future trends in the treatment of brain tumors. Seminars in Oncology, 2003, 30, 1-3.	0.8	1
35	State-of-the-art treatment of high-grade brain tumors. Seminars in Oncology, 2003, 30, 4-9.	0.8	94
36	WHI: Now that the dust has settled. American Journal of Obstetrics and Gynecology, 2003, 189, 621-626.	0.7	22

ARTICLE IF CITATIONS # Positron Emission Tomography in Diagnosis and Management of Invasive Breast Cancer: Current 37 1.1 45 Status and Future Perspectives. Clinical Breast Cancer, 2003, 4, S55-S63. Gefitinib in the Treatment of Advanced, Refractory Non–Small-Cell Lung Cancer: Results in 124 1.1 Patients. Clinical Lung Cancer, 2003, 4, 347-355. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric 39 228 1.1 analysis of microarray data. BMC Cancer, 2003, 3, 31. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detection 34 and Prevention, 2003, 27, 434-441. Pathologic evaluation of inguinal sentinel lymph nodes in vulvar cancer patients: a comparison of immunohistochemical staining versus ultrastaging with hematoxylin and eosin staining. Gynecologic 41 0.6 68 Oncology, 2003, 91, 378-382. Is there a prognostic difference between depth of myometrial invasion and the tumor-free distance from the uterine serosa in endometrial cancer?. Gynecologic Oncology, 2003, 91, 547-551. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent 43 carboplatin originally treated with carboplatin and paclitaxel. Gynecologic Oncology, 2003, 91, 0.6 45 584-590. Sentinel node identification and the ability to detect metastatic tumor to inguinal lymph nodes in 44 96 squamous cell cancer of the vulva. Gynecologic Oncology, 2003, 89, 475-479. Is observation and salvage (when necessary) an appropriate approach to intermediate risk endometrial 45 0.6 9 cancer?. Gynecologic Oncology, 2003, 89, 199-200. The role of PET scanning in the detection of recurrent cervical cancer. Gynecologic Oncology, 2003, 118 90, 186-190. Breast cancer metastatic to abdomen and pelvis: role of surgical resectiona<sup>7</sup>t. Gynecologic Oncology, 47 49 0.6 2003, 90, 397-401. Survival and prognosis of women with invasive cervical cancer according to age. Gynecologic 54 Oncology, 2003, 91, 395-401. Follow-up strategies after curative resection of colorectal cancer. Seminars in Oncology, 2003, 30, 49 0.8 58 349-360. Post-treatment surveillance of patients with lymphoma treated with curative intent. Seminars in 0.8 Oncology, 2003, 30, 375-381. Combined treatment for limited small cell lung cancer. Seminars in Oncology, 2003, 30, 56-70. 51 0.8 10 Combined modality therapy for pancreatic cancer. Seminars in Oncology, 2003, 30, 71-79. Combined modality treatment for prostate cancer: role of chemotherapy. Seminars in Oncology, 2003, 53 0.8 6 30, 95-100. 54 Combined modality therapy for rectal and colon cancer. Seminars in Oncology, 2003, 30, 101-112.

		CITATION RE	PORT	
#	Article		IF	CITATIONS
55	Role of bisphosphonates in prostate cancer bone metastases. Seminars in Oncology, 20	03, 30, 717-723.	0.8	10
56	Predicting clinical end points: treatment nomograms in prostate cancer. Seminars in Or 30, 567-586.	cology, 2003,	0.8	33
57	Differentiating agents and the treatment of prostate cancer: vitamin D and peroxisome proliferator-activated receptor gamma ligands. Seminars in Oncology, 2003, 30, 698-70	)8.	0.8	14
58	Endothelin receptor antagonists in the treatment of prostate cancer. Seminars in Onco 678-688.	ogy, 2003, 30,	0.8	32
59	Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leuco treatment of colorectal cancer. Seminars in Oncology, 2003, 30, 40-46.	vorin in the	0.8	19
60	Radioimmunotherapy for non-Hodgkin's lymphomas: A historical perspective. Seminars 2003, 30, 10-21.	in Oncology,	0.8	10
61	Seeking the solution to the problem of metastatic renal carcinoma. Cancer, 2003, 97, 2	941-2944.	2.0	4
62	Racial differences in survival after diagnosis with primary malignant brain tumor. Cancer 603-609.	, 2003, 98,	2.0	74
63	Prognostic significance of psychosocial factors in African-American and white breast car Cancer, 2003, 98, 1299-1308.	ncer patients.	2.0	85
64	Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinon 2003, 98, 1643-1648.	na. Cancer,	2.0	155
65	Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma. Canc 1855-1862.	er, 2003, 98,	2.0	32
66	Vinblastine and estramustine phosphate in metastatic renal cell carcinoma. Cancer, 200	93, 98, 1837-1841.	2.0	10
67	Familial sarcoma. Cancer, 2003, 98, 1947-1957.		2.0	44
68	Attitudes of medical oncologists toward palliative care for patients with advanced and i cancer. Cancer, 2003, 98, 2502-2510.	ncurable	2.0	173
69	Impact of race on outcome after definitive radiotherapy for squamous cell carcinoma of neck. Cancer, 2003, 98, 2467-2472.	the head and	2.0	29
70	A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-sti factor support in patients with hormone-refractory prostate carcinoma. Cancer, 2003, 9		2.0	88
71	Is endometrial carcinoma intrinsically more aggressive in elderly patients?. Cancer, 2003	3, 98, 2368-2377.	2.0	79
72	Prostate carcinoma tissue proteomics for biomarker discovery. Cancer, 2003, 98, 2576-	2582.	2.0	82

#	Article	IF	Citations
π 73	The evolution of lung cancer screening. Journal of Surgical Oncology, 2003, 84, 234-238.	0.8	3
74	Occupational cancer among women: Where have we been and where are we going?. American Journal of Industrial Medicine, 2003, 44, 565-575.	1.0	65
75	Biochemical recurrence of prostate cancer. Current Problems in Cancer, 2003, 27, 243-272.	1.0	5
76	Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: A population-based study. International Journal of Radiation Oncology Biology Physics, 2003, 56, 1038-1045.	0.4	385
77	Radiation dose escalation in limited-stage small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2003, 57, 701-708.	0.4	65
78	The association between presentation PSA and race in two sequential time periods in prostate cancer patients seen at a university hospital and its community affiliates. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1292-1296.	0.4	10
79	Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose–volume histogram parameters. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1317-1322.	0.4	158
80	Rodent models for ovarian cancer research. International Journal of Gynecological Cancer, 2003, 13, 405-412.	1.2	45
81	The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer. BJU International, 2003, 92, 695-698.	1.3	8
82	Laterally directed biopsies detect more clinically threatening prostate cancer: Computer simulated results. Prostate, 2003, 57, 118-128.	1.2	18
83	Molecular characterization of human prostate carcinoma cell lines. Prostate, 2003, 57, 205-225.	1.2	555
84	Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines. Prostate, 2003, 57, 226-244.	1.2	52
85	Genomic scan of 254 hereditary prostate cancer families. Prostate, 2003, 57, 309-319.	1.2	59
86	Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 nearBRCA1. Prostate, 2003, 57, 326-334.	1.2	90
87	Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics, 2003, 3, 2142-2146.	1.3	199
88	Cost-effectiveness studies in ovarian cancer. International Journal of Gynecological Cancer, 2003, 13, 212-219.	1.2	12
89	Proteomic analysis for early detection of ovarian cancer: A realistic approach?. International Journal of Gynecological Cancer, 2003, 13, 133-139.	1.2	38
90	Testing an Intervention for Preventing Osteoporosis in Postmenopausal Breast Cancer Survivors. Journal of Nursing Scholarship, 2003, 35, 333-338.	1.1	45

#	ARTICLE	IF	CITATIONS
91	1α,25-Dihydroxyvitamin D3 (calcitriol) and its analogue, 19-nor-1α,25(OH)2D2, potentiate the effects of ionising radiation on human prostate cancer cells. British Journal of Cancer, 2003, 89, 746-753.	2.9	64
92	Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation. British Journal of Cancer, 2003, 89, 1096-1101.	2.9	45
93	Prognostic value of genomic alterations in head and neck squamous cell carcinoma detected by comparative genomic hybridisation. British Journal of Cancer, 2003, 89, 864-869.	2.9	56
94	Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. British Journal of Cancer, 2003, 89, 1180-1184.	2.9	58
95	Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene, 2003, 22, 6107-6110.	2.6	191
96	Genomic profiling identifies alterations in TGFβ signaling through loss of TGFβ receptor expression in human renal cell carcinogenesis and progression. Oncogene, 2003, 22, 8053-8062.	2.6	105
97	Translational strategies for cancer prevention in liver. Nature Reviews Cancer, 2003, 3, 321-329.	12.8	191
98	Mechanisms of sarcoma development. Nature Reviews Cancer, 2003, 3, 685-694.	12.8	406
99	Radiation exposure to operating room personnel during transperineal interstitial permanent prostate brachytherapy. Brachytherapy, 2003, 2, 98-102.	0.2	13
100	A Multicenter Clinical Trial On the Use of Complexed Prostate Specific Antigen in Low Prostate Specific Antigen Concentrations. Journal of Urology, 2003, 170, 1175-1179.	0.2	41
101	Chemotherapeutic strategies for renal cell carcinoma. Urologic Clinics of North America, 2003, 30, 601-609.	0.8	31
102	The natural history of prostate cancer. Urologic Clinics of North America, 2003, 30, 219-226.	0.8	59
103	Prostate cancer: cryotherapy. Urologic Clinics of North America, 2003, 30, 725-736.	0.8	31
104	Populations at high risk for prostate cancer. Urologic Clinics of North America, 2003, 30, 669-676.	0.8	25
105	A Single Nucleotide Primer Extension Assay to Detect the APC I1307K Gene Variant. Journal of Molecular Diagnostics, 2003, 5, 222-226.	1.2	9
106	Cyclopropane-Containing Polyamine Analogues Are Efficient Growth Inhibitors of a Human Prostate Tumor Xenograft in Nude Mice. Journal of Medicinal Chemistry, 2003, 46, 4586-4600.	2.9	29
107	The many faces of low-grade dysplasia. Gastroenterology, 2003, 125, 1531-1533.	0.6	8
108	Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology, 2003, 124, 1292-1299.	0.6	179

#	Article	IF	CITATIONS
109	Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery, 2003, 134, 946-954.	1.0	480
110	Should Adjuvant Therapy Remain the Standard of Care for Patients With Resected Adenocarcinoma of the Pancreas?. Annals of Surgical Oncology, 2003, 10, 539-545.	0.7	28
111	Why Aren't We Doing Better?. Clinical Breast Cancer, 2003, 4, 9.	1.1	1
112	Metastasis Suppressor Genes: Basic Biology and Potential Clinical Use. Clinical Breast Cancer, 2003, 4, 51-62.	1.1	139
113	Digital Mammography: A Review of Technical Development and Clinical Applications. Clinical Breast Cancer, 2003, 4, 63-70.	1.1	19
114	The Evolving Role of Capecitabine in Breast Cancer. Clinical Breast Cancer, 2003, 4, S20-S25.	1.1	19
115	Locoregional Strategies for Colorectal Hepatic Metastases. Clinical Colorectal Cancer, 2003, 3, 34-44.	1.0	20
116	Development of New Agents for the Treatment of Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2003, 3, 154-164.	1.0	5
117	Phase IIA Clinical Trial to Test the Efficacy and Safety of Toremifene in Men with High-Grade Prostatic Intraepithelial Neoplasia. Clinical Prostate Cancer, 2003, 2, 24-31.	2.1	50
118	Ten-Year Survival in Patients with Metastatic Prostate Cancer. Clinical Prostate Cancer, 2003, 2, 41-45.	2.1	66
119	Biweekly Administration of Low-Dose Docetaxel in Hormone-Resistant Prostate Cancer: Pilot Study of an Effective Subtoxic Therapy. Clinical Prostate Cancer, 2003, 2, 46-49.	2.1	13
120	Involvement of Growth Factor Receptors of the Epidermal Growth Factor Receptor Family in Prostate Cancer Development and Progression to Androgen Independence. Clinical Prostate Cancer, 2003, 2, 50-57.	2.1	55
121	Population Screening for Prostate Cancer and Emerging Concepts for Young Men. Clinical Prostate Cancer, 2003, 2, 87-97.	2.1	27
122	Characterization of Prostate Cancer Missed by Sextant Biopsy. Clinical Prostate Cancer, 2003, 2, 115-118.	2.1	30
123	The Role of Cyclooxygenase-2 Inhibition for the Prevention and Treatment of Prostate Carcinoma. Clinical Prostate Cancer, 2003, 2, 119-126.	2.1	34
124	The Combination of Antiangiogenic and Cytotoxic Agents in the Treatment of Prostate Cancer. Clinical Prostate Cancer, 2003, 2, 153-159.	2.1	19
125	Clinical Strategies in the Management of Biochemical Recurrence After Radical Prostatectomy. Clinical Prostate Cancer, 2003, 2, 160-166.	2.1	6
126	Weekly Docetaxel in Elderly Patients with Prostate Cancer: Efficacy and Toxicity in Patients Aged ≥ 70 Years Compared with Patients Aged < 70 Years. Clinical Prostate Cancer, 2003, 2, 167-172.	2.1	47

-		_	
СІТАТ	ION	VEDO	DT
CITAI	IUN	<b>NLFU</b>	IX I

#	Article	IF	CITATIONS
127	Therapeutic Approaches Targeting Prostate Cancer Progression Using Novel Voltage-Gated Ion Channel Blockers. Clinical Prostate Cancer, 2003, 2, 181-187.	2.1	29
128	Emerging Role of Topotecan in First-Line Therapy of Small-Cell Lung Cancer. Clinical Lung Cancer, 2003, 4, 279-287.	1.1	2
129	Molecular Fingerprinting in Human Lung Cancer. Clinical Lung Cancer, 2003, 5, 113-118.	1.1	24
130	Pegylated Liposomal Doxorubicin, Vincristine, and Reduced-Dose Dexamethasone as First-Line Therapy for Multiple Myeloma. Clinical Lymphoma and Myeloma, 2003, 4, S18-S22.	2.1	15
131	Inhibition of pancreatic cancer cell growth and induction of apoptosis with novel therapies directed against protein kinase A. Surgery, 2003, 134, 197-205.	1.0	28
132	Selective activation of PPARÎ <sup>3</sup> inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator. Surgery, 2003, 134, 206-212.	1.0	22
133	Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery, 2003, 134, 221-226.	1.0	81
134	The epidemiology of acute promyelocytic leukaemia. Best Practice and Research in Clinical Haematology, 2003, 16, 357-367.	0.7	68
135	Integrating Oxaliplatin and Capecitabine in Adjuvant Therapy of High-Risk Colorectal Cancer. Clinical Colorectal Cancer, 2003, 3, 150-153.	1.0	1
136	Management and Outcome of Colorectal Cancer in Elderly Patients. Clinical Colorectal Cancer, 2003, 3, 172-173.	1.0	1
137	Advances in the Use of Fecal DNA Screening for the Detection of Colorectal Cancer. Clinical Colorectal Cancer, 2003, 2, 210-212.	1.0	0
138	Time Trends in Clinical Risk Stratification for Prostate Cancer: Implications for Outcomes (Data From) Tj ETQq1	1 0.784314 0.2	rgBT /Overlo
139	Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. American Journal of Surgery, 2003, 186, 486-492.	0.9	56
140	Colorectal cancer screening at a veterans affairs hospital. American Journal of Surgery, 2003, 186, 468-471.	0.9	7
141	Keyhole limpet hemocyanin, a novel immune stimulant with promising anticancer activity in Barrett's esophageal adenocarcinoma. American Journal of Surgery, 2003, 186, 552-555.	0.9	56
142	Local and national trends over a decade in the surgical treatment of ductal carcinoma in situ. American Journal of Surgery, 2003, 186, 723-729.	0.9	14
143	Dose-dependent biodistribution of [99mTc]DTPA-mannosyl-dextran for breast cancer sentinel lymph node mapping. Nuclear Medicine and Biology, 2003, 30, 805-810.	0.3	44
144	Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient. Urology, 2003, 62, 147-154.	0.5	12

#	Article	IF	CITATIONS
145	The patient with hormone-refractory prostate cancer: determining who, when, and how to treat. Urology, 2003, 62, 134-140.	0.5	23
146	Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer. Urology, 2003, 62, 9-18.	0.5	72
147	Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology, 2003, 62, 128-133.	0.5	35
148	Non-Small-Cell Lung Cancer Molecular Signatures Recapitulate Lung Developmental Pathways. American Journal of Pathology, 2003, 163, 1949-1960.	1.9	203
149	Identical Allelic Losses in Mature Teratoma and Other Histologic Components of Malignant Mixed Germ Cell Tumors of the Testis. American Journal of Pathology, 2003, 163, 2477-2484.	1.9	78
150	The genetics of pancreatic cancer. American Journal of Surgery, 2003, 186, 279-286.	0.9	138
151	Esophageal Cancer. New England Journal of Medicine, 2003, 349, 2241-2252.	13.9	2,582
152	Variables in predicting survival based on treating "PSA-Only―relapse. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 292-304.	0.8	42
153	Metallothionein 2A interacts with the kinase domain of PKCμ in prostate cancer. Biochemical and Biophysical Research Communications, 2003, 310, 1032-1038.	1.0	32
154	Silibinin down-regulates survivin protein and mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papilloma RT4 cells. Biochemical and Biophysical Research Communications, 2003, 312, 1178-1184.	1.0	57
155	The polyglycine and polyglutamine repeats in the androgen receptor gene in Japanese and Caucasian populations. Biochemical and Biophysical Research Communications, 2003, 312, 1244-1247.	1.0	29
156	Unconventional therapy for prostate cancer: good, bad or questionable?. Nature Reviews Cancer, 2003, 3, 845-858.	12.8	47
157	Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer, 2003, 41, 29-42.	0.9	189
158	Imatinib in small cell lung cancer. Lung Cancer, 2003, 41, 49-53.	0.9	56
159	Adenocarcinoma of the lung among women: risk associated with smoking, prior lung disease, diet and menstrual and pregnancy history. Lung Cancer, 2003, 41, 283-293.	0.9	49
160	Prognostic factors in ovarian cancer: current evidence and future prospects. European Journal of Cancer, Supplement, 2003, 1, 127-145.	2.2	18
161	Highlights from the Third Annual Meeting of the Society of Urologic Oncology; Bethesda, Maryland, December 13-14, 2002. Clinical Prostate Cancer, 2003, 1, 203-206.	2.1	0
162	Radical Prostatectomy Improves Cancer-Specific Survival But Not Overall Survival in Early-Stage Prostate Cancer. Clinical Prostate Cancer, 2003, 2, 15-17.	2.1	1

		CITATION RE	PORT	
#	Article		IF	Citations
163	Models for Prostate Cancer Chemoprevention. Clinical Prostate Cancer, 2003, 2, 32-33	3.	2.1	1
164	In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocyte with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells Surgical Research, 2003, 112, 189-197.	s from patients s. Journal of	0.8	22
165	Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcir Urology, 2003, 61, 845-850.	ioma.	0.5	95
166	Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate can primary therapy. Urology, 2003, 62, 872-876.	cer after	0.5	29
167	A randomized double-blind prospective study evaluating patient tolerance of transrect ultrasound-guided biopsy of the prostate using prebiopsy rofecoxib. Urology, 2003, 62	al ., 1054-1057.	0.5	25
168	Use of skin and oral cancer examinations in the United States, 1998. Preventive Medic 278-282.	ine, 2003, 37,	1.6	12
169	Differences in physical performance between men and women with and without lymph commercial party having a direct financial interest in the results of the research suppor article has or will confer a benefit upon the authors(s) or upon any organization with w author(s) is/are associated Archives of Physical Medicine and Rehabilitation, 2003, 84	ting this hich the	0.5	26
170	Expression and characterization of Syrian golden hamster p16, a homologue of human suppressor p16INK4A. Biochemical and Biophysical Research Communications, 2003, 3	tumor 804, 241-247.	1.0	8
171	Protein kinase C μ is down-regulated in androgen-independent prostate cancer. Bioch Biophysical Research Communications, 2003, 307, 254-260.	nemical and	1.0	73
172	Colorectal cancer after renal transplantation. Transplantation Proceedings, 2003, 35, 1	410-1412.	0.3	37
173	Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinom and neck transplanted into nude mice. Cancer Letters, 2003, 199, 209-217.	a of the head	3.2	31
174	Adoption of new technologies for early detection of melanoma in dermatologic practic the American Academy of Dermatology, 2003, 49, 955-959.	e. Journal of	0.6	17
175	An overview of targeted treatments in cancer. Clinical Therapeutics, 2003, 25, 2121-2	137.	1.1	85
176	Oesophageal cancer: new developments in systemic therapy. Cancer Treatment Reviev 525-532.	vs, 2003, 29,	3.4	59
177	Molecular Pathways to Prostate Cancer. Journal of Urology, 2003, 170, 2444-2452.		0.2	119
178	Gastrointestinal optical coherence tomography. Techniques in Gastrointestinal Endosc 94-101.	ору, 2003, 5,	0.3	14
180	Diagnosis, treatment, and nursing care of acute leukemia. Seminars in Oncology Nursi 98-108.	ng, 2003, 19,	0.7	17
181	Decision-making in the diagnosis and treatment of leukemia. Seminars in Oncology Nu 142-149.	rsing, 2003, 19,	0.7	3

#	Article	IF	CITATIONS
182	Chemotherapeutic management of advanced ovarian cancer. Seminars in Oncology Nursing, 2003, 19, 3-18.	0.7	4
183	High-risk localized prostate cancer: primary surgery and adjuvant therapy. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 219-227.	0.8	19
184	New era in prostate-cancer care: what we know and what we don't. Lancet Oncology, The, 2003, 4, 204-205.	5.1	4
185	Assessment of Cognitive Function in Patients Receiving Adjuvant Endocrine Therapy. Clinical Breast Cancer, 2003, 4, 241-243.	1.1	0
186	Comparison of Sentinel Lymph Node Biopsy and Axillary Node Dissection in the Treatment of Early-Stage Breast Cancer. Clinical Breast Cancer, 2003, 4, 251-252.	1.1	0
187	Increased Sectioning of Pathologic Specimens with Ductal Carcinoma In Situ of the Breast: Are There Clinical Consequences?. Clinical Breast Cancer, 2003, 4, 198-202.	1.1	2
188	Bladder Cancer Facts: Accuracy of Information on the Internet. Journal of Urology, 2003, 170, 1756-1760.	0.2	33
189	Serum Osteoprotegerin and Receptor Activator of Nuclear Factor-κ B Ligand as Indicators of Disturbed Osteoclastogenesis in Patients With Prostate Cancer. Journal of Urology, 2003, 170, 2302-2305.	0.2	41
190	Sunscreen Use and the Risk for Melanoma: A Quantitative Review. Annals of Internal Medicine, 2003, 139, 966.	2.0	167
191	Differentiating a chronic hyperplastic mass from pancreatic cancer: a challenge remaining in multidetector CT of the pancreas. European Radiology, 2003, 13, 42-49.	2.3	22
192	Agent Orange: Management of Patients Exposed in Vietnam. Clinical Journal of Oncology Nursing, 2003, 7, 320-323.	0.3	3
193	The Mechanism of I-Canavanine Cytotoxicity: Arginyl tRNA Synthetase as a Novel Target for Anticancer Drug Discovery. Journal of Enzyme Inhibition and Medicinal Chemistry, 2003, 18, 383-394.	2.5	46
194	Racial Differences in Androgen Receptor Protein Expression in Men With Clinically Localized Prostate Cancer. Journal of Urology, 2003, 170, 990-993.	0.2	129
195	Expression and Degradation of Androgen Receptor: Mechanism and Clinical Implication. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4043-4054.	1.8	151
196	Correlation of expression of BP1, a homeobox gene, with estrogen receptor status in breast cancer. Breast Cancer Research, 2003, 5, R82-7.	2.2	36
197	New Approaches for the Prevention of Bone Metastases in Patients with Prostate Cancer. American Journal of Cancer, 2003, 2, 181-199.	0.4	2
198	Paclitaxel and Concurrent Radiation in Upper Gastrointestinal Cancers. Cancer Investigation, 2003, 21, 887-896.	0.6	22
199	Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer. New England Journal of Medicine, 2003, 349, 2091-2098.	13.9	2,773

#	Article	IF	CITATIONS
200	The role of epidermal growth factor receptor in advanced nonâ€small cell lung carcinoma. Annals of Medicine, 2003, 35, 450-457.	1.5	4
201	Combined bacillus Calmette–Guerin and interferon use in superficial bladder cancer. Expert Review of Anticancer Therapy, 2003, 3, 809-821.	1.1	16
202	Improving Survival in Patients with High-Risk and Metastatic Melanoma. American Journal of Clinical Dermatology, 2003, 4, 333-346.	3.3	30
203	Neoadjuvant chemotherapy for cervical cancer. Expert Opinion on Pharmacotherapy, 2003, 4, 859-867.	0.9	10
204	Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges. Expert Opinion on Pharmacotherapy, 2003, 4, 875-887.	0.9	13
205	An Update on Hepatic Arterial Infusion Chemotherapy for Colorectal Cancer. Oncologist, 2003, 8, 553-566.	1.9	105
206	Engineering cancer resistance in mice. Carcinogenesis, 2003, 24, 817-826.	1.3	17
207	Computed Tomographic Virtual Colonoscopy to Screen for Colorectal Neoplasia in Asymptomatic Adults. New England Journal of Medicine, 2003, 349, 2191-2200.	13.9	1,882
208	Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer. JAMA - Journal of the American Medical Association, 2003, 290, 2149.	3.8	2,360
209	Phase II study of flavopiridol in patients with advanced colorectal cancer. Annals of Oncology, 2003, 14, 1270-1273.	0.6	93
210	High-Risk Human Papillomaviruses May Have an Important Role in Non–Oral Habits–Associated Oral Squamous Cell Carcinomas in Taiwan. American Journal of Clinical Pathology, 2003, 120, 909-916.	0.4	36
211	Adjuvant Chemotherapy Followed by Goserelin Versus Either Modality Alone for Premenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial. Journal of the National Cancer Institute, 2003, 95, 1833-1846.	3.0	261
212	American Society of Clinical Oncology Policy Statement Update: Tobacco Control—Reducing Cancer Incidence and Saving Lives. Journal of Clinical Oncology, 2003, 21, 2777-2786.	0.8	41
213	Prior History of Allergies and Pancreatic Cancer in the San Francisco Bay Area. American Journal of Epidemiology, 2003, 158, 432-441.	1.6	86
214	Childhood Cancer Among Alaska Natives. Pediatrics, 2003, 112, e396-e396.	1.0	48
215	Skin Self-Examination in Patients at High Risk for Melanoma: A Pilot Study. Oncology Nursing Forum, 2003, 30, 1029-1036.	0.5	27
216	Oxaliplatin: A Novel Platinum Analog With Activity in Colorectal Cancer. Oncology Nursing Forum, 2003, 30, 957-966.	0.5	4
217	Effect of a Short Structured Session on Medical Student Breast Cancer Screening Knowledge. Breast Journal, 2003, 9, 295-297.	0.4	3

#	Article	IF	CITATIONS
218	Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors. Journal of the National Cancer Institute, 2003, 95, 1825-1833.	3.0	89
219	Ovarian Cancer: Early Symptom Patterns. Oncology Nursing Forum, 2003, 30, 927-933.	0.5	25
220	Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives. Journal of Clinical Oncology, 2003, 21, 4444-4454.	0.8	113
221	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11606-11611.	3.3	1,482
222	Potential Pitfalls in the Use of Surrogate Endpoints in Colorectal Adenoma Chemoprevention. Journal of the National Cancer Institute, 2003, 95, 697-699.	3.0	23
223	Novel pharmacological approaches in the treatment of breast cancer. Expert Opinion on Investigational Drugs, 2003, 12, 909-921.	1.9	4
224	Anthrax toxin: structures, functions and tumour targeting. Expert Opinion on Biological Therapy, 2003, 3, 843-853.	1.4	54
225	Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group. Journal of Clinical Oncology, 2003, 21, 3016-3024.	0.8	881
226	Free-standing, self referral centers for whole-body CT screening should be closed, or at least restricted to at-risk patients. Medical Physics, 2003, 30, 2569-2571.	1.6	1
227	Breast Cancer in Older Women: Quality of Life and Psychosocial Adjustment in the 15 Months After Diagnosis. Journal of Clinical Oncology, 2003, 21, 4027-4033.	0.8	227
228	Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11636-11641.	3.3	179
229	Recombinant toxin DAB389EGF is cytotoxic to human pancreatic cancer cells. Expert Opinion on Biological Therapy, 2003, 3, 1173-1180.	1.4	10
230	Virtual Reality Intervention for Older Women with Breast Cancer. Cyberpsychology, Behavior and Social Networking, 2003, 6, 301-307.	2.2	100
231	Pathological staging and therapy of oesophageal and gastric cancer. Expert Opinion on Pharmacotherapy, 2003, 4, 1083-1096.	0.9	4
232	Small Interfering RNA Targeting Bcl-2 Sensitizes Malignant Melanoma. Oligonucleotides, 2003, 13, 393-400.	2.7	56
234	Population Attributable Risks of Esophageal and Gastric Cancers. Journal of the National Cancer Institute, 2003, 95, 1404-1413.	3.0	675
235	Bortezomib Treatment for Multiple Myeloma. Annals of Pharmacotherapy, 2003, 37, 1825-1830.	0.9	18
236	Induction of cIAP-2 in Human Colon Cancer Cells through PKCÎ′/NF-κB. Journal of Biological Chemistry, 2003, 278, 51091-51099.	1.6	93

#	Article	IF	CITATIONS
237	Mammary carcinogenesis and molecular analysis of in vivo cII gene mutations in the mammary tissue of female transgenic rats treated with the environmental pollutant 6-nitrochrysene. Carcinogenesis, 2003, 25, 637-643.	1.3	15
238	An Attenuated Adenovirus, ONYX-015, As Mouthwash Therapy for Premalignant Oral Dysplasia. Journal of Clinical Oncology, 2003, 21, 4546-4552.	0.8	135
239	Phase I/II Study of Hepatic Arterial Therapy With Floxuridine and Dexamethasone in Combination With Intravenous Irinotecan As Adjuvant Treatment After Resection of Hepatic Metastases From Colorectal Cancer. Journal of Clinical Oncology, 2003, 21, 3303-3309.	0.8	123
240	LEEP in the Family Practice Setting. Journal of the American Board of Family Medicine, 2003, 16, 204-208.	0.8	5
241	Docetaxel in Advanced Gastric Cancer Review of the Main Clinical Trials. Acta Oncológica, 2003, 42, 693-700.	0.8	22
242	Frequent p16INK4A/CDKN2A alterations in chemically induced Syrian golden hamster pancreatic tumors. Carcinogenesis, 2003, 25, 263-268.	1.3	21
243	Reimbursement and Patient Assistance Programs for Oral Chemotherapy Agents. Clinical Journal of Oncology Nursing, 2003, 7, 31-36.	0.3	3
244	Radiotherapy Patterns of Care Study in Lung Carcinoma. Journal of Clinical Oncology, 2003, 21, 4553-4559.	0.8	105
245	Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial. Journal of Clinical Oncology, 2003, 21, 3133-3140.	0.8	307
246	The Prostate Cancer Conundrum. Journal of the National Cancer Institute, 2003, 95, 930-931.	3.0	15
247	Trastuzumab for the Treatment of Non—Small-Cell Lung Cancer. Annals of Pharmacotherapy, 2003, 37, 1904-1908.	0.9	6
248	Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer. Journal of Clinical Oncology, 2003, 21, 4356-4363.	0.8	78
249	Cancer mortality in a Texas county with prior uranium mining and milling activities, 1950–2001. Journal of Radiological Protection, 2003, 23, 247-262.	0.6	26
250	Lymphoscintigraphy for Lymphatic Mapping in Breast Carcinoma. Radiology, 2003, 228, 313-315.	3.6	12
251	Surgery in the Aged Population. Archives of Surgery, 2003, 138, 1061.	2.3	69
252	Lung Cancer Screening. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 1167-1173.	2.5	124
253	African-American and White Women's Appraisal of Their Breast Cancer. Journal of Psychosocial Oncology, 2003, 21, 43-61.	0.6	7
254	Adolescent Adjustment and Maternal Breast Cancer. Journal of Psychosocial Oncology, 2003, 21, 81-104.	0.6	69

		EPORT	
#	Article	IF	CITATIONS
255	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Cancer Nursing, 2003, 26, 21S???25S.	0.7	10
256	Antiproliferative effect of 1,4-phenylenebis(methylene)selenocyanate (p-XSC) on colonic epithelium of patients with adenomatous polyps in vitro. European Journal of Cancer Prevention, 2003, 12, 463-468.	0.6	0
257	Breast Cancer in Pregnant and Postpartum Women. Journal of Obstetrics and Gynaecology Canada, 2003, 25, 944-950.	0.3	15
258	Results of Therapy for Acute Lymphoblastic Leukemia in Black and White Children. JAMA - Journal of the American Medical Association, 2003, 290, 2001.	3.8	155
259	Stage Ia-IIa Cancer of the Cervix. Cancer Journal (Sudbury, Mass ), 2003, 9, 395-403.	1.0	2
260	The Role of Chemotherapy in the Management of Carcinoma of the Cervix. Cancer Journal (Sudbury,) Tj ETQq1	1 0.784314 1.0	4 rggT /Ove
261	Conservation Therapy in T1-T2 Breast Cancer. Cancer Journal (Sudbury, Mass ), 2003, 9, 442-453.	1.0	19
262	Treatment Advances in Ovarian Cancer. Cancer Nursing, 2003, 26, 16S???20S.	0.7	10
263	Randomized Phase II Study of Daily Versus Continuous-Infusion Schedules of Topotecan in the Treatment of Extensive-Stage Small Cell Lung Cancers. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 236-240.	0.6	10
264	Barriers to Colorectal Cancer Screening With Fecal Occult Blood Testing in a Predominantly Minority Urban Population: A Qualitative Study. American Journal of Public Health, 2003, 93, 1268-1271.	1.5	61
265	COX-2 Inhibitor as a Radiation Enhancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, S70-S74.	0.6	14
266	Knowledge, Attitudes, and Practices Surrounding Breast Cancer Screening in Educated Appalachian Women. Oncology Nursing Forum, 2003, 30, 659-667.	0.5	33
267	A Comprehensive Approach to Improving Cancer Pain Management and Patient Satisfaction. Oncology Nursing Forum, 2003, 30, 857-864.	0.5	20
268	Cognitive Dysfunction Following Adjuvant Chemotherapy for Breast Cancer: Two Case Studies. Oncology Nursing Forum, 2003, 30, 473-478.	0.5	42
269	Evidence-Based Use of Colony-Stimulating Factors in Elderly Cancer Patients. Cancer Control, 2003, 10, 487-499.	0.7	47
270	Design and Testing of the Use of a Complementary and Alternative Therapies Survey in Women With Breast Cancer. Oncology Nursing Forum, 2003, 30, 811-821.	O.5	39
271	Cancer Genetics in Primary Care. Journal of Nutrition, 2003, 133, 3767S-3772S.	1.3	8
272	Thalidomide and Its Derivatives: New Promise for Multiple Myeloma. Cancer Control, 2003, 10, 375-383.	0.7	36

#	Article	IF	CITATIONS
273	Cancer Inhibition by Inositol Hexaphosphate (IP6) and Inositol: From Laboratory to Clinic. Journal of Nutrition, 2003, 133, 3778S-3784S.	1.3	252
274	Prostate cancer intervention. Postgraduate Medicine, 2003, 114, 43-49.	0.9	10
275	Immunofluorometric Quantification of Human Kallikrein 5 Expression in Ovarian Cancer Cytosols and Its Association with Unfavorable Patient Prognosis. Tumor Biology, 2003, 24, 299-309.	0.8	45
276	A Systematic Review and Lessons Learned from Early Lung Cancer Detection Trials Using Low-Dose Computed Tomography of the Chest. Cancer Control, 2003, 10, 306-314.	0.7	49
277	Microarrays in Cancer: Research and Applications. BioTechniques, 2003, 34, S4-S15.	0.8	34
278	Current and Evolving Strategies for Colorectal Cancer Screening. Cancer Control, 2003, 10, 193-204.	0.7	32
279	Metastatic Colorectal Cancer: Systemic Treatment in the New Millennium. Cancer Control, 2003, 10, 224-238.	0.7	34
280	Hereditary Colorectal Cancer. , 0, , 151-169.		0
281	Understanding Novel Therapeutic Agents for Multiple Myeloma. Clinical Journal of Oncology Nursing, 2003, 7, 521-528.	0.3	10
282	The Emergence of Thalidomide in Treating Advanced Renal Cell Carcinoma. Oncology Nursing Forum, 2003, 30, 501-511.	0.5	1
283	Human Papillomavirus and Cervical Cancer: Not Just a Sexually Transmitted Disease. Clinical Journal of Oncology Nursing, 2003, 7, 271-276.	0.3	14
284	Depression in Patients With Advanced Cancer. Clinical Journal of Oncology Nursing, 2003, 7, 281-288.	0.3	24
286	Stage at Diagnosis and Survival in a Multiethnic Cohort of Prostate Cancer Patients. American Journal of Public Health, 2003, 93, 1753-1759.	1.5	62
287	Bisphosphonates for Men With Prostate Cancer: Sifting Through the Rubble. Journal of Clinical Oncology, 2003, 21, 4261-4262.	0.8	11
288	Renal Cancer Treatment: A Review of the Literature. Tumori, 2003, 89, 476-484.	0.6	16
289	Diagnostic Approach and Prognostic Factors of Cancers. Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association, 2003, 46, 1117.	0.1	0
291	Patient Education for Women Being Fitted for Breast Prostheses. Clinical Journal of Oncology Nursing, 2003, 7, 194-199.	0.3	18
292	Lung Cancer. Clinical Journal of Oncology Nursing, 2003, 7, 699-702.	0.3	2

	Сіта	tion Report	
#	Article	IF	CITATIONS
293	Management of Acute Myelogenous Leukemia in the Elderly. Cancer Control, 2003, 10, 469-477.	0.7	19
294	What's Old Is New Again: Patients Receiving Hepatic Arterial Infusion Chemotherapy. Clinical Journal of Oncology Nursing, 2003, 7, 647-652.	0.3	3
295	Treating Hot Flashes in Breast Cancer Survivors: A Review of Alternative Treatments to Hormone Replacement Therapy. Clinical Journal of Oncology Nursing, 2003, 7, 637-640.	0.3	13
296	Advances in Radiation Treatment of Patients With Breast Cancer. Clinical Journal of Oncology Nursing, 2003, 7, 629-636.	0.3	8
297	Surgical and Ablative Modalities for the Treatment of Colorectal Cancer Metastatic to the Liver. Clinical Journal of Oncology Nursing, 2003, 7, 178-184.	0.3	3
298	New Approaches for Small-Cell Lung Cancer: Local Treatments. Cancer Control, 2003, 10, 289-296.	0.7	21
299	Dietary Exposure to Whey Proteins Alters Rat Mammary Gland Proliferation, Apoptosis, and Gene Expression during Postnatal Development. Journal of Nutrition, 2004, 134, 3370-3377.	1.3	31
300	Molecular-Targeted Agents in Pancreatic Cancer. Cancer Control, 2004, 11, 32-38.	0.7	24
301	Preradiation Chemotherapy with VM-26 and CCNU in Patients with Glioblastoma Multiforme. Tumori, 2004, 90, 562-566.	0.6	8
302	Folate and colorectal neoplasia: relation between plasma and dietary markers of folate and adenoma recurrence. American Journal of Clinical Nutrition, 2004, 79, 691-697.	2.2	68
303	Palliative Care in Pancreatic Cancer. Cancer Control, 2004, 11, 39-45.	0.7	19
305	Cancer Prevention. , 2004, , 137-156.		0
306	Epidemiology of Uterine Corpus Cancers. , 2004, , 188-207.		3
307	Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2004, 30, 3-11.	0.7	2
308	The role of HER2/neu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma. Sao Paulo Medical Journal, 2004, 122, 124-127.	0.4	9
310	Indole-3-Carbinol and Prostate Cancer. Journal of Nutrition, 2004, 134, 3493S-3498S.	1.3	121
311	Imaging of esophageal cancer. Cancer Imaging, 2004, 4, 125-132.	1.2	31
312	Pharmacogenetics of human androgens and prostate cancer – an update. Pharmacogenomics, 2004, 5 283-294.	5, 0.6	7

#	Article	IF	CITATIONS
313	Radioimmunotherapy of non-Hodgkin's lymphoma: Clinical development of the Zevalin regimen. Biotechnology Annual Review, 2004, 10, 265-295.	2.1	19
314	Neoplasms of the Reproductive Tract: The Role of Hormone Exposure. ILAR Journal, 2004, 45, 179-188.	1.8	16
315	Effects of a combination of docosahexaenoic acid and 1,4-phenylene bis(methylene) selenocyanate on cyclooxygenase 2, inducible nitric oxide synthase and β-catenin pathways in colon cancer cells. Carcinogenesis, 2004, 25, 2443-2449.	1.3	74
316	Poloâ€like kinase (Plk) 1: a novel target for the treatment of prostate cancer. FASEB Journal, 2004, 18, 5-7.	0.2	38
317	Regression of HPV-Positive Tumors Treated With a New Listeria monocytogenes Vaccine. JAMA Otolaryngology, 2004, 130, 92.	1.5	56
318	Gene Expression Profiling Identifies a Unique Androgen-Mediated Inflammatory/Immune Signature and a PTEN (Phosphatase and Tensin Homolog Deleted on Chromosome 10)-Mediated Apoptotic Response Specific to the Rat Ventral Prostate. Molecular Endocrinology, 2004, 18, 2895-2907.	3.7	41
319	Chemotherapeutic options in the management of anal cancer. Expert Opinion on Pharmacotherapy, 2004, 5, 2479-2484.	0.9	2
320	Plasma Lipoprotein Profile in the Male Cynomolgus Monkey under Normal, Hypogonadal, and Combined Androgen Blockade Conditions. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1849-1857.	1.8	15
321	<b>Time Interval Between Abnormalities Seen on CT and the Clinical Diagnosis of Pancreatic Cancer:</b> Retrospective Review of CT Scans Obtained Before Diagnosis. American Journal of Roentgenology, 2004, 182, 897-903.	1.0	226
323	Glycogen Synthase Kinase-3β Activity Is Required for Androgen-Stimulated Gene Expression in Prostate Cancer. Endocrinology, 2004, 145, 2941-2949.	1.4	83
324	Prostate Cancer: Incremental Value of Endorectal MR Imaging Findings for Prediction of Extracapsular Extension. Radiology, 2004, 232, 133-139.	3.6	205
325	Hand-Assisted Laparoscopic Nephroureterectomy for Upper Urinary-Tract Transitional-Cell Carcinoma. Journal of Endourology, 2004, 18, 351-358.	1.1	14
326	Abnormal Selective Cytology Results Predict Recurrence of Upper-Tract Transitional-Cell Carcinoma Treated with Ureteroscopic Laser Ablation. Journal of Endourology, 2004, 18, 912-916.	1.1	22
327	Is PM More Toxic Than the Sum of Its Parts? Risk-Assessment Toxicity Factorsvs.PM-Mortality "Effect Functions― Inhalation Toxicology, 2004, 16, 19-29.	0.8	22
328	Automatic detection of linear artifacts in medical images. Medical Physics, 2004, 31, 2707-2710.	1.6	0
329	Deficient Nucleotide Excision Repair Capacity Enhances Human Prostate Cancer Risk. Cancer Research, 2004, 64, 1197-1201.	0.4	68
330	ZD1839 Modulates Paclitaxel Response in Renal Cancer by Blocking Paclitaxel-Induced Activation of the Epidermal Growth Factor Receptor–Extracellular Signal-Regulated Kinase Pathway. Clinical Cancer Research, 2004, 10, 794-801.	3.2	60
331	RESPONSE: Re: Radiation Therapy in the Treatment of Hodgkin's DiseaseDo You See What I See?. Journal of the National Cancer Institute, 2004, 96, 236-237.	3.0	0

#	Article	IF	CITATIONS
332	Interleukin 6 Mediates the Lysophosphatidic Acid-regulated Cross-talk between Stromal and Epithelial Prostate Cancer Cells. Journal of Biological Chemistry, 2004, 279, 21154-21159.	1.6	35
333	Ovarian Cancer and Polymorphisms in the Androgen and Progesterone Receptor Genes: A HuGE Review. American Journal of Epidemiology, 2004, 159, 319-335.	1.6	56
334	A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2004, 10, 4680-4687.	3.2	65
335	Claudin 4 Protein Expression in Primary and Metastatic Pancreatic Cancer. American Journal of Clinical Pathology, 2004, 121, 226-230.	0.4	149
336	Blockage of 2-Deoxy-d-Ribose-Induced Angiogenesis with Rapamycin Counteracts a Thymidine Phosphorylase-Based Escape Mechanism Available for Colon Cancer under 5-Fluorouracil Therapy. Clinical Cancer Research, 2004, 10, 1843-1852.	3.2	60
337	Adjuvant Interferon Therapy for Melanoma: High-Dose, Low-Dose, No Dose, Which Dose?. Journal of Clinical Oncology, 2004, 22, 7-10.	0.8	80
338	Allogeneic Lymphocytes Induce Tumor Regression of Advanced Metastatic Breast Cancer. Journal of Clinical Oncology, 2004, 22, 3886-3892.	0.8	103
339	Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic Marker. Journal of Clinical Oncology, 2004, 22, 678-685.	0.8	73
340	Colorectal Cancer Screening Knowledge, Attitudes, and Beliefs Among Veterans: Does Literacy Make a Difference?. Journal of Clinical Oncology, 2004, 22, 2617-2622.	0.8	154
341	DNA Methylation Profiles of Lymphoid and Hematopoietic Malignancies. Clinical Cancer Research, 2004, 10, 2928-2935.	3.2	59
342	Acceptability and feasibility of a community-based screening programme for melanoma in Australia. Health Promotion International, 2004, 19, 437-444.	0.9	35
343	Fertility preservation in female patients. Human Reproduction Update, 2004, 10, 251-266.	5.2	443
344	Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells. Clinical Cancer Research, 2004, 10, 2307-2318.	3.2	181
345	Bowel Inflammation as Measured by Fecal Calprotectin. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 279-284.	1.1	189
346	Expression of Thyrotropin-Releasing Hormone by Human Melanoma and Nevi. Clinical Cancer Research, 2004, 10, 5531-5536.	3.2	20
347	No Rational Theory for Drug Pricing. Journal of Clinical Oncology, 2004, 22, 962-963.	0.8	9
348	Osteopontin But Not Osteonectin Messenger RNA Expression Is a Prognostic Marker in Curatively Resected Non-Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 1588-1596.	3.2	67
349	A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer. Clinical Cancer Research, 2004, 10, 924-928.	3.2	71

		CITATION REPORT		
#	Article		IF	CITATIONS
350	Intermittent Androgen Deprivation Therapy for Prostate Cancer. Oncologist, 2004, 9, 2	295-301.	1.9	60
351	A Prospective Study of Aspirin Use and the Risk of Pancreatic Cancer in Women. Journ National Cancer Institute, 2004, 96, 22-28.	al of the	3.0	133
352	ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened survival. Journal of Clinical Pathology, 2004, 57, 1160-1164.	l patient	1.0	229
353	Lung Cancer in US Women. JAMA - Journal of the American Medical Association, 2004,	291, 1763.	3.8	220
354	The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Pr Management. Journal of Clinical Oncology, 2004, 22, 2141-2149.	imary	0.8	528
355	Requirement for G proteins in insulin-like growth factor-l-induced growth of prostate c of Molecular Endocrinology, 2004, 33, 165-173.	ells. Journal	1.1	6
356	Silencing of the Hypoxia-Inducible Cell Death Protein BNIP3 in Pancreatic Cancer. Canc 2004, 64, 5338-5346.	er Research,	0.4	211
357	Defects in Cell Growth Regulation by C18:0-Ceramide and Longevity Assurance Gene 1 and Neck Squamous Cell Carcinomas. Journal of Biological Chemistry, 2004, 279, 443		1.6	196
358	Peripheral Lung Nodules. Annals of Surgery, 2004, 240, 481-489.		2.1	131
359	Hath1, Down-Regulated in Colon Adenocarcinomas, Inhibits Proliferation and Tumorig Cancer Cells. Cancer Research, 2004, 64, 6050-6057.	enesis of Colon	0.4	117
360	Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cance Benefits and by How Much?. Journal of Clinical Oncology, 2004, 22, 1797-1806.	r: Who	0.8	913
361	Age‧pecific Prevalence of Anal Human Papillomavirus Infection in HIVâ€Negative Se Who Have Sex with Men: The EXPLORE Study. Journal of Infectious Diseases, 2004, 19	xually Active Men 0, 2070-2076.	1.9	246
362	Comprehensive expression analysis of retinoic acid receptors and retinoid X receptors cell lung cancer: implications for tumor development and prognosis. Carcinogenesis, 2 525-530.		1.3	60
363	Changes in endocrine therapy: Anastrozole and advanced breast cancer in postmenop American Journal of Hospice and Palliative Medicine, 2004, 21, 457-465.	ausal women.	0.8	0
364	Relation of Contraceptive and Reproductive History to Ovarian Cancer Risk in Carriers Noncarriers of BRCA1 Gene Mutations. American Journal of Epidemiology, 2004, 160,		1.6	114
365	Fruit, Vegetable, and Antioxidant Intake and All-Cause, Cancer, and Cardiovascular Dis in a Community-dwelling Population in Washington County, Maryland. American Jourr Epidemiology, 2004, 160, 1223-1233.		1.6	313
366	Detection of Bladder Cancer in Urine by a Tumor Suppressor Gene Hypermethylation F Cancer Research, 2004, 10, 1887-1893.	anel. Clinical	3.2	177
367	Loss of Fhit Expression in Head and Neck Squamous Cell Carcinoma and Its Potential C Implication. Clinical Cancer Research, 2004, 10, 5554-5557.	Clinical	3.2	20

#	Article	IF	CITATIONS
368	Apoptosis-Based Evaluation of Chemosensitivity in Ovarian Cancer Patients. Journal of the Society for Gynecologic Investigation, 2004, 11, 252-259.	1.9	26
369	Neural network fusion strategies for identifying breast masses. , 0, , .		20
370	Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition. Cancer Research, 2004, 64, 4912-4918.	0.4	152
371	Emerging drugs for head and neck cancer. Expert Opinion on Emerging Drugs, 2004, 9, 91-104.	1.0	3
372	Salvage Radiotherapy for Recurrent Prostate Cancer. JAMA - Journal of the American Medical Association, 2004, 291, 1380.	3.8	24
373	Combined Genome-Wide Scan for Prostate Cancer Susceptibility Genes. Journal of the National Cancer Institute, 2004, 96, 1240-1247.	3.0	72
374	Ejaculation Frequency and Subsequent Risk of Prostate Cancer. JAMA - Journal of the American Medical Association, 2004, 291, 1578.	3.8	108
375	Phase II Trial of PS-341 in Patients With Renal Cell Cancer: A University of Chicago Phase II Consortium Study. Journal of Clinical Oncology, 2004, 22, 115-119.	0.8	144
376	Inhibition of Rat Mammary Gland Carcinogenesis by Simultaneous Targeting of Cyclooxygenase-2 and Peroxisome Proliferator-activated Receptor γ. Cancer Research, 2004, 64, 1181-1189.	0.4	59
377	Loss of Heterozygosity of Chromosome 3p21 Is Associated with Mutant TP53 and Better Patient Survival in Non–Small-Cell Lung Cancer. Cancer Research, 2004, 64, 8702-8707.	0.4	48
378	EGF Gene Polymorphism and the Risk of Incident Primary Melanoma. Cancer Research, 2004, 64, 2668-2672.	0.4	49
379	Analysis of Methylated Genes in Peritoneal Fluids of Ovarian Cancer Patients: A New Prognostic Tool. Clinical Chemistry, 2004, 50, 2171-2173.	1.5	37
380	The Certainties and the Uncertainties of Ductal Carcinoma In Situ. Journal of the National Cancer Institute, 2004, 96, 424-425.	3.0	21
381	A Transcriptional Profiling Study of CCAAT/Enhancer Binding Protein Targets Identifies Hepatocyte Nuclear Factor 3β as a Novel Tumor Suppressor in Lung Cancer. Cancer Research, 2004, 64, 4137-4147.	0.4	66
382	The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARÂ pathway. Carcinogenesis, 2004, 25, 1805-1812.	1.3	26
383	Increased Insulin-Like Growth Factor I Receptor Expression and Signaling Are Components of Androgen-Independent Progression in a Lineage-Derived Prostate Cancer Progression Model. Cancer Research, 2004, 64, 8620-8629.	0.4	148
384	Phase II Trial of Pleural Photodynamic Therapy and Surgery for Patients With Non–Small-Cell Lung Cancer With Pleural Spread. Journal of Clinical Oncology, 2004, 22, 2192-2201.	0.8	105
385	Topotecan in the Treatment of Relapsed Small Cell Lung Cancer Patients with Poor Performance Status. Oncologist, 2004, 9, 173-181.	1.9	37

#	Article	IF	CITATIONS
386	Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion. Journal of Biological Chemistry, 2004, 279, 9190-9198.	1.6	462
387	The complex genetic epidemiology of prostate cancer. Human Molecular Genetics, 2004, 13, 103R-121.	1.4	298
388	Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association with Early-Stage Disease and Improved Outcome. Cancer Research, 2004, 64, 8767-8772.	0.4	60
389	Identification of an Autoregulatory Feedback Pathway Involving Interleukin-11± in Induction of Constitutive NF-1ºB Activation in Pancreatic Cancer Cells. Journal of Biological Chemistry, 2004, 279, 16452-16462.	1.6	97
390	Reduced Lecithin. Clinical Cancer Research, 2004, 10, 3429-3437.	3.2	36
391	Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583). Journal of Clinical Oncology, 2004, 22, 1025-1033.	0.8	464
392	The Framingham School Nevus Study. Archives of Dermatology, 2004, 140, 545-51.	1.7	48
393	Identification of Patients With Head and Neck Cancer Using Serum Protein Profiles. JAMA Otolaryngology, 2004, 130, 98.	1.5	107
394	Restoration of Bone Morphogenetic Protein Receptor Type II Expression Leads to a Decreased Rate of Tumor Growth in Bladder Transitional Cell Carcinoma Cell Line TSU-Pr1. Cancer Research, 2004, 64, 7355-7360.	0.4	35
396	Changing trends of prostate cancer in Asia. Aging Male, 2004, 7, 120-132.	0.9	101
397	Phase I Trial of Combined-Modality Therapy for Localized Esophageal Cancer: Escalating Doses of Continuous-Infusion Paclitaxel With Cisplatin and Concurrent Radiation Therapy. Journal of Clinical Oncology, 2004, 22, 45-52.	0.8	66
398	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Does Not Improve Paclitaxel Effect in an Orthotopic Mouse Model of Lung Cancer. Clinical Cancer Research, 2004, 10, 8613-8619.	3.2	17
399	The Androgen Axis in Recurrent Prostate Cancer. Clinical Cancer Research, 2004, 10, 440-448.	3.2	629
400	Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry. Clinical Cancer Research, 2004, 10, 860-868.	3.2	273
401	The Watchful Waiting Management Option for Older Men with Prostate Cancer: State of the Science. Oncology Nursing Forum, 2004, 31, 1057-1066.	0.5	11
402	Virtual Reality as a Distraction Intervention for Women Receiving Chemotherapy. Oncology Nursing Forum, 2004, 31, 81-88.	0.5	150
403	Factors Predictive of Tumor-Positive Nonsentinel Lymph Nodes After Tumor-Positive Sentinel Lymph Node Dissection for Melanoma. Journal of Clinical Oncology, 2004, 22, 3677-3684.	0.8	157
404	Prognostic Significance of Molecular Upstaging of Paraffin-Embedded Sentinel Lymph Nodes in Melanoma Patients. Journal of Clinical Oncology, 2004, 22, 2671-2680.	0.8	137

#	Article	IF	CITATIONS
405	The Adrenal Androgen Androstenediol Is Present in Prostate Cancer Tissue after Androgen Deprivation Therapy and Activates Mutated Androgen Receptor. Cancer Research, 2004, 64, 765-771.	0.4	164
406	An Autoantibody-Mediated Immune Response to Calreticulin Isoforms in Pancreatic Cancer. Cancer Research, 2004, 64, 5504-5510.	0.4	119
407	Profiling the Evolution of Human Metastatic Bladder Cancer. Cancer Research, 2004, 64, 7813-7821.	0.4	88
408	Serum Protein Profiles to Identify Head and Neck Cancer. Clinical Cancer Research, 2004, 10, 1625-1632.	3.2	110
409	Identifying Superficial, Muscle-Invasive, and Metastasizing Transitional Cell Carcinoma of the Bladder. Clinical Cancer Research, 2004, 10, 3410-3421.	3.2	110
410	Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer. Clinical Cancer Research, 2004, 10, 3474-3478.	3.2	85
411	Alternative Splicing of the Multidrug Resistance Protein 1/ATP Binding Cassette Transporter Subfamily Gene in Ovarian Cancer Creates Functional Splice Variants and Is Associated with Increased Expression of the Splicing Factors PTB and SRp20. Clinical Cancer Research, 2004, 10, 4652-4660.	3.2	106
412	Serum Levels of Insulin Growth Factor (IGF-I) and IGF-Binding Protein Predict Risk of Second Primary Tumors in Patients with Head and Neck Cancer. Clinical Cancer Research, 2004, 10, 3988-3995.	3.2	72
413	Expression of the ELAV-Like Protein HuR Is Associated with Higher Tumor Grade and Increased Cyclooxygenase-2 Expression in Human Breast Carcinoma. Clinical Cancer Research, 2004, 10, 5580-5586.	3.2	142
414	Promoter Hypermethylation Profile of Kidney Cancer. Clinical Cancer Research, 2004, 10, 3972-3979.	3.2	144
415	Combination Immunotherapy of B-Cell Non-Hodgkin's Lymphoma with Rituximab and Interleukin-2. Clinical Cancer Research, 2004, 10, 6101-6110.	3.2	74
416	Oral Cavity and Esophageal Carcinogenesis Modeled in Carcinogen-Treated Mice. Clinical Cancer Research, 2004, 10, 301-313.	3.2	314
418	Topotecan in the Treatment of Recurrent Small Cell Lung Cancer: An Update. Oncologist, 2004, 9, 4-13.	1.9	478
419	Validity of Self-reported Skin Screening Histories. American Journal of Epidemiology, 2004, 159, 1098-1105.	1.6	38
420	Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis, 2004, 25, 1517-1524.	1.3	80
421	Identification of a prostate cancer susceptibility locus on chromosome 7q11–21 in Jewish families. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1939-1944.	3.3	23
422	Cryosurgery for Breast Cancer. Technology in Cancer Research and Treatment, 2004, 3, 165-175.	0.8	23
423	The Role of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: Comparison of the Clinical Trials. Oncologist, 2004, 9, 116-125.	1.9	36

#	Article	IF	CITATIONS
424	Membranous Expression of Secreted Frizzled-Related Protein 4 Predicts for Good Prognosis in Localized Prostate Cancer and Inhibits PC3 Cellular Proliferation in Vitro. Clinical Cancer Research, 2004, 10, 615-625.	3.2	79
425	The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma. Clinical Cancer Research, 2004, 10, 6956-6961.	3.2	360
426	Detection and Grading of Soft Tissue Sarcomas of the Extremities with 18F-3′-Fluoro-3′-Deoxy-l-Thymidine. Clinical Cancer Research, 2004, 10, 1685-1690.	3.2	93
427	Proteomic Analysis to Identify Breast Cancer Biomarkers in Nipple Aspirate Fluid. Clinical Cancer Research, 2004, 10, 7500-7510.	3.2	155
428	Interleukin-1 Receptor Antagonist Polymorphism in Patients with Prostate Cancer and Benign Prostatic Hyperplasia: A Case Control Study from North India. UroOncology, 2004, 4, 131-134.	0.1	6
429	The eicosanoid cascade: possible role in gliomas and meningiomas. Journal of Clinical Pathology, 2004, 57, 6-13.	1.0	80
430	Green vegetables, red meat and colon cancer: chlorophyll prevents the cytotoxic and hyperproliferative effects of haem in rat colon. Carcinogenesis, 2004, 26, 387-393.	1.3	96
431	The Beta-Carotene and Retinol Efficacy Trial: Incidence of Lung Cancer and Cardiovascular Disease Mortality During 6-Year Follow-up After Stopping Â-Carotene and Retinol Supplements. Journal of the National Cancer Institute, 2004, 96, 1743-1750.	3.0	382
432	The T Cell Receptor Î <sup>3</sup> Chain Alternate Reading Frame Protein (TARP), a Prostate-specific Protein Localized in Mitochondria. Journal of Biological Chemistry, 2004, 279, 24561-24568.	1.6	25
433	Cyclooxygenase-2 in Lung Carcinogenesis and Chemoprevention. Chest, 2004, 125, 134S-140S.	0.4	13
434	Occupational Exposures and Non-Hodgkin's Lymphoma in Southern Sweden. International Journal of Occupational and Environmental Health, 2004, 10, 13-21.	1.2	61
435	Analysis of Candidate Genes for Prostate Cancer. Human Heredity, 2004, 57, 172-178.	0.4	45
436	Surgical Treatment of Oesophageal Cancer. Digestive Diseases, 2004, 22, 213-220.	0.8	10
437	In VitroEvaluation of Cytochrome P450-mediated Drug Interactions between Cytarabine, Idarubicin, Itraconazole and Caspofungin. Hematology, 2004, 9, 217-221.	0.7	43
438	Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer. Clinical Cancer Research, 2004, 10, 8594-8602.	3.2	154
439	Colon Cancer Screening Practices After Genetic Counseling and Testing for Hereditary Nonpolyposis Colorectal Cancer. Journal of Clinical Oncology, 2004, 22, 39-44.	0.8	136
440	Genetic Variation in the Leptin Receptor Gene and Obesity in Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study. Journal of Clinical Oncology, 2004, 22, 3558-3562.	0.8	123
441	Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Annals of Oncology, 2004, 15, 1352-1357.	0.6	100

	CITATION	Report	
# 442	ARTICLE Towards automated segmentation and classification of masses in mammograms. , 2004, 2004, 1814-7.	IF	CITATIONS
443	Should men with serum PSA levels of 4.0 ng/ml or less undergo a prostate biopsy?. Nature Reviews Urology, 2004, 1, 12-13.	1.4	0
444	Randomized, Double-Blind, Placebo-Controlled Phase IIB Trial of the Cyclooxygenase Inhibitor Ketorolac as an Oral Rinse in Oropharyngeal Leukoplakia. Clinical Cancer Research, 2004, 10, 1565-1573.	3.2	90
445	Protein Kinase CβII Regulates Its Own Expression in Rat Intestinal Epithelial Cells and the Colonic Epithelium in Vivo. Journal of Biological Chemistry, 2004, 279, 45556-45563.	1.6	49
446	Effects of a High-Fiber, Low-Fat Diet Intervention on Serum Concentrations of Reproductive Steroid Hormones in Women With a History of Breast Cancer. Journal of Clinical Oncology, 2004, 22, 2379-2387.	0.8	100
447	In Vivo Suppression of Hormone-Refractory Prostate Cancer Growth by Inositol Hexaphosphate. Clinical Cancer Research, 2004, 10, 244-250.	3.2	71
448	A Definitive Role of RhoC in Metastasis of Orthotopic Lung Cancer in Mice. Clinical Cancer Research, 2004, 10, 1192-1200.	3.2	90
449	Oncogenic K-ras Drives Cell Cycle Progression and Phenotypic Conversion of Primary Pancreatic Duct Epithelial Cells. Cancer Research, 2004, 64, 5659-5663.	0.4	80
450	Quantitative Proteomic Analysis of Proteins Released by Neoplastic Prostate Epithelium. Cancer Research, 2004, 64, 347-355.	0.4	118
451	Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers. Clinical Cancer Research, 2004, 10, 2386-2392.	3.2	250
452	Altered Expression of Metastasis-Associated and Regulatory Molecules in Effusions from Breast Cancer Patients. Clinical Cancer Research, 2004, 10, 7335-7346.	3.2	66
453	Chemosensitization of Androgen-Independent Prostate Cancer with Neutral Endopeptidase. Clinical Cancer Research, 2004, 10, 260-266.	3.2	19
454	Protein Kinase C (PKC) βll Induces Cell Invasion through a Ras/Mek-, PKCι/Rac 1-dependent Signaling Pathway. Journal of Biological Chemistry, 2004, 279, 22118-22123.	1.6	127
455	Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer. Journal of Clinical Oncology, 2004, 22, 2532-2539.	0.8	316
456	Gemcitabine and ISIS-2503 for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma: A North Central Cancer Treatment Group Phase II Trial. Journal of Clinical Oncology, 2004, 22, 4944-4950.	0.8	91
457	Targeting Endogenous Transforming Growth Factor Î <sup>2</sup> Receptor Signaling in SMAD4-Deficient Human Pancreatic Carcinoma Cells Inhibits Their Invasive Phenotype 1. Cancer Research, 2004, 64, 5200-5211.	0.4	133
458	Prognostic Factors in Resected Stage I Non–Small-Cell Lung Cancer: A Multivariate Analysis of Six Molecular Markers. Journal of Clinical Oncology, 2004, 22, 4575-4583.	0.8	137
459	Advances in Chemoprevention of Head and Neck Cancer. Oncologist, 2004, 9, 302-311.	1.9	32

ARTICLE IF CITATIONS # Tobacco Carcinogen-Induced Cellular Transformation Increases Activation of the 460 0.4 129 Phosphatidylinositol 3â€<sup>2</sup>-Kinase/Akt Pathway in Vitro and in Vivo. Cancer Research, 2004, 64, 446-451. Screening Flexible Sigmoidoscopy Using an Upper Endoscope is Better Tolerated by Women. American Journal of Gastroenterology, 2004, 99, 1074-1080. 0.2 Induction of macroautophagy in human colon cancer cells by soybean B-group triterpenoid saponins. 462 1.3 140 Carcinogenesis, 2004, 26, 159-167. Barriers to Endoscopic Colorectal Cancer Screening: Are Women Different from Men?. American Journal of Gastroenterology, 2004, 99, 341-349. Prospective Comparison of Contrast Enhanced CT Colonography and Conventional Colonoscopy for Detection of Colorectal Neoplasms in a Single Institutional Study Using Second-Look Colonoscopy 464 0.2 32 with Discrepant Results. American Journal of Gastroenterology, 2004, 99, 1924-1935. Geographic Variation among Medicare Beneficiaries in the Use of Colorectal Carcinoma Screening 0.2 Procedures. American Journal of Gastroenterology, 2004, 99, 1544-1550. A National Survey of Flexible Sigmoidoscopy Training in Primary Care Graduate and Postgraduate 466 0.2 9 Education Programs. American Journal of Gastroenterology, 2004, 99, 830-836. Reproducibility of a Multitarget Stool-Based DNA Assay for Colorectal Cancer Detection. American 467 0.2 Journal of Gastroenterology, 2004, 99, 1338-1341. Genetic Replacement of the Adenovirus Shaft Fiber Reduces Liver Tropism in Ovarian Cancer Gene 468 1.4 36 Therapy. Human Gene Therapy, 2004, 15, 509-518. Gallium nitrate for the treatment of non-Hodgkin's lymphoma. Expert Opinion on Investigational Drugs, 2004, 13, 531-541. Mapping Tumor Epitope Space by Direct Selection of Single-Chain Fv Antibody Libraries on Prostate 470 0.4 90 Cancer Cells. Cancer Research, 2004, 64, 704-710. Estrogen plus Progestin and Colorectal Cancer in Postmenopausal Women. New England Journal of 471 13.9 585 Medicine, 2004, 350, 991-1004. Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases. Cancer Research, 2004, 472 0.4 816 64, 9209-9216. Identification by Proteomic Analysis of Calreticulin as a Marker for Bladder Cancer and Evaluation of 1.5 the Diagnostic Accuracy of Its Detection in Urine. Clinical Chemistry, 2004, 50, 857-866. 474 DNA Hypomethylation and Ovarian Cancer Biology. Cancer Research, 2004, 64, 4472-4480. 221 0.4 EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma. Clinical Cancer Research, 2004, 10, 5145-5150. Molecular Signatures in Biopsy Specimens of Lung Cancer. American Journal of Respiratory and 476 2.5105 Critical Care Medicine, 2004, 170, 167-174. Genetically Engineered Mouse Models for Lung Cancer. Annual Review of Physiology, 2004, 66, 647-663.

#	Article	IF	CITATIONS
478	Human Prostate Cell Lines Mimic Heterogeneity of Cadherin Expression in Human Prostate Cancer. UroOncology, 2004, 4, 15-25.	0.1	0
479	Detection of Prostate Cancer and Predicting Progression. Clinical Cancer Research, 2004, 10, 3943-3953.	3.2	151
480	Relationship between Non-Small Cell Lung Cancer Fluorodeoxyglucose Uptake at Positron Emission Tomography and Surgical Stage with Relevance to Patient Prognosis. Clinical Cancer Research, 2004, 10, 4709-4716.	3.2	48
481	Surgical Management of Testicular Cancer. Clinical Journal of Oncology Nursing, 2004, 8, 355-360.	0.3	2
482	Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer. Annals of Oncology, 2004, 15, 474-477.	0.6	22
483	Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis, 2004, 25, 1575-1585.	1.3	65
484	Chronic Inhalation Exposure to Mainstream Cigarette Smoke Increases Lung and Nasal Tumor Incidence in Rats. Toxicological Sciences, 2004, 81, 280-292.	1.4	69
485	Increased Risk for Hereditary Nonpolyposis Colorectal Cancer-Associated Synchronous and Metachronous Malignancies in Patients with Microsatellite Instability-Positive Endometrial Carcinoma Lacking MLH1 Promoter Methylation. Clinical Cancer Research, 2004, 10, 481-490.	3.2	45
486	Neurocognitive Performance in Breast Cancer Survivors Exposed to Adjuvant Chemotherapy and Tamoxifen. Journal of Clinical and Experimental Neuropsychology, 2004, 26, 955-969.	0.8	338
487	Current treatment of renal cell carcinoma. Annals of Oncology, 2004, 15, iv319-iv328.	0.6	22
488	Weekly Paclitaxel and Nedaplatin With Concurrent Radiotherapy for Locally Advanced Non-small-cell Lung Cancer: a Phase I/II Study. Japanese Journal of Clinical Oncology, 2004, 34, 647-653.	0.6	10
489	Targeting the Platelet-Derived Growth Factor Receptor in Antivascular Therapy for Human Ovarian Carcinoma. Clinical Cancer Research, 2004, 10, 897-908.	3.2	94
490	A randomized trial of recruitment methods for older African American men in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Clinical Trials, 2004, 1, 343-351.	0.7	73
491	Pulmonary Prostacyclin Synthase Overexpression Chemoprevents Tobacco Smoke Lung Carcinogenesis in Mice. Cancer Research, 2004, 64, 5897-5904.	0.4	117
492	Indole-3-carbinol stimulates transcription of the interferon gamma receptor 1 gene and augments interferon responsiveness in human breast cancer cells. Carcinogenesis, 2004, 25, 1119-1128.	1.3	28
493	Combining longitudinal studies of PSA. Biostatistics, 2004, 5, 483-500.	0.9	32
494	MUC1 Immunobiology: From Discovery to Clinical Applications. Advances in Immunology, 2004, 82, 249-293.	1.1	202
495	The Challenges of Long-Term Treatment Outcomes in Adults With Malignant Gliomas. Clinical Journal of Oncology Nursing, 2004, 8, 368-376.	0.3	35

		ATION REPOR	रा	
#	Article	IF		CITATIONS
496	Allogeneic Vaccination With a B7.1 HLA-A Gene-Modified Adenocarcinoma Cell Line in Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2004, 22, 2800-2807.	0.	8	103
497	Feeding of soy protein isolate to rats during pregnancy and lactation suppresses formation of aberrant crypt foci in their progeny's colons: interaction of diet with fetal alcohol exposure. Journal of Carcinogenesis, 2004, 3, 14.	2.8	5	14
498	Acute Ascending Cholangitis. Clinical Journal of Oncology Nursing, 2004, 8, 157-160.	0.	3	76
499	Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treament With Gemcitabine Followed by Docetaxel in the Treatment of Sarcoma. Journal of Clinical Oncology, 2004, 22, 1706-1712	2. 0.	8	225
500	Thermal ablation of prostate diseases: advantages and limitations. International Journal of Hyperthermia, 2004, 20, 679-697.	1.1	1	41
501	Changing Patterns in Health Behaviors and Risk Factors Related to Chronic Diseases, 1990–2000. American Journal of Health Promotion, 2004, 19, 19-27.	0.	9	84
502	Superficial transitional (Ta/T1/CIS) cell carcinoma of the bladder. BJU International, 2004, 94, 18-21.	1.5	3	26
503	Patients with bladder and lung cancer: a long-term outcome analysis. BJU International, 2004, 93, 1225-1227.	1.5	3	8
504	Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma-synuclein,) Tj E	TQq0 0 0 rgBJ	Ç /Ove	rlock 10 Tf 5 107
505	Determinants of sensitivity and resistance to gemcitabine: The roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Science, 2004, 95, 753-757.	, 1.7	7	126
506	Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. British Journal of Dermatology, 2004, 150, 179-185.	1.4	4	512
507	Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. British Journal of Haematology, 2004, 125, 343-352.	1.2	2	74
508	Low electric field enhanced chemotherapy can cure mice with CT-26 colon carcinoma and induce anti-tumour immunity. Clinical and Experimental Immunology, 2004, 138, 410-416.	1.1	1	16
509	Documenting Dermatology Practice: Ratio of Cutaneous Tumors Biopsied That Are Malignant. Dermatologic Surgery, 2004, 30, 1208-1209.	0.	4	12
510	Morpheaform Basal Cell Carcinoma in African Americans. Dermatologic Surgery, 2004, 30, 1550-1552.	. 0.	4	19
511	Clinical Evaluation and Patterns of Chemotherapy-Induced Peripheral Neuropathy. Journal of the American Academy of Nurse Practitioners, 2004, 16, 353-359.	1.4	4	29
512	Balancing the ideal versus the practical-considerations of colorectal cancer prevention and screening. Alimentary Pharmacology and Therapeutics, 2004, 19, 71-76.	1.9	9	6

513	Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. International Journal of Gynecological Cancer, 2004, 14, 348-353.	1.2	2 11	.6
-----	--	-----	------	----

	CITATION	n Report	
#	Article	IF	Citations
514	Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients. International Journal of Gynecological Cancer, 2004, 14, 804-814.	1.2	12
515	Whole-body positron emission tomography and positron emission tomography/computed tomography in gynecologic oncology. International Journal of Gynecological Cancer, 2004, 14, 12-22.	1.2	23
516	Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review. International Journal of Gynecological Cancer, 2004, 14, 399-422.	1.2	72
517	Vulvar cancer patients' quality of life: a qualitative assessment. International Journal of Gynecological Cancer, 2004, 14, 875-881.	1.2	95
518	Tandem BRAF Mutations in Primary Invasive Melanomas. Journal of Investigative Dermatology, 2004, 122, 1245-1250.	0.3	51
519	XAF1 Expression Is Significantly Reduced in Human Melanoma. Journal of Investigative Dermatology, 2004, 123, 1127-1134.	0.3	56
520	Correspondence 2: Cancer vaccines: pessimism in check. Nature Medicine, 2004, 10, 1279-1279.	15.2	22
521	High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplantation, 2004, 34, 161-167.	1.3	82
522	Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplantation, 2004, 34, 235-239.	1.3	62
523	Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplantation, 2004, 34, 485-490.	1.3	52
524	EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene, 2004, 23, 1448-1456.	2.6	206
525	Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors. Oncogene, 2004, 23, 1481-1488.	2.6	68
526	RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene, 2004, 23, 1539-1548.	2.6	227
527	High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene, 2004, 23, 2716-2726.	2.6	98
528	RRR-α-tocopheryl succinate inhibits human prostate cancer cell invasiveness. Oncogene, 2004, 23, 3080-3088.	2.6	67
529	The role of translation in neoplastic transformation from a pathologist's point of view. Oncogene, 2004, 23, 3230-3247.	2.6	114
530	Identification of 27 5′ CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene, 2004, 23, 8705-8710.	2.6	115
531	Detection and expression of human BK virus sequences in neoplastic prostate tissues. Oncogene, 2004, 23, 7031-7046.	2.6	76

#	Article	IF	CITATIONS
532	Suppression subtractive hybridization and expression profiling identifies a unique set of genes overexpressed in non-small-cell lung cancer. Oncogene, 2004, 23, 7734-7745.	2.6	67
533	Identification and characterization of somatic steroid 5î±-reductase (SRD5A2) mutations in human prostate cancer tissue. Oncogene, 2004, 23, 7399-7405.	2.6	38
534	Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene, 2004, 23, 7651-7659.	2.6	71
535	Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene, 2004, 23, 8065-8077.	2.6	118
536	Tumor formation in p53 mutant ovaries transplanted into wild-type female hosts. Oncogene, 2004, 23, 7722-7725.	2.6	21
537	An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene, 2004, 23, 8859-8867.	2.6	61
538	Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. British Journal of Cancer, 2004, 90, 815-821.	2.9	157
539	ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. British Journal of Cancer, 2004, 90, 1053-1058.	2.9	121
540	A population-based study of immunohistochemical detection of p53 alteration in bladder cancer. British Journal of Cancer, 2004, 90, 1572-1576.	2.9	52
541	RNA profiling of cyclooxygenases 1 and 2 in colorectal cancer. British Journal of Cancer, 2004, 91, 1015-1018.	2.9	11
542	Laparoscopic radical prostatectomy a review of the literature and comparison with open techniques. Prostate Cancer and Prostatic Diseases, 2004, 7, 295-301.	2.0	17
543	Tissue Microarray Analysis Reveals Prognostic Significance of COX-2 Expression for Local Relapse in T1???2N0 Larynx Cancer Treated with Primary Radiation Therapy. Laryngoscope, 2004, 114, 2001-2008.	1.1	23
544	Calcium and Colorectal Cancer: Some Questions Remain. Nutrition Reviews, 2004, 62, 115-120.	2.6	18
545	Inhibition of $\hat{1}\pm5$ integrin decreases PI3K activation and cell adhesion of human colon cancers. Surgery, 2004, 136, 143-149.	1.0	48
546	Combined histone deacetylase and NF-κB inhibition sensitizes non-small cell lung cancer to cell death. Surgery, 2004, 136, 416-425.	1.0	64
547	The management of rectal cancer in the elderly. Surgical Oncology, 2004, 13, 223-234.	0.8	23
548	Adjuvant treatment of colorectal cancer. Surgical Oncology, 2004, 13, 63-73.	0.8	14
549	Transplacental lung carcinogenesis: molecular mechanisms and pathogenesis. Toxicology and Applied Pharmacology, 2004, 198, 95-110.	1.3	30

#	Article	IF	Citations
550	Perillyl alcohol-mediated inhibition of lung cancer cell line proliferation: potential mechanisms for its chemotherapeutic effects. Toxicology and Applied Pharmacology, 2004, 195, 232-246.	1.3	50
551	Mechanisms of mammary cancer chemoprevention by organoselenium compounds. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004, 551, 181-197.	0.4	158
552	A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004, 555, 21-32.	0.4	65
553	Clinicopathologic features in colorectal cancer patients with microsatellite instability. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004, 568, 275-282.	0.4	78
554	Benefits of resection for metachronous lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2004, 127, 836-842.	0.4	82
555	Expression profiling of non–small cell lung carcinoma identifies metastatic genotypes based on lymph node tumor burden. Journal of Thoracic and Cardiovascular Surgery, 2004, 127, 1332-1342.	0.4	25
556	Imaging of gynecologic malignancy. Seminars in Roentgenology, 2004, 39, 428-436.	0.2	4
557	Diagnosis and staging of pancreatic tumors. Seminars in Roentgenology, 2004, 39, 397-411.	0.2	27
558	Knowledge and behaviors of primary care physicians on oral cancer in Italy. Oral Oncology, 2004, 40, 490-495.	0.8	30
559	Teaching head and neck cancer patients coping strategies: results of a feasibility study. Oral Oncology, 2004, 40, 538-544.	0.8	45
560	Mouse models of pancreatic cancer. Cancer Cell, 2004, 5, 7-11.	7.7	78
561	Focus on epithelial ovarian cancer. Cancer Cell, 2004, 5, 19-24.	7.7	267
562	Cetuximab in cancers of the lung and head & neck. Seminars in Oncology, 2004, 31, 61-67.	0.8	24
563	The role of HER2/neu expression and trastuzumab in non-small cell lung cancer. Seminars in Oncology, 2004, 31, 75-82.	0.8	56
564	Lymphoma and myeloma in older patients. Seminars in Oncology, 2004, 31, 198-205.	0.8	30
565	Gastrointestinal cancer in older patients. Seminars in Oncology, 2004, 31, 206-219.	0.8	30
566	Breast cancer in older patients. Seminars in Oncology, 2004, 31, 234-248.	0.8	26
567	Genitourinary cancer in the elderly. Seminars in Oncology, 2004, 31, 249-263.	0.8	7

	Сітатіс	CITATION REPORT	
#	Article	IF	Citations
568	Update on the management of connective tissue malignancies. Seminars in Oncology, 2004, 31, 16-19.	0.8	3
569	The care of the lung cancer patient in the 21st century: A new age. Seminars in Oncology, 2004, 31, 11-15.	0.8	43
570	Sentinel lymph node mapping technique in colon cancer. Seminars in Oncology, 2004, 31, 374-381.	0.8	54
571	Lymphatic mapping for gynecologic malignancies. Seminars in Oncology, 2004, 31, 394-402.	0.8	11
572	COX-2 inhibition in upper aerodigestive tract tumors. Seminars in Oncology, 2004, 31, 30-35.	0.8	66
573	COX-2 inhibition and lung cancer. Seminars in Oncology, 2004, 31, 45-52.	0.8	100
574	Treatment of metastatic esophagus and gastric cancer. Seminars in Oncology, 2004, 31, 574-587.	0.8	43
575	Screening for upper gastrointestinal tract malignancies. Seminars in Oncology, 2004, 31, 487-497.	0.8	5
576	Organ preservation for cancer of the larynx: current indications and future directions. Seminars in Radiation Oncology, 2004, 14, 167-177.	1.0	5
577	Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecologic Oncology, 2004, 92, 232-239.	0.6	77
578	Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma. Gynecologic Oncology, 2004, 92, 719-725.	0.6	48
579	Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology, 2004, 92, 10-14.	0.6	233
580	Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecologic Oncology, 2004, 92, 635-638.	0.6	54
581	Endometrial carcinoma: paraaortic dissemination. Gynecologic Oncology, 2004, 92, 833-838.	0.6	117
582	Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecologic Oncology, 2004, 93, 170-181.	0.6	246
583	Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecologic Oncology, 2004, 93, 78-86.	0.6	80
584	Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer. Gynecologic Oncology, 2004, 93, 223-228.	0.6	8
585	Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecologic Oncology, 2004, 94, 650-654.	0.6	286

#	Article	IF	CITATIONS
586	Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecologic Oncology, 2004, 93, 301-306.	0.6	76
587	Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts. Gynecologic Oncology, 2004, 93, 315-319.	0.6	25
588	The impact of complete surgical staging on adjuvant treatment decisions in endometrial cancer. Gynecologic Oncology, 2004, 93, 536-539.	0.6	35
589	The benefit of video-assisted thoracoscopic surgery before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions. Gynecologic Oncology, 2004, 94, 307-311.	0.6	45
590	Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma. Gynecologic Oncology, 2004, 94, 312-319.	0.6	58
591	Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer. Gynecologic Oncology, 2004, 94, 533-539.	0.6	13
592	Vaginal radical trachelectomy: an oncologically safe fertility-preserving surgery. An updated series of 72 cases and review of the literature. Gynecologic Oncology, 2004, 94, 614-623.	0.6	240
593	Panniculectomy: improving lymph node yield in morbidly obese patients with endometrial neoplasms. Gynecologic Oncology, 2004, 94, 436-441.	0.6	26
594	Phase II trial of 3-h infusion of paclitaxel in patients with adenocarcinoma of endometrium: Japanese Multicenter Study Group. Gynecologic Oncology, 2004, 94, 471-476.	0.6	22
595	E-cadherin and catenins in early squamous cervical carcinoma. Gynecologic Oncology, 2004, 94, 521-527.	0.6	29
596	Primary lung large cell carcinoma metastatic to the vulva: a case report and review of the literature. Gynecologic Oncology, 2004, 94, 829-831.	0.6	14
597	Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecologic Oncology, 2004, 94, 685-692.	0.6	56
598	Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecologic Oncology, 2004, 95, 32-36.	0.6	59
599	Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB–IVA carcinoma of the cervix: a Southwest Oncology Group study. Gynecologic Oncology, 2004, 95, 145-151.	0.6	54
600	Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. Gynecologic Oncology, 2004, 95, 506-512.	0.6	25
601	Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer, 2004, 4, 34.	1.1	92
602	Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BMC Cancer, 2004, 4, 5.	1.1	109
603	Cyclooxygenase-2 Inhibitors in Lung Cancer. Clinical Lung Cancer, 2004, 5, 245-253.	1.1	7

#	ARTICLE	IF	CITATIONS
604	siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity1 1No competing interests declared.This work was funded by the National Pancreas Foundation and departmental funding, Brigham and Women's Hospital Journal of the American College of Surgeons, 2004, 198, 953-959.	0.2	73
605	In-transit melanoma: The role of alkylating-agent resistance in regional therapy1 , *1. Journal of the American College of Surgeons, 2004, 199, 419-427.	0.2	20
606	Changing Concepts in the Surgical Management of Renal Cell Carcinoma. European Urology, 2004, 45, 692-705.	0.9	124
607	Weekly Docetaxel and Vinorelbine (VIN-DOX) as First Line Treatment in Patients with Hormone Refractory Prostate Cancer. European Urology, 2004, 46, 712-716.	0.9	16
608	Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. Experimental Hematology, 2004, 32, 277-281.	0.2	27
609	Cryoablation of benign breast tumors: evolution of technique and technology. Breast, 2004, 13, 397-407.	0.9	49
610	Quality of life intervention for prostate cancer patients: design and baseline characteristics of the active for life after cancer trial. Contemporary Clinical Trials, 2004, 25, 265-285.	2.0	28
611	The value of a complete blood count in predicting cancer of the colon. Cancer Detection and Prevention, 2004, 28, 37-42.	2.1	119
612	Up-regulation of hypoxia-inducible factor $1\hat{l}\pm$ is an early event in prostate carcinogenesis. Cancer Detection and Prevention, 2004, 28, 88-93.	2.1	171
613	Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer. Cancer Detection and Prevention, 2004, 28, 244-251.	2.1	71
614	Psychological stress and the risk of breast cancer: a case–control study. Cancer Detection and Prevention, 2004, 28, 399-408.	2.1	76
615	Diagnoses and outcomes in cervical cancer screening: A population-based study. American Journal of Obstetrics and Gynecology, 2004, 191, 105-113.	0.7	218
616	Digital rectal fecal occult blood screening during gynecologic examination. American Journal of Obstetrics and Gynecology, 2004, 190, 1422-1423.	0.7	2
617	Morbidity of cytoreductive surgery in the elderly. American Journal of Obstetrics and Gynecology, 2004, 190, 1398-1400.	0.7	65
618	Role of cyclooxygenase-2 in colorectal cancer. Cancer and Metastasis Reviews, 2004, 23, 63-75.	2.7	163
619	Multifocal Pathomorphological Study of Bladder Cancer with the Use of Luminescence Analysis. Bulletin of Experimental Biology and Medicine, 2004, 137, 308-312.	0.3	1
620	Is Male Breast Cancer Similar or Different than Female Breast Cancer?. Breast Cancer Research and Treatment, 2004, 83, 77-86.	1.1	259
621	Treatment-Related Osteoporosis in Men With Prostate Cancer. Clinical Reviews in Bone and Mineral Metabolism, 2004, 2, 115-122.	1.3	0

#	Article	IF	CITATIONS
622	Acinar Cell Carcinoma of the Pancreas. International Journal of Gastrointestinal Cancer, 2004, 34, 067-072.	0.4	24
623	Expression and Initial Promoter Characterization of PCAN1 in Retinal Tissue and Prostate Cell Lines. Medical Oncology, 2004, 21, 145-154.	1.2	4
624	Inhibition of Akt/Protein Kinase B Signaling by Naltrindole in Small Cell Lung Cancer Cells. Cancer Research, 2004, 64, 8723-8730.	0.4	38
625	Depression burden, psychological adjustment, and quality of life in women with breast cancer: Patterns over time. Research in Nursing and Health, 2004, 27, 19-28.	0.8	88
626	Outer Breast Quadrants Demonstrate Increased Levels of Genomic Instability. Annals of Surgical Oncology, 2004, 11, 861-868.	0.7	55
627	Failure to detect prostate cancer in the PSA era: comments on N Engl J Med 2003; 349: 215–224 and N Engl J Med 2003; 349: 335–342. Cancer Causes and Control, 2004, 15, 91-94.	0.8	4
628	Prostate cancer screening and mortality: A case–control study (United States). Cancer Causes and Control, 2004, 15, 133-138.	0.8	30
629	Body Mass Index and Risk of Colorectal Cancer in Women (United States). Cancer Causes and Control, 2004, 15, 581-589.	0.8	88
630	Prevalence of Whole-Body Skin Self-Examination in a Population at High Risk for Skin Cancer (Australia). Cancer Causes and Control, 2004, 15, 453-463.	0.8	68
631	The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions. Clinical and Experimental Metastasis, 2004, 21, 191-199.	1.7	26
632	A fluorescent orthotopic model of metastatic cervical carcinoma. Clinical and Experimental Metastasis, 2004, 21, 275-282.	1.7	31
633	A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum. Investigational New Drugs, 2004, 22, 53-61.	1.2	12
634	Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer. Investigational New Drugs, 2004, 22, 307-313.	1.2	3
635	9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium. Investigational New Drugs, 2004, 22, 323-327.	1.2	6
636	A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: A Southwest Oncology Group Study. Investigational New Drugs, 2004, 22, 335-341.	1.2	3
637	Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. Investigational New Drugs, 2004, 22, 343-349.	1.2	23
638	Analyzing Geographic Patterns of Disease Incidence: Rates of Late-Stage Colorectal Cancer in Iowa. Journal of Medical Systems, 2004, 28, 223-236.	2.2	75
639	Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. British Journal of Cancer, 2004, 90, 1814-1824.	2.9	50

		LPORT	
#	ARTICLE Changes in psychological distress of women in long-term remission from breast cancer in two	IF	CITATIONS
640	different geographical settings: a randomized study. Supportive Care in Cancer, 2004, 12, 10-18.	1.0	17
641	Microarray-based gene expression profiling in pancreatic ductal carcinoma: status quo and perspectives. International Journal of Colorectal Disease, 2004, 19, 401-13.	1.0	25
642	Radiotherapie bei limited SCLC. Onkologe, 2004, 10, 409-418.	0.7	0
644	Effects of Estrogen on Messenger Ribonucleic Acid Expression Patterns of Extracellular Matrix Proteases in the Primate Colon. Diseases of the Colon and Rectum, 2004, 47, 919-928.	0.7	0
645	Practice Parameters for Colon Cancer. Diseases of the Colon and Rectum, 2004, 47, 1269-1284.	0.7	127
646	Prognostic significance of dysadherin expression in cervical squamous cell carcinoma. Pathology and Oncology Research, 2004, 10, 212-218.	0.9	16
647	Capsaicin-induced apoptosis and reduced release of reactive oxygen species in MBT-2 Murine Bladder Tumor cells. Archives of Pharmacal Research, 2004, 27, 1147-1153.	2.7	39
648	The role of new targeted therapies in small-cell lung cancer. Critical Reviews in Oncology/Hematology, 2004, 51, 45-53.	2.0	18
649	Multimodality approaches for rectal cancer. Current Problems in Cancer, 2004, 28, 316-342.	1.0	1
650	Management of rectal cancer. Journal of Gastrointestinal Surgery, 2004, 8, 139-149.	0.9	17
651	Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine. Journal of Gastrointestinal Surgery, 2004, 8, 1072-1078.	0.9	41
652	Role of cell cycle in mediating sensitivity to radiotherapy. International Journal of Radiation Oncology Biology Physics, 2004, 59, 928-942.	0.4	870
653	The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: Feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1056-1065.	0.4	108
654	Familial pancreatic carcinoma in Jews. Familial Cancer, 2004, 3, 233-240.	0.9	35
655	SGK1, a potential regulator of c-fms related breast cancer aggressiveness. Clinical and Experimental Metastasis, 2004, 21, 477-483.	1.7	39
656	Immunoblot analysis of c-Met expression in human colorectal cancer: Overexpression is associated with advanced stage cancer. Clinical and Experimental Metastasis, 2004, 21, 409-417.	1.7	41
657	Involvement of metabotropic glutamate receptor�1, a G protein coupled receptor, in melanoma development. Journal of Molecular Medicine, 2004, 82, 735-749.	1.7	53
659	PET/CT and breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, S135-S142.	3.3	98

#	Article	IF	CITATIONS
660	Current role of bone scan with phosphonates in the follow-up of breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, S143-S148.	3.3	38
661	Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1614-1620.	3.3	215
662	Colorectal carcinoma: detection and staging with multislice CT (MSCT) colonography. Abdominal Imaging, 2004, 30, 13-19.	2.0	17
663	Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study. Cancer Chemotherapy and Pharmacology, 2004, 53, 439-444.	1.1	13
664	In vitro assessment of nucleoside analogs in multiple myeloma. Cancer Chemotherapy and Pharmacology, 2004, 54, 113-21.	1.1	11
665	Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemotherapy and Pharmacology, 2004, 54, 343-53.	1.1	89
666	Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemotherapy and Pharmacology, 2004, 54 Suppl 1, S4-11.	1.1	25
667	Treatment of T-cell non-hodgkin' lymphoma. Current Treatment Options in Oncology, 2004, 5, 289-303.	1.3	33
668	Hepatocellular carcinoma: Updates in primary prevention. Current Gastroenterology Reports, 2004, 6, 37-43.	1.1	7
669	Novel therapies for pancreatic adenocarcinoma. Current Gastroenterology Reports, 2004, 6, 119-125.	1.1	14
670	Novel therapies for pancreatic adenocarcinoma. Current Oncology Reports, 2004, 6, 199-206.	1.8	20
671	Heat shock-peptide complex vaccine as adjuvant therapy for high-risk patients with resected renal cell carcinoma. Current Urology Reports, 2004, 5, 11-12.	1.0	1
672	The role of lymphadenectomy in renal cell carcinoma. Current Urology Reports, 2004, 5, 25-29.	1.0	2
673	Radiofrequency ablation of renal tumors. Current Urology Reports, 2004, 5, 39-44.	1.0	6
674	Gastric adenocarcinoma. Current Treatment Options in Gastroenterology, 2004, 7, 149-157.	0.3	3
675	Geographic and Patient Variation in Receipt of Surveillance Procedures After Local Excision of Cutaneous Melanoma11Tables 4, 6, and appendix can be found at http://www.blackwellpublishing.com/products/journals/suppmat/jid/jid22238/jid22238sm.htm. Journal of Investigative Dermatology. 2004. 122. 246-255.	0.3	17
676	Differential expression of cell cycle regulatory molecules and evidence for a ?cyclin switch? during progression of prostate cancer. Prostate, 2004, 58, 335-344.	1.2	47
677	Treatment of epigallocatechin-3-gallate inhibits matrix metalloproteinases-2 and -9 via inhibition of activation of mitogen-activated protein kinases, c-jun and NF-?B in human prostate carcinoma DU-145 cells. Prostate, 2004, 59, 33-42.	1.2	101

#	Article	IF	CITATIONS
678	Apoptotic impact of ?1-blockers on prostate cancer growth: A myth or an inviting reality?. Prostate, 2004, 59, 91-100.	1.2	37
679	Development of prostate cancer treatment: The good news. Prostate, 2004, 58, 211-224.	1.2	74
680	Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate, 2004, 59, 234-242.	1.2	98
681	Imaging of bioluminescent LNCaP-luc-M6 Tumors: A new animal model for the study of metastatic human prostate cancer. Prostate, 2004, 59, 292-303.	1.2	66
682	Androgen receptor protein expression in prostatic tissues in black and caucasian men. Prostate, 2004, 59, 460-468.	1.2	23
683	Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate, 2004, 59, 311-318.	1.2	176
684	Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate, 2004, 60, 240-245.	1.2	166
685	The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate, 2004, 60, 332-337.	1.2	160
686	Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-?B. Prostate, 2004, 61, 105-113.	1.2	49
687	Restoration of fibroblast growth factor receptor2 suppresses growth and tumorigenicity of malignant human prostate carcinoma PC-3 cells. Prostate, 2004, 61, 236-242.	1.2	51
688	Vitamin D receptor gene polymorphisms and disease free survival after radical prostatectomy. Prostate, 2004, 61, 267-275.	1.2	28
689	Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate, 2004, 61, 332-353.	1.2	279
690	Effect of four-day psyllium supplementation on bowel preparation for colonoscopy:A prospective double blind randomized trial [ISRCTN76623768]. BMC Gastroenterology, 2004, 4, 2.	0.8	6
691	Current standards of surgery for pancreatic cancer. British Journal of Surgery, 2004, 91, 1410-1427.	0.1	282
692	Polymorphisms of GSTT1 and related genes in head and neck cancer risk. Head and Neck, 2004, 26, 63-70.	0.9	34
693	Gamma radiation-induced apoptosis, G2 delay, and the risk of salivary and thyroid carcinomas?a preliminary report. Head and Neck, 2004, 26, 612-618.	0.9	10
694	Is breast cancer survival improving?. Cancer, 2004, 100, 44-52.	2.0	469
695	Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma. Cancer, 2004, 100, 82-88.	2.0	12

#	Article	IF	Citations
696	Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine. Cancer, 2004, 100, 531-537.	2.0	59
697	Racial disparities in the use of and indications for colorectal procedures in Medicare beneficiaries. Cancer, 2004, 100, 418-424.	2.0	105
698	The natural history of incidentally detected small renal masses. Cancer, 2004, 100, 738-745.	2.0	481
699	Intestinal expression of mutant and wild-type progastrin significantly increases colon carcinogenesis in response to azoxymethane in transgenic mice. Cancer, 2004, 100, 1311-1323.	2.0	45
700	Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: Who benefits?. Cancer, 2004, 100, 1152-1161.	2.0	131
701	Risk perception and concern among brothers of men with prostate carcinoma. Cancer, 2004, 100, 1537-1544.	2.0	34
702	Radical retropubic prostatectomy in Hispanic patients. Cancer, 2004, 100, 1628-1632.	2.0	7
703	Racial differences in diagnosis, treatment, and clinical delays in a population-based study of patients with newly diagnosed breast carcinoma. Cancer, 2004, 100, 1595-1604.	2.0	183
704	Diagnostic strategies for unknown primary cancer. Cancer, 2004, 100, 1776-1785.	2.0	227
705	Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma. Cancer, 2004, 100, 1833-1842.	2.0	17
706	Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer, 2004, 100, 2139-2147.	2.0	88
707	The development of interval breast malignancies in patients withBRCA mutations. Cancer, 2004, 100, 2079-2083.	2.0	148
708	Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma. Cancer, 2004, 100, 2132-2138.	2.0	24
709	Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma. Cancer, 2004, 100, 2125-2131.	2.0	118
710	Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer, 2004, 100, 2376-2386.	2.0	89
711	Breast carcinoma in men. Cancer, 2004, 101, 51-57.	2.0	685
712	The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer, 2004, 101, 346-352.	2.0	165
713	Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma. Cancer, 2004, 101, 379-384.	2.0	61

#	Article	IF	CITATIONS
714	Human prostate cancer risk factors. Cancer, 2004, 101, 2371-2490.	2.0	500
715	Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer, 2004, 101, 1609-1615.	2.0	95
716	Young age and outcome for women with early-stage invasive breast carcinoma. Cancer, 2004, 101, 1264-1274.	2.0	87
717	Ductoscopic cytology and image analysis to detect breast carcinoma. Cancer, 2004, 101, 1283-1292.	2.0	16
718	Adjuvant postoperative radiotherapy for colon carcinoma. Cancer, 2004, 101, 1338-1344.	2.0	14
719	Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly. Cancer, 2004, 101, 1733-1744.	2.0	9
720	Uterine serous and grade 3 endometrioid carcinomas. Cancer, 2004, 101, 2214-2221.	2.0	106
721	Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma. Cancer, 2004, 101, 2557-2566.	2.0	28
722	Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer, 2004, 101, 2837-2842.	2.0	120
723	Extrapulmonary tuberculosis as a mimicker of neoplasia. Diagnostic Cytopathology, 2004, 30, 82-87.	0.5	8
724	Inhibition of prostate cancer metastatic colonization by ?4.2 Mb of human chromosome 12. International Journal of Cancer, 2004, 108, 15-22.	2.3	5
725	HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. International Journal of Cancer, 2004, 108, 540-548.	2.3	73
726	Combined90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft. International Journal of Cancer, 2004, 109, 618-626.	2.3	52
727	Expression mapping at 12p12-13 in advanced prostate carcinoma. International Journal of Cancer, 2004, 109, 668-672.	2.3	21
728	Alterations in tropomyosin isoform expression in human transitional cell carcinoma of the urinary bladder. International Journal of Cancer, 2004, 110, 368-373.	2.3	75
729	Cellular interactions in the tropism of prostate cancer to bone. International Journal of Cancer, 2004, 110, 497-503.	2.3	60
730	Mapping and analysis of HPV16 integration sites in a head and neck cancer cell line. International Journal of Cancer, 2004, 110, 701-709.	2.3	77
731	Gene transfer to cervical cancer with fiber-modified adenoviruses. International Journal of Cancer, 2004, 111, 698-704.	2.3	36

#	Article	IF	CITATIONS
732	Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. International Journal of Cancer, 2004, 112, 184-189.	2.3	47
733	Omega-3 fatty acids in colorectal cancer prevention. International Journal of Cancer, 2004, 112, 1-7.	2.3	60
734	Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy. International Journal of Cancer, 2004, 112, 14-25.	2.3	282
735	Treatment of aggressive thyroid cancer with an oncolytic herpes virus. International Journal of Cancer, 2004, 112, 525-532.	2.3	29
736	Dynamic process of prostate cancer metastasis to bone. Journal of Cellular Biochemistry, 2004, 91, 706-717.	1.2	91
737	Colon cancer specific nuclear matrix protein alterations in human colonic adenomatous polyps. Journal of Cellular Biochemistry, 2004, 91, 365-374.	1.2	14
738	Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. Journal of Cellular Biochemistry, 2004, 91, 232-242.	1.2	120
739	GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. Journal of Cellular Biochemistry, 2004, 91, 540-552.	1.2	195
740	Molecular basis for the antiandrogen withdrawal syndrome. Journal of Cellular Biochemistry, 2004, 91, 3-12.	1.2	85
741	Efficacy of sentinel lymph node biopsy in male breast cancer. Journal of Surgical Oncology, 2004, 86, 74-77.	0.8	61
743	Esophageal cancer: Outcomes of surgery, neoadjuvant chemotherapy, and three-dimension conformal radiotherapy. Journal of Surgical Oncology, 2004, 87, 68-74.	0.8	11
744	Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Medicinal Research Reviews, 2004, 24, 13-39.	5.0	140
745	The potentials of MS-based subproteomic approaches in medical science: The case of lysosomes and breast cancer. Mass Spectrometry Reviews, 2004, 23, 393-442.	2.8	19
746	Chromosome 17p13.2 transfer reverts transformation phenotypes and fas-mediated apoptosis in breast epithelial cells. Molecular Carcinogenesis, 2004, 39, 234-246.	1.3	1
747	Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. Journal of Gene Medicine, 2004, 6, 1343-1357.	1.4	31
748	Analysis of serial CT scans to assess template and catheter movement in prostate HDR brachytherapy. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1063-1071.	0.4	67
749	Phase l–Il trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer—interim report on PSA response and biopsy data. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1520-1529.	0.4	63
750	Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non–small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1258-1267.	0.4	249

# 751	ARTICLE Preliminary analysis of RTOG 9708: adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. International Journal of Radiation Oncology Biology Physics, 2004, 59, 168-173.	IF 0.4	CITATIONS
752	Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: extraprostatic seed placement correlates with migration. International Journal of Radiation Oncology Biology Physics, 2004, 59, 419-425.	0.4	325
753	Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1017-1021.	0.4	420
754	Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1107-1115.	0.4	18
755	Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. International Journal of Radiation Oncology Biology Physics, 2004, 59, 562-571.	0.4	38
756	Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2004, 59, 943-951.	0.4	172
757	Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 2004, 60, 24-29.	0.4	28
758	Genetic effects of radiotherapy for childhood cancer: Gonadal dose reconstruction. International Journal of Radiation Oncology Biology Physics, 2004, 60, 542-552.	0.4	91
759	Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: Mature results of phase II study. International Journal of Radiation Oncology Biology Physics, 2004, 60, 111-122.	0.4	27
760	Improved local control with higher doses of radiation in large-volume stage III non–small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2004, 60, 741-747.	0.4	146
761	Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: A patterns of care study. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1144-1153.	0.4	118
762	Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: A preliminary report. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1410-1418.	0.4	90
763	Intrahepatic cholangiocarcinoma masked as fever of unknown origin. Journal of Gastrointestinal Surgery, 2004, 8, 217-219.	0.9	3
764	Treatment outcomes associated with surgery for gallbladder cancer: a 20-year experience. Journal of Gastrointestinal Surgery, 2004, 8, 183-190.	0.9	103
765	Overview: epidemiology, indications, goals, extent, and nature of work-up. Journal of Gastrointestinal Surgery, 2004, 8, 259-261.	0.9	6
766	Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. Journal of Gastrointestinal Surgery, 2004, 8, 448-453.	0.9	81
767	Molecular biology of squamous cell carcinoma of the anus: a comparison of HIV-positive and HIV-negative patients. Journal of Gastrointestinal Surgery, 2004, 8, 1024-1031.	0.9	29
768	C-kit receptor expression in acute leukemias—association with patient and disease characteristics and with outcome. Leukemia Research, 2004, 28, 373-378.	0.4	21

#	Article	IF	CITATIONS
769	The role of targeted therapy in non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2004, 51, 29-44.	2.0	21
770	Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations. Current Problems in Cancer, 2004, 28, 7-40.	1.0	17
771	A comparison of the precision of seeds deposited as loose seeds versus suture embedded seeds: a randomized trial. Brachytherapy, 2004, 3, 7-9.	0.2	35
772	Application of IL-2 and other cytokines in renal cancer. Expert Opinion on Biological Therapy, 2004, 4, 455-468.	1.4	81
773	Bortezomib (Velcade). A New Therapy for Multiple Myeloma. Clinical Research and Regulatory Affairs, 2004, 21, 29-38.	2.1	0
774	CommentaryDNA Base Excision Repair Defects in Human Pathologies. Free Radical Research, 2004, 38, 1037-1054.	1.5	30
775	Antisense approaches in prostate cancer. Expert Opinion on Biological Therapy, 2004, 4, 927-936.	1.4	23
776	Proteasome inhibition in hematologic malignancies. Annals of Medicine, 2004, 36, 304-314.	1.5	59
777	Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer. Cancer Research, 2004, 64, 1975-1986.	0.4	467
778	LACK OF EFFECTS OF POSTNATAL EXPOSURE TO A MIXTURE OF ARYL HYDROCARBON-RECEPTOR AGONISTS ON THE DEVELOPMENT OF METHYLNITROSOUREA-INDUCED MAMMARY TUMORS IN SPRAGUE-DAWLEY RATS. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2004, 67, 1457-1475.	1.1	8
779	Ovarian tissue banking for cancer patients: Fertility preservation, not just ovarian cryopreservation. Human Reproduction, 2004, 19, 477-480.	0.4	90
780	Quality of Life at the End of Primary Treatment of Breast Cancer: First Results From the Moving Beyond Cancer Randomized Trial. Journal of the National Cancer Institute, 2004, 96, 376-387.	3.0	429
781	Expression of Mesenchyme-Specific Gene HMGA2 in Squamous Cell Carcinomas of the Oral Cavity. Cancer Research, 2004, 64, 2024-2029.	0.4	174
782	Creating Optimal Healing Environments for Patients with Cancer and Their Families: Insights, Challenges, and Lessons Learned from a Decade of Experience. Journal of Alternative and Complementary Medicine, 2004, 10, S-93-S-102.	2.1	5
783	Identification of 5-(Deoxyguanosin-N2-yl)- 1,2-dihydroxy-1,2-dihydro-6-aminochrysene as the Major DNA Lesion in the Mammary Gland of Rats Treated with the Environmental Pollutant 6-Nitrochrysene. Chemical Research in Toxicology, 2004, 17, 1591-1599.	1.7	22
784	Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor. Journal of Clinical Oncology, 2004, 22, 1201-1208.	0.8	1,663
785	From the Archives of the AFIP. Radiographics, 2004, 24, 225-246.	1.4	119
786	Chemoprevention of lung cancer—from biology to clinical reality. Annals of Oncology, 2004, 15, 185-196.	0.6	38

#	Article	IF	CITATIONS
787	Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Human Molecular Genetics, 2004, 13, 1303-1313.	1.4	171
788	USE OF PROSTATE SPECIFIC ANTIGEN TO MEASURE BLADDER TUMOR GROWTH IN A MOUSE ORTHOTOPIC MODEL. Journal of Urology, 2004, 172, 2414-2420.	0.2	10
789	THE CONTEMPORARY MANAGEMENT OF PROSTATE CANCER IN THE UNITED STATES: LESSONS FROM THE CANCER OF THE PROSTATE STRATEGIC UROLOGIC RESEARCH ENDEAVOR (CAPSURE), A NATIONAL DISEASE REGISTRY. Journal of Urology, 2004, 171, 1393-1401.	0.2	315
790	Screening and surveillance in Barrett's esophagus: A call to action. Clinical Gastroenterology and Hepatology, 2004, 2, 861-864.	2.4	17
791	Quality-of-life trials in lung cancer: past achievements and future challenges. Hematology/Oncology Clinics of North America, 2004, 18, 161-186.	0.9	7
792	A COMPARISON OF EXTENDED BIOPSY AND SEXTANT BIOPSY SCHEMES FOR PREDICTING THE PATHOLOGICAL STAGE OF PROSTATE CANCER. Journal of Urology, 2004, 171, 2203-2208.	0.2	31
793	Redifferentiation therapy for thyroid cancer. Surgical Clinics of North America, 2004, 84, 921-943.	0.5	23
794	Imaging to optimally stage lung cancer: Conventional modalities and PET/CT. Journal of the American College of Radiology, 2004, 1, 957-964.	0.9	11
795	Quality of life after lung cancer resection. Thoracic Surgery Clinics, 2004, 14, 353-365.	0.4	32
796	The role of extended resection in pancreatic adenocarcinoma: Is there good evidence-based justification?. Pancreatology, 2004, 4, 561-566.	0.5	23
797	ORTHOTOPIC BLADDER SUBSTITUTION IN WOMEN: NONTRADITIONAL APPLICATIONS. Journal of Urology, 2004, 171, 1585-1588.	0.2	42
798	Resection for lung cancer in the elderly patient. Thoracic Surgery Clinics, 2004, 14, 163-171.	0.4	21
799	Prognostic Significance of Tumor Thrombus Level in Patients With Renal Cell Carcinoma and Venous Tumor Thrombus Extension. Is All T3b the Same?. Journal of Urology, 2004, 171, 598-601.	0.2	201
800	El uso de filtros solares no aumenta el riesgo de presentar un melanoma, según una revisión cualitativa de la bibliografÃa. FMC Formacion Medica Continuada En Atencion Primaria, 2004, 11, 359.	0.0	0
801	Altered Gene Expression Profile in Mouse Bladder Cancers Induced by Hydroxybutyl(butyl)nitrosamine. Neoplasia, 2004, 6, 569-577.	2.3	29
802	Gene Expression Alterations in Prostate Cancer Predicting Tumor Aggression and Preceding Development of Malignancy. Journal of Clinical Oncology, 2004, 22, 2790-2799.	0.8	674
803	Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proceedings of the United States of America, 2004, 101, 811-816.	3.3	1,175
804	Surveillance Strategies after Curative Treatment of Colorectal Cancer. New England Journal of Medicine, 2004, 350, 2375-2382.	13.9	139

#	Article	IF	CITATIONS
805	Detection of Prostate Cancer Using Serum Proteomics Pattern in a Histologically Confirmed Population. Journal of Urology, 2004, 171, 1782-1787.	0.2	65
806	Adjuvant therapy for pancreatic cancer: current status and future directions. Surgical Oncology Clinics of North America, 2004, 13, 737-749.	0.6	2
808	Gene Expression Profiling of Microdissected Pancreatic Ductal Carcinomas Using High-Density DNA Microarrays. Neoplasia, 2004, 6, 611-622.	2.3	183
809	MR evaluation of solid renal masses. Magnetic Resonance Imaging Clinics of North America, 2004, 12, 413-427.	0.6	17
810	Angiogenesis in colorectal cancer: therapeutic implications and future directions. Hematology/Oncology Clinics of North America, 2004, 18, 1087-1119.	0.9	5
811	Interleukin-12 Immunotherapy of Murine Transitional Cell Carcinoma of the Bladder: Dose Dependent Tumor Eradication and Generation of Protective Immunity. Journal of Urology, 2004, 171, 1330-1335.	0.2	46
812	Assessment methodologies and statistical issues for computer-aided diagnosis of lung nodules in computed tomography. Academic Radiology, 2004, 11, 462-475.	1.3	76
813	Prostate Stem Cell Antigen Expression is Associated With Gleason Score, Seminal Vesicle Invasion and Capsular Invasion in Prostate Cancer. Journal of Urology, 2004, 171, 1117-1121.	0.2	110
814	High-Resolution Genomic and Expression Profiling Reveals 105 Putative Amplification Target Genes in Pancreatic Cancer. Neoplasia, 2004, 6, 432-439.	2.3	104
815	Basic treatment considerations: chemotherapy. Hematology/Oncology Clinics of North America, 2004, 18, 13-28.	0.9	3
816	Overview of smoking and all cancers. Medical Clinics of North America, 2004, 88, 1655-1675.	1.1	38
817	Inositol Hexaphosphate Inhibits Growth and Induces G1 Arrest and Apoptotic Death of Androgen-Dependent Human Prostate Carcinoma LNCaP Cells. Neoplasia, 2004, 6, 646-659.	2.3	59
818	Detection and Isolation of Circulating Tumor Cells in Urologic Cancers: A Review. Neoplasia, 2004, 6, 302-309.	2.3	53
819	CONTROVERSIES IN PROSTATE CANCER SCREENING. Journal of Urology, 2004, 172, 1822-1824.	0.2	34
820	The evolving role of postoperative adjuvant radiation therapy for pancreatic cancer. Surgical Oncology Clinics of North America, 2004, 13, 589-604.	0.6	2
821	SYSTEMATIC IN VITRO EVALUATION OF SURVIVIN DIRECTED ANTISENSE OLIGODEOXYNUCLEOTIDES IN BLADDER CANCER CELLS. Journal of Urology, 2004, 171, 2471-2476.	0.2	47
822	Prostate Cancer Chemoprevention: An Overview of United States Trials. Journal of Urology, 2004, 171, S5-8; discussion S9.	0.2	18
823	Thyroglobulin: a specific serum marker for the management of thyroid carcinoma. Clinics in Laboratory Medicine, 2004, 24, 29-47.	0.7	59

#	Article	IF	CITATIONS
824	The wizards of odds: Cost-effectiveness, Barrett's screening, and surveillance guidelines. Clinical Gastroenterology and Hepatology, 2004, 2, 865-867.	2.4	3
825	RACIAL DIFFERENCES IN PROSTATE ANDROGEN LEVELS IN MEN WITH CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 2004, 171, 2277-2280.	0.2	49
826	Colorectal neoplasia screening with virtual colonoscopy: when, at what cost, and with what national impact?. Clinical Gastroenterology and Hepatology, 2004, 2, 554-563.	2.4	106
827	EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS PREDICTS BONE METASTASIS IN PATIENTS PRESENTING WITH RENAL CELL CARCINOMA: IMPLICATION FOR PREOPERATIVE BONE SCANS. Journal of Urology, 2004, 172, 867-870.	0.2	58
828	The potential role of cyclooxygenase-2 inhibitors and $5\hat{l}_{\pm}$ -reductase inhibitors in the prevention of urologic conditions. Urologic Clinics of North America, 2004, 31, 213-218.	0.8	2
829	Palliative surgery of soft tissue sarcoma. Surgical Oncology Clinics of North America, 2004, 13, 531-541.	0.6	7
830	The etiology and epidemiology of anal cancer. Surgical Oncology Clinics of North America, 2004, 13, 263-275.	0.6	101
831	Screening for prostate cancer: current recommendations. Urologic Clinics of North America, 2004, 31, 219-226.	0.8	31
833	Hilar cholangiocarcinoma: surgical and endoscopic approaches. Surgical Clinics of North America, 2004, 84, 525-542.	0.5	14
834	Palliation of malignant extrahepatic biliary obstruction with plastic versus expandable metal stents: an evidence-based approach. Clinical Gastroenterology and Hepatology, 2004, 2, 273-285.	2.4	152
835	Four-dimensional elastic light-scattering fingerprints as preneoplastic markers in the rat model of colon carcinogenesisâ~†. Gastroenterology, 2004, 126, 1071-1081.	0.6	113
836	Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology, 2004, 126, 1270-1279.	0.6	142
837	Rectal bleeding and diminutive colon polyps. Gastroenterology, 2004, 126, 1167-1174.	0.6	22
838	The incidence of colorectal cancer following a negative screening sigmoidoscopy: Implications for screening interval. Gastroenterology, 2004, 127, 714-722.	0.6	59
839	Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology, 2004, 127, 1044-1050.	0.6	326
840	Colorectal cancer vaccines: Principles, results, and perspectives. Gastroenterology, 2004, 127, 1821-1837.	0.6	31
841	MR imaging of the bladder. Magnetic Resonance Imaging Clinics of North America, 2004, 12, 545-555.	0.6	35
842	GUIDELINES FOR THE SURVEILLANCE OF LOCALIZED RENAL CELL CARCINOMA BASED ON THE PATTERNS OF RELAPSE AFTER NEPHRECTOMY. Journal of Urology, 2004, 172, 58-62.	0.2	181

#	Article	IF	Citations
843	THE ECONOMIC BURDEN OF METASTATIC AND PROSTATE SPECIFIC ANTIGEN PROGRESSION IN PATIENTS WITH PROSTATE CANCER: FINDINGS FROM A RETROSPECTIVE ANALYSIS OF HEALTH PLAN DATA. Journal of Urology, 2004, 171, 2250-2254.	0.2	29
844	Radical retropubic prostatectomy frustrated by prior laparoscopic mesh herniorrhaphy. Surgery, 2004, 135, 452-453.	1.0	38
845	Prostate cancer in the ageing male. The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender, 2004, 1, 47-54.	0.3	10
846	What is early lung cancer?. Lung Cancer, 2004, 45, 267-277.	0.9	31
847	A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer. Lung Cancer, 2004, 45, 243-253.	0.9	14
848	High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer, 2004, 46, 333-340.	0.9	116
849	Using molecular markers in sputum for the early detection of lung cancer: A review. Lung Cancer, 2004, 45, S21-S27.	0.9	31
850	Early Versus Delayed Hormonal Therapy for Prostate Specific Antigen Only Recurrence of Prostate Cancer After Radical Prostatectomy. Journal of Urology, 2004, 171, 1141-1147.	0.2	226
851	Ovarian Neoplasms in Patients with Colorectal Cancer: Understanding the Role of Prophylactic Oophorectomy. Clinical Colorectal Cancer, 2004, 3, 215-222.	1.0	40
852	Oxaliplatin plus Oral Fluoropyrimidines in Colorectal Cancer. Clinical Colorectal Cancer, 2004, 4, S37-S42.	1.0	14
853	Does Finasteride Alter the Pathology of the Prostate and Cancer Grading?. Clinical Prostate Cancer, 2004, 2, 228-235.	2.1	73
854	An Unsupervised Approach to Identify Molecular Phenotypic Components Influencing Breast Cancer Features. Cancer Research, 2004, 64, 1584-1588.	0.4	21
855	Do benefits and barriers differ by stage of adoption for colorectal cancer screening?. Health Education Research, 2004, 20, 137-148.	1.0	74
856	Controversies in the Multimodality Management of Locally Advanced Esophageal Cancer: Evidence-Based Review of Surgery Alone and Combined-Modality Therapy. Annals of Surgical Oncology, 2004, 11, 665-673.	0.7	50
857	Early-Stage Gastric Cancer: A Highly Treatable Disease. Annals of Surgical Oncology, 2004, 11, 127-129.	0.7	80
858	RESTRUCTURING DYNAMICS OF DU 145 AND LNCaP PROSTATE CANCER SPHEROIDS. In Vitro Cellular and Developmental Biology - Animal, 2004, 40, 262.	0.7	12
859	Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer. Reproductive Biology and Endocrinology, 2004, 2, 2.	1.4	119
860	Melanoma Vaccines. American Journal of Cancer, 2004, 3, 377-386.	0.4	0

#	Article	IF	CITATIONS
862	Adjuvant Therapy for Rectal Cancer in the Elderly. Drugs and Aging, 2004, 21, 437-451.	1.3	14
863	What can proteomic analyses contribute to understanding the molecular biology and clinical behavior of prostate cancer?. Expert Review of Proteomics, 2004, 1, 485-492.	1.3	1
864	FINDING PROSTATE CANCER SUSCEPTIBILITY GENES. Annual Review of Genomics and Human Genetics, 2004, 5, 151-175.	2.5	36
865	Return to work after thoracic surgery: an overlooked outcome measure in quality-of-life studies. Thoracic Surgery Clinics, 2004, 14, 409-416.	0.4	8
866	Surgical palliation of thoracic malignancies. Surgical Oncology Clinics of North America, 2004, 13, 429-453.	0.6	7
867	Classification of Proliferative Pulmonary Lesions of the Mouse. Cancer Research, 2004, 64, 2307-2316.	0.4	313
869	IMPACT OF BODY MASS INDEX ON RADICAL CYSTECTOMY. Journal of Urology, 2004, 172, 1281-1285.	0.2	152
870	Overview of anal cancer for the surgeon. Surgical Oncology Clinics of North America, 2004, 13, 249-262.	0.6	15
871	A Cost-Effectiveness Comparison of Three Tailored Interventions to Increase Mammography Screening. Journal of Women's Health, 2004, 13, 909-918.	1.5	61
872	Design of a novel MRI compatible manipulator for image guided prostate intervention. , 2004, , .		24
873	A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. New England Journal of Medicine, 2004, 350, 1200-1210.	13.9	2,442
874	Aging and innate immune cells. Journal of Leukocyte Biology, 2004, 76, 291-299.	1.5	315
875	Gender and lung cancer. Clinics in Chest Medicine, 2004, 25, 391-400.	0.8	57
876	Molecular Epidemiology of Androgen-Metabolic Loci in Prostate Cancer: Predisposition and Progression. Journal of Urology, 2004, 171, S25-8; discussion S28-9.	0.2	17
877	RACIAL/ETHNIC DISPARITIES IN THE TREATMENT OF LOCALIZED/REGIONAL PROSTATE CANCER. Journal of Urology, 2004, 171, 1504-1507.	0.2	140
878	Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis. Hematology/Oncology Clinics of North America, 2004, 18, 1143-1159.	0.9	9
879	Expression of the Platelet-Derived Growth Factor Receptor in Prostate Cancer and Treatment Implications with Tyrosine Kinase Inhibitors. Neoplasia, 2004, 6, 503-512.	2.3	49
880	Current melanoma staging. Clinics in Dermatology, 2004, 22, 223-227.	0.8	14

ARTICLE IF CITATIONS Gastric carcinoma. Disease-a-Month, 2004, 50, 532-539. 881 0.4 0 Inherited pancreatic cancer: improvements in our understanding of genetics and screening. International Journal of Biochemistry and Cell Biology, 2004, 36, 1386-1392. 1.2 Effect of linoleic acid on proliferation and gene expression in the breast cancer cell line T47D. Cancer 883 3.2 47 Letters, 2004, 209, 25-35. Reduced expression of liver–intestine cadherin is associated with progression and lymph node 884 49 metastasis of human colorectal carcinoma. Cancer Letters, 2004, 212, 253-259. No evidence for germline mutations of the LKB1/STK11 gene in familial pancreatic carcinoma. Cancer 885 3.2 22 Letters, 2004, 214, 63-68. 886 Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resistance Updates, 2004, 7, 169-184. 6.5 89 887 Spontaneous and genetically engineered animal models. European Journal of Cancer, 2004, 40, 858-880. 1.3 202 Monoclonal antibodies in the treatment of colorectal cancer. European Journal of Cancer, 2004, 40, 888 1.3 74 1292-1301. The clinical significance of axillary lymph node micrometastases in breast cancer. European Journal 889 0.5 44 of Surgical Oncology, 2004, 30, 807-816. Chromosome 13q12 encoded Rho GTPase activating protein suppresses growth of breast carcinoma cells, and yeast two-hybrid screen shows its interaction with several proteins. Biochemical and 1.0 Biophysical Research Communications, 2004, 313, 654-665. Pancreatic cancer stimulates pancreatic stellate cell proliferation and TIMP-1 production through 891 1.0 45 the MAP kinase pathway. Biochemical and Biophysical Research Communications, 2004, 323, 1241-1245. Attitudes and intentions in relation to skin checks for early signs of skin cancer. Preventive Medicine, 1.6 2004, 39, 11-18. Processes of care in cervical and breast cancer screening and follow-upâ€"the importance of 893 1.6 74 communication. Preventive Medicine, 2004, 39, 81-90. Autoschizis: a new form of cell death for human ovarian carcinoma cells following ascorbate:menadione treatment. Tissue and Cell, 2004, 36, 197-209. 894 1.0 Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical 895 0.6 46 trials. Protein Expression and Purification, 2004, 33, 123-133. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nuclear Medicine and 896 208 Biology, 2004, 31, 179-189. Fusaric acid: A novel agent and mechanism to treat HNSCC. Otolaryngology - Head and Neck Surgery, 897 1.1 25 2004, 131, 54-60. Functional significance of gastrin gene expression in human cancer cells. Regulatory Peptides, 2004, 898 117, 167-173.

#	Article	IF	CITATIONS
899	Race, education, and knowledge of bone marrow registry: Indicators of willingness to donate bone marrow among African Americans and Caucasians. Transplantation Proceedings, 2004, 36, 3212-3219.	0.3	23
900	Natural history and clinical outcome of sporadic renal cortical tumors diagnosed in the young adult. Urology, 2004, 63, 41-45.	0.5	36
901	Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. Urology, 2004, 63, 414-418.	0.5	59
902	Association between Agent Orange and prostate cancer: a pilot case-control study. Urology, 2004, 63, 757-760.	0.5	35
903	Selenium levels of patients with newly diagnosed prostate cancer compared with control group. Urology, 2004, 63, 912-916.	0.5	31
904	Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology, 2004, 63, 940-945.	0.5	326
905	Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology, 2004, 64, 383-388.	0.5	165
906	Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. Urology, 2004, 64, 488-493.	0.5	45
907	Urethral recurrence after cystoprostatectomy: Implications for urinary diversion and monitoring. Urology, 2004, 64, 950-954.	0.5	79
908	Radiotherapy for a rising PSA following radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 57-61.	0.8	5
909	The role of retroperitoneal lymph node dissection in the management of testicular cancer. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 225-233.	0.8	70
910	Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance. American Journal of Pathology, 2004, 164, 217-227.	1.9	514
911	Differential Gene Expression in Ovarian Carcinoma. American Journal of Pathology, 2004, 165, 397-414.	1.9	224
912	Biological Significance of Focal Adhesion Kinase in Ovarian Cancer. American Journal of Pathology, 2004, 165, 1087-1095.	1.9	232
913	Hypermethylation of Growth Arrest DNA Damage-Inducible Gene 45 β Promoter in Human Hepatocellular Carcinoma. American Journal of Pathology, 2004, 165, 1689-1699.	1.9	71
914	Expression of Myopodin Induces Suppression of Tumor Growth and Metastasis. American Journal of Pathology, 2004, 164, 1799-1806.	1.9	61
915	Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. Journal of the American Academy of Dermatology, 2004, 51, 399-405.	0.6	71
916	Improved imaging and the clinician: the role of positron emission tomography in the management of colorectal cancer. Molecular Imaging and Biology, 2004, 6, 208-213.	1.3	11

#	Article	IF	CITATIONS
917	Lung nodules and beyond: approaches, challenges and opportunities in thoracic CAD. International Congress Series, 2004, 1268, 896-901.	0.2	7
918	Cytotoxic activities of Coriolus versicolor (Yunzhi) extract on human leukemia and lymphoma cells by induction of apoptosis. Life Sciences, 2004, 75, 797-808.	2.0	132
919	Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. Journal of Steroid Biochemistry and Molecular Biology, 2004, 89-90, 533-537.	1.2	90
920	The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. Journal of Steroid Biochemistry and Molecular Biology, 2004, 92, 237-253.	1.2	151
921	Major impact of hormonal therapy in localized prostate cancer—death can already be an exception. Journal of Steroid Biochemistry and Molecular Biology, 2004, 92, 327-344.	1.2	18
922	Noninvasive staging of esophageal carcinoma. Journal of Surgical Research, 2004, 117, 127-133.	0.8	22
923	Current status of multimodality therapy for esophageal carcinoma. Journal of Surgical Research, 2004, 117, 22-29.	0.8	4
924	Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. Journal of Hepatology, 2004, 40, 472-477.	1.8	641
925	Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. Journal of Hand Surgery, 2004, 29, 654-660.	0.7	35
926	Patient adherence to skin self-examination. American Journal of Preventive Medicine, 2004, 26, 152-155.	1.6	69
927	Total laryngectomy and postoperative radiotherapy for T4 laryngeal cancer: a 14-year review. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2004, 25, 88-93.	0.6	33
928	Mastectomy and concomitant sentinel lymph node biopsy for invasive breast cancer. American Journal of Surgery, 2004, 187, 673-678.	0.9	9
929	Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast. American Journal of Surgery, 2004, 188, 371-376.	0.9	55
930	Gender differences in non–small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Annals of Thoracic Surgery, 2004, 78, 209-215.	0.7	226
931	Evolution of surgical outcomes for nonsmall cell lung cancer: time trends in 1,465 consecutive patients undergoing complete resection. Annals of Thoracic Surgery, 2004, 77, 1926-1930.	0.7	66
932	Arterial Invasion Predicts Early Mortality in Stage I Non–Small Cell Lung Cancer. Annals of Thoracic Surgery, 2004, 78, 1748-1753.	0.7	40
933	Repeat FDG-PET After Neoadjuvant Therapy is a Predictor of Pathologic Response in Patients With Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2004, 78, 1903-1909.	0.7	170
934	Differentiation of Human Prostate Cancer PC-3 Cells Induced by Inhibitors of Inosine 5′-Monophosphate Dehydrogenase. Cancer Research, 2004, 64, 9049-9056.	0.4	45

#	Article	IF	CITATIONS
935	Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 20-24.	0.8	26
936	Microarray analysis of differential gene expression in androgen independent prostate cancer using a metastatic human prostate cancer cell line model. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 313-320.	0.8	7
937	PROSTATE CANCER DETECTION ON URINALYSIS FOR $\hat{I}\pm$ METHYLACYL COENZYME A RACEMASE PROTEIN. Journal of Urology, 2004, 172, 1501-1503.	0.2	97
938	Medical Castration With LHRH Agonists: 25 Years Later With Major Benefits Achieved on Survival in Prostate Cancer. Journal of Andrology, 2004, 25, 305-313.	2.0	26
939	Novel therapies for chronic lymphocytic leukemia. Blood Reviews, 2004, 18, 137-148.	2.8	29
940	Recent developments in diagnosis of pancreatic cancer. BMJ: British Medical Journal, 2004, 329, 668-673.	2.4	76
941	Lymphoma: Present and future challenges. Seminars in Hematology, 2004, 41, 26-31.	1.8	13
942	Growth factor receptors as targets for lung cancer therapy. Seminars in Thoracic and Cardiovascular Surgery, 2004, 16, 3-12.	0.4	17
943	Modulation of antiapoptotic cell signaling pathways in non-small cell lung cancer: the role of NF-κB. Seminars in Thoracic and Cardiovascular Surgery, 2004, 16, 28-39.	0.4	58
944	Angiogenesis in non-small cell lung cancer. Seminars in Thoracic and Cardiovascular Surgery, 2004, 16, 13-18.	0.4	29
945	Clinical and sociodemographic factors associated with colon surveillance among patients with a history of colorectal cancer. Gastrointestinal Endoscopy, 2004, 59, 239-247.	0.5	28
946	To the Editor. Radiotherapy and Oncology, 2004, 70, 207-208.	0.3	2
947	Preventing Bone Complications in Patients with Prostate Cancer: The Emerging Role of Zoledronic Acid. European Urology Supplements, 2004, 3, 25-33.	0.1	6
948	Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet, The, 2004, 363, 594-599.	6.3	406
949	Pancreatic cancer. Lancet, The, 2004, 363, 1049-1057.	6.3	1,761
950	Thalidomide. Lancet, The, 2004, 363, 1802-1811.	6.3	535
951	Surgical Management of Early-Stage Pancreatic Cancer. Cancer Control, 2004, 11, 23-31.	0.7	31
952	OCCUPATIONAL RISK FACTORS FOR SELECTED CANCERS. American Journal of Public Health, 2004, 94, 1078-1078.	1.5	4

#	Article	IF	CITATIONS
953	Activation and Role of MAP Kinases in 15d-PGJ2–Induced Apoptosis in the Human Pancreatic Cancer Cell Line MIA PaCa-2. Pancreas, 2004, 28, 153-159.	0.5	32
954	Social and Cultural Barriers to Papanicolaou Test Screening in an Urban Population. Obstetrics and Gynecology, 2004, 104, 1355-1361.	1.2	111
955	Performance evaluation of an information-theoretic CAD scheme for the detection of mammographic architectural distortion. , 2004, , .		8
956	The Emerging Role of Bisphosphonates in Prostate Cancer. American Journal of Therapeutics, 2004, 11, 60-73.	0.5	4
958	Inflammatory Mechanisms Contributing to Pancreatic Cancer Development. Annals of Surgery, 2004, 239, 763-771.	2.1	144
959	FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma. Cancer Research, 2004, 64, 1911-1914.	0.4	201
960	HOMEDES AND UGALDE RESPOND. American Journal of Public Health, 2004, 94, 1077-a-1078.	1.5	0
962	An Illustrated Consensus on the Classification of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary Mucinous Neoplasms. American Journal of Surgical Pathology, 2004, 28, 977-987.	2.1	964
963	Phase II Trial of Estramustine and Etoposide in Androgen-Sensitive Metastatic Prostate Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 550-554.	0.6	11
964	Screening for Lung Cancer: Current Status and Future Directions. Chest, 2004, 125, 158S-162S.	0.4	46
965	The Impact of Smoking Status on the Behavior and Survival Outcome of Patients With Advanced Non-small Cell Lung Cancer. Chest, 2004, 126, 1750-1756.	0.4	127
966	Screening for lung cancer. Current Opinion in Oncology, 2004, 16, 141-145.	1.1	5
967	Dimensions of Neutropenia in Adult Cancer Patients. Cancer Nursing, 2004, 27, 275-284.	0.7	10
968	Vulvar Melanoma: Review of Diagnosis, Staging, and Therapy. Journal of Lower Genital Tract Disease, 2004, 8, 58-69.	0.9	24
969	Improved Survival in Never-Smokers vs Current Smokers With Primary Adenocarcinoma of the Lung. Chest, 2004, 126, 347-351.	0.4	210
970	ZYC101a for Treatment of High-Grade Cervical Intraepithelial Neoplasia. Obstetrics and Gynecology, 2004, 103, 317-326.	1.2	180
971	Update on screening and early detection of prostate cancer. Current Opinion in Urology, 2004, 14, 151-156.	0.9	7
972	Update on hormone-refractory prostate cancer. Current Opinion in Urology, 2004, 14, 185-193.	0.9	31

#	Article	IF	CITATIONS
973	Morpheaform Basal Cell Carcinoma in African Americans. Dermatologic Surgery, 2004, 30, 1550-1552.	0.4	6
974	Novel Systemic Therapy Options for Hepatocellular Carcinoma. Cancer Journal (Sudbury, Mass ), 2004, 10, 97-103.	1.0	22
975	Terminally Modified Oligodeoxynucleotides Directed Against p53 in an Orthotopic Xenograft Model: A Novel Adjuvant Treatment Strategy for Pancreatic Ductal Carcinoma. Pancreas, 2004, 28, 1-12.	0.5	17
976	A small randomized phase III single-center trial on postoperative UFT administration in patients with completely resected non-small cell lung cancer. Anti-Cancer Drugs, 2004, 15, 29-33.	0.7	8
977	A Pilot Study of Antiangiogenic Therapy with Bevacizumab and Thalidomide in Patients with Metastatic Renal Cell Carcinoma. Journal of Immunotherapy, 2004, 27, 259-264.	1.2	42
978	Pancreatic Intraepithelial Neoplasia. Pancreas, 2004, 28, 257-262.	0.5	73
979	Ductoscopic Cytology to Detect Breast Cancer. Cancer Journal (Sudbury, Mass ), 2004, 10, 33-41.	1.0	43
980	Current Role of Hepatic Artery Infusion and Isolated Liver Perfusion for the Treatment of Colorectal Cancer Liver Metastases. Cancer Journal (Sudbury, Mass ), 2004, 10, 128-138.	1.0	15
981	A Clinician??s Guide to Hereditary Colon Cancer. Cancer Journal (Sudbury, Mass ), 2004, 10, 280-287.	1.0	11
982	Apoptosis-Inducing Effect of Chemotherapeutic Agents Is Potentiated by Soy Isoflavone Genistein, a Natural Inhibitor of NF-??B in BxPC-3 Pancreatic Cancer Cell Line. Pancreas, 2004, 28, e90-e95.	0.5	111
983	Cytoreductive Surgery for Ovarian Cancer. Postgraduate Obstetrics & Gynecology, 2004, 24, 1-6.	0.1	1
984	Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anti-Cancer Drugs, 2004, 15, 203-209.	0.7	53
985	Intracavitary Placement of Autologous Lymphokine-Activated Killer (LAK) Cells after Resection of Recurrent Glioblastoma. Journal of Immunotherapy, 2004, 27, 398-404.	1.2	112
986	Clinicopathologic Analysis of Early-stage Sporadic Ovarian Carcinoma. American Journal of Surgical Pathology, 2004, 28, 147-159.	2.1	77
987	Evaluation of Local Recurrence and Second Malignancy in Patients with T1 and T2 Squamous Cell Carcinoma of the Larynx. Cancer Journal (Sudbury, Mass ), 2004, 10, 61-66.	1.0	27
988	Advances in the Surgical Management of Liver Malignancies. Cancer Journal (Sudbury, Mass ), 2004, 10, 74-87.	1.0	19
989	PET and Brain Tumor Image Fusion. Cancer Journal (Sudbury, Mass ), 2004, 10, 234-242.	1.0	45
990	Systemic or Regional Chemotherapy for Liver Metastases from Colorectal Cancer. Cancer Journal (Sudbury, Mass ), 2004, 10, 271-279.	1.0	3

# 991	ARTICLE Primary Squamous Carcinoma of the Uterine Cervix. Postgraduate Obstetrics & Gynecology, 2004, 24,	IF 0.1	CITATIONS
992	1-5. First-Line Chemotherapy for the Treatment of Epithelial Ovarian Cancer. Postgraduate Obstetrics & Gynecology, 2004, 24, 1-5.	0.1	0
993	Documenting Dermatology Practice. Dermatologic Surgery, 2004, 30, 1208-1209.	0.4	8
994	Vaccine Therapy for a Patient with Androgen-Insensitive Prostate Cancer without Evidence of Measurable Disease on Scans. American Journal of Therapeutics, 2004, 11, 238-241.	0.5	2
995	Cervical Cancer Screening: Will Human Papillomavirus Testing Replace Cytology?. Journal of Lower Genital Tract Disease, 2004, 8, 6-9.	0.9	2
996	Immunohistochemical Localization of Survivin in Serous Tumors of the Ovary. Applied Immunohistochemistry and Molecular Morphology, 2004, 12, 40-43.	0.6	10
997	Nephroblastoma Arising in a Germ Cell Tumor of Testicular Origin. American Journal of Surgical Pathology, 2004, 28, 687-692.	2.1	57
998	Prostate Carcinoma With Squamous Differentiation. American Journal of Surgical Pathology, 2004, 28, 651-657.	2.1	93
999	Bladder cancer. Current Opinion in Oncology, 2004, 16, 257-262.	1.1	14
1000	Hereditary Pancreatitis as the Premalignant Disease. Pancreas, 2004, 28, 305-310.	0.5	28
1001	Surgical Resection for Lung Cancer in the Octogenarian. Chest, 2004, 126, 733-738.	0.4	120
1002	Barriers to colorectal cancer screening in a low income, urban population: a descriptive study. Health Education, 2004, 104, 68-76.	0.4	5
1003	G Proteins in Cancer: The Prostate Cancer Paradigm. Science Signaling, 2004, 2004, re2-re2.	1.6	92
1004	Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer. Archives of Surgery, 2004, 139, 532.	2.3	36
1005	Dietary Corn Oil Promotes Colon Cancer by Inhibiting Mitochondria-Dependent Apoptosis in Azoxymethane-Treated Rats. Experimental Biology and Medicine, 2004, 229, 1017-1025.	1.1	45
1006	The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. American Journal of Physiology - Renal Physiology, 2004, 287, F1-F6.	1.3	62
1007	Comparison of Endoscopic Ultrasonography and Multidetector Computed Tomography for Detecting and Staging Pancreatic Cancer. Annals of Internal Medicine, 2004, 141, 753.	2.0	465
1008	Coexpression of Keratinocyte Growth Factor and Its Receptor in Normal and Prostate Cancer Tissues: Possible Formation of Autonomous Andromedin Loop. Acta Histochemica Et Cytochemica, 2004, 37, 379-389.	0.8	4

#	Article	IF	CITATIONS
1009	Full-Body Skin Examinations. Archives of Dermatology, 2004, 140, 530-4.	1.7	28
1010	Staging Workup, Sentinel Node Biopsy, and Follow-up Tests for Melanoma. Archives of Dermatology, 2004, 140, 107-13.	1.7	44
1011	Genetics and Prevention of Pancreatic Cancer. Cancer Control, 2004, 11, 6-14.	0.7	31
1012	Sentinel Lymph Node Mapping in Colon and Rectal Cancer. Cancer Treatment and Research, 2005, 127, 105-122.	0.2	27
1013	Targeting Cytokine Receptors and Pathways in the Treatment of Breast Cancer. , 2005, 126, 243-262.		0
1014	A Bibliometric Analysis of Global Research Production in Respiratory Medicine. Chest, 2005, 128, 3993-3998.	0.4	118
1015	ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer. Chest, 2005, 127, 978-983.	0.4	264
1016	Targeted Therapy for the Treatment of Advanced Non-small Cell Lung Cancer. Chest, 2005, 128, 3975-3984.	0.4	98
1017	Presurgical Staging of Non-small Cell Lung Cancer. Chest, 2005, 128, 2289-2297.	0.4	125
1018	Effects of Breast-Conserving Therapy on Lactation After Pregnancy. Cancer Journal (Sudbury, Mass ), 2005, 11, 399-403.	1.0	51
1019	Neoplasms of the Lung, Pleura and Chest Wall. , 2005, , 165-183.		0
1021	Cancer: Clinical Challenges and Opportunities. , 2005, , 9-20.		0
1022	Functional Characterization of Prostate Cancer by Integrated Magnetic Resonance Imaging and Oxygenation Changes During Carbogen Breathing. Investigative Radiology, 2005, 40, 102-109.	3.5	19
1023	Costs and Survival of Patients With Colorectal Cancer in a Health Maintenance Organization and a Preferred Provider Organization. Medical Care, 2005, 43, 1043-1048.	1.1	17
1024	Precursors to Invasive Pancreatic Cancer. Advances in Anatomic Pathology, 2005, 12, 81-91.	2.4	266
1025	Human Papillomavirus Infection in Women. Infectious Diseases in Clinical Practice, 2005, 13, 154-157.	0.1	0
1026	Recent Developments in Nuclear Medicine in the Management of Bone Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 513-520.	0.6	19
1027	Comparative Analysis of Loss of Heterozygosity and Microsatellite Instability in Adult and Pediatric Melanoma. American Journal of Dermatopathology, 2005, 27, 279-285.	0.3	25

#	Article	IF	CITATIONS
1028	Recurrent Colorectal Carcinoma Detected by Routine Cervicovaginal Papanicolaou Smear Testing. Journal of Lower Genital Tract Disease, 2005, 9, 236-238.	0.9	8
1029	Chemosensitization of Pancreatic Carcinoma Cells to Enhance T Cell-Mediated Cytotoxicity Induced by Tumor Lysate-Pulsed Dendritic Cells. Journal of Immunotherapy, 2005, 28, 332-342.	1.2	33
1030	Postoperative Computed Tomography Scan Surveillance for Patients With Stage II and III Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 30-35.	0.6	9
1031	Recent Advances on the Molecular Mechanisms Involved in Pancreatic Cancer Progression and Therapies. Pancreas, 2005, 31, 301-316.	0.5	91
1032	Assessment of HER-2 Status in Pancreatic Adenocarcinoma. American Journal of Surgical Pathology, 2005, 29, 1125-1134.	2.1	54
1033	CEACAM6 Is a Novel Biomarker in Pancreatic Adenocarcinoma and PanIN Lesions. Annals of Surgery, 2005, 241, 491-496.	2.1	78
1034	Overexpressed P-Cadherin/CDH3 Promotes Motility of Pancreatic Cancer Cells by Interacting with p120ctn and Activating Rho-Family GTPases. Cancer Research, 2005, 65, 3092-3099.	0.4	163
1035	Clinical Features of 5,628 Primary Lung Cancer Patients. Chest, 2005, 128, 452-462.	0.4	386
1036	Milk/dairy products consumption, galactose metabolism and ovarian cancer: meta-analysis of epidemiological studies. European Journal of Cancer Prevention, 2005, 14, 13-19.	0.6	46
1037	Prognostic Significance of DCC and p27Kip1 in Colorectal Cancer. Applied Immunohistochemistry and Molecular Morphology, 2005, 13, 45-54.	0.6	7
1038	Phase I Study of Concomitant Chemoradiotherapy with Irinotecan, 5-FU., and Hydroxyurea for Patients with Advanced and/or Recurrent Head and Neck Cancer. Cancer Journal (Sudbury, Mass ), 2005, 11, 140-146.	1.0	10
1039	Fertility preservation and pregnancy outcome after malignancy. Current Opinion in Obstetrics and Gynecology, 2005, 17, 21-26.	0.9	65
1040	Epidemiology of male osteoporosis and prostate cancer. Current Opinion in Urology, 2005, 15, 23-27.	0.9	14
1041	Proteasome Inhibition in Cancer Therapy. Journal of Infusion Nursing, 2005, 28, 258-264.	1.2	3
1042	Measuring Physical Symptoms in Children and Adolescents With Cancer. Cancer Nursing, 2005, 28, 16-26.	0.7	32
1043	Phase 2 Bioadjuvant Study of Interferon Alfa-2a, Isotretinoin, and Vitamin E in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngology, 2005, 131, 304.	1.5	41
1044	Estrogen Can Prevent Breast Cancer by Mimicking the Protective Effect of Pregnancy. , 2005, , 153-165.		4
1045	Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution. Blood, 2005, 105, 4583-4589.	0.6	39

#	Article	IF	CITATIONS
1046	Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules. Blood, 2005, 106, 3515-3523.	0.6	32
1047	Docetaxel for Metastatic Cancer and Its Role in Combination Therapies for Advanced Prostate Cancer. , 2005, , 255-292.		0
1048	Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma. Leukemia Research, 2005, 29, 1233-1234.	0.4	4
1049	A predictive mathematical model in the recurrence of bladder cancer. Mathematical and Computer Modelling, 2005, 42, 621-634.	2.0	6
1050	Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy. Journal of Photochemistry and Photobiology B: Biology, 2005, 79, 231-241.	1.7	187
1051	Bronchial stenosis: An underreported complication of high-dose external beam radiotherapy for lung cancer?. International Journal of Radiation Oncology Biology Physics, 2005, 61, 64-69.	0.4	104
1052	Factors associated with the frequency of self-intermittent catheterization after prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2005, 61, 60-63.	0.4	16
1053	Low bax protein expression correlates with disease recurrence in preoperatively irradiated rectal carcinoma. International Journal of Radiation Oncology Biology Physics, 2005, 61, 85-91.	0.4	23
1054	Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. International Journal of Radiation Oncology Biology Physics, 2005, 61, 1393-1402.	0.4	176
1055	Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2005, 62, 97-103.	0.4	8
1056	Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. International Journal of Radiation Oncology Biology Physics, 2005, 62, 448-453.	0.4	188
1057	Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1325-1330.	0.4	41
1058	Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1400-1412.	0.4	113
1059	Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2005, 63, 320-323.	0.4	308
1060	Ovarian cancer diagnosis by hippocampus and neocortex-inspired learning memory structures. Neural Networks, 2005, 18, 818-825.	3.3	35
1061	SAR studies of 2-arylthiazolidine-4-carboxylic acid amides: A novel class of cytotoxic agents for prostate cancer. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4010-4013.	1.0	20
1062	Alcohol and pancreatic cancer. Alcohol, 2005, 35, 205-211.	0.8	85
1063	Annual effective dose of ionizing radiation from natural sources: United States based airline pilots compared with non-flying residents of the United States. Advances in Space Research, 2005, 36, 1653-1656.	1.2	9

#	Article	IF	CITATIONS
1064	Endoscopic Ultrasound for Thoracic Malignancy: A Review. Current Problems in Diagnostic Radiology, 2005, 34, 106-115.	0.6	13
1065	Molecular prognostic factors in resectable non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2005, 53, 193-197.	2.0	21
1066	Screening for lung cancer: New horizons?. Critical Reviews in Oncology/Hematology, 2005, 56, 311-320.	2.0	23
1067	A Role for Hath1, a bHLH Transcription Factor, in Colon Adenocarcinoma. Annals of the New York Academy of Sciences, 2005, 1059, 174-183.	1.8	25
1068	Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Investigational New Drugs, 2005, 23, 79-84.	1.2	68
1069	Use of a Patient Navigator to Increase Colorectal Cancer Screening in an Urban Neighborhood Health Clinic. Journal of Urban Health, 2005, 82, 216-224.	1.8	202
1070	Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. International Journal of Gynecological Cancer, 2005, 15, 785-792.	1.2	219
1071	Isolated Hepatic Perfusion for the Treatment of Patients With Colorectal Cancer Liver Metastases After Irinotecan-Based Therapy. Annals of Surgical Oncology, 2005, 12, 138-144.	0.7	43
1072	Induction of Apoptosis and Cell Cycle Arrest by Imexon in Human Pancreatic Cancer Cell Lines. International Journal of Gastrointestinal Cancer, 2005, 36, 015-028.	0.4	22
1073	Ten Years of Disease-Free Survival between Two Diagnoses of Small-Cell Lung Cancer: A Case Report and a Literature Review. Medical Oncology, 2005, 22, 089-098.	1.2	11
1074	A Phase II Study of Weekly Paclitaxel and Carboplatin in Previously Untreated Patients with Advanced Non-Small-Cell Lung Cancer. Medical Oncology, 2005, 22, 145-152.	1.2	6
1075	Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): A major prognostic indicator in uterine serous papillary cancer. American Journal of Obstetrics and Gynecology, 2005, 192, 813-818.	0.7	122
1076	The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. American Journal of Obstetrics and Gynecology, 2005, 192, 1214-1221.	0.7	163
1077	Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial. American Journal of Obstetrics and Gynecology, 2005, 193, 1630-1639.	0.7	307
1078	Pigment Epithelium–Derived Factor Gene Therapy Inhibits Human Pancreatic Cancer in Mice. Clinical Cancer Research, 2005, 11, 8737-8744.	3.2	63
1079	Laparoscopic-assisted vaginal hysterectomy versus abdominal hysterectomy in patients with stage I and II endometrial cancer. International Journal of Gynecological Cancer, 2005, 15, 932-937.	1.2	39
1080	Whole-body [18F]fluoro-2-deoxyglucose positron emission tomography scan staging prior to planned radical hysterectomy and pelvic lymphadenectomy. International Journal of Gynecological Cancer, 2005, 15, 1060-1064.	1.2	14
1081	A novel early-stage orthotopic model for ovarian cancer in the Fischer 344 rat. International Journal of Gynecological Cancer, 2005, 15, 246-254.	1.2	5

#	Article	IF	CITATIONS
1082	Abnormal cervical cytology: a risk factor for endometrial cancer recurrence. International Journal of Gynecological Cancer, 2005, 15, 517-522.	1.2	15
1083	Treatment goals in ovarian cancer. International Journal of Gynecological Cancer, 2005, 15, 3-11.	1.2	219
1084	Presenting symptoms of epithelial ovarian cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2005, 45, 211-214.	0.4	43
1085	Federal Sponsorship of Cost-Effectiveness and Related Research in Health Care: 1997–2001. Value in Health, 2005, 8, 223-236.	0.1	7
1086	The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management. BJU International, 2005, 95, 2-7.	1.3	43
1087	Kit (CD117) immunoreactivity is rare in renal cell and upper urinary tract transitional cell carcinomas. BJU International, 2005, 95, 315-318.	1.3	15
1088	Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?. BJU International, 2005, 95, 231-237.	1.3	58
1089	Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer. BJU International, 2005, 96, 29-33.	1.3	33
1090	The src-family kinase inhibitor PP2 suppresses the in vitro invasive phenotype of bladder carcinoma cells via modulation of Akt. BJU International, 2005, 96, 416-422.	1.3	18
1091	Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology. BJU International, 2005, 96, 1031-1035.	1.3	115
1092	Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU International, 2005, 96, 1241-1246.	1.3	186
1093	Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. Journal of Internal Medicine, 2005, 258, 115-123.	2.7	102
1094	Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas. Cancer Science, 2005, 96, 403-408.	1.7	113
1095	Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia. Alimentary Pharmacology and Therapeutics, 2005, 22, 267-271.	1.9	35
1096	Prostate epithelial stem cells. Cell Proliferation, 2005, 38, 363-374.	2.4	99
1097	Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. British Journal of Cancer, 2005, 92, 1561-1573.	2.9	105
1098	Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. British Journal of Cancer, 2005, 92, 1372-1381.	2.9	325
1099	Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. British Journal of Cancer, 2005, 93, 70-80.	2.9	74

#	Article	IF	Citations
1100	Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Therapy, 2005, 12, 350-358.	2.2	84
1101	Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. Gene Therapy, 2005, 12, 30-38.	2.3	36
1102	Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene, 2005, 24, 850-858.	2.6	144
1103	Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression. Oncogene, 2005, 24, 4806-4812.	2.6	60
1104	Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene, 2005, 24, 5079-5088.	2.6	172
1105	FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene, 2005, 24, 5218-5225.	2.6	295
1106	Synergistic induction of the MUC4 mucin gene by interferon-Î <sup>3</sup> and retinoic acid in human pancreatic tumour cells involves a reprogramming of signalling pathways. Oncogene, 2005, 24, 6143-6154.	2.6	40
1107	Impact of the 1998 World Health Organization/International Society of Urological Pathology classification system for urothelial neoplasms of the kidney. Modern Pathology, 2005, 18, 11-18.	2.9	31
1108	Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma. Modern Pathology, 2005, 18, 547-557.	2.9	159
1109	Global histone modification patterns predict risk of prostate cancer recurrence. Nature, 2005, 435, 1262-1266.	13.7	991
1110	The second-look operation improves survival in suboptimally debulked stage III ovarian cancer patients. International Journal of Gynecological Cancer, 2005, 15, 19-25.	1.2	16
1111	Determination of the Presence and Extent of Pure Ductal Carcinoma in Situ by Mammography and Magnetic Resonance Imaging. Breast Journal, 2005, 11, 382-390.	0.4	202
1112	Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome?. Cancer Genetics and Cytogenetics, 2005, 156, 31-36.	1.0	81
1113	Alterations of 9p in squamous cell carcinoma and adenocarcinoma of the lung: association with smoking, TP53, and survival. Cancer Genetics and Cytogenetics, 2005, 162, 115-121.	1.0	12
1114	Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell, 2005, 7, 239-249.	7.7	274
1115	PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer. Cancer Detection and Prevention, 2005, 29, 170-174.	2.1	28
1116	Analysis of paired primary lung and lymph node tumor cells: A model of metastatic potential by multiple genetic programs. Cancer Detection and Prevention, 2005, 29, 509-517.	2.1	19
1117	Classification of breast ultrasound images using fractal feature. Clinical Imaging, 2005, 29, 235-245.	0.8	130

# 1118	ARTICLE Retroperitoneoscopy-Assisted Cryoablation of Renal Tumors Using Multiple 1.5mm Ultrathin Cryoprobes: A Preliminary Report. European Urology, 2005, 47, 474-479.	IF 0.9	Citations 34
1119	Prostatic Intraepithelial Neoplasia (PIN): Importance and Clinical Management. European Urology, 2005, 48, 379-385.	0.9	27
1120	The Prevalence of Prostate Carcinoma and Its Precursor in Hungary: An Autopsy Study. European Urology, 2005, 48, 739-744.	0.9	95
1121	Differentially expressed nucleolar TGF-β1 target (DENTT) shows tissue-specific nuclear and cytoplasmic localization and increases TGF-β1-responsive transcription in primates. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2005, 1728, 163-180.	2.4	17
1122	Adjuvant therapy of colon cancer. Seminars in Oncology, 2005, 32, 95-102.	0.8	26
1123	Docetaxel in the Treatment of Esophageal Cancer. Seminars in Oncology, 2005, 32, 39-51.	0.8	21
1124	Brief Communication: A New Combination in the Treatment of Advanced Pancreatic Cancer. Seminars in Oncology, 2005, 32, 5-6.	0.8	64
1125	State of malnutrition in Cuban hospitals. Nutrition, 2005, 21, 487-497.	1.1	25
1126	Status Quo of Palliative Care in Pediatric Oncology—A Nationwide Survey in Germany. Journal of Pain and Symptom Management, 2005, 29, 156-164.	0.6	46
1127	The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. Journal of Thoracic and Cardiovascular Surgery. 2005. 129. 1232-1241.	0.4	238
1128	Understanding mesenchymal cancer: the liposarcoma-associated FUS–DDIT3 fusion gene as a model. Seminars in Cancer Biology, 2005, 15, 206-214.	4.3	32
1129	Regional and Systemic Chemotherapy for Primary Hepatobiliary Cancers and for Colorectal Cancer Metastatic to the Liver. Seminars in Radiation Oncology, 2005, 15, 284-298.	1.0	18
1131	Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer. BMC Cancer, 2005, 5, 71.	1.1	7
1132	Design of a Novel MRI Compatible Manipulator for Image Guided Prostate Interventions. IEEE Transactions on Biomedical Engineering, 2005, 52, 306-313.	2.5	263
1133	Management of patients with metastatic cancer of unknown primary. Current Problems in Surgery, 2005, 42, 12-66.	0.6	22
1134	Hereditary colon cancer—Part I. Current Problems in Surgery, 2005, 42, 195-256.	0.6	24
1135	Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology, 2005, 331, 269-291.	1.1	179
1136	Molecular genetic characterization of tamoxifen-associated endometrial cancer. Gynecologic Oncology, 2005, 96, 25-31.	0.6	32

#	Article	IF	CITATIONS
1137	Recurrent small cell lung cancer presenting as bilateral adnexal masses. Gynecologic Oncology, 2005, 96, 232-234.	0.6	10
1138	Evaluation of germline PTEN mutations in endometrial cancer patients. Gynecologic Oncology, 2005, 96, 21-24.	0.6	35
1139	Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecologic Oncology, 2005, 96, 103-107.	0.6	52
1140	HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecologic Oncology, 2005, 96, 42-47.	0.6	90
1141	Overexpression of the TGF-β antagonist Smad7 in endometrial cancer. Gynecologic Oncology, 2005, 96, 368-373.	0.6	61
1142	Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer. Gynecologic Oncology, 2005, 96, 651-657.	0.6	68
1143	Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6–12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. Gynecologic Oncology, 2005, 96, 810-817.	0.6	15
1144	Utility and limitations of abdominal radiotherapy in the management of endometrial carcinomas. Gynecologic Oncology, 2005, 96, 635-642.	0.6	4
1145	Practice patterns of SGO members for stage IIIA endometrial cancer. Gynecologic Oncology, 2005, 98, 77-83.	0.6	22
1146	Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: Updated results and long-term survival. Gynecologic Oncology, 2005, 98, 267-273.	0.6	39
1147	A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology, 2005, 98, 249-253.	0.6	50
1148	The accuracy of examination under anesthesia and transvaginal sonography in evaluating ovarian size. Gynecologic Oncology, 2005, 99, 400-403.	0.6	38
1149	Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecologic Oncology, 2005, 99, 689-695.	0.6	99
1150	Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Gynecologic Oncology, 2005, 99, 462-471.	0.6	34
1151	Structural and functional analysis of domains mediating interaction between NKX-3.1 and PDEF. Journal of Cellular Biochemistry, 2005, 94, 168-177.	1.2	22
1152	An interaction between apolipoprotein E and TERE1 with a possible association with bladder tumor formation. Journal of Cellular Biochemistry, 2005, 95, 419-428.	1.2	35
1153	Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. Journal of Cellular Physiology, 2005, 204, 36-44.	2.0	176
1154	A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. Head and Neck, 2005, 27, 771-784.	0.9	82

#	Article	IF	CITATIONS
1155	Lower levels of nuclear ?-catenin predict for a poorer prognosis in localized prostate cancer. International Journal of Cancer, 2005, 113, 415-422.	2.3	59
1156	Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activityin vitro andin vivo. International Journal of Cancer, 2005, 113, 841-848.	2.3	41
1157	Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers. International Journal of Cancer, 2005, 113, 811-818.	2.3	58
1158	Low doses of β-carotene and lutein inhibit AOM-induced rat colonic ACF formation but high doses augment ACF incidence. International Journal of Cancer, 2005, 113, 798-802.	2.3	32
1159	Hypermethylation of RASSF1A and BLU tumor suppressor genes in nonâ€small cell lung cancer: Implications for tobacco smoking during adolescence. International Journal of Cancer, 2005, 114, 219-223.	2.3	62
1160	hOGG1 Ser326Cys polymorphism and G:C-to-T:A mutations: No evidence for a role in tobacco-related non small cell lung cancer. International Journal of Cancer, 2005, 114, 387-393.	2.3	20
1161	Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSUâ€68). International Journal of Cancer, 2005, 114, 224-229.	2.3	42
1162	Treatment of multi-focal colorectal carcinoma metastatic to the liver of immune-competent and syngeneic rats by hepatic artery infusion of oncolytic vesicular stomatitis virus. International Journal of Cancer, 2005, 114, 659-664.	2.3	26
1163	Novel real-time PCR assay using a universal molecular marker for diagnosis of hematologic cancers. International Journal of Cancer, 2005, 116, 656-660.	2.3	6
1164	Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer. International Journal of Cancer, 2005, 117, 274-280.	2.3	36
1165	FTY720, a fungus metabolite, inhibitsin vivo growth of androgen-independent prostate cancer. International Journal of Cancer, 2005, 117, 1039-1048.	2.3	77
1166	Racial treatment trends in localized/regional prostate carcinoma: 1992-1999. Cancer, 2005, 103, 538-545.	2.0	85
1167	Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Cancer, 2005, 103, 680-688.	2.0	43
1168	Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma. Cancer, 2005, 103, 931-942.	2.0	71
1169	Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer, 2005, 103, 1631-1643.	2.0	385
1170	Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer, 2005, 103, 1615-1624.	2.0	309
1171	Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer, 2005, 103, 2575-2583.	2.0	72
1172	Improving the quality of life of patients with prostate carcinoma. Cancer, 2005, 104, 752-762.	2.0	117

#	Article	IF	CITATIONS
1173	Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer, 2005, 104, 2766-2774.	2.0	138
1174	Role of radiation therapy in patients with a diagnosis of both systemic lupus erythematosus and cancer. Arthritis and Rheumatism, 2005, 53, 67-72.	6.7	37
1175	Forequarter amputation for recurrent breast cancer: A case report and review of the literature. Journal of Surgical Oncology, 2005, 92, 134-141.	0.8	13
1176	Localization of the human hedgehog-interacting protein (Hip) in the normal and diseased pancreas. Molecular Carcinogenesis, 2005, 42, 183-192.	1.3	32
1177	Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. Molecular Carcinogenesis, 2005, 43, 215-224.	1.3	75
1178	Epigenetic silencing of thePRSS3 putative tumor suppressor gene in non-small cell lung cancer. Molecular Carcinogenesis, 2005, 44, 146-150.	1.3	28
1179	Lower extremity compartmental anatomy: clinical relevance to radiologists. Skeletal Radiology, 2005, 34, 307-313.	1.2	56
1180	Dual-phase 18F-fluoro-2-deoxy-d-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 389-397.	3.3	58
1181	A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunology, Immunotherapy, 2005, 54, 453-467.	2.0	61
1182	Gene Overexpression in Pancreatic Adenocarcinoma: Diagnostic and Therapeutic Implications. World Journal of Surgery, 2005, 29, 297-305.	0.8	26
1183	Salvage Abdominoperineal Resection and Perineal Wound Healing in Local Recurrent or Persistent Anal Cancer. World Journal of Surgery, 2005, 29, 1452-1457.	0.8	74
1184	Nonmyeloablative allogeneic stem cell transplantation in metastatic renal cell carcinoma: a new therapeutic option or just a clinical experiment?. World Journal of Urology, 2005, 23, 213-220.	1.2	3
1185	Salvage of suboptimal prostate seed implantation: Reimplantation of underdosed region of prostate base. Brachytherapy, 2005, 4, 163-170.	0.2	15
1186	Blockade of epidermal growth factor receptor (EGFR) activity. Critical Reviews in Oncology/Hematology, 2005, 53, 179-192.	2.0	23
1187	A New Format of Single Chain Tri-specific Antibody with Diminished Molecular Size Efficiently Induces Ovarian Tumor Cell Killing. Biotechnology Letters, 2005, 27, 1821-1827.	1.1	6
1188	Clinical course and surgical long-term outcome in geriatric patients with non-small cell carcinoma. Zeitschrift Fur Herz-, Thorax- Und Gefasschirurgie, 2005, 19, 37-45.	0.0	0
1189	Sensitivity of Upper Endoscopy in Diagnosing Esophageal Cancer. Dysphagia, 2005, 20, 278-282.	1.0	19
1190	Colonoscopy vs CT colonography to screen for colorectal neoplasia in average-risk patients. Surgical Endoscopy and Other Interventional Techniques, 2005, 19, 448-456.	1.3	5

#	Article	IF	CITATIONS
1191	Review and critique of the quality of exercise recommendations for cancer patients and survivors. Supportive Care in Cancer, 2005, 13, 493-502.	1.0	44
1192	Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?. Langenbeck's Archives of Surgery, 2005, 390, 94-103.	0.8	89
1193	Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels. Journal of Cancer Research and Clinical Oncology, 2005, 131, 715-722.	1.2	27
1194	Global detection of molecular changes reveals concurrent alteration of several biological pathways in nonsmall cell lung cancer cells. Molecular Genetics and Genomics, 2005, 274, 141-154.	1.0	15
1195	Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer. International Journal of Clinical Oncology, 2005, 10, 333-337.	1.0	11
1196	Tumeurs intestinales, quelle strat $ ilde{A}$ ©gie proposer?. Acta Endoscopica, 2005, 35, 157-169.	0.0	0
1197	Prostate cancer screening. Comprehensive Therapy, 2005, 31, 119-123.	0.2	0
1198	Management strategies for patients with hereditary pancreatic cancer. Current Treatment Options in Oncology, 2005, 6, 437-445.	1.3	64
1199	The influence of aging on the early detection, diagnosis, and treatment of breast cancer. Current Oncology Reports, 2005, 7, 23-30.	1.8	10
1200	The Value of PSA, Free-to-total PSA Ratio and PSA Density in the Prediction of Pathologic Stage for Clinically Localized Prostate Cancer. International Urology and Nephrology, 2005, 37, 511-514.	0.6	15
1201	Brain metastases: epidemiology and pathophysiology. Journal of Neuro-Oncology, 2005, 75, 5-14.	1.4	816
1202	Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Research and Treatment, 2005, 89, 149-157.	1.1	98
1203	Racial and ethnic disparities in breast cancer rates by age: NAACCR Breast Cancer Project. Breast Cancer Research and Treatment, 2005, 92, 97-105.	1.1	60
1204	RhoC-GTPase is a Novel Tissue Biomarker Associated with Biologically Aggressive Carcinomas of the Breast. Breast Cancer Research and Treatment, 2005, 93, 101-110.	1.1	101
1205	Incidence of Male Breast Cancer in California, 1988–2000: Racial/Ethnic Variation in 1759 Men. Breast Cancer Research and Treatment, 2005, 93, 145-150.	1.1	23
1206	Inhibition of Either Phosphatidylinositol 3-kinase/Akt or the Mitogen/Extracellular-regulated Kinase, MEK/ERK, Signaling Pathways Suppress Growth of Breast Cancer Cell Lines, but MEK/ERK Signaling is Critical for Cell Survival. Breast Cancer Research and Treatment, 2005, 93, 177-188.	1.1	34
1207	Cancer-specific beliefs and survival: A population-based study of African-American and White breast cancer patients. Cancer Causes and Control, 2005, 16, 105-114.	0.8	17
1208	Are risk factors for breast cancer associated with follow-up procedures in diverse women with abnormal mammography?. Cancer Causes and Control, 2005, 16, 245-253.	0.8	8

#	Article	IF	CITATIONS
1209	Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes and Control, 2005, 16, 643-650.	0.8	52
1210	Role of nuclear factor-lº B in melanoma. Cancer and Metastasis Reviews, 2005, 24, 301-313.	2.7	176
1211	Constitutive expression of growth regulated oncogene (gro) in human colon carcinoma cells with different metastatic potential and its role in regulating their metastatic phenotype. Clinical and Experimental Metastasis, 2005, 21, 571-579.	1.7	77
1212	MUC1, MUC2, MUC4, MUC5AC and MUC6 Expression in the Progression of Prostate Cancer. Clinical and Experimental Metastasis, 2005, 22, 565-573.	1.7	111
1213	KiSS1 Suppresses Metastasis in Human Ovarian Cancer via Inhibition of Protein Kinase C Alpha. Clinical and Experimental Metastasis, 2005, 22, 369-376.	1.7	114
1214	Quality of life and diet intervention in individuals at risk for recurrence of colorectal adenomas. Psycho-Oncology, 2005, 14, 85-93.	1.0	15
1215	Disclosure between patients with gastrointestinal cancer and their spouses. Psycho-Oncology, 2005, 14, 1030-1042.	1.0	141
1216	Explaining racial differences in prostate cancer in the United States: Sociology or biology?. Prostate, 2005, 62, 243-252.	1.2	117
1217	Obesity and the risk of prostate cancer. Prostate, 2005, 62, 316-321.	1.2	107
1218	Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. Prostate, 2005, 62, 224-232.	1.2	38
1219	Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. Prostate, 2005, 63, 187-197.	1.2	62
1220	Polymorphisms in the androgen receptor and the prostate-specific antigen genes and prostate cancer risk. Prostate, 2005, 65, 58-65.	1.2	40
1221	Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer. Prostate, 2005, 65, 260-267.	1.2	73
1222	Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. Journal of Pathology, 2005, 205, 359-376.	2.1	162
1223	High-risk surgically resected pediatric melanoma and adjuvant interferon therapy. Pediatric Blood and Cancer, 2005, 44, 441-448.	0.8	49
1224	Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. Proteomics, 2005, 5, 4296-4304.	1.3	84
1225	Dietary Genistein Reduces Metastasis in a Postsurgical Orthotopic Breast Cancer Model. Cancer Research, 2005, 65, 3396-3403.	0.4	89
1226	Computer-aided detection for virtual colonoscopy. Cancer Imaging, 2005, 5, 11-16.	1.2	9

ARTICLE IF CITATIONS Health-Related Quality-of-Life in Low-Income, Uninsured Men with Prostate Cancer. Journal of Health 1227 0.4 40 Care for the Poor and Underserved, 2005, 16, 375-390. In Situ Gene Therapy for Prostate Cancer. Current Gene Therapy, 2005, 5, 111-119. 24 Evaluation of Screening Strategies for Improving Oral Cancer Mortality: A Cochrane Systematic 1229 0.7 84 Review. Journal of Dental Education, 2005, 69, 255-265. Cisplatin and Weekly Docetaxel as First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer a Phase II Study. Tumori, 2005, 91, 131-134. Chemoprevention of Lung Cancer. Recent Results in Cancer Research, 2005, 166, 145-165. 1231 1.8 2 Biological Basis of Cancer in the Older Person., 2005, , 189-221. Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with 1233 1.1 17 Advanced Colorectal Cancer. Journal of Korean Medical Science, 2005, 20, 806. Lung Cancer Chemotherapy for Radiation Oncologists., 2005, , 135-154. 1234 Staging and Therapeutic Approaches for Patients with Localized, Potentially Curable Pancreatic 1235 0 Adenocarcinoma., 2005, , 184-196. Information and Involvement Preferences of Women in Their 40s Before Their First Screening 4.3 Mammogram. Archives of Internal Medicine, 2005, 165, 1370. High Nuclear S100A6 (Calcyclin) Is Significantly Associated with Poor Survival in Pancreatic Cancer 1237 123 0.4 Patients. Cancer Research, 2005, 65, 3218-3225. Ultrasonographic Contrast Media. Journal of Ultrasound in Medicine, 2005, 24, 517-531. 0.8 36 Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin as First-line Therapy for Advanced 1240 0.6 6 Colorectal Cancer. Japanese Journal of Clinical Oncology, 2005, 35, 214-217. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer and Prostatic Diseases, 2005, 8, 316-320. 1241 Gene therapy and immunotherapy of prostate cancer: Adenoviral-based strategies. Acta OncolÃ<sup>3</sup>gica, 1242 0.8 13 2005, 44, 610-627. Effective Inhibition of Experimental Human Ovarian Cancers with a Targeted Cytotoxic Bombesin 1243 23 Analogue AN-215. Clinical Cancer Research, 2005, 11, 2408-2415. Age-associated changes in the expression pattern of cyclooxygenase-2 and related apoptotic markers 1244 1.311 in the cancer susceptible region of rat prostate. Carcinogenesis, 2005, 26, 1650-1650. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: 1245 1.3 a potential target for prevention. Carcinogenesis, 2005, 26, 785-791.

#	Article	IF	CITATIONS
1246	(Neo-)adjuvant treatments in colorectal cancer. Annals of Oncology, 2005, 16, ii133-ii140.	0.6	10
1247	The race associated allele of Semaphorin 3B ( SEMA3B ) T415I and its role in lung cancer in African-Americans and Latino-Americans. Carcinogenesis, 2005, 26, 1446-1449.	1.3	17
1248	TGFBR1*6A is not associated with prostate cancer in men of European ancestry. Prostate Cancer and Prostatic Diseases, 2005, 8, 50-53.	2.0	9
1249	In vivo Radioiodide Imaging and Treatment of Breast Cancer Xenografts after MUC1-Driven Expression of the Sodium Iodide Symporter. Clinical Cancer Research, 2005, 11, 1483-1489.	3.2	77
1250	Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade. Prostate Cancer and Prostatic Diseases, 2005, 8, 127-132.	2.0	16
1251	Frequency, symptoms and outcome of intestinal metastases of bronchopulmonary cancer. Case report and review of the literature. International Seminars in Surgical Oncology, 2005, 2, 13.	1.1	32
1252	Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases. Prostate Cancer and Prostatic Diseases, 2005, 8, 327-334.	2.0	17
1253	Serum Trans-Fatty Acids Are Associated with Risk of Prostate Cancer in Â-Carotene and Retinol Efficacy Trial. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 988-992.	1.1	68
1254	Regulation of androgen receptor signaling in prostate cancer. Expert Review of Anticancer Therapy, 2005, 5, 63-74.	1.1	79
1255	Prognostic Significance of Activated Akt Expression in Melanoma: A Clinicopathologic Study of 292 Cases. Journal of Clinical Oncology, 2005, 23, 1473-1482.	0.8	274
1256	Sugar-Sweetened Soft Drink Consumption and Risk of Pancreatic Cancer in Two Prospective Cohorts. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2098-2105.	1.1	96
1257	Intraprostatic Chemotherapy: Distribution and Transport Mechanisms. Clinical Cancer Research, 2005, 11, 4204-4211.	3.2	24
1258	Profile of Daily Life in Children With Brain Tumors: An Assessment of Health-Related Quality of Life. Journal of Clinical Oncology, 2005, 23, 5493-5500.	0.8	192
1259	Access and equity to cancer care in the USA: a review and assessment. Postgraduate Medical Journal, 2005, 81, 674-679.	0.9	39
1260	Difficult Diagnostic Cases. Journal of Clinical Oncology, 2005, 23, 3622-3624.	0.8	2
1261	Catalytic Subunit of Human Telomerase Reverse Transcriptase Is an Independent Predictor of Survival in Patients Undergoing Curative Resection of Hepatic Colorectal Metastases: A Multicenter Analysis. Journal of Clinical Oncology, 2005, 23, 3086-3093.	0.8	57
1262	Routine frozen-section biopsy from the surgical bed should be performed during nephron-sparing surgery for renal cell carcinoma. Scandinavian Journal of Urology and Nephrology, 2005, 39, 222-225.	1.4	21
1263	Tobacco components stimulate Akt-dependent proliferation and NFκB-dependent survival in lung cancer cells. Carcinogenesis, 2005, 26, 1182-1195.	1.3	266

ARTICLE IF CITATIONS The role of docosahexaenoic acid in mediating mitochondrial membrane lipid oxidation and apoptosis 97 1264 1.3 in colonocytes. Carcinogenesis, 2005, 26, 1914-1921. Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience. Journal 0.8 of Clinical Oncology, 2005, 23, 2763-2771. Colorectal cancer: screening. Annals of Oncology, 2005, 16, ii127-ii132. 1266 0.6 25 Intrinsic Chemoresistance to Gemcitabine Is Associated with Decreased Expression of BNIP3 in 1267 Pancreatic Cancer. Clinical Cancer Research, 2005, 11, 3094-3101. Non-steroidal anti-inflammatory drugs and colorectal cancer prevention. Postgraduate Medical 1268 0.9 22 Journal, 2005, 81, 223-227. A Transforming Growth Factor-Î<sup>2</sup> Receptor–Interacting Protein Frequently Mutated in Human Ovarian Cancer. Cancer Research, 2005, 65, 6526-6533. 0.4 A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, 1270 Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate 3.2 158 Cancer. Clinical Cancer Research, 2005, 11, 6625-6633. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. 1271 1.6 Endocrine-Related Cancer, 2005, 12, 511-532. Tunicamycin Enhances Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis 1272 0.4 145 in Human Prostate Cancer Cells. Cancer Research, 2005, 65, 6364-6370. Differential DNA Hypermethylation of Critical Genes Mediates the Stage-Specific Tobacco 3.2 140 Smoke-Induced Neoplastic Progression of Lung Cancer. Clinical Cancer Research, 2005, 11, 2466-2470. Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides. Proceedings of the National Academy of Sciences of the United States of 1274 3.3 60 America, 2005, 102, 17436-17441. Single-Agent Versus Combination Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730). Journal of Clinical Oncology, 2005, 23, 190-196. 0.8 436 Kallikrein 4 Expression Is Up-Regulated in Epithelial Ovarian Carcinoma Cells in Effusions. American 1276 0.4 22 Journal of Clinical Pathology, 2005, 123, 360-368. Hey1, a Mediator of Notch Signaling, Is an Androgen Receptor Corepressor. Molecular and Cellular 1277 1.1 Biology, 2005, 25, 1425-1436. 1278 Tumeurs de vessie., 2005, , 381-389. 0 Overexpression of Osteopontin Is Associated with More Aggressive Phenotypes in Human Non-Small 1279 3.2 140 Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 4646-4652. Tissue-Specific Attenuation of Endogenous DNA I-Compounds in Rats by Carcinogen Azoxymethane: 1280 Possible Role of Dietary Fish Oil in Colon Cancer Prevention. Cancer Epidemiology Biomarkers and 1.1 9 Prevention, 2005, 14, 1230-1235. Proteome analysis of prostate cancer. Prostate Cancer and Prostatic Diseases, 2005, 8, 14-21.

#	Article	IF	Citations
1282	Lung Cancer in Women. Journal of Clinical Oncology, 2005, 23, 3212-3218.	0.8	137
1283	Weekly Paclitaxel and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium: A Phase II Hoosier Oncology Group Study. Journal of Clinical Oncology, 2005, 23, 1185-1191.	0.8	97
1284	Surgery for Non-Small Cell Carcinoma in Geriatric Patients: 15-Year Experience. Asian Cardiovascular and Thoracic Annals, 2005, 13, 330-336.	0.2	20
1285	Retrospective Analysis of Selective Lymphadenectomy in Apparent Early-Stage Endometrial Cancer. Journal of Clinical Oncology, 2005, 23, 3668-3675.	0.8	406
1286	Cyr61 Induces Gastric Cancer Cell Motility/Invasion via Activation of the Integrin/Nuclear Factor-κB/Cyclooxygenase-2 Signaling Pathway. Clinical Cancer Research, 2005, 11, 5809-5820.	3.2	88
1287	Contralateral Breast Cancer: Where Does It All Begin?. Journal of Clinical Oncology, 2005, 23, 4585-4587.	0.8	6
1288	Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study. Journal of Clinical Oncology, 2005, 23, 1228-1236.	0.8	203
1289	Age-Related Prevalence of Anal Cancer Precursors in Homosexual Men: The EXPLORE Study. Journal of the National Cancer Institute, 2005, 97, 896-905.	3.0	203
1290	Retinoic Acid and the Histone Deacetylase Inhibitor Trichostatin A Inhibit the Proliferation of Human Renal Cell Carcinoma in a Xenograft Tumor Model. Clinical Cancer Research, 2005, 11, 3558-3566.	3.2	70
1291	Quantitative Assessment of Telomerase Activity and Human Telomerase Reverse Transcriptase Messenger RNA Levels in Pancreatic Juice Samples for the Diagnosis of Pancreatic Cancer. Clinical Cancer Research, 2005, 11, 2285-2292.	3.2	55
1293	Colorectal Cancer: Epidemiology, Risk Factors, and Health Services. Clinics in Colon and Rectal Surgery, 2005, 18, 133-140.	0.5	119
1294	Evaluation of Gas-filled Microparticles and Sonoporation as Gene Delivery System: Feasibility Study in Rodent Tumor Models. Radiology, 2005, 236, 572-578.	3.6	108
1295	Lung Cancer Surgery. , 2005, , 47-58.		0
1296	Relationship of Treatment Delay with Surgical Defect Size from Keratinocyte Carcinoma (Basal Cell) Tj ETQq1 1 C 308-314.	.784314 r 0.3	gBT /Overloc 45
1297	Activation of Androgen Receptor in Prostate Cancer: Role of Protein Kinase A and Extracellular Signal-regulated Kinases. , 2005, , 515-521.		0
1298	Early Lung Cancer Detection Using Spiral Computed Tomography and Positron Emission Tomography. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1378-1383.	2.5	163
1299	Thalidomide: present and future in multiple myeloma. Expert Review of Anticancer Therapy, 2005, 5, 25-31.	1.1	11
1300	Multiple myeloma: an update of developments in targeted therapy. Expert Review of Anticancer Therapy, 2005, 5, 379-389.	1.1	4

$\sim$			<u> </u>	
( 11	ΓΔΤ	ION		PORT
$\sim$	171		IVEL	

#	Article	IF	CITATIONS
1301	Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Therapy, 2005, 12, 187-193.	2.3	49
1302	Cost implications of post-surgical morbidity following blood transfusion in cancer patients undergoing elective colorectal resection: an evaluation in the US hospital setting. Current Medical Research and Opinion, 2005, 21, 447-455.	0.9	8
1303	Inhibition of Growth of Experimental Human Endometrial Cancer by an Antagonist of Growth Hormone-Releasing Hormone. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3614-3621.	1.8	35
1304	Reproductive and Menstrual Risk Factors for Pancreatic Cancer: A Population-based Study of San Francisco Bay Area Women. American Journal of Epidemiology, 2005, 161, 741-747.	1.6	44
1305	Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 2005, 23, 5578-5587.	0.8	382
1306	Raloxifene and Colorectal Cancer. Journal of Women's Health, 2005, 14, 299-305.	1.5	5
1307	Targeting ECM–Integrin Interaction with Liposome-Encapsulated Small Interfering RNAs Inhibits the Growth of Human Prostate Cancer in a Bone Xenograft Imaging Model. Molecular Therapy, 2005, 12, 634-643.	3.7	82
1308	Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer. Journal of Clinical Oncology, 2005, 23, 792-799.	0.8	1,285
1309	CT-Directed Microcoil Localization of Small Peripheral Lung Nodules: A Feasibility Study in Pigs. Journal of Investigative Surgery, 2005, 18, 265-272.	0.6	16
1310	An Efficient Colon Segmentation method for Oral Contrast-Enhanced CT Colonography. , 2005, 2005, 3429-32.		6
1311	Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Annals of Oncology, 2005, 16, 7-15.	0.6	123
1312	Colorectal Cancer in African Americans. American Journal of Gastroenterology, 2005, 100, 515-523.	0.2	282
1313	Adenoviral Vectors Expressing Human Endostatin–Angiostatin and Soluble Tie2: Enhanced Suppression of Tumor Growth and Antiangiogenic Effects in a Prostate Tumor Model. Molecular Therapy, 2005, 12, 1091-1100.	3.7	29
1314	Women with a Prior Diagnosis of Breast Cancer Are Not at an Increased Risk for Subsequent Colorectal Cancer. American Journal of Gastroenterology, 2005, 100, 2759-2764.	0.2	16
1315	Individualised cancer therapeutics: dream or reality?. Expert Opinion on Therapeutic Targets, 2005, 9, 1189-1201.	1.5	7
1316	Increased fluid secretion after adenoviral-mediated transfer of the human aquaporin-1 cDNA to irradiated miniature pig parotid glands. Molecular Therapy, 2005, 11, 444-451.	3.7	117
1317	RNA Interference-directed Knockdown of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor Inhibits Prostate Cancer Cell Invasion, Survival, and Tumorigenicity in Vivo. Journal of Biological Chemistry, 2005, 280, 36529-36540.	1.6	251
1318	Choice of endogenous control for gene expression in nonsmall cell lung cancer. European Respiratory Journal, 2005, 26, 1002-1008.	3.1	55

#	Article	IF	CITATIONS
1319	Complement Factor H as a Marker for Detection of Bladder Cancer. Clinical Chemistry, 2005, 51, 856-863.	1.5	60
1320	Calcium/Calmodulin-Dependent Kinase I and Calcium/Calmodulin-Dependent Kinase Kinase Participate in the Control of Cell Cycle Progression in MCF-7 Human Breast Cancer Cells. Cancer Research, 2005, 65, 5408-5416.	0.4	80
1321	Ethnicity and Breast Cancer: Factors Influencing Differences in Incidence and Outcome. Journal of the National Cancer Institute, 2005, 97, 439-448.	3.0	539
1322	Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer. Clinical Cancer Research, 2005, 11, 3958-3965.	3.2	87
1323	Curcumin Suppresses Growth of Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2005, 11, 6994-7002.	3.2	174
1324	Allergies and the Risk of Pancreatic Cancer: A Meta-analysis with Review of Epidemiology and Biological Mechanisms. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1908-1916.	1.1	107
1325	Establishment of a Serum Tumor Marker for Preclinical Trials of Mouse Prostate Cancer Models. Clinical Cancer Research, 2005, 11, 7911-7919.	3.2	24
1326	Concurrent Administration of High-Dose Rituximab Before and After Autologous Stem-Cell Transplantation for Relapsed Aggressive B-Cell Non-Hodgkin's Lymphomas. Journal of Clinical Oncology, 2005, 23, 2240-2247.	0.8	127
1327	Markers of apoptosis in stage IB squamous cervical carcinoma. Journal of Clinical Pathology, 2005, 58, 590-594.	1.0	4
1328	Down-regulation of Integrin α2 Surface Expression by Mutant Epidermal Growth Factor Receptor (EGFRvIII) Induces Aberrant Cell Spreading and Focal Adhesion Formation. Cancer Research, 2005, 65, 9280-9286.	0.4	50
1329	Mass Spectrometry-based Expression Profiling of Clinical Prostate Cancer. Molecular and Cellular Proteomics, 2005, 4, 545-554.	2.5	61
1330	Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients. Expert Opinion on Drug Safety, 2005, 4, 1051-1067.	1.0	17
1331	Assessing oral cancer knowledge among dental students in South Carolina. Journal of the American Dental Association, 2005, 136, 373-378.	0.7	54
1332	Environmental influences in cancer aetiology. Journal of Nutritional and Environmental Medicine, 2005, 15, 56-114.	0.1	16
1333	Treatment of Renal Tumors with Radiofrequency Ablation. Journal of Endourology, 2005, 19, 643-653.	1.1	35
1334	Chemoradiation With and Without Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of the Esophagus. Journal of Clinical Oncology, 2005, 23, 2310-2317.	0.8	1,221
1335	Influence of Surgical Resection and Post-Operative Complications on Survival following Adjuvant Treatment for Pancreatic Cancer in the ESPAC-1 Randomized Controlled Trial. Digestive Surgery, 2005, 22, 353-363.	0.6	68
1336	Regression of Colorectal Adenomas With Intravenous Cytotoxic Chemotherapy in a Patient With Familial Adenomatous Polyposis. Journal of Clinical Oncology, 2005, 23, 6278-6280.	0.8	3

#	Article	IF	CITATIONS
1337	Treatment of Chemotherapy-Resistant Human Ovarian Cancer Xenografts in C.B-17/SCID Mice by Intraperitoneal Administration of Clostridium perfringens Enterotoxin. Cancer Research, 2005, 65, 4334-4342.	0.4	111
1338	Pancreatic Cancer Cell Radiation Survival and Prenyltransferase Inhibition: The Role of K-Ras. Cancer Research, 2005, 65, 8433-8441.	0.4	69
1339	Safety and Efficacy of Weight Training in Recent Breast Cancer Survivors to Alter Body Composition, Insulin, and Insulin-Like Growth Factor Axis Proteins. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1672-1680.	1.1	269
1340	Combined Evaluation of Expressions of Cyclin E and p53 Proteins as Prognostic Factors for Patients with Gastric Cancer. Clinical Cancer Research, 2005, 11, 1447-1453.	3.2	48
1341	Human Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer. Clinical Cancer Research, 2005, 11, 3320-3325.	3.2	52
1342	A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2005, 11, 5526-5533.	3.2	99
1343	Mcl-1, Vascular Endothelial Growth Factor-R2, and 14-3-3σ Expression Might Predict Primary Response against Radiotherapy and Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinomas of the Head and Neck. Clinical Cancer Research, 2005, 11, 8632-8636.	3.2	32
1344	Lower Incidence of Inguinal Hernia: Minilaparotomy Radical Retropubic Prostatectomy Compared with Conventional Technique. Urologia Internationalis, 2005, 74, 32-37.	0.6	39
1345	Treatment of Small Cell Lung Cancer in the Elderly. Oncologist, 2005, 10, 399-411.	1.9	48
1346	Emodin Down-Regulates Androgen Receptor and Inhibits Prostate Cancer Cell Growth. Cancer Research, 2005, 65, 2287-2295.	0.4	155
1347	Galanin Receptor 1 Has Anti-proliferative Effects in Oral Squamous Cell Carcinoma. Journal of Biological Chemistry, 2005, 280, 22564-22571.	1.6	51
1348	CaSm-Mediated Cellular Transformation Is Associated with Altered Gene Expression and Messenger RNA Stability. Cancer Research, 2005, 65, 6228-6236.	0.4	25
1349	PSA Kinetics and Risk of Death From Prostate Cancer. JAMA - Journal of the American Medical Association, 2005, 294, 493.	3.8	7
1350	Colorectal Papillomavirus Infection in Patients with Colorectal Cancer. Clinical Cancer Research, 2005, 11, 2862-2867.	3.2	120
1351	[18F]Fluorodeoxyglucose Uptake by Positron Emission Tomography Predicts Outcome of Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 1136-1143.	0.8	274
1352	Association of Vitamin D Receptor Gene Polymorphism and Risk of Prostate Cancer in India. Urologia Internationalis, 2005, 74, 315-318.	0.6	27
1353	Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Annals of Oncology, 2005, 16, 869-877.	0.6	62
1354	Differential requirement of signal pathways for benzo[ a ]pyrene (B[ a ]P)-induced nitric oxide synthase (iNOS) in rat esophageal epithelial cells. Carcinogenesis, 2005, 26, 1035-1043.	1.3	26

#	Article	IF	CITATIONS
1355	The soy isoflavone genistein promotes apoptosis in mammary epithelial cells by inducing the tumor suppressor PTEN. Carcinogenesis, 2005, 26, 1793-1803.	1.3	92
1356	Toll-Like Receptor 4 in Butylated Hydroxytoluene–Induced Mouse Pulmonary Inflammation and Tumorigenesis. Journal of the National Cancer Institute, 2005, 97, 1778-1781.	3.0	75
1357	The T393C Polymorphism of the GÂs Gene (GNAS1) Is a Novel Prognostic Marker in Bladder Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 871-877.	1.1	73
1358	Calcium-Binding Proteins S100A8 and S100A9 as Novel Diagnostic Markers in Human Prostate Cancer. Clinical Cancer Research, 2005, 11, 5146-5152.	3.2	225
1359	Neoplastic and Non-neoplastic Diseases of the Stomach. , 2005, , 237-251.		0
1360	Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma. Endocrine-Related Cancer, 2005, 12, 973-981.	1.6	65
1361	Identification of SFRP1 as a Candidate Mediator of Stromal-to-Epithelial Signaling in Prostate Cancer. Cancer Research, 2005, 65, 10423-10430.	0.4	150
1362	Baseline Chest Radiograph for Lung Cancer Detection in the Randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Journal of the National Cancer Institute, 2005, 97, 1832-1839.	3.0	112
1363	Lung Cancer in Women. Chest, 2005, 127, 768-777.	0.4	243
1364	Positron Emission Tomography Does Not Add to Computed Tomography for the Diagnosis and Staging of Pancreatic Cancer. Digestive Surgery, 2005, 22, 55-62.	0.6	62
1365	Expression of KIT (CD117) in Renal Cell Carcinoma and Renal Oncocytoma. Oncology, 2005, 68, 269-275.	0.9	41
1366	Synergistic Induction of DOC-2/DAB2 Gene Expression in Transitional Cell Carcinoma in the Presence of GATA6 and Histone Deacetylase Inhibitor. Cancer Research, 2005, 65, 6089-6096.	0.4	21
1367	High Cyclooxygenase-2 Expression Following Neoadjuvant Radiochemotherapy Is Associated with Minor Histopathologic Response and Poor Prognosis in Esophageal Cancer. Clinical Cancer Research, 2005, 11, 8341-8347.	3.2	56
1368	Phase I Study of Hepatic Arterial Melphalan Infusion and Hepatic Venous Hemofiltration Using Percutaneously Placed Catheters in Patients With Unresectable Hepatic Malignancies. Journal of Clinical Oncology, 2005, 23, 3465-3474.	0.8	112
1369	Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet, The, 2005, 366, 1784-1793.	6.3	1,101
1370	Stage II Colorectal Cancer: To Treat or not to Treat. Oncologist, 2005, 10, 332-334.	1.9	35
1371	A RANDOMIZED, PHASE II TRIAL OF KETOCONAZOLE PLUS ALENDRONATE VERSUS KETOCONAZOLE ALONE IN PATIENTS WITH ANDROGEN INDEPENDENT PROSTATE CANCER AND BONE METASTASES. Journal of Urology, 2005, 173, 790-796.	0.2	66
1372	Testosterone Substitution and the Prostate. European Urology Supplements, 2005, 4, 16-23.	0.1	4

#	Article	IF	CITATIONS
1373	Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone–releasing hormone analogues AN-152 and AN-207. Fertility and Sterility, 2005, 83, 1125-1133.	0.5	29
1374	The risks and benefits of cyclo-oxygenase-2 inhibitors in prostate cancer: A review. International Journal of Surgery, 2005, 3, 278-285.	1.1	13
1375	ASCE guideline: the role of endoscopy in the diagnosis, staging, and management of colorectal cancer. Gastrointestinal Endoscopy, 2005, 61, 1-7.	0.5	76
1376	The utility of EUS-guided FNA in the diagnosis of metastatic breast cancer to the esophagus and the mediastinum. Gastrointestinal Endoscopy, 2005, 61, 416-420.	0.5	41
1377	Women patients' preference for women physicians is a barrier to colon cancer screening. Gastrointestinal Endoscopy, 2005, 62, 219-223.	0.5	117
1378	CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Experimental Cell Research, 2005, 310, 117-130.	1.2	148
1379	Human Tissue Kallikreins: From Gene Structure to Function and Clinical Applications. Advances in Clinical Chemistry, 2005, 39, 11-79.	1.8	58
1380	Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Carcinoma Is Associated With Significantly Improved Survival. Journal of Clinical Oncology, 2005, 23, 4330-4337.	0.8	434
1381	Changing trends in the incidence, stage, survival, and screen-detection of colorectal cancer: A population-based study. Clinical Gastroenterology and Hepatology, 2005, 3, 150-158.	2.4	97
1382	Pancreatic neoplasms. Gastrointestinal Endoscopy Clinics of North America, 2005, 15, 117-142.	0.6	9
1383	New Frontiers in Endoscopic Imaging. Gastrointestinal Endoscopy Clinics of North America, 2005, 15, 631-651.	0.6	1
1384	Prevalence of Polyps Greater Than 9 mm in a Consortium of Diverse Clinical Practice Settings in the United States. Clinical Gastroenterology and Hepatology, 2005, 3, 798-805.	2.4	77
1385	Cervical Cancer: Current Management of Early/Late Disease. Surgical Oncology Clinics of North America, 2005, 14, 249-266.	0.6	2
1386	Projected National Impact of Colorectal Cancer Screening on Clinical and Economic Outcomes and Health Services Demand. Gastroenterology, 2005, 129, 1151-1162.	0.6	152
1387	Is There Disparity in the Care of Minority Patients with Upper Aerodigestive Tract Malignancy?. Medical Clinics of North America, 2005, 89, 1033-1043.	1.1	1
1388	Optical Coherence Tomography Imaging of the Pancreas: A Needle-Based Approach. Clinical Gastroenterology and Hepatology, 2005, 3, S49-S52.	2.4	25
1390	MONITORING INTRAVESICAL THERAPY FOR SUPERFICIAL BLADDER CANCER USING FLUORESCENCE IN SITU HYBRIDIZATION. Journal of Urology, 2005, 173, 401-404.	0.2	114
1391	VARIATIONS AMONG HIGH VOLUME SURGEONS IN THE RATE OF COMPLICATIONS AFTER RADICAL PROSTATECTOMY: FURTHER EVIDENCE THAT TECHNIQUE MATTERS. Journal of Urology, 2005, 173, 2099-2103.	0.2	190

#	Article	IF	CITATIONS
1392	1–40 Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period. Breast Diseases, 2005, 16, 76-77.	0.0	0
1393	A NOVEL COMPUTER BASED EXPERT DECISION MAKING MODEL FOR PROSTATE CANCER DISEASE MANAGEMENT. Journal of Urology, 2005, 174, 2310-2318.	0.2	23
1394	Molecular Biology of Esophageal Cancer in the Genomics Era. Surgical Clinics of North America, 2005, 85, 539-553.	0.5	19
1395	Type 2 Diabetes Mellitus and the Risk of Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2005, 3, 587-594.	2.4	128
1396	The Polycomb Group Protein EZH2 Impairs DNA Repair in Breast Epithelial Cells. Neoplasia, 2005, 7, 1011-1019.	2.3	86
1397	Ovarian cancer diagnosis using complementary learning fuzzy neural network. , 0, , .		4
1398	Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): The Expanded Access Protocol Experience at the University of Pennsylvania. Cancer Investigation, 2005, 23, 296-302.	0.6	18
1399	Human Papillomavirus: A Catalyst to a Killer. American Journal of Health Education, 2005, 36, 166-173.	0.3	2
1400	Oral Cancer Diagnosis with Optical Coherence Tomography. , 2005, 2005, 7227-9.		5
1401	Primary Culture of Polarized Human Salivary Epithelial Cells for Use in Developing an Artificial Salivary Gland. Tissue Engineering, 2005, 11, 172-181.	4.9	77
1402	RELATIONSHIP BETWEEN BODY SIZE AND PROSTATE CANCER IN A SIBLING BASED CASE-CONTROL STUDY. Journal of Urology, 2005, 174, 2169-2173.	0.2	9
1403	Growth Inhibitory and Antimetastatic Effect of Green Tea Polyphenols on Metastasis-Specific Mouse Mammary Carcinoma 4T1 Cells In vitro and In vivo Systems. Clinical Cancer Research, 2005, 11, 1918-1927.	3.2	151
1404	American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer. Journal of Clinical Oncology, 2005, 23, 7703-7720.	0.8	1,674
1405	Molecular Detection of Early-Stage Laryngopharyngeal Squamous Cell Carcinomas. Clinical Cancer Research, 2005, 11, 2547-2551.	3.2	14
1406	Health risks associated with obesity. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2005, 10, 56-61.	0.4	5
1407	A Role of Androgen Receptor Protein in Cell Growth of an Androgen-Independent Prostate Cancer Cell Line. Bioscience, Biotechnology and Biochemistry, 2005, 69, 2236-2239.	0.6	10
1408	Celecoxib and Curcumin Synergistically Inhibit the Growth of Colorectal Cancer Cells. Clinical Cancer Research, 2005, 11, 6738-6744.	3.2	212
1409	Noninvasive Detection of Prostate Cancer by Quantitative Analysis of Telomerase Activity. Clinical Cancer Research, 2005, 11, 3243-3249.	3.2	45

#	Article	IF	CITATIONS
1410	Detection and Quantification of N-(Deoxyguanosin-8-yl)-4-aminobiphenyl Adducts in Human Pancreas Tissue Using Capillary Liquid Chromatography-Microelectrospray Mass Spectrometry. Chemical Research in Toxicology, 2005, 18, 692-699.	1.7	43
1411	Chromosome analysis in childhood cancer survivors and their offspring—No evidence for radiotherapy-induced persistent genomic instability. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2005, 583, 198-206.	0.9	42
1412	Risks and benefits of population-based genetic testing for Mendelian subsets of common diseases were examined using the example of colorectal cancer risk. Journal of Clinical Epidemiology, 2005, 58, 934-941.	2.4	5
1413	Photodynamic therapy of high grade glioma – long term survival. Journal of Clinical Neuroscience, 2005, 12, 389-398.	0.8	199
1414	MAPK and PI3K Inhibition Reduces Proliferation of Barrett's Adenocarcinoma in Vitro1. Journal of Surgical Research, 2005, 127, 53-57.	0.8	16
1415	PTEN expression in non–small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Human Pathology, 2005, 36, 768-776.	1.1	231
1416	Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Human Pathology, 2005, 36, 1186-1196.	1.1	106
1417	Hereditary cancer syndromes of the skin. Clinics in Dermatology, 2005, 23, 85-106.	0.8	16
1418	The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treatment Reviews, 2005, 31, 115-142.	3.4	60
1419	Will the dark sky over advanced renal cell carcinoma soon become brighter?. European Journal of Cancer, 2005, 41, 1246-1253.	1.3	12
1420	PKA-dependent growth stimulation of cells derived from human pulmonary adenocarcinoma and small airway epithelium by dexamethasone. European Journal of Cancer, 2005, 41, 2745-2753.	1.3	11
1421	Hormone replacement therapy (HRT) and endometrial morphology under consideration of the different molecular pathways in endometrial carcinogenesis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2005, 122, 4-12.	0.5	18
1422	Comparison of quantitative and visual analysis of Tc-99m MIBI scintimammography for detection of primary breast cancer. European Journal of Radiology, 2005, 53, 192-198.	1.2	12
1423	The value of contrast enhanced power Doppler ultrasonography in differentiating hypoehoic lesions in the peripheral zone of prostate. European Journal of Radiology, 2005, 54, 148-155.	1.2	18
1424	Changing gastric cancer treatment in the United States and the pursuit of quality. European Journal of Surgical Oncology, 2005, 31, 605-615.	0.5	12
1425	Lack of prepubertal administration of ethinyl estradiol on susceptibility to multiple organ carcinogenesis in rats exposed to 7,12-dimethylbenz[a]anthracene and N-bis(2-hydroxypropyl)nitrosamine during adolescence. Cancer Letters, 2005, 223, 37-46.	3.2	2
1426	Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer. FEBS Letters, 2005, 579, 2873-2877.	1.3	80
1427	Analysis of Tumor Vessel Supply in Lewis Lung Carcinoma in Mice by Fluorescent Microsphere Distribution and Imaging with Micro- and Flat-Panel Computed Tomography. American Journal of Pathology, 2005, 167, 937-946.	1.9	32

#	Article	IF	CITATIONS
1428	Constitutive Activation of JAK3/STAT3 in Colon Carcinoma Tumors and Cell Lines. American Journal of Pathology, 2005, 167, 969-980.	1.9	195
1429	Expression of S100P and Its Novel Binding Partner S100PBPR in Early Pancreatic Cancer. American Journal of Pathology, 2005, 166, 81-92.	1.9	119
1430	Is routine postoperative chest radiography needed after open nephrectomy?. Urology, 2005, 65, 256-259.	0.5	5
1431	Impact of lymphadenectomy and nodal burden in renal cell carcinoma: Retrospective analysis of the National Surveillance, Epidemiology, and End Results database. Urology, 2005, 65, 675-680.	0.5	77
1432	Cystoprostatectomy and orthotopic ileal neobladder reconstruction for management of bacille Calmette GuÉrin-induced bladder contractures. Urology, 2005, 65, 909-912.	0.5	21
1433	Quality of life after radical treatment of prostate cancer: Validation of the Italian version of the University of California-Los Angeles Prostate Cancer Index. Urology, 2005, 66, 338-343.	0.5	30
1434	Efficacy of prostatic fossa biopsy in detecting local recurrence after radical prostatectomy. Urology, 2005, 66, 350-355.	0.5	34
1435	Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: A preliminary analysis. Urology, 2005, 66, 547-551.	0.5	22
1436	Correlates and prevalence of prostatitis in a large community-based cohort of older men. Urology, 2005, 66, 964-970.	0.5	51
1437	Laparoscopic radical prostatectomy: Conventional and robotic. Urology, 2005, 66, 101-104.	0.5	107
1438	Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 163-167.	0.8	3
1439	Prostate cancer screening between low-income African-American and Caucasian menâ~†. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 333-340.	0.8	33
1440	Relative importance of PSA in prostate cancer treatment. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 238-245.	0.8	2
1441	Aberrant expression of E-cadherin and beta-catenin in human prostate cancerâ~†. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 402-406.	0.8	90
1442	An update on randomized clinical trials in localized and locoregional prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 280-288.	0.8	19
1443	Inhibition of growth and telomerase activity by novel cationic ceramide analogs with high solubility in human head and neck squamous cell carcinoma cells. Otolaryngology - Head and Neck Surgery, 2005, 132, 55-62.	1.1	48
1444	Tumor-dendritic cell fusion as a basis for cancer immunotherapy. Otolaryngology - Head and Neck Surgery, 2005, 132, 755-764.	1.1	23
1445	Endoscopic Ultrasound-Guided Fine Needle Aspiration of Mediastinal Lymph Node in Patients With Suspected Lung Cancer After Positron Emission Tomography and Computed Tomography Scans. Annals of Thoracic Surgery, 2005, 79, 263-268.	0.7	212

#	Article	IF	CITATIONS
1446	Randomized trial of a low-intensity dietary intervention in rural residents. American Journal of Preventive Medicine, 2005, 28, 162-168.	1.6	32
1447	Clinical utility and cost-effectiveness of routine preoperative computed tomography scanning in patients with colon cancer. American Journal of Surgery, 2005, 189, 512-517.	0.9	41
1448	An update of sentinel lymph node mapping in patients with ductal carcinoma in situ. American Journal of Surgery, 2005, 190, 563-566.	0.9	126
1449	Endoscopic ultrasound: impact on survival in patients with esophageal cancer. American Journal of Surgery, 2005, 190, 682-686.	0.9	8
1450	Intestinal and oncocytic variants of pancreatic intraepithelial neoplasia. A morphological and immunohistochemical study. Annals of Diagnostic Pathology, 2005, 9, 69-76.	0.6	20
1451	The value of postmortem examination in cases of metastasis of unknown origin—20-year retrospective data from a tertiary care center. Annals of Diagnostic Pathology, 2005, 9, 77-80.	0.6	45
1452	Clinico-pathological features of bladder carcinoma in women in Pakistan and smokeless tobacco as a possible risk factor. World Journal of Surgical Oncology, 2005, 3, 53.	0.8	10
1453	The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. Journal of Translational Medicine, 2005, 3, 22.	1.8	94
1454	Targeting Breast and Prostate Cancers Through Their Hormone Receptors1. Biology of Reproduction, 2005, 73, 860-865.	1.2	49
1455	The Value of Peritoneal Cytology as a Preoperative Predictor in Patients With Gastric Carcinoma Undergoing a Curative Resection. Annals of Surgical Oncology, 2005, 12, 347-353.	0.7	191
1456	Improving Outcomes in Advanced Malignant Melanoma. Drugs, 2005, 65, 733-743.	4.9	35
1457	Evolution of Radical Procedures for Urologic Cancer. Surgical Oncology Clinics of North America, 2005, 14, 553-568.	0.6	5
1459	Cholangiocarcinoma. Gastroenterology, 2005, 128, 1655-1667.	0.6	417
1460	Proteomic Analysis of Chronic Pancreatitis and Pancreatic Adenocarcinoma. Gastroenterology, 2005, 129, 1454-1463.	0.6	162
1461	Utilization of colonoscopy in the United States: results from a national consortium. Gastrointestinal Endoscopy, 2005, 62, 875-883.	0.5	184
1462	Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer, 2005, 47, 129-138.	0.9	132
1463	Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?. Lung Cancer, 2005, 48, 93-102.	0.9	33
1464	Monoclonal antibody 2C5-mediated binding of liposomes to brain tumor cells in vitro and in subcutaneous tumor model in vivo. Journal of Drug Targeting, 2005, 13, 337-343.	2.1	36

#	Article	IF	CITATIONS
1465	Characterization of Proteins in Human Pancreatic Cancer Serum Using Differential Gel Electrophoresis and Tandem Mass Spectrometry. Journal of Proteome Research, 2005, 4, 1742-1751.	1.8	144
1466	Enhancement of Gemcitabine-Induced Apoptosis by Restoration of p53 Function in Human Pancreatic Tumors. Oncology, 2005, 68, 179-189.	0.9	18
1467	Radical Gastrectomy and Lymphadenectomy: Historic Overview, Surgical Trends, and Lessons from the Past. Surgical Oncology Clinics of North America, 2005, 14, 511-532.	0.6	2
1468	Controlled Physical Activity Trials in Cancer Survivors: A Systematic Review and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1588-1595.	1.1	567
1469	UPDATE ON CHEMOTHERAPY FOR ADVANCED BLADDER CANCER. Journal of Urology, 2005, 174, 14-20.	0.2	147
1470	Supportive Care in Lung Cancer. Hematology/Oncology Clinics of North America, 2005, 19, 369-387.	0.9	5
1471	Current Staging of Esophageal Carcinoma. Surgical Clinics of North America, 2005, 85, 555-567.	0.5	20
1472	MEDICAL AND SURGICAL PALLIATIVE CARE OF PATIENTS WITH UROLOGICAL MALIGNANCIES. Journal of Urology, 2005, 174, 1177-1182.	0.2	49
1473	Developments and Current Treatment Standards in Cervical Cancer. American Journal of Cancer, 2005, 4, 373-381.	0.4	0
1474	Vaccination Against Cervical Cancer. American Journal of Cancer, 2005, 4, 207-219.	0.4	4
1475	Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer.		52
	Pancreatology, 2005, 5, 370-379.	0.5	
1476	Milk Thistle and Prostate Cancer: Differential Effects of Pure Flavonolignans from Silybum marianum on Antiproliferative End Points in Human Prostate Carcinoma Cells. Cancer Research, 2005, 65, 4448-4457.	0.5	194
1476 1477	Milk Thistle and Prostate Cancer: Differential Effects of Pure Flavonolignans from Silybum marianum on Antiproliferative End Points in Human Prostate Carcinoma Cells. Cancer Research, 2005, 65,		194 28
	Milk Thistle and Prostate Cancer: Differential Effects of Pure Flavonolignans from Silybum marianum on Antiproliferative End Points in Human Prostate Carcinoma Cells. Cancer Research, 2005, 65, 4448-4457. Conserved transcription factor binding sites of cancer markers derived from primary lung	0.4	
1477	Milk Thistle and Prostate Cancer: Differential Effects of Pure Flavonolignans from Silybum marianum on Antiproliferative End Points in Human Prostate Carcinoma Cells. Cancer Research, 2005, 65, 4448-4457. Conserved transcription factor binding sites of cancer markers derived from primary lung adenocarcinoma microarrays. Nucleic Acids Research, 2005, 33, 409-421. Statins and Prostate Cancer Risk: A Case-Control Study. American Journal of Epidemiology, 2005, 162,	0.4 6.5	28
1477 1478	Milk Thistle and Prostate Cancer: Differential Effects of Pure Flavonolignans from Silybum marianum on Antiproliferative End Points in Human Prostate Carcinoma Cells. Cancer Research, 2005, 65, 4448-4457. Conserved transcription factor binding sites of cancer markers derived from primary lung adenocarcinoma microarrays. Nucleic Acids Research, 2005, 33, 409-421. Statins and Prostate Cancer Risk: A Case-Control Study. American Journal of Epidemiology, 2005, 162, 318-325.	0.4 6.5 1.6	28 217
1477 1478 1479	Milk Thistle and Prostate Cancer: Differential Effects of Pure Flavonolignans from Silybum marianum on Antiproliferative End Points in Human Prostate Carcinoma Cells. Cancer Research, 2005, 65, 4448-4457. Conserved transcription factor binding sites of cancer markers derived from primary lung adenocarcinoma microarrays. Nucleic Acids Research, 2005, 33, 409-421. Statins and Prostate Cancer Risk: A Case-Control Study. American Journal of Epidemiology, 2005, 162, 318-325. IN VIVO MODELS OF PROSTATE CANCER METASTASIS TO BONE. Journal of Urology, 2005, 174, 820-826. Investigation of secondary neutron dose for 18MV dynamic MLC IMRT delivery. Medical Physics, 2005,	0.4 6.5 1.6 0.2	28 217 67

#	Article	IF	CITATIONS
1483	TRANSURETHRAL BLADDER TUMOR RESECTION: INTRAOPERATIVE AND POSTOPERATIVE COMPLICATIONS IN A RESIDENCY SETTING. Journal of Urology, 2005, 174, 2307-2309.	0.2	122
1484	Computer-aided diagnostic scheme for distinction between benign and malignant nodules in thoracic low-dose CT by use of massive training artificial neural network. IEEE Transactions on Medical Imaging, 2005, 24, 1138-1150.	5.4	199
1485	Clinical trial update: International Breast Cancer Study Group. Breast Cancer Research, 2005, 7, 252-4.	2.2	21
1486	Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro. Virology Journal, 2006, 3, 8.	1.4	13
1487	Taxanes in the Treatment of Non-Small Cell Lung Cancer. Treatments in Respiratory Medicine, 2006, 5, 181-191.	1.4	6
1488	Calcium plus Vitamin D Supplementation and the Risk of Colorectal Cancer. New England Journal of Medicine, 2006, 354, 684-696.	13.9	907
1489	Phase II Study of Cisplatin Combined with Weekly Gemcitabine in the Treatment of Patients with Metastatic Pancreatic Carcinoma. Pancreatology, 2006, 6, 635-641.	0.5	7
1490	Role of Radiation Therapy in Pediatric Cancer. Hematology/Oncology Clinics of North America, 2006, 20, 455-470.	0.9	33
1491	Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma. Cytotherapy, 2006, 8, 141-148.	0.3	16
1492	Epidermal growth factor receptor status in anaplastic thyroid carcinoma. Journal of Clinical Pathology, 2006, 60, 881-884.	1.0	39
1493	Health-Related Quality of Life for Latino Survivors of Childhood Cancer. Journal of Psychosocial Oncology, 2006, 24, 125-145.	0.6	17
1494	Feasibility of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia and Lymphoma, 2006, 47, 1593-1598.	0.6	13
1495	DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis, 2006, 27, 1160-1168.	1.3	138
1496	β-Escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21waf1/cip1 in colon cancer cells. Molecular Cancer Therapeutics, 2006, 5, 1459-1466.	1.9	80
1497	Combining Targeted Therapies and Drugs with Multiple Targets in the Treatment of NSCLC. Oncologist, 2006, 11, 274-284.	1.9	86
1498	XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. British Journal of Cancer, 2006, 94, 969-975.	2.9	114
1499	H-REV107-1 Stimulates Growth in Non-Small Cell Lung Carcinomas via the Activation of Mitogenic Signaling. American Journal of Pathology, 2006, 169, 1427-1439.	1.9	24
1500	Life After Cancer. Medical Journal Armed Forces India, 2006, 62, 102-103.	0.3	0

#	Article	IF	CITATIONS
1501	Synthesis and biological evaluation of a fluorine-18-labeled nonsteroidal androgen receptor antagonist, N-(3-[18F]fluoro-4-nitronaphthyl)-cis-5-norbornene-endo-2,3-dicarboxylic imide. Nuclear Medicine and Biology, 2006, 33, 615-624.	0.3	19
1502	Breast Cancer Ablation: Current Status 2006. Seminars in Breast Disease, 2006, 9, 3-12.	0.0	0
1503	Changes in Glucose Metabolism and Blood Flow Following Chemotherapy for Breast Cancer. PET Clinics, 2006, 1, 71-81.	1.5	18
1504	An Update on Imaging of Colorectal Cancer. Surgical Clinics of North America, 2006, 86, 819-847.	0.5	14
1505	The Role of Bisphosphonates in Preventing Skeletal Complications of Hormonal Therapy. Urologic Clinics of North America, 2006, 33, 191-199.	0.8	4
1506	Analysis of survival after laparoscopic-assisted vaginal hysterectomy compared with the conventional abdominal approach for early-stage endometrial carcinoma: A review of the literature. Journal of Minimally Invasive Gynecology, 2006, 13, 26-35.	0.3	48
1507	Proteomic Classification of Pancreatic Adenocarcinoma Tissue Using Protein Chip Technology. Gastroenterology, 2006, 130, 1670-1678.	0.6	41
1508	Imaging Upper Gastrointestinal Malignancy. Seminars in Roentgenology, 2006, 41, 105-112.	0.2	7
1509	Stable low-level expression of p21WAF1/CIP1 in A549 human bronchogenic carcinoma cell line-derived clones down-regulates E2F1 mRNA and restores cell proliferation control. Molecular Cancer, 2006, 5, 1.	7.9	70
1510	Prognostic significance of new onset ascites in patients with pancreatic cancer. World Journal of Surgical Oncology, 2006, 4, 16.	0.8	26
1511	[1] The Affymetrix GeneChip® Platform: An Overview. Methods in Enzymology, 2006, 410, 3-28.	0.4	163
1512	Monoclonal antibody combinations in CLL: evolving strategies. Best Practice and Research in Clinical Haematology, 2006, 19, 781-793.	0.7	7
1513	Right-side shift of colorectal adenomas with aging. Gastrointestinal Endoscopy, 2006, 63, 453-458.	0.5	37
1514	EUS-guided FNA of proximal biliary strictures after negative ERCP brush cytology results. Gastrointestinal Endoscopy, 2006, 64, 325-333.	0.5	209
1515	Incidence of advanced adenomas at surveillance colonoscopy in patients with a personal history of colon adenomas: a meta-analysis and systematic review. Gastrointestinal Endoscopy, 2006, 64, 614-626.	0.5	171
1516	Cytotoxicity of a non-cyclooxygenase-2 inhibitory derivative of celecoxib in non-small-cell lung cancer A549 cells. Lung Cancer, 2006, 52, 117-124.	0.9	23
1517	A randomized phase II trial evaluating standard (50mg/min) versus low (10mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer, 2006, 52, 319-325.	0.9	33
1518	Transesophageal ultrasound-guided fine needle aspiration improves mediastinal staging in patients with non-small cell lung cancer and normal mediastinum on computed tomography. Lung Cancer, 2006, 54, 35-40.	0.9	35

#	Article	IF	CITATIONS
1519	Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. Lung Cancer, 2006, 54, 193-199.	0.9	35
1520	Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting. Clinical Cancer Research, 2006, 12, 5064-5073.	3.2	440
1521	Colorectal Cancer Screening. American Journal of Preventive Medicine, 2006, 30, 378-384.	1.6	17
1522	The clinical applications of mammary ductoscopy. American Journal of Surgery, 2006, 191, 211-215.	0.9	26
1523	Interferon receptors and the caspase cascade regulate the antitumor effects of interferons on human pancreatic cancer cell lines. American Journal of Surgery, 2006, 191, 358-363.	0.9	23
1524	Positron-emission tomography as a prognostic tool for early-stage lung cancer. American Journal of Surgery, 2006, 191, 433-436.	0.9	20
1526	Perioperative Morbidity and Mortality After Reconstruction for Metastatic Tumors of the Proximal Femur and Acetabulum. Journal of Arthroplasty, 2006, 21, 227-232.	1.5	17
1527	Feasibility and Outcomes of an Early Extubation Policy After Esophagectomy. Annals of Thoracic Surgery, 2006, 82, 2037-2041.	0.7	58
1528	Oocyte cryopreservation. Fertility and Sterility, 2006, 86, 1037-1046.	0.5	141
1529	Consolidation with High-Dose Combination Alkylating Agents with Bone Marrow Transplantation Significantly Improves Disease-Free Survival in Hormone-Insensitive Metastatic Breast Cancer in Complete Remission Compared with Intensive Standard-Dose Chemotherapy Alone. Biology of Blood and Marrow Transplantation, 2006, 12, 195-203.	2.0	30
1530	Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 541-551.	2.0	84
1531	Ovarian cancer: Homeobox genes, autocrine/paracrine growth, and kinase signaling. International Journal of Biochemistry and Cell Biology, 2006, 38, 1450-1456.	1.2	21
1532	Mycophenolic acid-induced replication arrest, differentiation markers and cell death of androgen-independent prostate cancer cells DU145. Cancer Letters, 2006, 231, 20-29.	3.2	44
1533	Administration of human umbilical cord blood cells delays the onset of prostate cancer and increases the lifespan of the TRAMP mouse. Cancer Letters, 2006, 231, 123-128.	3.2	9
1534	Increased expression of connexin 26 in the invasive component of lung squamous cell carcinoma: Significant correlation with poor prognosis. Cancer Letters, 2006, 234, 239-248.	3.2	63
1535	Paclitaxel suppresses the growth of primary prostate tumours (RM-1) and metastases in the lung in C57BL/6 mice. Cancer Letters, 2006, 233, 185-191.	3.2	13
1536	Tissue-specificity of prostate specific antigens: Comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Letters, 2006, 236, 229-238.	3.2	124
1537	Anti-proliferative effects of green tea polyphenol EGCG on Ha-Ras-induced transformation of intestinal epithelial cells. Cancer Letters, 2006, 238, 260-270.	3.2	33

		ATION REPORT	
#	Article	IF	CITATIONS
1539	Metastatic colorectal cancer. Cancer Treatment Reviews, 2006, 32, 557-571.	3.4	11
1540	Cancer and pregnancy: Poena magna, not anymore. European Journal of Cancer, 2006, 42, 126-140.	1.3	229
1541	Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: Clinical considerations. European Journal of Cancer, 2006, 42, 2296-2302.	1.3	59
1542	Growth inhibition and apoptosis by (â^')-epicatechin gallate are mediated by cyclin D1 suppression in head and neck squamous carcinoma cells. European Journal of Cancer, 2006, 42, 3260-3266.	1.3	54
1543	Targeting events in melanoma carcinogenesis for the prevention of melanoma. Expert Review of Anticancer Therapy, 2006, 6, 1559-1568.	1.1	59
1544	Cytotoxic, antioxidant and antibacterial activities of Varthemia iphionoides Boiss. extracts. Journal of Ethnopharmacology, 2006, 108, 287-293.	2.0	44
1545	Laparoscopic technology for the treatment of endometrial cancer. International Journal of Gynecology and Obstetrics, 2006, 93, 176-181.	1.0	16
1546	Photodynamic therapy of cerebral glioma – A review Part II – Clinical studies. Journal of Clinical Neuroscience, 2006, 13, 709-717.	0.8	86
1547	Wilms' tumor arising within a mediastinal teratoma. Journal of Pediatric Surgery, 2006, 41, e1-e5.	0.8	9
1548	Les cancers d'origine indéterminée. Revue De Medecine Interne, 2006, 27, S272-S274.	0.6	0
1549	Synthesis and biological evaluation of a nonsteroidal bromine-76-labeled androgen receptor ligand 3-[76Br]bromo-hydroxyflutamide. Nuclear Medicine and Biology, 2006, 33, 705-713.	0.3	31
1550	Chiral dimethylamine flutamide derivatives—modeling, synthesis, androgen receptor affinities and carbon-11 labeling. Nuclear Medicine and Biology, 2006, 33, 695-704.	0.3	18
1551	Symptom Correlates in the Gero-Oncology Population. Seminars in Oncology Nursing, 2006, 22, 20-30.	0.7	22
1552	Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy. Urology, 2006, 67, 769-773.	0.5	11
1553	Literacy, race, and PSA level among low-income men newly diagnosed with prostate cancer. Urology, 2006, 68, 89-93.	0.5	84
1555	Identification of a Specific Vimentin isoform that Induces an Antibody Response in Pancreatic Cancer. Biomarker Insights, 2006, 1, 117727190600100.	1.0	21
1556	Significance of Noninvasive Diagnosis of Prostate Cancer with Cytologic Examination of Prostatic Fluid. Journal of Nippon Medical School, 2006, 73, 129-135.	0.3	2
1557	Breast Cancer Screening. AMA Journal of Ethics, 2006, 8, 7-15.	0.4	0

#	Article	IF	CITATIONS
1559	Radical hysterectomy. , 0, , 660-662.		0
1560	Acute lymphoblastic leukemia. , 0, , 439-472.		7
1562	Prostate cancer in Alaska Native men, 1969–2003. International Journal of Circumpolar Health, 2006, 65, 8-17.	0.5	10
1563	Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2006, 1, 520-525.	0.5	22
1564	Chapter 6 The role of fluoro-deoxy glucose (FDG) positron emission tomography (PET) in the management of differentiated thyroid cancer. Advances in Molecular and Cellular Endocrinology, 2006, 4, 107-116.	0.1	0
1565	Women With Pathologic Stage I, II, and III Non-small Cell Lung Cancer Have Better Survival Than Men. Chest, 2006, 130, 1796-1802.	0.4	127
1566	Genetically Induced Pancreatic Adenocarcinoma Is Highly Immunogenic and Causes Spontaneous Tumor-Specific Immune Responses. Cancer Research, 2006, 66, 508-516.	0.4	40
1567	Targeted Molecular Therapy of the PI3K Pathway. Annals of Surgery, 2006, 243, 833-844.	2.1	98
1568	The Neurotrophic Factor Artemin Promotes Pancreatic Cancer Invasion. Annals of Surgery, 2006, 244, 274-281.	2.1	126
1569	Vascular Endothelial Growth Factor (VEGF) Is Suppressed in WT1-Transfected LNCaP Cells. Gene Expression, 2006, 13, 1-14.	0.5	15
1570	Differences in Immune Cells Engaged in Cell-Mediated Immunity After Chemotherapy for Far Advanced Pancreatic Cancer. Pancreas, 2006, 32, 29-36.	0.5	30
1571	Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2006, 1, 520-525.	0.5	32
1572	Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2006, 1, 417-424.	0.5	11
1573	Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer. Anti-Cancer Drugs, 2006, 17, 1041-1044.	0.7	38
1574	On the Mechanisms of 12-Otetradecanoylphorbol-13-acetate-induced Growth Arrest in Pancreatic Cancer Cells. Pancreas, 2006, 33, 148-155.	0.5	13
1575	Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer. Anti-Cancer Drugs, 2006, 17, 697-704.	0.7	62
1576	Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. Journal of Pathology, 2006, 208, 673-685.	2.1	142
1577	Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers. Journal of Pathology, 2006, 210, 192-204.	2.1	143

#	Article	IF	CITATIONS
1578	The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. Prostate, 2006, 66, 413-420.	1.2	28
1579	A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate, 2006, 66, 1359-1370.	1.2	68
1580	Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate, 2006, 66, 822-830.	1.2	54
1581	Breast Cancer in the Elderly: Treatment of 1500 Patients. Breast Journal, 2006, 12, 353-359.	0.4	22
1582	Management of the elderly patient with advanced †non-small cell lung cancer. International Journal of Clinical Practice, 2006, 60, 340-343.	0.8	10
1583	Salvage abdominoperineal resection after failed Nigro protocol: modest success, major morbidity. Colorectal Disease, 2006, 8, 124-129.	0.7	90
1584	Assessment of aberrations on chromosome 8 in prostatic atrophy. BJU International, 2006, 98, 184-188.	1.3	18
1585	Management of locoregional stage esophageal cancer: a single center experience. Ecological Management and Restoration, 2006, 19, 78-83.	0.2	10
1586	Fertility preservation in female oncology patients. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2006, 46, 15-23.	0.4	29
1587	Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer. International Journal of Gynecological Cancer, 2006, 16, 57-64.	1.2	7
1588	Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer. International Journal of Gynecological Cancer, 2006, 16, 65-70.	1.2	31
1589	Preclinical in vivo activity of a combination gemcitabine/liposomal doxorubicin against cisplatin-resistant human ovarian cancer (A2780/CDDP). International Journal of Gynecological Cancer, 2006, 16, 222-230.	1.2	13
1590	Primary gynecological neoplasms and clinical outcomes in patients diagnosed with breast carcinoma. International Journal of Gynecological Cancer, 2006, 16, 118-122.	1.2	3
1591	Preoperative and intraoperative assessment of myometrial invasion and histologic grade in endometrial cancer: role of magnetic resonance imaging and frozen section. International Journal of Gynecological Cancer, 2006, 16, 385-390.	1.2	93
1592	The influence of aquaporin-1 and microvessel density on ovarian carcinogenesis and ascites formation. International Journal of Gynecological Cancer, 2006, 16, 400-405.	1.2	36
1593	Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property. International Journal of Gynecological Cancer, 2006, 16, 1536-1544.	1.2	20
1594	Role of lymphadenectomy and pelvic radiotherapy in patients with clinical FIGO stage I endometrial adenocarcinoma: an analysis of 208 patients. International Journal of Gynecological Cancer, 2006, 16, 1885-1893.	1.2	5
1595	Black-white differences in risk perceptions of breast cancer survival and screening mammography benefit. Journal of General Internal Medicine, 2006, 21, 371-377.	1.3	28

#	ARTICLE Application of surface-enhanced laser desorption/ionization time-of-flight-based serum proteomic	IF	Citations
1596	array technique for the early diagnosis of prostate cancer. Asian Journal of Andrology, 2006, 8, 45-51.	0.8	26
1597	Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic juice for pancreatic carcinoma. Cancer Science, 2006, 97, 1267-1273.	1.7	29
1598	Gastroenterologists utilize the referral for EGD to enhance colon cancer screening more effectively than primary care physicians. Alimentary Pharmacology and Therapeutics, 2006, 23, 953-962.	1.9	7
1599	GLUT1 and p63 expression in endometrial intraepithelial and uterine serous papillary carcinoma. Histopathology, 2006, 49, 75-81.	1.6	17
1600	Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. British Journal of Cancer, 2006, 95, 450-456.	2.9	10
1601	Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplantation, 2006, 37, 1017-1022.	1.3	52
1602	Lack of Association between BRAF Mutation and MAPK ERK Activation in Melanocytic Nevi. Journal of Investigative Dermatology, 2006, 126, 161-166.	0.3	67
1603	Multitargeted therapy: Can promiscuity be praised in an era of political correctness?. Critical Reviews in Oncology/Hematology, 2006, 59, 150-158.	2.0	30
1604	Cetuximab in advanced non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2006, 59, 139-149.	2.0	17
1605	The inherited genetics of pancreatic cancer and prospects for secondary screening. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 253-283.	1.0	43
1606	Long-term outcome and mortality trends in early-stage, Grade 1–2 follicular lymphoma treated with radiation therapy. International Journal of Radiation Oncology Biology Physics, 2006, 64, 928-934.	0.4	138
1607	Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1120-1128.	0.4	29
1608	A Structurally Optimized Celecoxib Derivative Inhibits Human Pancreatic Cancer Cell Growth. Journal of Gastrointestinal Surgery, 2006, 10, 207-214.	0.9	25
1609	Antitumor Agents. 250.â€Design and Synthesis of New Curcumin Analogues as Potential Anti-Prostate Cancer Agents. Journal of Medicinal Chemistry, 2006, 49, 3963-3972.	2.9	164
1610	Short hain Fatty Acids: Ready for Prime Time?. Nutrition in Clinical Practice, 2006, 21, 351-366.	1.1	365
1611	Real-Time Quantification of Human Telomerase Reverse Transcriptase mRNA in the Plasma of Patients with Prostate Cancer. Annals of the New York Academy of Sciences, 2006, 1075, 204-210.	1.8	41
1612	Real-time In Situ Monitoring of Human Prostate Photodynamic Therapy with Diffuse Light. Photochemistry and Photobiology, 2006, 82, 1279.	1.3	102
1613	Liver resection in octogenarians. Hpb, 2006, 8, 206-210.	0.1	24

			2
#	Article	IF	CITATIONS
1614	Utilizing Quantitative Polymerase Chain Reaction to Evaluate Prostate Stem Cell Antigen as a Tumor Marker in Pancreatic Cancer. Annals of Surgical Oncology, 2006, 13, 1645-1654.	0.7	27
1615	Confocal laser endoscopy: new approach to the early diagnosis of tumors of the esophagus and stomach. Future Oncology, 2006, 2, 469-476.	1.1	41
1616	Real-Time Electromagnetic Navigation Bronchoscopy to Peripheral Lung Lesions Using Overlaid CT Images. Chest, 2006, 129, 988-994.	0.4	318
1617	Effects of Cyclooxygenase-2 Inhibition on Serum and Tumor Gastrins and Expression of Apoptosis-Related Proteins in Colorectal Cancer. Digestive Diseases and Sciences, 2006, 51, 779-787.	1.1	19
1618	Risk of Advanced Proximal Adenoma and Cancer According to Rectosigmoid Findings in the Korean Population. Digestive Diseases and Sciences, 2006, 51, 2206-2212.	1.1	8
1619	A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Investigational New Drugs, 2006, 24, 141-149.	1.2	16
1620	The effect of single agent oral fusaric acid (FA) on the growth of subcuta neously xenografted SCC-1 cells in a nude mouse model. Investigational New Drugs, 2006, 24, 377-381.	1.2	12
1621	Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study. Investigational New Drugs, 2006, 24, 537-542.	1.2	9
1622	The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer. Journal of Molecular Histology, 2006, 37, 219-223.	1.0	31
1623	The Survivor Health and Resilience Education (SHARE) Program: Development and Evaluation of a Health Behavior Intervention for Adolescent Survivors of Childhood Cancer. Journal of Clinical Psychology in Medical Settings, 2006, 13, 161-168.	0.8	6
1625	Gallbladder metastases from ductal papillary carcinoma of the breast. Journal of Hepato-Biliary-Pancreatic Surgery, 2006, 13, 591-593.	2.0	20
1626	Chemoprevention of Colorectal Cancer. Diseases of the Colon and Rectum, 2006, 49, 113-125.	0.7	33
1627	Significant growth inhibition of orthotopic pancreatic ductal adenocarcinoma by CpG oligonucleotides in immunodeficient mice. International Journal of Colorectal Disease, 2006, 21, 365-372.	1.0	8
1628	Assessment of risk-independent follow-up to detect asymptomatic recurrence after curative resection of colorectal cancer. Langenbeck's Archives of Surgery, 2006, 391, 369-375.	0.8	9
1629	Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 788-796.	1.4	83
1630	Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient. Journal of Cancer Research and Clinical Oncology, 2006, 132, 275-286.	1.2	27
1631	The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2006, 132, 709-717.	1.2	77
1632	Genome-wide linkage scan for prostate cancer susceptibility genes in men with aggressive disease: significant evidence for linkage at chromosome 15q12. Human Genetics, 2006, 119, 400-407.	1.8	21

		CITATION REPORT		
#	Article		IF	CITATIONS
1633	Early renal cell cancer. International Journal of Clinical Oncology, 2006, 11, 22-27.		1.0	11
1634	Microvessel density and p53 in detecting cervical cancer by FDG PET in cases of suspect European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1408-1416.	ed recurrence.	3.3	11
1635	Endoscopy-assisted Breast-Conserving Surgery for Early Breast Cancer. World Journal of 2006, 30, 957-964.	Surgery,	0.8	50
1636	Survival After Neoadjuvant Therapy Compared with Surgery Alone for Resectable Esophain a Population-based Study. World Journal of Surgery, 2006, 30, 2182-2190.	ageal Cancer	0.8	20
1637	New antiangiogenetic agents and non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2006, 60, 76-86.		2.0	22
1638	Erlotinib in a previously treated advanced non-small cell lung cancer elderly patient: a cli Targeted Oncology, 2006, 1, 56-58.	nical case.	1.7	0
1639	Targeted therapies in the treatment of advanced non-small cell lung cancer elderly patie Oncology, 2006, 1, 13-22.	nts. Targeted	1.7	1
1640	The biological effect of hepsin on the proliferation and invasion of PC-3 prostate cancer Chinese Journal of Clinical Oncology, 2006, 3, 288-291.	cells.	0.0	0
1641	Investigational strategies in autologous stem cell transplantation for follicular lymphom Oncology Reports, 2006, 8, 368-375.	a. Current	1.8	3
1642	Neoadjuvant chemotherapy in vulvar cancer: Avoiding primary exenteration. Gynecologi 2006, 100, 53-57.	c Oncology,	0.6	77
1643	Concurrent cisplatin/gemcitabine chemotherapy along with radiotherapy in locally adva carcinoma: A phase II trial. Gynecologic Oncology, 2006, 100, 70-75.	nced cervical	0.6	42
1644	Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. Gynecolog Oncology, 2006, 100, 139-144.	yic	0.6	52
1645	Quality of life and mental health in cervical and endometrial cancer survivors. Gynecolog Oncology, 2006, 100, 479-486.	jic	0.6	133
1646	Impact of age on outcome in patients with advanced ovarian cancer treated within a pro randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ova Study Group (AGO-OVAR). Gynecologic Oncology, 2006, 100, 300-307.		0.6	50
1647	Expression and localization of aquaporin-5 in the epithelial ovarian tumors. Gynecologic 2006, 100, 294-299.	Oncology,	0.6	82
1648	Salvage treatment with high-dose-rate brachytherapy for isolated vaginal endometrial ca recurrence. Gynecologic Oncology, 2006, 101, 445-449.	incer	0.6	54
1649	Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncology, 2006, 103, 155-159.		0.6	240
1650	ISSM SYMPOSIUM: Do Patients and Partners Really Want to Have a Sex Life After Prosta Psychological Impact of Diagnosis and Treatment. Journal of Sexual Medicine, 2006, 3, 8	te Cancer? 3-84.	0.3	0

ARTICLE IF CITATIONS Real-time detection of mesothelin in pancreatic cancer cell line supernatant using an acoustic wave 2.1 31 1651 immunosensor. Cancer Detection and Prevention, 2006, 30, 180-187. Lack of Prophylactic Effect of Incadronate on Skeletal Lesions Associated with Implants of Prostate Cancer. European Urology, 2006, 49, 176-182. Worldwide burden of gynaecological cancer: The size of the problem. Best Practice and Research in 1653 1.4 557 Clinical Obstetrics and Gynaecology, 2006, 20, 207-225. Genetic Basis of Cancer of the Kidney. Seminars in Oncology, 2006, 33, 544-551. 1654 44 Preservation of Fertility and the Impact of Subsequent Pregnancy in Patients With Premenopausal 1655 0.8 12 Breast Cancer. Seminars in Oncology, 2006, 33, 664-671. Expression of cytokeratin-20 in pancreatic cancer: An indicator of poor outcome after R0 resection. Surgery, 2006, 139, 104-108. 1.0 Strategy for prevention of local recurrence of pancreatic cancer after pancreatectomy: antitumor 1657 effect of gemcitabine mixed with fibrin glue in an orthotopic nude mouse model. Surgery, 2006, 140, 1.0 10 66-71. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell 0.8 carcinoma of the head and neck. Oral Oncology, 2006, 42, 430-439. Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer, 2006, 6, 201. 1659 1.1 80 Profiling alternatively spliced mRNA isoforms for prostate cancer classification. BMC Bioinformatics, 1.2 2006, 7, 202. Molecular biology of squamous cell carcinoma of the anus. British Journal of Surgery, 2006, 93, 1661 0.1 56 531-538. Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor  $\hat{l}^2 1$ , and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma 1662 0.1 of the small intestine. British Journal of Surgery, 2006, 93, 1424-1432 Recurrent coamplification of cytoskeleton-associated genesEMS1 andSHANK2 withCCND1 in oral 1663 1.5 60 squamous cell carcinoma. Genes Chromosomes and Cancer, 2006, 45, 118-125. The glycine 90 to aspartate alteration in the  $A^{2}$  subunit of PP2A (PPP2R1B) associates with breast cancer 1664 1.5 and causes a deficit in protein function. Genes Chromosomes and Cancer, 2006, 45, 182-190. Patterns of exercise across the cancer trajectory in brain tumor patients. Cancer, 2006, 106, 2224-2232. 2.0 1666 36 The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly 2.0 diagnosed metastatic prostate cancer. Cancer, 2006, 107, 489-496. Recommendations for the use of Yttrium-90 ibritumomab tiuxetan in malignant lymphoma. Cancer, 1668 2.0 35 2006, 107, 686-695. 1669 Chemoprevention: Drug pricing and mortality. Cancer, 2006, 107, 950-958.

#	Article	lF	CITATIONS
1670	Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer, 2006, 107, 2866-2872.	2.0	391
1671	Distinct array comparative genomic hybridization profiles in oral squamous cell carcinoma occurring in young patients. Head and Neck, 2006, 28, 330-338.	0.9	35
1672	Aberrant promoter methylation of multiple genes during multistep pathogenesis of colorectal cancers. International Journal of Cancer, 2006, 118, 924-931.	2.3	33
1673	Homozygous deletion of p16INK4aand tobacco carcinogen exposure in nonsmall cell lung cancer. International Journal of Cancer, 2006, 118, 1364-1369.	2.3	31
1674	Molecular profiling of platinum resistant ovarian cancer. International Journal of Cancer, 2006, 118, 1963-1971.	2.3	139
1675	ARLTS1 variants and melanoma risk. International Journal of Cancer, 2006, 119, 1736-1737.	2.3	24
1676	Epigenetic inactivation of theSFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma. International Journal of Cancer, 2006, 119, 1761-1766.	2.3	111
1677	CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. International Journal of Cancer, 2006, 119, 1819-1828.	2.3	98
1678	No association of primary adenocarcinomas of the small bowel with Epstein-Barr virus infection. Molecular Carcinogenesis, 2006, 45, 349-352.	1.3	10
1679	Green tea polyphenol (â^)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. Molecular Carcinogenesis, 2006, 45, 309-319.	1.3	128
1680	Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer. Molecular Carcinogenesis, 2006, 45, 447-454.	1.3	79
1681	Comparison of Endobronchial Ultrasound, Positron Emission Tomography, and CT for Lymph Node Staging of Lung Cancer. Chest, 2006, 130, 710-718.	0.4	467
1682	Peroxisome Proliferator-Activated Receptor-Î <sup>3</sup> Polymorphism, Body Mass and Prostate Cancer Risk: Evidence for Gene-Environment Interaction. Oncology, 2006, 70, 185-189.	0.9	18
1683	Hypnosis to Manage Anxiety and Pain Associated with Colonoscopy for Colorectal Cancer Screening:Case Studies and Possible Benefits. International Journal of Clinical and Experimental Hypnosis, 2006, 54, 416-431.	1.1	45
1684	Pharmacotherapy of multiple myeloma. Expert Opinion on Pharmacotherapy, 2006, 7, 767-781.	0.9	4
1685	Hormonal Replacement Therapy after Gynaecological Cancer. Gynakologisch-geburtshilfliche Rundschau, 2006, 46, 191-196.	0.9	10
1686	Retained Seminal Vesicles After Radical Prostatectomy: Frequency, MRI Characteristics, and Clinical Relevance. American Journal of Roentgenology, 2006, 186, 539-546.	1.0	54
1687	Evolving Role of Serum Biomarkers in the Management of Ovarian Cancer. Women's Health, 2006, 2, 141-158.	0.7	4

ARTICLE IF CITATIONS Fertility Preservation in Cancer Patients. Women's Health, 2006, 2, 479-489. 0.7 3 1688 An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients. Annals of Oncology, 2006, 17, 1146-1151. Operations of the Biliary Tract. Technical Aspects., 2006, , 297-313. 0 1691 Triapine (3-aninopyridine-2-carboxaldehyde thiosemicarbazone) Induces Apoptosis in Ovarian Cancer 1.9 Cells. Journal of the Society for Gynecologic Investigation, 2006, 13, 145-152. Loss of heterozygosity of M6P/IGF2R gene is an early event in the development of prostate cancer. 1693 2.0 21 Prostate Cancer and Prostatic Diseases, 2006, 9, 62-67. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous 1694 1.0 melanoma: a case-control study. Journal of Clinical Pathology, 2006, 59, 166-173. Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras 1695 1.337 oncogene in rat pancreas. Carcinogenesis, 2006, 27, 2497-2510. Gene Expression Profiling of Localized Esophageal Carcinomas: Association With Pathologic Response 1696 0.8 160 to Preoperative Chemoradiation. Journal of Clinical Oncology, 2006, 24, 259-267. Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective 1697 outcome comparison between platinum-sensitive and platinum-resistant patients. Acta OncolÅ3gica, 0.8 12 2006, 45, 463-468. Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer. Journal of Clinical Oncology, 0.8 2006, 24, 2038-2043. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced 1699 0.6 29 ovarian cancer patients. Annals of Oncology, 2006, 17, 429-436. A phase II trial of neoadjuvant cisplatin–fluorouracil followed by postoperative intraperitoneal floxuridine–leucovorin in patients with locally advanced gastric cancer. Annals of Oncology, 2006, 0.6 17, 1404-1411 Evaluation of Relationships Among National Colorectal Cancer Mortality Rates, Genetic Lactase 1701 Non-Persistence Status, and Per Capita Yearly Milk and Milk Product Consumption. Nutrition and 0.9 9 Cancer, 2006, 55, 151-156. Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-kB ligand. Journal of Clinical Pathology, 2006, 60, 290-284. 1702 1.0 Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of 1703 1.0 46 pancreatic cancer. Journal of Clinical Pathology, 2006, 60, 885-895. Non-Hodgkin's lymphoma in patients 80 years of age or older. Annals of Oncology, 2006, 17, 928-934. 1704 Germ-Line Mutation of NKX3.1 Cosegregates with Hereditary Prostate Cancer and Alters the 1705 0.4 48 Homeodomain Structure and Function. Cancer Research, 2006, 66, 69-77. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit 1706 human and mouse ovarian cancer. Proceedings of the National Academy of Sciences of the United 3.3 States of America, 2006, 103, 17426-17431

#	Article	IF	CITATIONS
1707	Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2006, 24, 4721-4730.	0.8	335
1708	Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. Annals of Oncology, 2006, 17, ii73-ii75.	0.6	13
1709	Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells. Carcinogenesis, 2006, 27, 508-516.	1.3	129
1710	Expanding role of chemotherapy in lung cancer. Annals of Oncology, 2006, 17, x101-x107.	0.6	2
1711	p8 Is a New Target of Gemcitabine in Pancreatic Cancer Cells. Clinical Cancer Research, 2006, 12, 235-241.	3.2	92
1712	The Effect of Medicare Health Care Delivery Systems on Survival for Patients with Breast and Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 769-773.	1.1	20
1713	Expression of EphA2 and Ephrin A-1 in Carcinoma of the Urinary Bladder. Clinical Cancer Research, 2006, 12, 353-360.	3.2	109
1714	Evaluation of the 4q32-34 Locus in European Familial Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1948-1955.	1.1	50
1715	Cannabinoids Induce Apoptosis of Pancreatic Tumor Cells via Endoplasmic Reticulum Stress–Related Genes. Cancer Research, 2006, 66, 6748-6755.	0.4	302
1716	Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis, 2006, 27, 361-373.	1.3	222
1717	Whole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer. Gut, 2006, 55, 68-73.	6.1	62
1718	Hormonal Control of Androgen Receptor Function through SIRT1. Molecular and Cellular Biology, 2006, 26, 8122-8135.	1.1	214
1719	Adeno-Associated Virus–Mediated Delivery of a Mutant Endostatin in Combination with Carboplatin Treatment Inhibits Orthotopic Growth of Ovarian Cancer and Improves Long-term Survival. Cancer Research, 2006, 66, 4319-4328.	0.4	40
1720	Prognostic Significance of p53 and Ki-67 Antigen Expression in Surgically Treated Non–Small Cell Lung Cancer. American Journal of Clinical Pathology, 2006, 125, 425-431.	0.4	22
1721	Enhancer of Zeste 2 as a Marker of Preneoplastic Progression in the Breast: Figure 1 Cancer Research, 2006, 66, 9352-9355.	0.4	60
1722	Elevated E2F1 Inhibits Transcription of the Androgen Receptor in Metastatic Hormone-Resistant Prostate Cancer. Cancer Research, 2006, 66, 11897-11906.	0.4	100
1723	Colonoscopy in Colorectal-Cancer Screening for Detection of Advanced Neoplasia. New England Journal of Medicine, 2006, 355, 1863-1872.	13.9	697
1724	Effect of Cromolyn on S100P Interactions With RAGE and Pancreatic Cancer Growth and Invasion in Mouse Models. Journal of the National Cancer Institute, 2006, 98, 1806-1818.	3.0	138

#	Article	IF	CITATIONS
1725	Chemotherapy and targeted molecular therapies for brain metastases. Expert Review of Neurotherapeutics, 2006, 6, 1465-1479.	1.4	12
1726	NK- and B-Cell Infiltration Correlates With Worse Outcome in Metastatic Ovarian Carcinoma. American Journal of Clinical Pathology, 2006, 125, 451-458.	0.4	148
1727	Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib. Cancer Research, 2006, 66, 10100-10111.	0.4	313
1728	Prostate Cancer Screening Behavior in Men from Seven Ethnic Groups: the Fear Factor. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 228-237.	1.1	94
1729	Polymorphisms in Polycyclic Aromatic Hydrocarbon Metabolism and Conjugation Genes, Interactions with Smoking and Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 756-761.	1.1	37
1730	S100A11, A Putative Tumor Suppressor Gene, Is Overexpressed in Pancreatic Carcinogenesis. Clinical Cancer Research, 2006, 12, 5417-5422.	3.2	82
1731	NKX3.1 Is Regulated by Protein Kinase CK2 in Prostate Tumor Cells. Molecular and Cellular Biology, 2006, 26, 3008-3017.	1.1	46
1732	Celecoxib and Curcumin Additively Inhibit the Growth of Colorectal Cancer in a Rat Model. Digestion, 2006, 74, 140-144.	1.2	62
1733	A phase II study of Gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature. Annals of Oncology, 2006, 17, v133-v136.	0.6	3
1734	Contribution of Routine Chest X-Ray in the Long-Term Follow-Up of Patients with Differentiated Thyroid Carcinoma. Thyroid, 2006, 16, 303-306.	2.4	2
1735	trans-10,cis-12 Conjugated Linoleic Acid Inhibits the G1–S Cell Cycle Progression in DU145 Human Prostate Carcinoma Cells. Journal of Medicinal Food, 2006, 9, 293-299.	0.8	25
1736	Chemotherapy-Induced Carcinoembryonic Antigen Surge in Patients with Metastatic Colorectal Cancer. Oncology, 2006, 70, 49-53.	0.9	29
1737	Phase II Trial of Intravesical Gemcitabine in Bacille Calmette-Guérin–Refractory Transitional Cell Carcinoma of the Bladder. Journal of Clinical Oncology, 2006, 24, 2729-2734.	0.8	160
1738	N-Acetylglucosaminyltransferase V and $\hat{l}^2$ 1-6 Branching N-Linked Oligosaccharides Are Associated with Good Prognosis of Patients with Bladder Cancer. Clinical Cancer Research, 2006, 12, 2506-2511.	3.2	41
1739	Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma. Journal of Clinical Oncology, 2006, 24, 4309-4316.	0.8	129
1740	Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. British Journal of Cancer, 2006, 94, 227-230.	2.9	197
1741	Prognostic relevance of Tiam1 protein expression in prostate carcinomas. British Journal of Cancer, 2006, 95, 1081-1086.	2.9	77
1742	Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. British Journal of Cancer, 2006, 94, 1465-1471.	2.9	76

#	Article	IF	CITATIONS
1744	Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Annals of Oncology, 2006, 17, 1185-1196.	0.6	68
1745	Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14513-14518.	3.3	33
1746	Recombinant Human Mullerian Inhibiting Substance Inhibits Long-term Growth of MIS Type II Receptor–Directed Transgenic Mouse Ovarian Cancers In vivo. Clinical Cancer Research, 2006, 12, 1593-1598.	3.2	49
1747	Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10403-10407.	3.3	40
1748	Sorafenib and Sunitinib in the Treatment of Advanced Non‧mall Cell Lung Cancer. Oncologist, 2007, 12, 191-200.	1.9	109
1749	Analysis of mammogram using self-organizing neural networks based on spatial isomorphism. Neural Networks (IJCNN), International Joint Conference on, 2007, , .	0.0	6
1750	Identification of HLA-CW3, GNAS and IMPA as Cytotoxic T-Lymphocyte (CTL) Target Antigens Using an Allogeneic Mixed Lymphocyte Tumor Cell Culture (MLTC) System and Subsequent cDNA Library Screening. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 206-222.	0.7	1
1751	Effects of Resectoscope Loop Manipulation. Journal of Endourology, 2007, 21, 1187-1194.	1.1	1
1752	Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5103-5108.	3.3	211
1753	Fear, Knowledge, and Efficacy Beliefs Differentially Predict the Frequency of Digital Rectal Examination Versus Prostate Specific Antigen Screening in Ethnically Diverse Samples of Older Men. American Journal of Men's Health, 2007, 1, 29-43.	0.7	47
1754	Lack of Colonic Neoplastic Lesions in Patients Under 50 Yr of Age With Hematochezia: A Multicenter Prospective Study. American Journal of Gastroenterology, 2007, 102, 2011-2015.	0.2	29
1755	Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: A Hospital-Based Case?Control Study. American Journal of Gastroenterology, 2007, 102, 1016-1021.	0.2	235
1756	State-of-the-art surgical management of testicular tumors. Expert Review of Anticancer Therapy, 2007, 7, 1301-1308.	1.1	0
1757	A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. British Journal of Cancer, 2007, 97, 1021-1027.	2.9	90
1758	Leisureâ€ŧime physical activity in relation to the risk of breast cancer. European Journal of Sport Science, 2007, 7, 81-91.	1.4	1
1759	Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncológica, 2007, 46, 1131-1137.	0.8	80
1760	Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Annals of Oncology, 2007, 18, 305-310.	0.6	59
1761	Predictive factors in pancreatic ductal adenocarcinoma: Role of the inflammatory response. Scandinavian Journal of Gastroenterology, 2007, 42, 754-759.	0.6	42

#	Article	IF	CITATIONS
1762	Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer. Journal of Clinical Oncology, 2007, 25, 257-262.	0.8	127
1763	S100A6 Is Increased in a Stepwise Manner during Pancreatic Carcinogenesis: Clinical Value of Expression Analysis in 98 Pancreatic Juice Samples. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 649-654.	1.1	53
1764	Intersex-like (IXL) Is a Cell Survival Regulator in Pancreatic Cancer with 19q13 Amplification. Cancer Research, 2007, 67, 1943-1949.	0.4	68
1765	Potentiation of High-LET Radiation by Gemcitabine: Targeting HER2 with Trastuzumab to Treat Disseminated Peritoneal Disease. Clinical Cancer Research, 2007, 13, 1926-1935.	3.2	65
1766	Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Annals of Oncology, 2007, 18, 1348-1353.	0.6	22
1767	Nicotine Stimulates Human Lung Cancer Cell Growth by Inducing Fibronectin Expression. American Journal of Respiratory Cell and Molecular Biology, 2007, 37, 681-690.	1.4	106
1768	Smart Near-Infrared Imaging Probes—A Quantum Leap for Early Detection of Colorectal Cancer?. Radiology, 2007, 244, 1-2.	3.6	3
1769	FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. British Journal of Radiology, 2007, 80, 508-515.	1.0	54
1770	Molecular prognostic factors in patients with pancreatic cancer. Expert Opinion on Therapeutic Targets, 2007, 11, 1553-1569.	1.5	25
1771	Hybrid Segmentation of Colon Boundaries in CT Images based on Geometric Deformable Model. , 2007, ,		1
1772	Cryotherapy for localised prostate cancer. The Cochrane Library, 2007, , CD005010.	1.5	34
1773	The Association of 5α-Reductase II (SRD5A2) and 17 Hydroxylase (CYP17) Gene Polymorphisms with Prostate Cancer Patients in The Turkish Population. DNA and Cell Biology, 2007, 26, 100-107.	0.9	24
1774	p300 expression repression by hypermethylation associated with tumour invasion and metastasis in oesophageal squamous cell carcinoma. Journal of Clinical Pathology, 2007, 60, 1249-1253.	1.0	21
1775	Attitudes towards screening for lung cancer among smokers and their non-smoking counterparts. Thorax, 2007, 62, 126-130.	2.7	153
1776	Inhibitory effect of snake venom toxin from Vipera lebetina turanica on hormone-refractory human prostate cancer cell growth: induction of apoptosis through inactivation of nuclear factor IºB. Molecular Cancer Therapeutics, 2007, 6, 675-683.	1.9	74
1777	Microenvironmental Regulation of Membrane Type 1 Matrix Metalloproteinase Activity in Ovarian Carcinoma Cells via Collagen-induced EGR1 Expression. Journal of Biological Chemistry, 2007, 282, 4924-4931.	1.6	83
1778	Demethylation-Linked Activation of Urokinase Plasminogen Activator Is Involved in Progression of Prostate Cancer. Cancer Research, 2007, 67, 930-939.	0.4	76
1779	Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients. Clinical Chemistry and Laboratory Medicine, 2007, 45, 30-4.	1.4	62

#	Article	IF	Citations
1780	Causal Attributions in Individuals With Suspected Lung Cancer: Relationships to Illness Coherence and Emotional Responses. Journal of the American Psychiatric Nurses Association, 2007, 13, 109-115.	0.4	17
1781	Integrating Chinese and Conventional Medicine in Colorectal Cancer Treatment. Integrative Cancer Therapies, 2007, 6, 89-94.	0.8	9
1782	Murine Cell Lines Derived from <i>Pten</i> Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development. Cancer Research, 2007, 67, 6083-6091.	0.4	158
1783	Nicotine Induces Hypoxia-Inducible Factor-1α Expression in Human Lung Cancer Cells via Nicotinic Acetylcholine Receptor–Mediated Signaling Pathways. Clinical Cancer Research, 2007, 13, 4686-4694.	3.2	146
1785	Bronchoalveolar Lavage in the Diagnosis and Management of Interstitial Lung Diseases. Clinical Pulmonary Medicine, 2007, 14, 148-156.	0.3	4
1786	Nuclear Factor-κB Is Central to the Expression of Truncated Neurokinin-1 Receptor in Breast Cancer: Implication for Breast Cancer Cell Quiescence within Bone Marrow Stroma. Cancer Research, 2007, 67, 1653-1659.	0.4	37
1787	Chest wall recurrence of breast cancer demonstrated on 99mTc-MIBI scintimammography. Nuclear Medicine Communications, 2007, 28, 842-846.	0.5	4
1788	Reoperation as a Quality Indicator in Colorectal Surgery. Annals of Surgery, 2007, 245, 73-79.	2.1	121
1789	Targeted therapies and non-small-cell lung cancer: new developments. Current Opinion in Oncology, 2007, 19, 75-77.	1.1	3
1790	Fertility preservation in gynecologic cancers. Current Opinion in Oncology, 2007, 19, 506-511.	1.1	27
1791	Fertility Preservation Options for Women With Malignancies. Obstetrical and Gynecological Survey, 2007, 62, 58-72.	0.2	92
1792	Risk of Colorectal Cancer in Women With a Prior Diagnosis of Gynecologic Malignancy. Journal of Clinical Gastroenterology, 2007, 41, 291-296.	1.1	8
1793	Microsatellite Analysis in Serum DNA as a Diagnostic Tool for Distinction of Patients With Unknown Pancreatic Masses. Diagnostic Molecular Pathology, 2007, 16, 174-178.	2.1	1
1794	Factors determining early adherence to a lung cancer screening protocol. European Respiratory Journal, 2007, 30, 532-537.	3.1	49
1796	Combined targeted therapies in non-small cell lung cancer: a winner strategy?. Current Opinion in Oncology, 2007, 19, 98-102.	1.1	20
1797	Infrared light utilized for photodynamic therapy by activation of rare earth phosphors for visible light generation. , 2007, , .		0
1798	Health-Related Goals in Female Cancer Survivors After Treatment. Cancer Nursing, 2007, 30, 9-15.	0.7	15
1799	Local Control and Long-Term Disease-Free Survival for Stage D1 (T2-T4N1-N2M0) Prostate Cancer After Radical Prostatectomy in the PSA Era. Urology, 2007, 70, 723-727.	0.5	30

#	Article	IF	CITATIONS
1800	The functional significance of nuclear receptor acetylation. Steroids, 2007, 72, 221-230.	0.8	78
1801	Treatment outcomes in patients with signet ring cell carcinoma of the colorectum. American Journal of Surgery, 2007, 194, 294-298.	0.9	59
1802	Disparities in time to definitive surgical treatment between black and white women diagnosed with ductal carcinoma in situ. American Journal of Surgery, 2007, 194, 521-523.	0.9	16
1803	Surgical Techniques and Results for Partial or Circumferential Sleeve Resection of the Pulmonary Artery for Patients with Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2007, 83, 1971-1977.	0.7	61
1804	Accessing the Aortopulmonary Window (#5) and the Paraaortic (#6) Lymph Nodes in Patients With Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2007, 84, 940-945.	0.7	56
1805	Melanoma contains CD133 and ABCC2 positive cells with enhanced tumourigenic potential. European Journal of Cancer, 2007, 43, 935-946.	1.3	523
1806	MR imaging in local staging of prostate cancer. European Journal of Radiology, 2007, 63, 328-334.	1.2	63
1807	Suppression of 5-lipoxygenase gene is involved in triptolide-induced apoptosis in pancreatic tumor cell lines. Biochimica Et Biophysica Acta - General Subjects, 2007, 1770, 1021-1027.	1.1	36
1808	Diacylglycerol kinase α suppresses tumor necrosis factor-α-induced apoptosis of human melanoma cells through NF-κB activation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2007, 1771, 462-474.	1.2	69
1809	Ovarian cryopreservation with transposition of a contralateral ovary: a combined approach for fertility preservation in women receiving pelvic radiation. Fertility and Sterility, 2007, 87, 189.e5-189.e7.	0.5	41
1810	The cancer incidence temporality index: An index to show temporal changes in the age of onset of overall and specific cancer (England and Wales, 1971–1999). Biomedicine and Pharmacotherapy, 2007, 61, 623-630.	2.5	6
1811	Lifestyle-related factors and environmental agents causing cancer: An overview. Biomedicine and Pharmacotherapy, 2007, 61, 640-658.	2.5	251
1812	Combining siRNAs at Two Different Sites in the EGFR to Suppress its Expression, Induce Apoptosis, and Enhance 5-Fluorouracil Sensitivity of Colon Cancer Cells. Journal of Surgical Research, 2007, 138, 56-63.	0.8	16
1813	Antrodia camphorata extract induces replicative senescence in superficial TCC, and inhibits the absolute migration capability in invasive bladder carcinoma cells. Journal of Ethnopharmacology, 2007, 109, 93-103.	2.0	59
1814	Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo. Molecular and Cellular Endocrinology, 2007, 260-262, 183-189.	1.6	54
1815	Conjugates of lytic peptides and LHRH or Î <sup>2</sup> CG target and cause necrosis of prostate cancers and metastases. Molecular and Cellular Endocrinology, 2007, 269, 26-33.	1.6	39
1816	Intérêt de la TEP au [18F]-FDG double phase avec acquisition tardive dans la détection des tumeurs cérébrales. Medecine Nucleaire, 2007, 31, 250-261.	0.2	1
1817	Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncology, The, 2007, 8, 311-316.	5.1	156

#	Article	IF	Citations
1818	Genetic alterations in lung cancer: Assessing limitations in routine clinical use. Revista Portuguesa De Pneumologia, 2007, 13, 9-34.	0.7	0
1819	Repression of BCL2 by the Tumor Suppressor Activity of the Lysyl Oxidase Propeptide Inhibits Transformed Phenotype of Lung and Pancreatic Cancer Cells. Cancer Research, 2007, 67, 6278-6285.	0.4	83
1820	Biodegradable intraprostatic doxorubicin implants. AAPS Journal, 2007, 9, E241-E250.	2.2	20
1821	Secondary Carcinogenesis in Patients Treated with Radiation: A Review of Data on Radiation-Induced Cancers in Human, Non-human Primate, Canine and Rodent Subjects. Radiation Research, 2007, 167, 12-42.	0.7	226
1822	Spiral Saphenous Vein Graft for Portal Vein Reconstruction in Pancreatic Cancer Surgery. Vascular and Endovascular Surgery, 2007, 41, 149-152.	0.3	21
1823	Protection of ovarian function and fertility using a combination of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist during cancer treatment in young females. Gynecological Endocrinology, 2007, 23, 290-294.	0.7	15
1824	Alterations of Metastasis-Related Genes Identified Using an Oligonucleotide Microarray of Genistein-Treated HCC1395 Breast Cancer Cells. Nutrition and Cancer, 2007, 58, 239-246.	0.9	33
1825	Traitement endoscopique du carcinome in situ. Revue Des Maladies Respiratoires, 2007, 24, 68-71.	1.7	0
1826	Cost Utility of Screening for Barrett's Esophagus With Esophageal Capsule Endoscopy Versus Conventional Upper Endoscopy. Clinical Gastroenterology and Hepatology, 2007, 5, 312-318.	2.4	83
1828	Cáncer de próstata en el paciente de edad avanzada. EMC - UrologÃa, 2007, 39, 1-5.	0.0	0
1830	MR Imaging of the Pancreas: 1.5T versus 3T. Magnetic Resonance Imaging Clinics of North America, 2007, 15, 349-353.	0.6	21
1831	Celecoxib Toxicity Is Cell Cycle Phase Specific. Cancer Research, 2007, 67, 3801-3808.	0.4	37
1832	Association of Testis Derived Transcript Gene Variants and Prostate Cancer Risk. Journal of Urology, 2007, 177, 894-898.	0.2	5
1833	On the role of transforming growth factor- $\hat{1}^2$ in the growth inhibitory effects of retinoic acid in human pancreatic cancer cells. Molecular Cancer, 2007, 6, 82.	7.9	29
1834	Cryospray ablation (CSA) in the palliative treatment of squamous cell carcinoma of the esophagus. World Journal of Surgical Oncology, 2007, 5, 34.	0.8	31
1835	Endoscopic palliation of malignant obstructive jaundice: An evidence-based review. Digestive and Liver Disease, 2007, 39, 375-388.	0.4	24
1836	Staging of esophageal cancer by EUS: staging accuracy revisited. Gastrointestinal Endoscopy, 2007, 66, 475-482.	0.5	58
1837	Overview of Resistance to Systemic Therapy in Patients with Breast Cancer. Advances in Experimental Medicine and Biology, 2007, 608, 1-22.	0.8	721

#	Article	IF	CITATIONS
1838	Brachytherapy Seed Localization Using Geometric and Linear Programming Techniques. IEEE Transactions on Medical Imaging, 2007, 26, 1291-1304.	5.4	14
1839	Pancreatic intraepithelial neoplasia and ductal adenocarcinoma induced by DMBA in mice: effects of alcohol and caffeine. Acta Cirurgica Brasileira, 2007, 22, 202-209.	0.3	23
1840	Identification and Characterization of Renal Cell Carcinoma Gene Markers. Cancer Informatics, 2007, 3, 117693510700300.	0.9	27
1841	Induction of Proteases in Peritoneal Carcinomatosis, the Role of ICAM-1/CD43 Interaction. Biomarker Insights, 2007, 2, 117727190700200.	1.0	10
1842	High Expression of Nuclear Factor of Activated T Cells in Chinese Primary Non-Small Cell Lung Cancer Tissues. International Journal of Biological Markers, 2007, 22, 221-225.	0.7	7
1843	Polypoid Spindle Cell Carcinoma of the Esophagus. American Surgeon, 2007, 73, 67-69.	0.4	1
1845	High survivin expression is associated with favorable outcome in advanced primary oral squamous cell carcinoma after radiation therapy. International Journal of Cancer, 2007, 120, 942-946.	2.3	36
1846	A novel approach for identification of tumor-associated antigens expressed on the surface of tumor cells. International Journal of Cancer, 2007, 120, 1293-1303.	2.3	12
1847	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. International Journal of Cancer, 2007, 121, 656-665.	2.3	173
1848	A gene expression signature associated with metastatic cells in effusions of breast carcinoma patients. International Journal of Cancer, 2007, 121, 1036-1046.	2.3	29
1849	Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy. Journal of Cellular Physiology, 2007, 210, 549-559.	2.0	37
1850	Molecular characterization of a t(9;12)(p21;q13) balanced chromosome translocation in combination with integrative genomics analysis identifiesC9orf14as a candidate tumor-suppressor. Genes Chromosomes and Cancer, 2007, 46, 155-162.	1.5	10
1851	Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer, 2007, 109, 205-212.	2.0	246
1852	Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer, 2007, 109, 1239-1246.	2.0	108
1853	Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer, 2007, 109, 2016-2024.	2.0	53
1854	Models and mechanisms in malignant melanoma. Molecular Carcinogenesis, 2007, 46, 671-678.	1.3	22
1855	Racial Differences in CYP3A4 Genotype and Survival Among Men Treated on Radiation Therapy Oncology Group (RTOG) 9202: A Phase III Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2007, 69, 79-87.	0.4	27
1856	Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials. Radiation Oncology, 2007, 2, 28.	1.2	99

#	Article	IF	CITATIONS
1857	Overâ€expression of <i>S100A2</i> in pancreatic cancer correlates with progression and poor prognosis. Journal of Pathology, 2007, 213, 275-282.	2.1	58
1858	Should ovarian cryopreservation be offered to girls with cancer. Pediatric Blood and Cancer, 2007, 48, 4-9.	0.8	38
1859	The PedsQLâ,,¢ brain tumor module: Initial reliability and validity. Pediatric Blood and Cancer, 2007, 49, 287-293.	0.8	131
1860	Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidemiology and Drug Safety, 2007, 16, 250-258.	0.9	136
1861	Medical therapy for diabetes is associated with increased use of lower endoscopy. Pharmacoepidemiology and Drug Safety, 2007, 16, 1195-1202.	0.9	21
1862	Whole cell profiling and identification of galectin-1 as a potential marker of renal cell carcinoma. Proteomics - Clinical Applications, 2007, 1, 200-214.	0.8	6
1863	Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer. Prostate, 2007, 67, 1081-1090.	1.2	48
1864	Proteome analysis of human androgen-independent prostate cancer cell lines: Variable metastatic potentials correlated with vimentin expression. Proteomics, 2007, 7, 1973-1983.	1.3	54
1865	Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene, 2007, 26, 765-773.	2.6	54
1866	Overexpression of NBS1 induces epithelial–mesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer. Oncogene, 2007, 26, 1459-1467.	2.6	138
1867	Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the β4 integrin and the PI3k pathway. Oncogene, 2007, 26, 2082-2094.	2.6	251
1868	Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro. Oncogene, 2007, 26, 4961-4968.	2.6	110
1869	Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene, 2007, 26, 5229-5237.	2.6	87
1870	Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays. British Journal of Cancer, 2007, 96, 82-88.	2.9	77
1871	Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. British Journal of Cancer, 2007, 97, 1432-1440.	2.9	65
1872	Coverage and Quality of Oral Cancer Information in Selected Popular Press: May 1998 to July 2003. Journal of Public Health Dentistry, 2004, 64, 231-236.	0.5	7
1873	Urinary markers for prostate cancer. BJU International, 2007, 99, 263-268.	1.3	30
1874	Patient participation in decision making: views of health professionals caring for people with colorectal cancer. Journal of Clinical Nursing, 2007, 16, 725-733.	1.4	35

#	Article	IF	CITATIONS
1875	Patient education and regular surveillance results in earlier diagnosis of second primary melanoma. International Journal of Dermatology, 2007, 46, 575-577.	0.5	44
1876	Cost-Benefit Analysis of a Follow-up Program in Patients with Breast Cancer: A Randomized Prospective Study. Breast Journal, 2007, 13, 571-574.	0.4	33
1877	A relative color approach to color discrimination for malignant melanoma detection in dermoscopy images. Skin Research and Technology, 2007, 13, 62-72.	0.8	77
1878	Improving Survival for Patients with Breast Cancer Compared with Intramural and Extramural Benchmarks. Clinical Breast Cancer, 2007, 7, 480-485.	1.1	3
1879	Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer, 2007, 7, 91.	1.1	94
1880	Outcomes of Patients with Prostate Cancer Receiving Zoledronic Acid or Pamidronate for Prevention of Skeletal-Related Events. Pharmacotherapy, 2007, 27, 207-217.	1.2	6
1881	Demalonyl thyrsiflorin A, a semisynthetic labdane-derived diterpenoid, induces apoptosis and necrosis in human epithelial cancer cells. Chemico-Biological Interactions, 2007, 169, 198-206.	1.7	12
1882	Lifetime physical activity and the risk of breast cancer: A case–control study. Cancer Detection and Prevention, 2007, 31, 18-28.	2.1	53
1883	Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial. European Urology, 2007, 52, 134-141.	0.9	286
1884	Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. Gynecologic Oncology, 2007, 106, 75-81.	0.6	74
1885	The glucocorticoid receptor signalling in breast cancer. Journal of Cellular and Molecular Medicine, 2008, 12, 145-163.	1.6	49
1886	Putrescine-1,4-dicinnamide from Pholiota spumosa (Basidiomycetes) inhibits cell growth of human prostate cancer cells. Phytomedicine, 2007, 14, 185-191.	2.3	22
1887	The role of adjuvant chemotherapy in colon cancer. Surgical Oncology, 2007, 16, 93-96.	0.8	13
1888	Effective tumor regression by anti-neovascular therapy in hypovascular orthotopic pancreatic tumor model. Journal of Controlled Release, 2007, 118, 303-309.	4.8	19
1889	Present Status of Management of Cancer Pancreas: A Brief Review. Apollo Medicine, 2007, 4, 310-315.	0.0	0
1890	Bacillus Calmette–Guérin and Bladder Cancer. Asian Journal of Surgery, 2007, 30, 302-309.	0.2	29
1891	Breast Cancer Cells Response to the Antineoplastic Agents Cisplatin, Carboplatin, and Doxorubicin at the mRNA Expression Levels of Distinct Apoptosis-Related Genes, Including the New Member, BCL2L12. Annals of the New York Academy of Sciences, 2007, 1095, 35-44.	1.8	38
1892	The Cyclooxygenase-2 Selective Inhibitor Celecoxib Suppresses Proliferation and Invasiveness in the Human Oral Squamous Carcinoma. Annals of the New York Academy of Sciences, 2007, 1095, 99-112.	1.8	31

#	Article	IF	CITATIONS
1893	The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 (Iressa) Suppresses Proliferation and Invasion of Human Oral Squamous Carcinoma Cells via p53 Independent and MMP, uPAR Dependent Mechanism. Annals of the New York Academy of Sciences, 2007, 1095, 113-128.	1.8	28
1894	Targeted Therapy of Breast and Gynecological Cancers with Cytotoxic Analogues of Peptide Hormones. Molecular Pharmaceutics, 2007, 4, 652-658.	2.3	57
1895	Synthesis and Biological Evaluation of [18F]Bicalutamide, 4-[76Br]Bromobicalutamide, and 4-[76Br]Bromo-thiobicalutamide as Non-Steroidal Androgens for Prostate Cancer Imaging. Journal of Medicinal Chemistry, 2007, 50, 1028-1040.	2.9	46
1896	Asbestos Surveillance Program Aachen (ASPA): initial results from baseline screening for lung cancer in asbestos-exposed high-risk individuals using low-dose multidetector-row CT. European Radiology, 2007, 17, 1193-1199.	2.3	60
1897	Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome. American Journal of Obstetrics and Gynecology, 2007, 196, 248.e1-248.e8.	0.7	87
1898	Secondary Cytoreductive Surgery in Patients with Platinum-Sensitive Recurrent Ovarian Cancer. Annals of Surgical Oncology, 2007, 14, 1136-1142.	0.7	82
1899	The Pylorus: Take It or Leave It? Systematic Review and Meta-Analysis of Pylorus-Preserving versus Standard Whipple Pancreaticoduodenectomy for Pancreatic or Periampullary Cancer. Annals of Surgical Oncology, 2007, 14, 1825-1834.	0.7	75
1900	Jacaranone: A cytotoxic constituent fromsenecio ambiguus subsp.ambiguus (Biv.) DC. Against renal adenocarcinoma achn and prostate carcinoma LNCaP cells. Archives of Pharmacal Research, 2007, 30, 701-707.	2.7	45
1901	Antibacterial and cytotoxic activities of extracts from (Tunisian)Rhamnus alaternus (Rhamnaceae). Annals of Microbiology, 2007, 57, .	1.1	29
1902	Scattered Dose to Gonads and Associated Risks from Radiotherapy for Common Pediatric Malignancies. Strahlentherapie Und Onkologie, 2007, 183, 332-337.	1.0	21
1904	Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1023-1030.	3.3	54
1905	Clinical Usefulness of Chest Radiography in Detection of Pulmonary Metastases After Curative Resection for Colorectal Cancer. World Journal of Surgery, 2007, 31, 1502-1506.	0.8	22
1906	A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology, 2007, 59, 165-174.	1.1	45
1907	Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemotherapy and Pharmacology, 2007, 60, 321-328.	1.1	51
1908	The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemotherapy and Pharmacology, 2007, 61, 167-175.	1.1	82
1909	Occupation and keratinocyte cancer risk: a population-based case–control study. Cancer Causes and Control, 2007, 18, 895-908.	0.8	43
1910	Follow-Up After Curative Resection of Colorectal Cancer: A Meta-Analysis. Diseases of the Colon and Rectum, 2007, 50, 1783-1799.	0.7	293
1912	HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. International Journal of Colorectal Disease, 2007, 22, 491-497.	1.0	88

#	Article	IF	CITATIONS
1913	Hematological malignancies in chronic inflammatory bowel diseases: report of five cases and review of the literature. International Journal of Colorectal Disease, 2007, 22, 553-558.	1.0	11
1914	Palliative Surgical Bypass for Pancreatic and Peri-ampullary Cancers. Journal of Gastrointestinal Cancer, 2007, 38, 102-107.	0.6	18
1915	Adjuvant chemoradiation for patients with adenocarcinoma of the pancreas: an expirence of single institute. Medical Oncology, 2007, 24, 384-387.	1.2	0
1916	Laparoscopic Deployment of Biliary Self-Expandable Metal Stent (SEMS) for One-Step Palliation in 23 Patients with Advanced Pancreatico-Biliary Tumors—a Pilot Trial. Journal of Gastrointestinal Surgery, 2007, 11, 1686-1691.	0.9	5
1917	A Bland-Altman Analysis of the Bias Between Computed Tomography and Ultrasound Prostate Volume Measurements. Medical Dosimetry, 2008, 33, 234-238.	0.4	3
1918	Type I collagen is overexpressed in medulloblastoma as a component of tumor microenvironment. Journal of Neuro-Oncology, 2008, 86, 133-141.	1.4	51
1920	[11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 9-17.	3.3	168
1921	Diagnostic impact of 18F-FDG PET–CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1775-1785.	3.3	72
1922	A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemotherapy and Pharmacology, 2008, 62, 77-84.	1.1	38
1924	Androgen receptor gene polymorphism may affect the risk of urothelial carcinoma. Journal of Biomedical Science, 2008, 15, 261-269.	2.6	11
1925	Biomedical vignette. Journal of Biomedical Science, 2008, 15, 133-136.	2.6	0
1926	Relationship between single nucleotide polymorphisms in â^174G/C and â^634C/G promoter region of interleukin-6 and prostate cancer. Journal of Huazhong University of Science and Technology [Medical Sciences], 2008, 28, 693-696.	1.0	24
1927	Recurrence and survival in surgically treated endometrioid endometrial cancer. Clinical and Translational Oncology, 2008, 10, 505-511.	1.2	1
1928	Insulin Therapy and Colorectal Adenoma Risk Among Patients with Type 2 Diabetes Mellitus: A Case-Control Study in Korea. Diseases of the Colon and Rectum, 2008, 51, 593-597.	0.7	72
1929	Modelling the Recurrence of Bladder Cancer. Acta Applicandae Mathematicae, 2008, 104, 91-105.	0.5	2
1930	Impact of polymorphism in IL-1RA gene on the risk of cervical cancer. Archives of Gynecology and Obstetrics, 2008, 277, 527-533.	0.8	19
1931	Role of magnetic resonance imaging and cause of pitfalls in detecting myometrial invasion and cervical involvement in endometrial cancer. Archives of Gynecology and Obstetrics, 2008, 278, 535-539.	0.8	38
1932	The presence of carboxypeptidase-M in tumour cells signifies epidermal growth factor receptor expression in lung adenocarcinomas. Journal of Cancer Research and Clinical Oncology, 2008, 134, 439-451.	1.2	20

$\sim$		<u> </u>	
		Repo	DT
$\sim$	паг	<b>KLPU</b>	ALC L

#	Article	IF	CITATIONS
1933	High-dose rate brachytherapy (HDRB) for primary or recurrent cancer in the vagina. Radiation Oncology, 2008, 3, 7.	1.2	38
1934	Parallel imaging enhanced MR colonography using a phantom model. Journal of Magnetic Resonance Imaging, 2008, 28, 664-672.	1.9	6
1935	Current status of biomarkers in head and neck cancer. Journal of Surgical Oncology, 2008, 97, 640-643.	0.8	55
1936	The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer. Cancer, 2008, 112, 300-306.	2.0	74
1937	Increased inducible nitric oxide synthase in lung carcinoma of smokers. Cancer, 2008, 112, 372-381.	2.0	29
1938	Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasion. Cancer, 2008, 112, 1632-1641.	2.0	41
1939	The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer, 2008, 112, 2130-2142.	2.0	116
1940	<i>ERCC1</i> expression as a prognostic marker in N2(+) nonsmallâ€cell lung cancer patients treated with platinumâ€based neoadjuvant concurrent chemoradiotherapy. Cancer, 2008, 113, 1379-1386.	2.0	69
1941	Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma. Cancer, 2008, 113, 1614-1622.	2.0	107
1942	Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party. Hematological Oncology, 2008, 26, 104-107.	0.8	8
1943	Twoâ€photon laserâ€scanning fluorescence microscopy applied for studies of human skin. Journal of Biophotonics, 2008, 1, 320-330.	1.1	28
1944	Regulation of apoptosis by modified naringenin derivatives in human colorectal carcinoma RKO cells. Journal of Cellular Biochemistry, 2008, 104, 259-273.	1.2	34
1945	Detection and significance of serum protein markers of smallâ€cell lung cancer. Journal of Clinical Laboratory Analysis, 2008, 22, 131-137.	0.9	17
1946	Targeted combinatorial therapy of nonâ€small cell lung carcinoma using a GSTâ€fusion protein of fullâ€length or truncated MDAâ€7/ILâ€24 with Tarceva. Journal of Cellular Physiology, 2008, 215, 827-836.	2.0	31
1947	Inactivation of the cystatin E/M tumor suppressor gene in cervical cancer. Genes Chromosomes and Cancer, 2008, 47, 740-754.	1.5	31
1948	Thiosulfinates from Allium tuberosum L. induce apoptosis via caspase-dependent and -independent pathways in PC-3 human prostate cancer cells. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 199-204.	1.0	22
1949	Feasibility of an Ovarian Cancer Quality-of-Life Psychoeducational Intervention. Journal of Cancer Education, 2008, 23, 214-221.	0.6	23
1950	Antecolic gastrointestinal reconstruction with pylorus dilatation. Does it improve delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy?. Hpb, 2008, 10, 472-476.	0.1	14

#	Article	IF	CITATIONS
1951	Adenovirus-mediated restoration of expression of the tumor suppressor gene DLC1 inhibits the proliferation and tumorigenicity of aggressive, androgen-independent human prostate cancer cell lines: prospects for gene therapy. Cancer Gene Therapy, 2008, 15, 371-381.	2.2	22
1952	Differential Capture of Serum Proteins for Expression Profiling and Biomarker Discovery in Pre―and Posttreatment Head and Neck Cancer Samples. Laryngoscope, 2008, 118, 61-68.	1.1	70
1953	EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology, 2008, 52, 738-746.	1.6	272
1954	Modelling prognostic factors in advanced pancreatic cancer. British Journal of Cancer, 2008, 99, 883-893.	2.9	117
1955	Calcium carbonate nanoparticle delivering vascular endothelial growth factor-C siRNA effectively inhibits lymphangiogenesis and growth of gastric cancer in vivo. Cancer Gene Therapy, 2008, 15, 193-202.	2.2	102
1956	Prostate specific antigen (PSA)â€based screening. International Journal of Urology, 2008, 15, 757-762.	0.5	4
1957	Estrogen and progesterone receptors in esophageal carcinoma. Ecological Management and Restoration, 2008, 21, 298-303.	0.2	46
1958	A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Ecological Management and Restoration, 2008, 21, 322-327.	0.2	89
1959	Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU International, 2008, 101, 809-816.	1.3	120
1960	Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference?. BJU International, 2008, 102, 24-27.	1.3	11
1961	Patterns of liver infiltration in lymphoproliferative disease. Histopathology, 2008, 53, 81-90.	1.6	48
1962	Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecologic Oncology, 2008, 108, 421-427.	0.6	83
1963	Loss of heterozygosity of DNA repair gene, hOGG1, in renal cell carcinoma but not in renal papillary adenoma. Pathology International, 2008, 58, 339-343.	0.6	4
1964	An integrated algorithm for gene selection and classification applied to microarray data of ovarian cancer. Artificial Intelligence in Medicine, 2008, 42, 81-93.	3.8	57
1965	Ovarian cancer diagnosis with complementary learning fuzzy neural network. Artificial Intelligence in Medicine, 2008, 43, 207-222.	3.8	44
1966	Apoptotic activities of ethanol extracts from some Apiaceae on human leukaemia cell lines. Fìtoterapìâ, 2008, 79, 487-497.	1.1	55
1967	Peroxisome proliferator-activated receptor-l <sup>3</sup> and growth inhibition by its ligands in prostate cancer. Cancer Detection and Prevention, 2008, 32, 259-266.	2.1	25
1968	Quantitative correlation between sonographic textural feature and histopathological components for breast cancer: preliminary results. Clinical Imaging, 2008, 32, 93-102.	0.8	5

#	Article	IF	CITATIONS
1969	RNA interferenceâ€mediated silencing of the <i>poloâ€like kinase 1</i> gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells. Journal of Cellular and Molecular Medicine, 2008, 12, 2334-2349.	1.6	24
1970	Focus on Breast and Ovarian Cancer. Placenta, 2008, 29, 184-190.	0.7	6
1971	Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA). Journal of Medicinal Chemistry, 2008, 51, 4504-4517.	2.9	223
1972	Aerosolized Chemotherapy. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, 21, 61-70.	0.7	120
1973	Current Clinical and Research Approaches to Optimizing Regional Chemotherapy: Novel Strategies Generated Through a Better Understanding of Drug Pharmacokinetics, Drug Resistance, and the Development of Clinically Relevant Animal Models. Surgical Oncology Clinics of North America, 2008, 17, 731-758.	0.6	7
1974	Association Between Use of Acid-Suppressive Drugs and RiskÂofÂGastric Cancer. Drug Safety, 2008, 31, 675-684.	1.4	47
1975	Endoscopic requirements of colorectal cancer screening programs in average-risk population. Estimation according to a Markov model. GastroenterologÃa Y HepatologÃa, 2008, 31, 405-412.	0.2	12
1976	Health state utilities for non small cell lung cancer. Health and Quality of Life Outcomes, 2008, 6, 84.	1.0	291
1977	PET/CT and Breast Cancer. , 2008, , 217-226.		0
1978	Deletion at chromosome arms 6q16–22 and 10q22.3–23.1 associated with initiation of prostate cancer. Prostate Cancer and Prostatic Diseases, 2008, 11, 357-361.	2.0	8
1979	Interleukin 1 beta gene polymorphism and risk of cervical cancer. International Journal of Gynecology and Obstetrics, 2008, 101, 47-52.	1.0	22
1980	Identification of Differentially Expressed Genes in Microsatellite Stable HNPCC and Sporadic Colon Cancer. Journal of Surgical Research, 2008, 144, 29-35.	0.8	22
1981	A Pilot Study of Perillyl Alcohol in Pancreatic Cancer. Journal of Surgical Research, 2008, 147, 194-199.	0.8	24
1982	Physical Activity. Seminars in Oncology Nursing, 2008, 24, 164-170.	0.7	17
1983	Indole-3-carbinol (I3C) exhibits inhibitory and preventive effects on prostate tumors in mice. Food and Chemical Toxicology, 2008, 46, 863-870.	1.8	46
1984	Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertility and Sterility, 2008, 90, 1635-1639.	0.5	79
1985	An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer. European Journal of Cancer, 2008, 44, 2418-2424.	1.3	370
1986	Dual time point FDG-PET/CT imaging… Potential tool for diagnosis of breast cancer. Clinical Radiology, 2008, 63, 1213-1227.	0.5	50

#	Article	IF	CITATIONS
1987	Biochemotherapy for the treatment of metastatic malignant melanoma: A systematic review. Cancer Treatment Reviews, 2008, 34, 145-156.	3.4	58
1988	Inhibition of CCN6 (Wnt-1-Induced Signaling Protein 3) Down-Regulates E-Cadherin in the Breast Epithelium through Induction of Snail and ZEB1. American Journal of Pathology, 2008, 172, 893-904.	1.9	60
1989	Minimally Invasive Endoscopic Staging of Suspected Lung Cancer. JAMA - Journal of the American Medical Association, 2008, 299, 540.	3.8	390
1990	Combination analysis of hypermethylated SFRP1 and SFRP2 gene in fecal as a novel epigenetic biomarker panel for colorectal cancer screening. Journal of Nanjing Medical University, 2008, 22, 96-101.	0.1	11
1991	Expression and Clinical Significance of CacyBP/SIP in Pancreatic Cancer. Pancreatology, 2008, 8, 470-477.	0.5	21
1992	Activation of MAP Kinase Signaling Through ERK5 But Not ERK1 Expression Is Associated with Lymph Node Metastases in Oral Squamous Cell Carcinoma (OSCC). Neoplasia, 2008, 10, 462-IN4.	2.3	68
1993	Translational Research in Breast Cancer. Surgical Oncology Clinics of North America, 2008, 17, 421-438.	0.6	3
1994	Ultrasound Breast Tumor Image Computer-Aided Diagnosis With Texture and Morphological Features. Academic Radiology, 2008, 15, 873-880.	1.3	52
1995	Human Papilloma Virus – Prevention and Treatment. Obstetrics and Gynecology Clinics of North America, 2008, 35, 199-217.	0.7	9
1996	Early Versus Delayed Hormonal Therapy for Prostate Specific Antigen Only Recurrence of Prostate Cancer After Radical Prostatectomy. Journal of Urology, 2008, 179, S53-9.	0.2	94
1997	Efficacy of chromoendoscopy with indigocarmine for the detection of ascending colon and cecum lesions. Scandinavian Journal of Gastroenterology, 2008, 43, 878-885.	0.6	28
1998	Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer. Journal of Medicinal Chemistry, 2008, 51, 7933-7943.	2.9	180
1999	News Coverage of Cancer in the United States: A National Sample of Newspapers, Television, and Magazines. Journal of Health Communication, 2008, 13, 523-537.	1.2	110
2000	Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. American Journal of Physiology - Cell Physiology, 2008, 295, C440-C450.	2.1	127
2001	E Series of Prostaglandin Receptor 2-Mediated Activation of Extracellular Signal-Regulated Kinase/Activator Protein-1 Signaling Is Required for the Mitogenic Action of Prostaglandin E <sub>2</sub> in Esophageal Squamous-Cell Carcinoma. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 258-267.	1.3	27
2002	Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. Journal of the Royal Society of Medicine, 2008, 101, 473-475.	1.1	15
2003	Multicenter Phase II Study of Cetuximab Plus Irinotecan in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin and Fluoropyrimidines. Japanese Journal of Clinical Oncology, 2008, 38, 762-769.	0.6	33
2004	An Object Lesson: Source Determines the Relations That Trait Anxiety, Prostate Cancer Worry, and Screening Fear Hold with Prostate Screening Frequency. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1631-1639.	1.1	50

#	Article	IF	CITATIONS
2005	Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Molecular Cancer Therapeutics, 2008, 7, 638-647.	1.9	61
2006	Hypoxia-inducible factor-2α regulates the expression of TRAIL receptor DR5 in renal cancer cells. Carcinogenesis, 2008, 29, 1734-1741.	1.3	15
2007	Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Future Oncology, 2008, 4, 71-83.	1.1	62
2008	Recent advances in the molecular diagnosis and prognosis of colorectal cancer. Expert Review of Molecular Diagnostics, 2008, 8, 277-288.	1.5	58
2009	Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes and Development, 2008, 22, 449-462.	2.7	296
2010	7α-18F-Fluoromethyl-Dihydrotestosterone and 7α-18F-Fluoromethyl-Nortestosterone: Ligands to Determine the Role of Sex Hormone–Binding Globulin for Steroidal Radiopharmaceuticals. Journal of Nuclear Medicine, 2008, 49, 987-994.	2.8	6
2011	Distribution of Tight Junction Proteins in Adult Human Salivary Glands. Journal of Histochemistry and Cytochemistry, 2008, 56, 1093-1098.	1.3	41
2012	A Theory of the Emergence, Persistence, and Expression of Geographic Variation in Psychological Characteristics. Perspectives on Psychological Science, 2008, 3, 339-369.	5.2	466
2013	<i>N</i> -[ <i>N</i> -[( <i>S</i> )-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl- <scp> </scp> -Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate Cancer. Clinical Cancer Research, 2008, 14, 3036-3043.	3.2	216
2014	Molecular Imaging of <i>bcl-2</i> Expression in Small Lymphocytic Lymphoma Using <sup>111</sup> In-Labeled PNA–Peptide Conjugates. Journal of Nuclear Medicine, 2008, 49, 430-438.	2.8	27
2015	Sexual Orientation and Smoking: Results From a Multisite Women's Health Study. Substance Use and Misuse, 2008, 43, 1218-1239.	0.7	33
2016	Retrospective analysis of surgical resection after induction chemotherapy for patients with T4b squamous cell head and neck cancer. Acta Oncológica, 2008, 47, 1584-1589.	0.8	0
2017	Clarifying the Diagnosis of Clinically Suspected Recurrence of Cervical Cancer: Impact of 18F-FDG PET. Journal of Nuclear Medicine, 2008, 49, 1936-1943.	2.8	31
2018	Association of ACE Inhibitors and Angiotensin Receptor Blockers with Keratinocyte Cancer Prevention in the Randomized VATTC Trial. Journal of the National Cancer Institute, 2008, 100, 1223-1232.	3.0	101
2019	Polymorphisms in Mitochondrial Genes and Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3558-3566.	1.1	48
2020	Resveratrol as an Inhibitor of Carcinogenesis. Pharmaceutical Biology, 2008, 46, 443-573.	1.3	83
2021	Prostate Cancer Risk in Relation to Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3: A Prospective Multiethnic Study. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 252-254.	1.1	26
2022	Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven. Journal of Clinical Oncology, 2008, 26, 4563-4571.	0.8	819

#	Article	IF	CITATIONS
2023	Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials. Annals of Oncology, 2008, 19, 1039-1044.	0.6	48
2024	Chemoprevention for Colorectal Neoplasia. Clinics in Colon and Rectal Surgery, 2008, 21, 304-312.	0.5	2
2025	Analysis of Basement Membrane Structure and Inflammation During the Development of Esophageal Squamous Cell Carcinoma in the Chinese Chaoshan High Risk Region. Cancer Investigation, 2008, 26, 296-305.	0.6	6
2026	Antiproliferative, Antioxidant, and Antimutagenic Activities of Flavonoid-Enriched Extracts from (Tunisian) <i>Rhamnus alaternus</i> L.: Combination with the Phytochemical Composition. Drug and Chemical Toxicology, 2008, 31, 61-80.	1.2	34
2027	Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate. Pharmacogenomics Journal, 2008, 8, 147-151.	0.9	62
2028	Study on Colon-Specific 5-Fu pH-Enzyme Di-Dependent Chitosan Microspheres. Chemical and Pharmaceutical Bulletin, 2008, 56, 963-968.	0.6	31
2029	Modulation of Cellular Invasion by VEGF-C Expression in Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngology, 2008, 134, 355.	1.5	17
2030	A Novel Splice Variant of the Nuclear Coactivator p120 Functions Strongly for Androgen Receptor: Characteristic Expression in Prostate Disease. Endocrine Journal, 2008, 55, 657-665.	0.7	9
2031	Anti-β1 Integrin Antibody Reduces Surgery-Induced Adhesion of Colon Carcinoma Cells to Traumatized Peritoneal Surfaces. Annals of Surgery, 2008, 247, 85-94.	2.1	50
2032	Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. Blood, 2008, 111, 2261-2268.	0.6	31
2033	Immunotherapy of Established Murine Squamous Cell Carcinoma Using Fused Dendritic-Tumor Cell Hybrids. JAMA Otolaryngology, 2008, 134, 608.	1.5	4
2034	Mammograms in Cosmetic Breast Surgery. The American Journal of Cosmetic Surgery, 2008, 25, 105-109.	0.1	1
2035	Biomarker Identification in Human Pancreatic Cancer Sera. Pancreas, 2008, 36, 61-69.	0.5	58
2036	Tc-99m-methoxy isobutyl isonitrile scintimammography: imaging postexcision biopsy for residual and multifocal breast tumor. Nuclear Medicine Communications, 2008, 29, 826-829.	0.5	4
2037	Significant Down-Regulation of the Plasminogen Activator Inhibitor 1 mRNA in Pancreatic Cancer. Pancreas, 2008, 36, 173-177.	0.5	12
2038	Present and Future Fertility Preservation Strategies for Female Cancer Patients. Obstetrical and Gynecological Survey, 2008, 63, 725-732.	0.2	52
2039	Fertility Preservation in Female and Male Cancer Patients. , 0, , 706-716.		0
2040	Testosterone for the aging male; current evidence and recommended practice. Clinical Interventions in Aging, 2008, Volume 3, 25-44.	1.3	119

#	Article	IF	CITATIONS
2042	Demographic and Socioeconomic Predictors of Melanoma Prognosis in the United States. Journal of Health Care for the Poor and Underserved, 2009, 20, 227-245.	0.4	39
2043	Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World Journal of Gastroenterology, 2008, 14, 3750.	1.4	55
2044	Vector-based RNA interference against vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of colorectal cancer in vivo in mice. Chinese Medical Journal, 2008, 121, 439-444.	0.9	18
2045	Incidental Finding of Colorectal Cancer in Screening Colonoscopy and Its Cost Effectiveness. American Surgeon, 2009, 75, 699-704.	0.4	9
2047	Resection of Portovenous Structures to Obtain Microscopically Negative Margins during Pancreaticoduodenectomy for Pancreatic Adenocarcinoma is Worthwhile. American Surgeon, 2009, 75, 804-810.	0.4	50
2049	Silencing of Claudin-11 Is Associated with Increased Invasiveness of Gastric Cancer Cells. PLoS ONE, 2009, 4, e8002.	1.1	93
2050	The Genetic Basis of Cancer of the Kidney. , 2009, , 497-508.		0
2051	An improving gene selection for microarray data. , 2009, , .		0
2052	Single Center Experience with Percutaneous and Laparoscopic Cryoablation of Small Renal Masses. Journal of Endourology, 2009, 23, 907-911.	1.1	46
2053	Diagnosis and management of thyroid carcinoma: a focus on serum thyroglobulin. Expert Review of Endocrinology and Metabolism, 2009, 4, 25-43.	1.2	44
2054	<i>Case Report</i> : Loss of Hernia Mesh after Simultaneous Laparoscopic Extraperitoneal Lymphadenectomy, Radical Prostatectomy, and Hernioplasty. Journal of Endourology, 2009, 23, 287-292.	1.1	0
2055	GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Pharmacogenomics Journal, 2009, 9, 202-207.	0.9	22
2056	Lung cancer in women: the differences in epidemiology, biology and treatment outcomes. Expert Review of Respiratory Medicine, 2009, 3, 627-634.	1.0	15
2057	Erlotinib for Metastatic Non-Small-Cell Lung Cancer: First-, Second- or Third-Line Setting – Does It Matter ?. Oncology, 2009, 76, 85-90.	0.9	8
2058	7-(O)-Carboxymethyl daidzein conjugated to N-t-Boc-hexylenediamine: A novel compound capable of inducing cell death in epithelial ovarian cancer stem cells. Cancer Biology and Therapy, 2009, 8, 1747-1753.	1.5	35
2059	Malignant cells are not found in ovarian cortex from breast cancer patients undergoing ovarian cortex cryopreservationÂ. Human Reproduction, 2009, 24, 2238-2243.	0.4	90
2060	Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity. Cancer Research, 2009, 69, 2461-2470.	0.4	28
2061	Clinical Stage T1c Prostate Cancer: Evaluation with Endorectal MR Imaging and MR Spectroscopic Imaging. Radiology, 2009, 253, 425-434.	3.6	57

	CHATION	INEPORT	
#	Article	IF	CITATIONS
2062	Post-genomic clinical trials - the perspective of ACGT. Ecancermedicalscience, 2009, 3, 66.	0.6	1
2063	DEAR1 Is a Dominant Regulator of Acinar Morphogenesis and an Independent Predictor of Local Recurrence-Free Survival in Early-Onset Breast Cancer. PLoS Medicine, 2009, 6, e1000068.	3.9	37
2064	Cancer patients without a known primary: Incidence and survival trends in Sweden 1960–2007. Acta Oncológica, 2009, 48, 915-920.	0.8	50
2065	Prostatakarzinom. , 2009, , 485-635.		0
2066	A Randomized Controlled Trial of the Effects of Transcendental Meditation on Quality of Life in Older Breast Cancer Patients. Integrative Cancer Therapies, 2009, 8, 228-234.	0.8	54
2067	Functional Genomic Analysis Identified Epidermal Growth Factor Receptor Activation as the Most Common Genetic Event in Oral Squamous Cell Carcinoma. Cancer Research, 2009, 69, 2568-2576.	0.4	143
2068	RE-1-silencing transcription factor shows tumor-suppressor functions and negatively regulates the oncogenic TAC1 in breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4408-4413.	3.3	69
2069	MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Molecular Cancer Therapeutics, 2009, 8, 1067-1074.	1.9	308
2070	Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses. Oral Oncology, 2009, 45, 1021-1027.	0.8	14
2071	Sociocultural considerations in aging men's health: implications and recommendations for the clinician. Journal of Men's Health, 2009, 6, 196-207.	0.1	2
2072	Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?. BMC Cancer, 2009, 9, 1.	1.1	220
2073	Cáncer de próstata en Latinoamérica. Actas Urológicas Españolas, 2009, 33, 1057-1061.	0.3	22
2074	African-American and Low–Socioeconomic Status Patients Have a Worse Prognosis for Invasive Ductal and Lobular Breast Carcinoma: Do Screening Criteria Need to Change?. Journal of the American College of Surgeons, 2009, 208, 853-868.	0.2	17
2075	Protective effect of ferulic acid on 7,12-dimethylbenz[a]anthracene-induced skin carcinogenesis in Swiss albino mice. Experimental and Toxicologic Pathology, 2009, 61, 205-214.	2.1	64
2076	Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head and Neck, 2009, 31, 625-634.	0.9	64
2077	Epigenetic regulation and molecular characterization of C/EBPÎ $\pm$ in pancreatic cancer cells. International Journal of Cancer, 2009, 124, 827-833.	2.3	43
2078	Core 2 <i>N</i> â€acetylglucosaminyltransferaseâ€1 expression induces aggressive potential of testicular germ cell tumor. International Journal of Cancer, 2010, 127, 1052-1059.	2.3	37
2079	Radioembolization of colorectal hepatic metastases using yttriumâ€90 microspheres. Cancer, 2009, 115, 1849-1858.	2.0	164

#	Article	IF	CITATIONS
2080	Partnerâ€∎ssisted emotional disclosure for patients with gastrointestinal cancer. Cancer, 2009, 115, 4326-4338.	2.0	117
2081	Young age is not associated with increased local recurrence for DCIS treated by breastâ€conserving surgery and radiation. Journal of Surgical Oncology, 2009, 100, 25-31.	0.8	24
2082	Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy. Journal of Cancer Research and Clinical Oncology, 2009, 135, 551-557.	1.2	15
2083	CCR1 knockdown suppresses human non-small cell lung cancer cell invasion. Journal of Cancer Research and Clinical Oncology, 2009, 135, 695-701.	1.2	21
2084	Salvage therapy with topotecan in heavily pretreated ovarian cancer patients. Journal of Cancer Research and Clinical Oncology, 2009, 135, 815-821.	1.2	5
2085	Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients. Journal of Cancer Research and Clinical Oncology, 2009, 135, 837-846.	1.2	42
2086	Clinical research on treatment of advanced androgen independent prostate cancer with Docetaxel and Thalidomide. Chinese-German Journal of Clinical Oncology, 2009, 8, 276-278.	0.1	0
2087	Gefitinib in the treatment of 41 cases with refractory non-small cell lung cancer. Chinese-German Journal of Clinical Oncology, 2009, 8, 314-316.	0.1	0
2088	Supraphysiological Thermal Injury in Different Human Bladder Carcinoma Cell Lines. Annals of Biomedical Engineering, 2009, 37, 2407-2415.	1.3	7
2089	An unusual case of recurrent endometrial cancer presented with isolated cervical lymph node metastasis. Archives of Gynecology and Obstetrics, 2009, 280, 153-156.	0.8	3
2090	Gender and psychological distress among middle- and older-aged colorectal cancer patients and their spouses: An unexpected outcome. Critical Reviews in Oncology/Hematology, 2009, 70, 71-82.	2.0	68
2091	No association of TAP1 and TAP2 genes polymorphism with risk of cervical cancer in north Indian population. Journal of Assisted Reproduction and Genetics, 2009, 26, 173-178.	1.2	8
2092	Racial, ethnic and socioeconomic disparities in the treatment of brain tumors. Journal of Neuro-Oncology, 2009, 93, 25-39.	1.4	116
2093	Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside. Journal of Neuro-Oncology, 2009, 93, 79-87.	1.4	31
2094	Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. Journal of Neuro-Oncology, 2009, 95, 129-134.	1.4	47
2095	Factors Influencing Choices for Colorectal Cancer Screening Among Previously Unscreened African and Caucasian Americans: Findings from a Triangulation Mixed Methods Investigation. Journal of Community Health, 2009, 34, 79-89.	1.9	48
2096	Anti-tumor immune response in ovarian cancer: clinical implications, prognostic significance and potential for novel treatment strategies. Oncology Reviews, 2009, 3, 173-186.	0.8	0
2097	Effective Treatment of Advanced Colorectal Cancer by Rapamycin and 5-FU/Oxaliplatin Monitored by TIMP-1. Journal of Gastrointestinal Surgery, 2009, 13, 1781-1790.	0.9	21

#	Article	IF	Citations
2098	Effect of atorvastatin on tumor growth and metastasis in a breast cancer cell xenograft model and its mechanism. Frontiers of Medicine in China, 2009, 3, 443-446.	0.1	1
2099	The value of FDG-PET/CT in assessing single pulmonary nodules in patients at high risk of lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 997-1004.	3.3	55
2100	A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites. Cancer Chemotherapy and Pharmacology, 2009, 63, 331-341.	1.1	5
2101	Human Bone Marrow-Derived Mesenchymal Stromal Cells Expressing S-TRAIL as a Cellular Delivery Vehicle for Human Glioma Therapy. Stem Cells, 2009, 27, 2320-2330.	1.4	168
2102	<i>In vivo</i> protective effect of crocetin on benzo(a)pyreneâ€induced lung cancer in Swiss albino mice. Phytotherapy Research, 2009, 23, 533-539.	2.8	43
2103	How relevant is marital status and gender variables in coping with colorectal cancer? A sample of middleâ€aged and older cancer survivors. Psycho-Oncology, 2009, 18, 866-874.	1.0	94
2104	Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Science, 2009, 100, 2292-2301.	1.7	41
2105	PCâ€407, a celecoxib derivative, inhibited the growth of colorectal tumor <i>in vitro</i> and <i>in vivo</i> . Cancer Science, 2009, 100, 2451-2458.	1.7	14
2106	<i>RegÂIV</i> enhances peritoneal metastasis in gastric carcinomas. Cell Proliferation, 2009, 42, 110-121.	2.4	41
2107	Prognostic importance of epithelial–mesenchymal transitionâ€related protein expression in gastric carcinoma. Histopathology, 2009, 54, 442-451.	1.6	131
2108	Purinergic receptorâ€mediated effects of adenosine 5′â€ŧriphosphate in urological malignant diseases. International Journal of Urology, 2009, 16, 143-150.	0.5	44
2109	Diagnosis of solid pancreatic masses by endoscopic ultrasoundâ€guided fineâ€needle aspiration. Internal Medicine Journal, 2009, 39, 32-37.	0.5	35
2110	ERLOTINIB ACTIVATES MITOCHONDRIAL DEATH PATHWAYS RELATED TO THE PRODUCTION OF REACTIVE OXYGEN SPECIES IN THE HUMAN NON‧MALL CELL LUNG CANCER CELL LINE A549. Clinical and Experimental Pharmacology and Physiology, 2009, 36, 487-494.	0.9	18
2111	Magnetic resonance imaging for assessment of deep endometrial invasion for patients with endometrial carcinoma. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2009, 49, 537-541.	0.4	17
2112	Radiotherapy With 8-MHz Radiofrequency-Capacitive Regional Hyperthermia for Stage III Non–Small-Cell Lung Cancer: The Radiofrequency-Output Power Correlates With the Intraesophageal Temperature and Clinical Outcomes. International Journal of Radiation Oncology Biology Physics, 2009, 73, 128-135.	0.4	34
2113	Protein microarray for the analysis of human melanoma biomarkers. Sensors and Actuators B: Chemical, 2009, 139, 2-8.	4.0	25
2114	Clinical Significance of Postradiotherapy [18F]-Fluorodeoxyglucose Positron Emission Tomography Imaging in Management of Head-and-Neck Cancer—A Long-Term Outcome Report. International Journal of Radiation Oncology Biology Physics, 2009, 74, 9-14.	0.4	108
2115	Physician, affective, and cognitive variables differentially predict initiation versus maintenance PSA screening profiles in diverse groups of men. British Journal of Health Psychology, 2009, 14, 303-322.	1.9	12

#	Article	IF	Citations
2116	A Review of Kinases Implicated in Pancreatic Cancer. Pancreatology, 2009, 9, 738-754.	0.5	35
2117	Current challenges in clinical management of endometrial cancer. Advanced Drug Delivery Reviews, 2009, 61, 883-889.	6.6	9
2118	Vascular Endothelial Growth Factor-C siRNA Delivered via Calcium Carbonate Nanoparticle Effectively Inhibits Lymphangiogenesis and Growth of Colorectal Cancer <i>In Vivo</i> . Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 249-259.	0.7	22
2119	Prevalence of anal squamous intra-epithelial lesion in women presenting genital squamous intra-epithelial lesion. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2009, 142, 73-75.	0.5	15
2120	Breast cancer with low FDG uptake: Characterization by means of dual-time point FDG-PET/CT. European Journal of Radiology, 2009, 70, 530-538.	1.2	31
2121	Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment. Cancer Letters, 2009, 285, 58-65.	3.2	8
2122	Physical activity and lymphedema (the PAL trial): Assessing the safety of progressive strength training in breast cancer survivors. Contemporary Clinical Trials, 2009, 30, 233-245.	0.8	116
2123	Non-AUG translational initiation of a short CAPC transcript generating protein isoform. Biochemical and Biophysical Research Communications, 2009, 380, 508-513.	1.0	6
2124	The association of physician-specialty density and melanoma prognosis in the United States, 1988 to 1993. Journal of the American Academy of Dermatology, 2009, 60, 51-58.	0.6	39
2125	Apoptosis-Inducing Factor and Colon Cancer. Journal of Surgical Research, 2009, 151, 163-170.	0.8	62
2126	Cordycepin causes p21WAF1-mediated G2/M cell-cycle arrest by regulating c-Jun N-terminal kinase activation in human bladder cancer cells. Archives of Biochemistry and Biophysics, 2009, 490, 103-109.	1.4	77
2127	Oncologic Outcomes. , 2009, , 117-124.		0
2128	Regulation of Prostate Cancer Progression by Galectin-3. American Journal of Pathology, 2009, 174, 1515-1523.	1.9	104
2129	Body image disturbance and surgical decision making in egyptian post menopausal breast cancer patients. World Journal of Surgical Oncology, 2009, 7, 66.	0.8	25
2130	Quantitative Serum Glycomics of Esophageal Adenocarcinoma and Other Esophageal Disease Onsets. Journal of Proteome Research, 2009, 8, 2656-2666.	1.8	71
2131	Surgical versus medical castration in the Bahamas: a male macho paradox. Infectious Agents and Cancer, 2009, 4, S4.	1.2	1
2132	Interactive Lung Segmentation Algorithm for CT Chest Images Based on Live-Wire Model and Snake Model. , 2009, , .		2
2133	Testing of neurosurgical needle steering via duty-cycled spinning in brain tissue in vitro. , 2009, 2009, 258-61.		21

#	Article	IF	CITATIONS
2134	Positive urine cytology but negative whiteâ€light cystoscopy: an indication for fluorescence cystoscopy?. BJU International, 2009, 103, 484-487.	1.3	34
2135	Caring for Patients with Malignancy in the Emergency Department: Patient–Provider Interactions. Emergency Medicine Clinics of North America, 2009, 27, 333-339.	0.5	10
2136	A Series of Halogenated Heterodimeric Inhibitors of Prostate Specific Membrane Antigen (PSMA) as Radiolabeled Probes for Targeting Prostate Cancer. Journal of Medicinal Chemistry, 2009, 52, 347-357.	2.9	255
2137	Prognostic significance of several histological features in intermediate and highâ€risk endometrial cancer patients treated with curative intent using surgery and adjuvant radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2009, 53, 107-113.	0.9	8
2138	Identification of a Novel Kindred with Familial Pancreatitis and Pancreatic Cancer. Pancreatology, 2009, 9, 273-279.	0.5	5
2140	The Role of Minimally Invasive Treatments in Surgical Oncology. Surgical Clinics of North America, 2009, 89, 53-77.	0.5	28
2141	Phytochemical, Antibacterial, Antiproliferative, and Antioxidant Potentials and DNA Damage-Protecting Activity ofAcacia salicinaExtracts. Journal of Medicinal Food, 2009, 12, 675-683.	0.8	11
2142	Managing menopausal symptoms after gynecological cancer. Current Opinion in Oncology, 2009, 21, 407-411.	1.1	26
2143	Patient Factors Predictive of Inadequate Bowel Preparation Using Polyethylene Glycol. Journal of Clinical Gastroenterology, 2009, 43, 448-452.	1.1	174
2144	The Perioperative Period is an Underutilized Window of Therapeutic Opportunity in Patients With Colorectal Cancer. Annals of Surgery, 2009, 249, 727-734.	2.1	175
2145	Eliminating Health Disparities Through Transdisciplinary Research, Cross-Agency Collaboration, and Public Participation. American Journal of Public Health, 2009, 99, 1955-1961.	1.5	35
2146	Interleukin-12 Gene Polymorphism and Cervical Cancer Risk. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 524-528.	0.6	19
2147	Salvage Treatment for Recurrent Oral Squamous Cell Carcinoma. Journal of Craniofacial Surgery, 2009, 20, 1093-1096.	0.3	12
2148	CpG island methylation of TMS1/ASC and CASP8 genes in cervical cancer. European Journal of Medical Research, 2009, 14, 71.	0.9	15
2149	Durability of Initial Antiretroviral Therapy in a Resource-Constrained Setting and the Potential Need for Zidovudine Weight-Based Dosing. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 215-221.	0.9	49
2150	The Utility of Sonographic Features During Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients With Lung Cancer. Chest, 2010, 138, 641-647.	0.4	247
2151	Anti-Pancreatic Cancer Effects of a Polar Extract From the Edible Sea Cucumber, Cucumaria frondosa. Pancreas, 2010, 39, 646-652.	0.5	31
2152	Vascular Endothelial Growth Factor and not Cyclooxygenase 2 Promotes Endothelial Cell Viability in the Pancreatic Tumor Microenvironment. Pancreas, 2010, 39, 595-603.	0.5	5

#	Article	IF	CITATIONS
2153	Genetic/Familial High-Risk Assessment: Breast and Ovarian. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 562-594.	2.3	253
2154	Expression of ERCC1 and Class III β-Tubulin in Resected Non-Small Cell Lung Cancer and its Correlation with Platinum-Based Adjuvant Chemotherapy. International Journal of Biological Markers, 2010, 25, 141-149.	0.7	5
2155	Anal HPV infection in Slovenian men who have sex with men. Open Medicine (Poland), 2010, 5, 698-703.	0.6	4
2156	Pharmacokinetics and pharmacodynamics of Phor21-βCG(ala), a lytic peptide conjugateâ€. Journal of Pharmacy and Pharmacology, 2010, 60, 1441-1448.	1.2	10
2157	Correlation Between Preoperative Endoscopic and Intraoperative Findings in Localizing Colorectal Lesions. World Journal of Surgery, 2010, 34, 1587-1591.	0.8	35
2159	Multiple primary malignancies involving colorectal cancer—clinical characteristics and prognosis with reference to surveillance. Langenbeck's Archives of Surgery, 2010, 395, 359-364.	0.8	19
2160	The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2010, 136, 1-7.	1.2	37
2161	Association between ovarian endometriosis and malignancy in the peri-menopausal period: report of two cases and review of the literature. Gynecological Surgery, 2010, 7, 13-17.	0.9	4
2162	Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumor Biology, 2010, 31, 171-180.	0.8	61
2163	Effect of Mad2 on paclitaxel-induced cell death in ovarian cancer cells. Journal of Huazhong University of Science and Technology [Medical Sciences], 2010, 30, 620-625.	1.0	15
2164	Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Medical Oncology, 2010, 27, 91-97.	1.2	15
2165	Understanding the Barriers and Facilitators of Colorectal Cancer Screening Among Low Income Immigrant Hispanics. Journal of Immigrant and Minority Health, 2010, 12, 462-469.	0.8	78
2166	Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3). Molecular and Cellular Biochemistry, 2010, 344, 173-184.	1.4	57
2167	Identification of Common Nail and Skin Disorders. Journal of Hand Therapy, 2010, 23, 187-198.	0.7	6
2168	Characterization of the association between 8q24 and colon cancer: gene-environment exploration and meta-analysis. BMC Cancer, 2010, 10, 670.	1.1	54
2169	Can primary optimal cytoreduction be predicted in advanced epithelial ovarian cancer preoperatively?. World Journal of Surgical Oncology, 2010, 8, 11.	0.8	5
2170	Human Prostate Fibroblasts Induce Growth and Confer Castration Resistance and Metastatic Potential in LNCaP Cells. European Urology, 2010, 58, 162-172.	0.9	36
2171	Characterization of variant diphtheria toxin–interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials. Biologicals, 2010, 38, 144-149.	0.5	7

			0
#		IF	CITATIONS
2173	Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy. Journal of Cellular and Molecular Medicine, 2010, 14, 805-817.	1.6	3
2174	Synthesis and Antitumor Activity of Ether Glycerophospholipids Bearing a Carbamate Moiety at the <i>sn</i> â€2 Position: Selective Sensitivity Against Prostate Cancer Cell Lines. ChemMedChem, 2010, 5, 1045-1052.	1.6	7
2175	Accuracy and sensitivity of computed tomographyâ€guided percutaneous needle biopsy of pulmonary hilar lymph nodes. Cancer, 2010, 116, 1974-1980.	2.0	13
2176	Enhanced cell migration and invasion of CD133 <sup>+</sup> pancreatic cancer cells cocultured with pancreatic stromal cells. Cancer, 2010, 116, 3357-3368.	2.0	62
2177	Clinical impact of tumorâ€infiltrating lymphocytes for survival in stage II colon cancer. Cancer, 2010, 116, 5188-5199.	2.0	105
2178	Diagnostic usefulness of serum interleukin 6 (ILâ€6) and Câ€reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. Journal of Clinical Laboratory Analysis, 2010, 24, 256-261.	0.9	91
2179	Thermoablation of colorectal liver metastasis. Journal of Surgical Oncology, 2010, 101, 699-705.	0.8	15
2180	Human papillomavirus (HPV) prevalence and type distribution, and HPVâ€associated cytological abnormalities in anal specimens from men infected with HIV who have sex with men. Journal of Medical Virology, 2010, 82, 592-596.	2.5	37
2181	Safety and feasibility of radiotherapy treatment in elderly non-small-cell lung cancer (NSCLC) patients. Archives of Gerontology and Geriatrics, 2010, 50, 185-191.	1.4	6
2182	The changing face of cancer in the elderly: Only a demographic change?. Archives of Gerontology and Geriatrics, 2010, 50, e59-e62.	1.4	4
2183	Monoclonal gammopathy in a tertiary referral hospital. Clinical Biochemistry, 2010, 43, 709-713.	0.8	4
2184	Inhibitory effect of curcumin on motility of human oral squamous carcinoma YDâ€∎OB cells via suppression of ERK and NFâ€₽B activations. Phytotherapy Research, 2010, 24, 577-582.	2.8	47
2185	Modulatory effects of curcumin and resveratrol on lung carcinogenesis in mice. Phytotherapy Research, 2010, 24, 1271-1277.	2.8	28
2186	Histamine receptors and cancer pharmacology. British Journal of Pharmacology, 2010, 161, 755-767.	2.7	146
2187	Inhibition of MMPâ€9 transcription and suppression of tumor metastasis by pyrroleâ€imidazole polyamide. Cancer Science, 2010, 101, 759-766.	1.7	54
2188	Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells. British Journal of Cancer, 2010, 102, 383-391.	2.9	15
2189	In vivo and in vitro propagation of intraductal papillary mucinous neoplasms. Laboratory Investigation, 2010, 90, 665-673.	1.7	14
2190	Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas. Cancer Gene Therapy, 2010, 17, 664-674.	2.2	29

#	Article	IF	CITATIONS
2191	The impact of volume on outcomes after oesophageal cancer surgery. ANZ Journal of Surgery, 2010, 80, 634-641.	0.3	24
2192	Correlation of granulin expression in intracranial meningiomas to clinical parameters. Experimental and Therapeutic Medicine, 2010, 1, 493-496.	0.8	5
2193	Rb–Raf-1 Interaction Disruptor RRD-251 Induces Apoptosis in Metastatic Melanoma Cells and Synergizes with Dacarbazine. Molecular Cancer Therapeutics, 2010, 9, 3330-3341.	1.9	18
2194	Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Annals of Oncology, 2010, 21, 312-318.	0.6	45
2195	Müllerian Inhibiting Substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers. Future Oncology, 2010, 6, 391-405.	1.1	39
2196	ldentification of Patients With Nonmelanoma Skin Cancer Using Health Maintenance Organization Claims Data. American Journal of Epidemiology, 2010, 171, 123-128.	1.6	66
2197	Molecular imaging agents: impact on diagnosis and therapeutics in oncology. Expert Reviews in Molecular Medicine, 2010, 12, e20.	1.6	28
2198	Individual Cell-Based Model for In-Vitro Mesothelial Invasion of Ovarian Cancer. Mathematical Modelling of Natural Phenomena, 2010, 5, 203-223.	0.9	31
2199	Identification of candidate molecular markers predicting chemotherapy resistance in non-small cell lung cancer. Clinical Chemistry and Laboratory Medicine, 2010, 48, 863-867.	1.4	12
2200	Implementing WHO Recommendations for Palliative Care into Routine Lung Cancer Therapy: A Feasibility Project. Journal of Palliative Medicine, 2010, 13, 727-732.	0.6	32
2201	Selection of a Patient Subgroup with Advanced Esophageal Squamous Carcinoma Who Could Benefit from Second-Line Chemotherapy. Oncology, 2010, 79, 363-369.	0.9	1
2202	Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance. Journal of Clinical Oncology, 2010, 28, 543-548.	0.8	142
2203	Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib. Cancer Biology and Therapy, 2010, 9, 572-582.	1.5	59
2204	Racial Disparities in Urologic Health Care. Journal of the National Medical Association, 2010, 102, 108-118.	0.6	29
2205	Perifissural Nodules Seen at CT Screening for Lung Cancer. Radiology, 2010, 254, 949-956.	3.6	132
2206	Male Osteoporosis. Clinics in Geriatric Medicine, 2010, 26, 301-309.	1.0	12
2207	Effect of Ovarian Cancer Ascites on Cell Migration and Gene Expression in an Epithelial Ovarian Cancer In Vitro Model. Translational Oncology, 2010, 3, 230-238.	1.7	33
2208	Lung Injury and Cancer. American Journal of Respiratory Cell and Molecular Biology, 2010, 43, 259-268.	1.4	68

#	Article	IF	CITATIONS
2209	Mortality in patients undergoing covered self-expandable metal stent revisions in malignant biliary stricture: Does pathology matter?. Digestive and Liver Disease, 2010, 42, 803-806.	0.4	3
2210	Techniques and results of portal vein/superior mesenteric vein reconstruction using femoral and saphenous vein during pancreaticoduodenectomy. Journal of Vascular Surgery, 2010, 51, 662-666.	0.6	54
2211	Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells. Molecular Oncology, 2010, 4, 323-334.	2.1	53
2212	Quercetin abrogates chemoresistance in melanoma cells by modulating ΔNp73. BMC Cancer, 2010, 10, 282.	1.1	31
2213	Surgical treatment of pancreatic adenocarcinoma using cephalic duodenopancreatectomy (Part 2). Long term follow up after 204 cases. CirugÃa Española (English Edition), 2010, 88, 374-382.	0.1	2
2214	Ultrasonographic characterisation of an experimental model of liver metastases from colon carcinoma in rats. Radiologia, 2010, 52, 37-44.	0.3	6
2215	False positive in pelvis in a PET-CT scan due to ovarian reimplantation: A case report. Revista Española De Medicina Nuclear, 2010, 29, 87-90.	0.3	0
2216	Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer. European Journal of Cancer, 2010, 46, 2104-2118.	1.3	60
2217	Lymph node size and metastatic infiltration in adenocarcinoma of the pancreatic head. European Journal of Surgical Oncology, 2010, 36, 993-996.	0.5	30
2218	Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist. Fertility and Sterility, 2010, 93, 1609-1614.	0.5	55
2219	Salvage Therapy With Bicalutamide 150 mg in Nonmetastatic Castration-resistant Prostate Cancer. Urology, 2010, 76, 1189-1193.	0.5	34
2221	Chagas disease and gynecologic neoplasias. Annals of Diagnostic Pathology, 2010, 14, 337-340.	0.6	7
2223	Surviving childhood and reproductive-age malignancy: effects on fertility and future parenthood. Lancet Oncology, The, 2010, 11, 490-498.	5.1	67
2224	The Gender-Specific Aspects of Lung Cancer. , 2010, , 260-269.		0
2225	Relative Biological Effectiveness and Cell-Killing Efficacy of Continuous Low-Dose-Rate 1251 Seeds on Prostate Carcinoma Cells In Vitro. Integrative Cancer Therapies, 2010, 9, 59-65.	0.8	15
2226	Adjuvant and Neoadjuvant Therapy in Curable Pancreatic Cancer. Surgical Clinics of North America, 2010, 90, 323-339.	0.5	10
2227	First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Review of Anticancer Therapy, 2010, 10, 47-60.	1.1	84
2228	Thymidine Phosphorylase Expression in Human Bladder Urothelial Carcinoma. Urological Science, 2011, 22, 32-37.	0.2	Ο

#	Article	IF	CITATIONS
2229	PPARÎ <sup>3</sup> disease gene network and identification of therapeutic targets for prostate cancer. Journal of Drug Targeting, 2011, 19, 781-796.	2.1	14
2230	Anal Cancer. , 2011, , 337-357.		4
2231	The role of positron emission tomography for non-small cell lung cancer. Practical Radiation Oncology, 2011, 1, 282-288.	1.1	6
2232	Local convection-enhanced delivery of chemotherapeutic agent transiently opens blood–brain barrier and improves efficacy of systemic chemotherapy in intracranial xenograft tumor model. Cancer Letters, 2011, 310, 77-83.	3.2	17
2233	Is anti-Müllerian hormone a marker of acute cyclophosphamide-induced ovarian follicular destruction in mice pretreated with cetrorelix?. Fertility and Sterility, 2011, 96, 180-186.e2.	0.5	12
2234	MRI for the size assessment of pure ductal carcinoma in situ (DCIS): A prospective study of 33 patients. European Journal of Radiology, 2011, 77, 462-467.	1.2	53
2235	The CXCR4-CXCL12 Pathway Facilitates the Progression of Pancreatic Cancer Via Induction of Angiogenesis and Lymphangiogenesis. Journal of Surgical Research, 2011, 171, 143-150.	0.8	54
2236	Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. British Journal of Cancer, 2011, 105, 1733-1740.	2.9	232
2238	Comparison of Physical Examination and Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography 4–6 Months After Radiotherapy to Assess Residual Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, e825-e832.	0.4	36
2239	Simultaneous forequarter amputation and radical mastectomy for metastatic breast carcinoma in a male patient: a case report. [Chapchi] Journal Taehan Oekwa Hakhoe, 2011, 81, S6.	1.1	3
2240	Apoptotic Effects of Genistein, Biochanin-A and Apigenin on LNCaP and PC-3 Cells by p21 through Transcriptional Inhibition of Polo-like Kinase-1. Journal of Korean Medical Science, 2011, 26, 1489.	1.1	78
2241	HÃBITOS ALIMENTARIOS Y RIESGO DE CANCER DE PIEL NO MELANOMA. Revista Chilena De Nutricion, 2011, 38, 15-21.	0.1	0
2242	Preditores de qualidade de vida em pacientes com melanoma cutâneo no serviço de dermatologia do Hospital de ClAnicas de Porto Alegre. Anais Brasileiros De Dermatologia, 2011, 86, 249-256.	0.5	19
2243	Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line. Experimental and Therapeutic Medicine, 2011, 2, 1091-1095.	0.8	13
2244	The Discovery of Putative Urine Markers for the Specific Detection of Prostate Tumor by Integrative Mining of Public Genomic Profiles. PLoS ONE, 2011, 6, e28552.	1.1	16
2245	Genetic Variants in DNA Repair Predicts the Survival of Patients with Esophageal Cancer. Annals of Surgery, 2011, 253, 918-927.	2.1	22
2246	Health-Related Quality of Life in Survivors With Breast Cancer 1 Year After Diagnosis Compared With the General Population. Annals of Surgery, 2011, 253, 101-108.	2.1	68
2247	Promoting Community Awareness of the Need for Colorectal Cancer Prevention and Screening. Gastroenterology Nursing, 2011, 34, 34-40.	0.2	5

#	Article	IF	CITATIONS
	Changing trends in polypoid colorectal cancer diagnosed by colonoscopy. Colorectal Disease, 2011, 13,		
2249	e37-41.	0.7	1
2250	Overexpression of dedicator of cytokinesis I (Dock180) in ovarian cancer correlated with aggressive phenotype and poor patient survival. Histopathology, 2011, 59, 1163-1172.	1.6	16
2251	Oral metastatic hepatocellular carcinoma: A changing demographic in Europe and North America. Immunohistochemical advances in the microscopic diagnosis. Oral Oncology, 2011, 47, 62-67.	0.8	10
2252	EcografÃa de los quistes y tumores del ovario. EMC - GinecologÃa-Obstetricia, 2011, 47, 1-24.	0.0	1
2253	Lobectomy in Octogenarians With Non-Small Cell Lung Cancer: Ramifications of Increasing Life Expectancy and the Benefits of Minimally Invasive Surgery. Annals of Thoracic Surgery, 2011, 92, 1951-1957.	0.7	101
2254	EGF enhances the migration of cancer cells by up-regulation of TRPM7. Cell Calcium, 2011, 50, 559-568.	1.1	93
2255	Neoplasms of the Gastrointestinal Tract and Liver. , 2011, , 528-539.e3.		0
2256	Proteomic identification of exosomal LRG1: A potential urinary biomarker for detecting NSCLC. Electrophoresis, 2011, 32, 1976-1983.	1.3	231
2257	Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone. Journal of Assisted Reproduction and Genetics, 2011, 28, 651-656.	1.2	22
2258	CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis. Breast Cancer Research and Treatment, 2011, 126, 47-54.	1.1	43
2259	INAA application in the age dynamics assessment of Br, Ca, Cl, K, Mg, Mn, and Na content in the normal human prostate. Journal of Radioanalytical and Nuclear Chemistry, 2011, 288, 197-202.	0.7	28
2260	KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Molecular Biology Reports, 2011, 38, 1315-1320.	1.0	35
2261	Synthesis and Ex Vivo Autoradiographic Evaluation of Ethyl-β-d-galactopyranosyl-(1,4′)-2′-deoxy-2′-[18F]fluoro-β-d-glucopyranoside—A Novel Radioligand for Lactose-Binding Protein: Implications for Early Detection of Pancreatic Carcinomas with PET. Molecular Imaging and Biology, 2011, 13, 536-546.	1.3	10
2262	EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 and P53 expression in preneoplastic lesions of bronchial epithelium: an immunohistochemical and genetic study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 571-581.	1.4	10
2263	Regulation of IGF2 transcript and protein expression by altered methylation in breast cancer. Journal of Cancer Research and Clinical Oncology, 2011, 137, 339-345.	1.2	35
2264	Short-term outcomes following laparoscopic resection for colon cancer. International Journal of Colorectal Disease, 2011, 26, 361-368.	1.0	13
2265	Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers. Archives of Gynecology and Obstetrics, 2011, 283, 603-610.	0.8	26
2266	Personalized Cancer Approach: Using RNA Interference Technology. World Journal of Surgery, 2011, 35, 1700-1714.	0.8	9

#	Article	IF	CITATIONS
2267	Expert system based on neuro-fuzzy rules for diagnosis breast cancer. Expert Systems With Applications, 2011, 38, 5719-5726.	4.4	123
2268	Prediction of lack of response to neoadjuvant chemotherapy in rare breast tumour histology with Tc-99m sestamibi scintimammography. Annals of Nuclear Medicine, 2011, 25, 524-527.	1.2	0
2269	CNS tumours in children and adolescents - differences to adult patients. Memo - Magazine of European Medical Oncology, 2011, 4, 3-5.	0.3	0
2270	Assessment of the Short Acculturation Scale for Hispanics (SASH) Among Low-Income, Immigrant Hispanics. Journal of Cancer Education, 2011, 26, 478-483.	0.6	63
2271	Hypoxic liver perfusion with mitomycin-C for treating multifocal metastases and unresectable primary tumours: a single-centre series of 42 patients. Radiologia Medica, 2011, 116, 1239-1249.	4.7	5
2272	Improvement in Treatment and Outcome of Pancreatic Ductal Adenocarcinoma in North China. Journal of Gastrointestinal Surgery, 2011, 15, 1026-1034.	0.9	10
2273	Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. Molecular Cancer, 2011, 10, 125.	7.9	40
2274	The Br, Fe, Rb, Sr, and Zn contents and interrelation in intact and morphologic normal prostate tissue of adult men investigated by energyâ€dispersive Xâ€ray fluorescent analysis. X-Ray Spectrometry, 2011, 40, 464-469.	0.9	29
2275	The CD40 D154 interaction would correlate with proliferation and immune escape in pancreatic ductal adenocarcinoma. Journal of Surgical Oncology, 2011, 103, 230-238.	0.8	9
2276	Linoleic acid and butyrate synergize to increase Bclâ€2 levels in colonocytes. International Journal of Cancer, 2011, 128, 63-71.	2.3	28
2277	Do Elderly Patients Experience Increased Perioperative or Postoperative Morbidity or Mortality When Given Neoadjuvant Chemoradiation Before Esophagectomy?. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1372-1376.	0.4	33
2278	The effect of age on Ag, Co, Cr, Fe, Hg, Rb, Sb, Sc, Se, and Zn contents in intact human prostate investigated by neutron activation analysis. Applied Radiation and Isotopes, 2011, 69, 827-833.	0.7	35
2279	CpG island methylator phenotype of cell-cycle regulators associated with TNM stage and poor prognosis in patients with oesophageal squamous cell carcinoma. Journal of Clinical Pathology, 2011, 64, 246-251.	1.0	26
2280	Embedded process for flexible conductive electrodes for applications in tissue electrical impedance scanning (EIS). , 2011, , .		3
2281	Contemporary Diagnostic Imaging Modalities for the Staging and Surveillance of Melanoma Patients: a Meta-analysis. Journal of the National Cancer Institute, 2011, 103, 129-142.	3.0	297
2282	Health-Related Quality of Life Among Long-Term Survivors of Colorectal Cancer: A Population-Based Study. Oncologist, 2011, 16, 1626-1636.	1.9	82
2283	5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma. Oncology, 2011, 80, 301-306.	0.9	88
2284	TP53-Associated Pediatric Malignancies. Genes and Cancer, 2011, 2, 485-490.	0.6	30

ARTICLE IF CITATIONS Reduced Plasma Level of CXC Chemokine Ligand 7 in Patients with Pancreatic Cancer. Cancer 2285 45 1.1 Epidemiology Biomarkers and Prevention, 2011, 20, 160-171. Anti-lipid peroxidation and induction of apoptosis in the erythroleukaemic cell line K562 by extracts 2286 1.0 from (Tunisian)Rhamnus alaternusL. (Rhamnaceae). Naturál Product Research, 2011, 25, 1047-1058. Aerosolized Gemcitabine in Patients with Carcinoma of the Lung: Feasibility and Safety Study. Journal 2287 0.7 60 of Aerosol Medicine and Pulmonary Drug Delivery, 2011, 24, 261-270. A Novel Bioluminescence Orthotopic Mouse Model for Advanced Lung Cancer. Radiation Research, 2011, 176, 486-493. Synergistic Effect of IFN-Î<sup>3</sup> Gene on LIGHT-induced Apoptosis in HepG2 Cells via Down Regulation of 2289 0.9 3 Bcl-2. Artificial Cells, Blood Substitutes, and Biotechnology, 2011, 39, 228-238. Conservative management of young patients with endometrial highly-differentiated adenocarcinoma. Journal of Obstetrics and Gynaecology, 2011, 31, 13-17. 2290 0.4 Dietary fish oil modulates the effect of dimethylhydrazine- induced colon cancer in rats. Grasas Y 2291 0.3 4 Aceites, 2011, 62, 253-267. The Vitamin D System and Colorectal Cancer Prevention., 2011, , 1711-1729. Swedish Lung Cancer Radiation Study Group: Predictive value of age at diagnosis for radiotherapy 2293 0.8 4 response in patients with non-small cell lung cancer. Acta OncolÃ<sup>3</sup>gica, 2012, 51, 759-767. Effects of Genetically Engineered Stem Cells Expressing Cytosine Deaminase and Interferon-Beta or 2294 Carboxyl Esterase on the Growth of LNCaP Prostate Cancer Cells. International Journal of Molecular 1.8 Sciences, 2012, 13, 12519-12532. Common Structural and Epigenetic Changes in the Genome of Castration-Resistant Prostate Cancer. 2295 0.4 111 Cancer Research, 2012, 72, 616-625. Extracellular Release of Annexin II From Pancreatic Cancer Cells and Resistance to Anticancer 2296 Drug–Induced Apoptosis by Supplementation of Recombinant Annexin II. Pancreas, 2012, 41, 1247-1254. Circulating MicroRNAs in Serum of Human K-ras Oncogene Transgenic Rats With Pancreatic Ductal 2297 0.5 46 Adenocarcinomas. Pancreas, 2012, 41, 1013-1018. Variability in melanoma post-treatment surveillance practices by country and physician specialty. 2298 0.6 Melanoma Research, 2012, 22, 376-385. Antiblastic Treatment, for Solid Tumors, during Pregnancy: A Crucial Decision. International Journal 2299 1.0 1 of Immunopathology and Pharmacology, 2012, 25, 1-19. Clinical outcome of docetaxel in advanced or metastatic endometrial cancer. Hematology/ Oncology and Stem Cell Therapy, 2012, 5, 146-151. The role of abiraterone in the management of metastatic castration-resistant prostate cancer. Expert 2301 1.1 2 Review of Anticancer Therapy, 2012, 12, 429-437. Hsp90 stabilizes Cdc25A and counteracts heat shock-mediated Cdc25A degradation and cell-cycle 1.4 attenuation in pancreatic carcinoma cells. Human Molecular Genetics, 2012, 21, 4615-4627.

#	Article	IF	CITATIONS
2303	Fertility sparing in cancer patients. Minimally Invasive Therapy and Allied Technologies, 2012, 21, 282-292.	0.6	8
2304	Study of Effects of Cigarette Smoke Condensates on Acetylcholinesterase Activity in Human Lung Epithelial Cells by Matrix-Assisted Laser Desorption/Ionization-Fourier Transform Mass Spectrometry. Analytical Letters, 2012, 45, 2687-2696.	1.0	2
2305	Fertility preservation in women: an update. Expert Review of Obstetrics and Gynecology, 2012, 7, 595-603.	0.4	1
2306	Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer. Cell Death and Disease, 2012, 3, e449-e449.	2.7	35
2307	The limitations of the clinical oral examination in detecting dysplastic oral lesions and oral squamous cell carcinoma. Journal of the American Dental Association, 2012, 143, 1332-1342.	0.7	83
2308	Prostate-Specific Antigen Test for Prostate Cancer Screening: American Society of Clinical Oncology Provisional Clinical Opinion. Journal of Oncology Practice, 2012, 8, 315-317.	2.5	9
2309	Small Cell Lung Cancer Doubling Time and its Effect on Clinical Presentation: A Concise Review. Clinical Medicine Insights: Oncology, 2012, 6, CMO.S9633.	0.6	32
2310	Basal Cell Carcinoma: A Single-Center Experience. ISRN Dermatology, 2012, 2012, 1-6.	1.9	12
2311	Stretch Test. Annals of Plastic Surgery, 2012, 68, 72-73.	0.5	4
2312	Baicalein - An Intriguing Therapeutic Phytochemical in Pancreatic Cancer. Current Drug Targets, 2012, 13, 1772-1776.	1.0	78
2313	Pharmacokinetic evaluation of pancreatic arterial infusion chemotherapy with lipid emulsion as a drug carrier in an animal model. Anti-Cancer Drugs, 2012, 23, 713-717.	0.7	1
2314	Meta-analysis. European Journal of Gastroenterology and Hepatology, 2012, 24, 1153-1157.	0.8	16
2315	Proteomic Assessment of Markers for Malignancy in the Mucus of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Pancreas, 2012, 41, 169-174.	0.5	18
2316	Anticancer immune reactivity and long-term survival after treatment of metastatic ovarian cancer with dendritic cells. Oncology Letters, 2012, 3, 66-74.	0.8	8
2317	Declines in serum CYFRA21-1 and carcinoembryonic antigen as predictors of chemotherapy response and survival in patients with advanced non-small cell lung cancer. Experimental and Therapeutic Medicine, 2012, 4, 243-248.	0.8	12
2318	The in vivo Therapeutic Effect of Free Wanderer Powder (逕éᠯM æ•£ xiÄo yáo sÇŽn, Xiaoyaosan) on Mice with 4T Cell Induced Breast Cancer Model. Journal of Traditional and Complementary Medicine, 2012, 2, 67-75.	1 <sub>1.5</sub>	11
2319	Support vector machines coupled with proteomics approaches for detecting biomarkers predicting chemotherapy resistance in small cell lung cancer. Oncology Reports, 2012, 28, 2233-2238.	1.2	19
2320	Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer. Oncology Letters, 2012, 4, 792-798.	0.8	17

	Сітат	TION REPORT	
#	Article	IF	CITATIONS
2321	Sex Differences and Sex Steroids in Lung Health and Disease. Endocrine Reviews, 2012, 33, 1-47.	8.9	320
2322	The association of osteopontin and LMX1A expression with World Health Organization grade in meningiomas and gliomas. Histopathology, 2012, 61, 844-856.	1.6	19
2323	Association between selfâ€reported questionnaire data on fertility and results of hormone analyses in women after childhood cancer: A crossâ€sectional study. Journal of Obstetrics and Gynaecology Research, 2012, 38, 1254-1259.	0.6	9
2324	<i>In situ</i> Identification and Localization of IGHA2 in the Breast Tumor Microenvironment by Mass Spectrometry. Journal of Proteome Research, 2012, 11, 4567-4574.	1.8	40
2326	Improving size, lymph node metastatic rate, breast conservation, and mortality of invasive breast cancer in Rhode Island women, a well-screened population. Breast Cancer Research and Treatment, 2012, 135, 831-837.	1.1	10
2327	Spatial brain distribution of intra-axial metastatic lesions in breast and lung cancer patients. Journal of Neuro-Oncology, 2012, 110, 79-87.	1.4	52
2328	The Influence of Testosterone Suppression and Recovery on Sexual Function in Men With Prostate Cancer: Observations From a Prospective Study in Men Undergoing Intermittent Androgen Suppression. Journal of Urology, 2012, 187, 2162-2167.	0.2	53
2329	Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 695-703.	0.8	20
2330	Principles of Surgical Oncology in the Elderly. Clinics in Geriatric Medicine, 2012, 28, 51-71.	1.0	28
2331	Predominance of females with oesophageal cancer in Gezira, Central Sudan. Arab Journal of Gastroenterology, 2012, 13, 174-177.	0.4	10
2332	N-Glycan Profiling by Microchip Electrophoresis to Differentiate Disease States Related to Esophageal Adenocarcinoma. Analytical Chemistry, 2012, 84, 3621-3627.	3.2	46
2333	Screening for Prostate Cancer With Prostate-Specific Antigen Testing: American Society of Clinical Oncology Provisional Clinical Opinion. Journal of Clinical Oncology, 2012, 30, 3020-3025.	0.8	128
2334	Palliative management for patients with subacute obstruction and stage IV unresectable rectosigmoid cancer: colostomy versus endoscopic stenting: final results of a prospective randomized trial. American Journal of Surgery, 2012, 204, 321-326.	0.9	66
2335	MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genetics, 2012, 205, 113-123.	0.2	85
2336	Induction of IGF-1R expression by EGR-1 facilitates the growth of prostate cancer cells. Cancer Letters, 2012, 317, 150-156.	3.2	29
2337	Cancer nanomedicines targeting tumor extracellular pH. Colloids and Surfaces B: Biointerfaces, 2012, 99, 116-126.	2.5	110
2338	Melanoma: Epidemiology, Diagnosis, Treatment, and Outcomes. Dermatologic Clinics, 2012, 30, 113-124	4. 1.0	58
2339	Expression level of pre-B-cell leukemia transcription factor 2 (PBX2) as a prognostic marker for gingival squamous cell carcinoma. Journal of Zhejiang University: Science B, 2012, 13, 168-175.	1.3	7

#	Article	IF	CITATIONS
2340	P53 Gene Mutation Increases Progastrin Dependent Colonic Proliferation and Colon Cancer Formation in Mice. Cancer Investigation, 2012, 30, 275-286.	0.6	16
2341	Treatment decisions for elderly patients with haematological malignancies: a dilemma. Lancet Oncology, The, 2012, 13, e344-e352.	5.1	39
2342	Lung and breast cancer mortality among women in France: Future trends. Cancer Epidemiology, 2012, 36, e341-e348.	0.8	11
2343	Role of Hormone Receptor Expression in Patients With Advanced-Stage Lung Cancer Treated With Chemotherapy. Clinical Lung Cancer, 2012, 13, 416-423.	1.1	17
2344	An unsolved conundrum: the ideal follow-up strategy after curative surgery for colorectal cancer. Gastrointestinal Endoscopy, 2012, 75, 1072-1079.	0.5	14
2345	Management of Advanced Colon Cancer in a Community Hospital—Impact of Age on Clinical Management and Survival. Journal of Gastrointestinal Cancer, 2012, 43, 426-430.	0.6	2
2346	Comparison of FIGO 1988 and 2009 staging systems for endometrial carcinoma. Medical Oncology, 2012, 29, 2955-2962.	1.2	9
2347	Bile-Based Detection of Extrahepatic Cholangiocarcinoma with Quantitative DNA Methylation Markers and Its High Sensitivity. Journal of Molecular Diagnostics, 2012, 14, 256-263.	1.2	33
2349	The role of enzalutamide in the treatment of castration-resistant prostate cancer. Future Oncology, 2012, 8, 1073-1081.	1.1	3
2350	Role of Neoadjuvant Chemotherapy (NACT) Followed by Surgical Cytoreduction in Advanced Epithelial Ovarian Cancer. Journal of Obstetrics and Gynecology of India, 2012, 62, 541-545.	0.3	3
2351	Preservation of Fertility in Females Treated for Cancer. International Journal of Biological Sciences, 2012, 8, 1005-1012.	2.6	19
2352	Metastatic brain tumors. , 2012, , 864-892.		16
2353	A computerized intervention to promote colorectal cancer screening for underserved populations: Theoretical background and algorithm development. Technology and Health Care, 2012, 20, 25-35.	0.5	5
2354	Potential Monoclonal Antibody Therapy for the Treatment of Ovarian Cancer. , 0, , .		9
2355	Electrochemical Assay of GSTP1-related DNA Sequence for Prostate Cancer Screening. Electrochemical Society Interface, 2012, 21, 71-75.	0.3	6
2356	ldentifying cancer biomarkers by mass spectrometryâ€based glycomics. Electrophoresis, 2012, 33, 1755-1767.	1.3	124
2357	Tobacco carcinogen metabolites and DNA adducts as biomarkers in Head and Neck cancer: Potential screening tools and prognostic indicators. Head and Neck, 2012, 34, 441-447.	0.9	33
2358	Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology, 2012, 56, 972-981.	3.6	119

#	Article	IF	CITATIONS
2359	Coâ€expression of hepatocyte growth factor and câ€Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/câ€Met signaling in gastric cancer. International Journal of Cancer, 2012, 130, 2912-2921.	2.3	81
2360	Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success. International Journal of Cancer, 2012, 131, 733-740.	2.3	123
2361	Development and validation of a highly sensitive method for the determination of abiraterone in rat and human plasma by LCâ€MS/MSâ€ESI: application to a pharmacokinetic study. Biomedical Chromatography, 2012, 26, 761-768.	0.8	26
2362	Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 245-251.	2.9	77
2363	The Effect of Age on 12 Chemical Element Contents in the Intact Prostate of Adult Men Investigated by Inductively Coupled Plasma Atomic Emission Spectrometry. Biological Trace Element Research, 2012, 147, 49-58.	1.9	34
2364	Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts. Medical Oncology, 2012, 29, 600-606.	1.2	8
2365	Hematological Malignancies in Al-Amal Oncology Unit, Aden. Indian Journal of Hematology and Blood Transfusion, 2012, 28, 19-23.	0.3	2
2366	Thiazolidenediones induce tumour-cell apoptosis through the Akt-GSK3β pathway. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 65-70.	0.7	4
2367	Trace elements of normal, benign hypertrophic and cancerous tissues of the Human prostate gland investigated by neutron activation analysis. Applied Radiation and Isotopes, 2012, 70, 81-87.	0.7	25
2368	Aberrant Promoter Methylation of CDH13 and MGMT Genes is Associated With Clinicopathologic Characteristics of Primary Non–Small-Cell Lung Carcinoma. Clinical Lung Cancer, 2012, 13, 297-303.	1.1	35
2369	1,2,4-Oxadiazoles: A new class of anti-prostate cancer agents. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1912-1916.	1.0	28
2370	Cell surface markers CD44 and CD166 localized specific populations of salivary acinar cells. Oral Diseases, 2012, 18, 162-168.	1.5	34
2371	Endobronchial ultrasound (EBUS) with tranbronchial needle aspiration (TBNA) versus mediastinoscopy for mediastinal staging in nonâ€small cell lung cancer (NSCLC) thoracic cancer. Thoracic Cancer, 2012, 3, 131-138.	0.8	9
2372	Cytologic features and diagnostic accuracy of analysis of effusions for detection of ovarian carcinoma in dogs. Veterinary Clinical Pathology, 2012, 41, n/a-n/a.	0.3	17
2373	Factors determining successful computed tomography–guided localization of lung nodules. Journal of Thoracic and Cardiovascular Surgery, 2012, 143, 809-814.	0.4	77
2374	The prognostic significant of percentage drop in serum CEA post curative resection for colon cancer. Surgical Oncology, 2012, 21, 45-51.	0.8	31
2375	Isolation of stem-like cells from spontaneous feline mammary carcinomas: Phenotypic characterization and tumorigenic potential. Experimental Cell Research, 2012, 318, 847-860.	1.2	25
2376	Breast cancer in men in Cote d'Or (France): epidemiological characteristics, treatments and prognostic factors. European Journal of Cancer Care, 2012, 21, 809-816.	0.7	10

#	Article	IF	CITATIONS
2377	Current Controversies in the Management of Colon Cancer. Current Problems in Surgery, 2012, 49, 398-460.	0.6	8
2378	Detection of collagen triple helix repeat containing-1 and nuclear factor (erythroid-derived 2)-like 3 in colorectal cancer. BMC Clinical Pathology, 2012, 12, 2.	1.8	12
2379	Associations between environmental factors and incidence of cutaneous melanoma. Review. Environmental Health, 2012, 11, S12.	1.7	66
2380	MicroRNA-10a is Overexpressed in Human Pancreatic Cancer and Involved in Its Invasiveness Partially via Suppression of the HOXA1 Gene. Annals of Surgical Oncology, 2012, 19, 2394-2402.	0.7	100
2381	FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells. Breast Cancer Research and Treatment, 2012, 131, 65-73.	1.1	82
2382	Behavioral risk factors and their relationship to tumor characteristics in Hispanic and non-Hispanic white long-term breast cancer survivors. Breast Cancer Research and Treatment, 2012, 131, 169-176.	1.1	29
2383	Dukes C colorectal cancer: is the metastatic lymph node ratio important?. International Journal of Colorectal Disease, 2012, 27, 309-317.	1.0	15
2384	Elevated levels of 1â€hydroxypyrene and N′â€nitrosonornicotine in smokers with head and neck cancer: A matched control study. Head and Neck, 2013, 35, 1096-1100.	0.9	10
2385	Development and validation of an enantioselective LC-MS/MS method to quantify enantiomers of (±)-TAK-700 in rat plasma: lack ofin vivoinversion of (+)-TAK-700 (Orteronel) to its antipode. Biomedical Chromatography, 2013, 27, 164-171.	0.8	0
2386	Validated RPâ€HPLC/UV method for the quantitation of abiraterone in rat plasma and its application to a pharmacokinetic study in rats. Biomedical Chromatography, 2013, 27, 203-207.	0.8	20
2387	Development and validation of a measurement tool to assess perceptions of palliative care. Psycho-Oncology, 2013, 22, 940-946.	1.0	15
2388	Brain metastatic volume and white matter lesions in advanced cancer patients. Journal of Neuro-Oncology, 2013, 113, 451-458.	1.4	14
2389	High incidence of prostate cancer metastasis in Afro-Brazilian men with low educational levels: a retrospective observational study. BMC Public Health, 2013, 13, 537.	1.2	4
2390	Health-Related Quality of Life in Patients with Oesophageal Cancer: Analysis at Different Steps of the Treatment Pathway. Journal of Gastrointestinal Surgery, 2013, 17, 421-433.	0.9	60
2391	Chemoradiotherapy in the Management of Locally Advanced Squamous Cell Carcinoma Esophagus: Is Surgical Resection Required?. Journal of Gastrointestinal Cancer, 2013, 44, 277-284.	0.6	23
2392	Effect of leuprolide acetate on ovarian function after cyclophosphamide–doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Medical Oncology, 2013, 30, 667.	1.2	55
2393	Oxidative Stress and Skin Cancer: An Overview. Indian Journal of Clinical Biochemistry, 2013, 28, 110-115.	0.9	82
2394	Advances in Conditioning Regimens for Older Adults Undergoing Allogeneic Stem Cell Transplantation to Treat Hematologic Malignancies. Drugs and Aging, 2013, 30, 373-381.	1.3	11

#	Article	IF	CITATIONS
2395	Primary solid pancreatic tumors: recent imaging findings updates with pathology correlation. Abdominal Imaging, 2013, 38, 1091-1105.	2.0	7
2396	Preoperative Prediction of Central Lymph Node Metastasis in Thyroid Papillary Microcarcinoma Using Clinicopathologic and Sonographic Features. World Journal of Surgery, 2013, 37, 385-391.	0.8	95
2397	Margin Size is an Independent Predictor of Local Tumor Progression After Ablation of Colon Cancer Liver Metastases. CardioVascular and Interventional Radiology, 2013, 36, 166-175.	0.9	262
2398	Barriers to screening colonoscopy in an urban population: a study to help focus further efforts to attain full compliance. International Journal of Colorectal Disease, 2013, 28, 1497-1503.	1.0	26
2399	Diagnostic spectrum of ovarian masses in women with breast cancer; magnetic resonance imaging: histopathology correlation. Annals of Diagnostic Pathology, 2013, 17, 441-447.	0.6	9
2400	The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro. Biochemical and Biophysical Research Communications, 2013, 440, 701-706.	1.0	32
2401	Estradiol increases ER-negative breast cancer metastasis in an experimental model. Clinical and Experimental Metastasis, 2013, 30, 711-721.	1.7	18
2402	Endoscopic and clinicopathological patterns of esophageal cancer in Tanzania: experiences from two tertiary health institutions. World Journal of Surgical Oncology, 2013, 11, 257.	0.8	25
2403	EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis. Breast Cancer Research and Treatment, 2013, 138, 741-752.	1.1	44
2404	Surgical techniques and results of the pulmonary artery reconstruction for patients with central non-small cell lung cancer. Journal of Cardiothoracic Surgery, 2013, 8, 219.	0.4	19
2405	Unfavorable cancers of unknown primaries: presentation and prognostic factors. A population-based 8-year experience. Medical Oncology, 2013, 30, 706.	1.2	10
2406	Development and validation of an RPâ€HPLC method for the quantitation of Orteronel (TAKâ€700), a CYP17A1 enzyme inhibitor, in rat plasma and its application to a pharmacokinetic study. Biomedical Chromatography, 2013, 27, 1590-1594.	0.8	1
2407	Back to Baseline: Erectile Function Recovery After Radical Prostatectomy from the Patients' Perspective. Journal of Sexual Medicine, 2013, 10, 1636-1643.	0.3	71
2408	Cytotoxic effects of <i>Cuscuta</i> extract on human cancer cell lines. Food and Agricultural Immunology, 2013, 24, 87-94.	0.7	9
2409	The effects of Photofrin-mediated photodynamic therapy on the modulation of EGFR in esophageal squamous cell carcinoma cells. Lasers in Medical Science, 2013, 28, 605-614.	1.0	20
2410	Clinical risk factors of delayed gastric emptying in patients after pancreaticoduodenectomy: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2013, 39, 213-223.	0.5	85
2411	Hematopoietic cytokines as tumor markers in breast malignancies. A multivariate analysis with ROC curve in breast cancer patients. Advances in Medical Sciences, 2013, 58, 207-215.	0.9	16
2412	A unified EM approach to bladder wall segmentation with coupled level-set constraints. Medical Image Analysis, 2013, 17, 1192-1205.	7.0	25

#	Article	IF	CITATIONS
2413	Overexpression of IQGAP1 in human pancreatic cancer. Hepatobiliary and Pancreatic Diseases International, 2013, 12, 540-545.	0.6	28
2414	Less stress, more success? Oncological implications of surgery-induced oxidative stress. Gut, 2013, 62, 461-470.	6.1	41
2415	Prognostic value of circulating cytokines for stage III colon cancer. Journal of Surgical Research, 2013, 182, 49-54.	0.8	29
2416	A modified frailty index to assess morbidity and mortality after lobectomy. Journal of Surgical Research, 2013, 183, 40-46.	0.8	221
2417	Increased incidence of thyroid cancer in Latina, Italy: A possible role of detection of subclinical disease. Cancer Epidemiology, 2013, 37, 262-269.	0.8	23
2418	HMGB1 recruits myeloid derived suppressor cells to promote peritoneal dissemination of colon cancer after resection. Biochemical and Biophysical Research Communications, 2013, 436, 156-161.	1.0	44
2419	Overweight Patients Operated on for Cancer of the Esophagus Survive Longer than Normal-Weight Patients. Journal of Gastrointestinal Surgery, 2013, 17, 218-227.	0.9	28
2420	Melanoma, Myeloma, and Sarcoma. , 2013, , 309-316.		0
2421	Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1207-1216.	1.8	93
2422	Cancer Predisposition Syndromes of the Gastrointestinal Tract. Molecular Pathology Library, 2013, , 109-130.	0.1	1
2423	VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: a multivariate analysis with ROC curve. Growth Factors, 2013, 31, 98-105.	0.5	14
2424	Vasohibin-1 Expression Is Regulated by Transforming Growth Factor-β/Bone Morphogenic Protein Signaling Pathway Between Tumor-Associated Macrophages and Pancreatic Cancer Cells. Journal of Interferon and Cytokine Research, 2013, 33, 428-433.	0.5	19
2425	Decision tree classifiers for automated medical diagnosis. Neural Computing and Applications, 2013, 23, 2387-2403.	3.2	148
2426	Phenethyl isothiocyanate suppresses EGF-stimulated SAS human oral squamous carcinoma cell invasion by targeting EGF receptor signaling. International Journal of Oncology, 2013, 43, 629-637.	1.4	30
2427	Prognosis markers for metastatic renal cell carcinoma: quantitative proteomics approach. Expert Review of Proteomics, 2013, 10, 21-24.	1.3	2
2428	Sinomenine sensitizes gastric cancer cells to 5-fluorouracil in vitro and in vivo. Oncology Letters, 2013, 6, 1604-1610.	0.8	25
2429	Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma. Oncology Letters, 2013, 5, 805-812.	0.8	43
2430	The Prognostic Value of the Apoptosis Pathway in Colorectal Cancer: A Review of the Literature on Biomarkers Identified by Immunohistochemistry. Biomarkers in Cancer, 2013, 5, BIC.S11475.	3.6	62

#	Article	IF	CITATIONS
2431	Src Mediates Cigarette Smoke–Induced Resistance to Tyrosine Kinase Inhibitors in NSCLC Cells. Molecular Cancer Therapeutics, 2013, 12, 1579-1590.	1.9	33
2432	Nanosecond pulsed electric fields adjuvant chemotherapy for breast cancer: An in vitro study. , 2013, ,		2
2433	A randomised, waitâ€list controlled trial: evaluation of a cognitive–behavioural group intervention on psychoâ€sexual adjustment for men with localised prostate cancer. Psycho-Oncology, 2013, 22, 2186-2192.	1.0	38
2434	Communication and Intimacy-Enhancing Interventions for Men Diagnosed with Prostate Cancer and Their Partners. Journal of Sexual Medicine, 2013, 10, 127-132.	0.3	29
2435	Metabolomic and transcriptomic profiling of human K- ras oncogene transgenic rats with pancreatic ductal adenocarcinomas. Carcinogenesis, 2013, 34, 1251-1259.	1.3	36
2436	Elevated TNFR1 and Serotonin in Bone Metastasis Are Correlated with Poor Survival following Bone Metastasis Diagnosis for Both Carcinoma and Sarcoma Primary Tumors. Clinical Cancer Research, 2013, 19, 2473-2485.	3.2	31
2437	Comparison of drug delivery systems: Nanotube and p- Sulphonatocalix[4]arene, by Density Functional Theory. Journal of Nanostructure in Chemistry, 2013, 3, 1.	5.3	16
2438	The Kiss-1/Kiss-1R complex as a negative regulator of cell motility and cancer metastasis (Review). International Journal of Molecular Medicine, 2013, 32, 747-754.	1.8	56
2439	Clinical Significance of Yes-Associated Protein Overexpression in Cervical Carcinoma. International Journal of Gynecological Cancer, 2013, 23, 735-742.	1.2	38
2440	Twenty-One Proteins Up-Regulated in Human H-ras Oncogene Transgenic Rat Pancreas Cancers are Up-Regulated in Human Pancreas Cancer. Pancreas, 2013, 42, 1034-1039.	0.5	5
2441	Molecular Pathways in Prostate Cancer. Nephro-Urology Monthly, 2013, 5, 792-800.	0.0	56
2442	Deguelin Induces Both Apoptosis and Autophagy in Cultured Head and Neck Squamous Cell Carcinoma Cells. PLoS ONE, 2013, 8, e54736.	1.1	54
2443	The Effect of Mirtazapine on Cisplatin-Induced Oxidative Damage and Infertility in Rat Ovaries. Scientific World Journal, The, 2013, 2013, 1-6.	0.8	34
2444	Treatment and Trials: Ovarian Cancer in Older Women. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 227-235.	1.8	7
2445	Cerebellar Degeneration-Related Autoantigen 1 (CDR1) Gene Expression in Prostate Cancer Cell Lines. International Journal of Biological Markers, 2014, 29, 288-290.	0.7	5
2446	Overexpression of Forkhead Box Protein M1 (FOXM1) in Ovarian Cancer Correlates with Poor Patient Survival and Contributes to Paclitaxel Resistance. PLoS ONE, 2014, 9, e113478.	1.1	76
2447	Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules. OncoTargets and Therapy, 2014, 7, 937.	1.0	8
2448	FT-IR Microspectrometry Reveals the Variation of Membrane Polarizability due to Epigenomic Effect on Epithelial Ovarian Cancer. International Journal of Molecular Sciences, 2014, 15, 17963-17973.	1.8	10

#	Article	IF	CITATIONS
2449	Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumors. Obstetrics and Gynecology Science, 2014, 57, 343.	0.6	48
2450	Practical Application of Health Belief Model to Enhance the Uptake of Colorectal Cancer Screening. , 2014, 04, .		5
2451	Mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application. Wspolczesna Onkologia, 2014, 2, 100-105.	0.7	3
2452	An Apple Oligogalactan Potentiates the Growth Inhibitory Effect of Celecoxib on Colorectal Cancer. Nutrition and Cancer, 2014, 66, 29-37.	0.9	7
2453	Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2. BMC Pulmonary Medicine, 2014, 14, 174.	0.8	47
2454	SOX2 regulates self-renewal and tumorigenicity of stem-like cells of head and neck squamous cell carcinoma. British Journal of Cancer, 2014, 111, 2122-2130.	2.9	130
2455	Addition of epirubicin to conventional chemotherapy in patients with advanced ovarian cancer: sequential therapy - a retrospective evaluation. Turkish Journal of Medical Sciences, 2014, 44, 212-219.	0.4	1
2456	C2-Ceramide Induces Cell Death and Protective Autophagy in Head and Neck Squamous Cell Carcinoma Cells. International Journal of Molecular Sciences, 2014, 15, 3336-3355.	1.8	29
2457	Two-incision approach for video-assisted thoracoscopic sleeve lobectomy treating the central lung cancer. Indian Journal of Cancer, 2014, 51, 18.	0.2	6
2458	Benefits and Risks of Lung Cancer Screening. Oncology Research and Treatment, 2014, 37, 58-66.	0.8	6
2459	p53 Expression Is a Strong Marker of Inferior Survival in De Novo Diffuse Large B-Cell Lymphoma and May Have Enhanced Negative Effect With MYC Coexpression. American Journal of Clinical Pathology, 2014, 141, 593-604.	0.4	46
2460	Lung Injury and Lung Cancer Caused by Cigarette Smoke-Induced Oxidative Stress: Molecular Mechanisms and Therapeutic Opportunities Involving the Ceramide-Generating Machinery and Epidermal Growth Factor Receptor. Antioxidants and Redox Signaling, 2014, 21, 2149-2174.	2.5	83
2461	Role of scintimammography in assessing the response of neoadjuvant chemotherapy in locally advanced breast cancer. World Journal of Nuclear Medicine, 2014, 13, 163.	0.3	8
2462	Human Papillomavirus (HPV) Biomarkers in Head and Neck Squamous Cell Carcinoma (HNSCC). , 2014, , 1-17.		1
2463	CCR5 Receptor Antagonists Block Metastasis to Bone of v-Src Oncogene–Transformed Metastatic Prostate Cancer Cell Lines. Cancer Research, 2014, 74, 7103-7114.	0.4	58
2464	Extracapsular Lymph Node Spread as a Negative Prognostic Factor of Adenocarcinoma of the Pancreas and Cancer of the Papilla of Vater. Pancreas, 2014, 43, 64-68.	0.5	14
2465	The Diagnostic Imaging of Bone Metastases. Deutsches Ärzteblatt International, 2014, 111, 741-7.	0.6	119
2466	Fertility preservation in young patients′ with cancer. Journal of Mid-Life Health, 2014, 5, 165.	0.4	4

#	Article	IF	CITATIONS
2467	PARP-1 and CASP3 genes are up-regulated in LNCaP and PC-3 prostate cancer cell lines. Human Cell, 2014, 27, 172-175.	1.2	4
2468	Paris saponin I induces apoptosis via increasing the Bax/Bcl-2 ratio and caspase-3 expression in gefitinib-resistant non-small cell lung cancer in vitro and in vivo. Molecular Medicine Reports, 2014, 9, 2265-2272.	1.1	89
2469	Cancer-promoting and Inhibiting Effects of Dietary Compounds: Role of the Aryl Hydrocarbon Receptor (AhR). Biochemistry & Pharmacology: Open Access, 2014, 03, .	0.2	9
2470	Increased Levels of Granulocytic Myeloid-Derived Suppressor Cells in Peripheral Blood and Tumour Tissue of Pancreatic Cancer Patients. Journal of Immunology Research, 2014, 2014, 1-9.	0.9	109
2471	Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients. Endocrine-Related Cancer, 2014, 21, R51-R65.	1.6	35
2472	MultipleMACE-Agenes as surveillance marker for the detection of circulating tumor cells in patients with ovarian cancer. Biomarkers, 2014, 19, 34-42.	0.9	28
2473	p14ARF repression induced by promoter methylation associated with metastasis in esophageal squamous cell carcinoma. Ecological Management and Restoration, 2014, 27, 182-187.	0.2	3
2474	miR-92a/DUSP10/JNK signalling axis promotes human pancreatic cancer cells proliferation. Biomedicine and Pharmacotherapy, 2014, 68, 25-30.	2.5	36
2475	Oxymatrine triggers apoptosis by regulating Bcl-2 family proteins and activating caspase-3/caspase-9 pathway in human leukemia HL-60 cells. Tumor Biology, 2014, 35, 5409-5415.	0.8	43
2476	Role of pelvic and paraâ€∎ortic lymphadenectomy in endometrial cancer: Current evidence. Journal of Obstetrics and Gynaecology Research, 2014, 40, 301-311.	0.6	143
2477	Complete pathological response after neoadjuvant treatment in locally advanced esophageal cancer predicts long term survival: A retrospective cohort study. International Journal of Surgery, 2014, 12, 621-625.	1.1	24
2478	miR-15a inhibits cell proliferation and epithelial to mesenchymal transition in pancreatic ductal adenocarcinoma by down-regulating Bmi-1 expression. Cancer Letters, 2014, 344, 40-46.	3.2	78
2479	Pulmonary Drugs and Genes Delivery Systems for Lung Disease Treatment. Chinese Journal of Chemistry, 2014, 32, 13-21.	2.6	11
2480	The association between physical activity and bladder cancer: systematic review and meta-analysis. British Journal of Cancer, 2014, 110, 1862-1870.	2.9	115
2481	Covalent Small Molecule Inhibitors of Ca <sup>2+</sup> -Bound S100B. Biochemistry, 2014, 53, 6628-6640.	1.2	35
2482	Evaluation of Clinical Outcomes of Antiangiogenic-Targeted Therapy in Patients with Pulmonary Metastatic Renal Cell Carcinoma Using Non–Contrast-Enhanced Computed Tomography. Academic Radiology, 2014, 21, 1434-1440.	1.3	0
2483	Low-dose decitabine induces MAGE-A expression and inhibits invasion via suppression of NF-κB2 and MMP2 in Eca109 cells. Biomedicine and Pharmacotherapy, 2014, 68, 745-750.	2.5	9
2484	Design and synthesis of optically pure 3-aryl-6-methyl-2-thioxotetrahydropyrimidin-4(1H)-ones as anti-prostate cancer agents. RSC Advances, 2014, 4, 37868-37877.	1.7	8

#	Article	IF	CITATIONS
2485	Staging accuracy of pancreatic cancer: Comparison between non-contrast-enhanced and contrast-enhanced PET/CT. European Journal of Radiology, 2014, 83, 1734-1739.	1.2	23
2486	Use of INAA and ICP-MS for the assessment of trace element mass fractions in adult and geriatric prostate. Journal of Radioanalytical and Nuclear Chemistry, 2014, 301, 383-397.	0.7	21
2487	Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. Journal of Neuro-Oncology, 2014, 118, 61-72.	1.4	82
2488	INAA application in the assessment of chemical element mass fractions in adult and geriatric prostate glands. Applied Radiation and Isotopes, 2014, 90, 62-73.	0.7	20
2489	Sleep disturbances and quality of life in postoperative management after esophagectomy for esophageal cancer. World Journal of Surgical Oncology, 2014, 12, 156.	0.8	14
2491	Interleukin-8 gene silencing on pancreatic cancer cells using biodegradable polymer nanoplexes. Biomaterials Science, 2014, 2, 1007-1015.	2.6	21
2492	REMOVED: Protective effect of Daucus carota against UV–DMBA induced skin cancer in mice. Chemico-Biological Interactions, 2014, 219, 48-56.	1.7	0
2493	The significance of added ADC value to conventional MR imaging in differentiation between benign and malignant ovarian neoplasms. Egyptian Journal of Radiology and Nuclear Medicine, 2014, 45, 997-1002.	0.3	7
2494	The 15-year outcomes of high-dose-rate brachytherapy for radical dose escalation in patients with prostate cancer—A benchmark for high-tech external beam radiotherapy alone?. Brachytherapy, 2014, 13, 117-122.	0.2	35
2495	Development of a novel liposomal nanodelivery system for bioluminescence imaging and targeted drug delivery in ErbB2-overexpressing metastatic ovarian carcinoma. International Journal of Molecular Medicine, 2014, 34, 1225-1232.	1.8	14
2496	The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer. International Journal of Oncology, 2014, 45, 1658-1672.	1.4	61
2498	Endoscopic Submucosal Dissection (ESD) with Additional Therapy for Superficial Esophageal Cancer with Submucosal Invasion. Internal Medicine, 2015, 54, 2803-2813.	0.3	61
2499	Identification of dysregulated pathways associated with pancreatic cancer by survival analysis. Molecular Medicine Reports, 2015, 11, 277-282.	1.1	2
2500	Apatone ® induces endometrioid ovarian carcinoma (MDAH 2774) cells to undergo karyolysis and cell death by autoschizis: A potent and safe anticancer treatment. Translational Research in Anatomy, 2015, 1, 25-39.	0.3	5
2501	Increased expression of Six1 correlates with progression and prognosis of prostate cancer. Cancer Cell International, 2015, 15, 63.	1.8	17
2502	The histone demethylase PHF8 promotes prostate cancer cell growth by activating the oncomiR miR-125b. OncoTargets and Therapy, 2015, 8, 1979.	1.0	15
2503	MicroRNA-222 Controls Human Pancreatic Cancer Cell Line Capan-2 Proliferation by P57 Targeting. Journal of Cancer, 2015, 6, 1230-1235.	1.2	17
2504	SD-208, a Novel Protein Kinase D Inhibitor, Blocks Prostate Cancer Cell Proliferation and Tumor Growth In Vivo by Inducing G2/M Cell Cycle Arrest. PLoS ONE, 2015, 10, e0119346.	1.1	36

#	Article	IF	Citations
2505	Application of Combined Two-Dimensional and Three-Dimensional Transvaginal Contrast Enhanced Ultrasound in the Diagnosis of Endometrial Carcinoma. BioMed Research International, 2015, 2015, 1-10.	0.9	7
2506	MicroRNAs in Pancreatic Cancer: Involvement in Carcinogenesis and Potential Use for Diagnosis and Prognosis. Gastroenterology Research and Practice, 2015, 2015, 1-11.	0.7	30
2507	Selection of Elderly Acute Myeloid Leukemia Patients for Intensive Chemotherapy: Effectiveness of Intensive Chemotherapy and Subgroup Analysis. Acta Haematologica, 2015, 133, 300-309.	0.7	8
2508	Clinically applicable human adipose tissue-derived mesenchymal stem cells delivering therapeutic genes to brainstem gliomas. Cancer Gene Therapy, 2015, 22, 302-311.	2.2	27
2509	Alternative method for jejunostomy in <scp>I</scp> vorâ€ <scp>L</scp> ewis esophagectomy. Thoracic Cancer, 2015, 6, 296-302.	0.8	3
2510	Surveillance and Survivorship after Treatment for Colon Cancer. Clinics in Colon and Rectal Surgery, 2015, 28, 262-270.	0.5	10
2511	Downregulation of microRNA-1 and microRNA-145 contributes synergistically to the development of colon cancer. International Journal of Molecular Medicine, 2015, 36, 1630-1638.	1.8	24
2512	THERAPY OF ENDOCRINE DISEASE: Response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis. European Journal of Endocrinology, 2015, 172, R215-R225.	1.9	60
2513	Diffusion-weighted MRI and MR- volumetry - in the evaluation of tumor response after preoperative chemoradiotherapy in patients with locally advanced rectal cancer. Magnetic Resonance Imaging, 2015, 33, 201-212.	1.0	43
2514	Curcumin induces apoptosis through mitochondrial pathway and caspases activation in human melanoma cells. Molecular Biology Reports, 2015, 42, 267-275.	1.0	63
2515	Neoadjuvant chemotherapy followed by radical surgery as an alternative treatment to concurrent chemoradiotherapy for young premenopausal patients with FIGO stage IIB squamous cervical carcinoma. Tumor Biology, 2015, 36, 4349-4356.	0.8	5
2516	Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients. Quality of Life Research, 2015, 24, 473-484.	1.5	4
2517	Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells. Experimental Cell Research, 2015, 336, 23-32.	1.2	38
2518	Use of 99m-technetium-glucoheptonate as a tracer for brain tumor imaging: An overview of its strengths and pitfalls. Indian Journal of Nuclear Medicine, 2015, 30, 1.	0.1	8
2519	Decision-making Processes among Prostate Cancer Survivors with Rising PSA Levels. Medical Decision Making, 2015, 35, 477-486.	1.2	21
2520	Hormone receptor-independent CXCL10 production is associated with the regulation of cellular factors linked to breast cancer progression and metastasis. Experimental and Molecular Pathology, 2015, 99, 163-172.	0.9	42
2521	Transcriptomic Analysis Predicts Survival and Sensitivity to Anticancer Drugs of Patients with a Pancreatic Adenocarcinoma. American Journal of Pathology, 2015, 185, 1022-1032.	1.9	46
2522	Men's experience with penile rehabilitation following radical prostatectomy: a qualitative study with the goal of informing a therapeutic intervention. Psycho-Oncology, 2015, 24, 1646-1654.	1.0	26

#	Article	IF	CITATIONS
2523	Cyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cells. Molecular Biology of the Cell, 2015, 26, 1971-1984.	0.9	38
2524	The Noninvasive Detection of RARβ2 Promoter Methylation for the Diagnosis of Prostate Cancer. Cell Biochemistry and Biophysics, 2015, 71, 925-930.	0.9	4
2525	Mediastinoscopy-assisted oesophagectomy in T1 oesophageal cancer patients with serious comorbidities: a 5-year long-term follow-up. Interactive Cardiovascular and Thoracic Surgery, 2015, 20, 477-481.	0.5	13
2526	Lymphoma in older patients: clinical and therapeutic characteristics. Reviews in Clinical Gerontology, 2015, 25, 1-11.	0.5	0
2527	Inter-fraction variation in interstitial high-dose-rate brachytherapy. Journal of Radiotherapy in Practice, 2015, 14, 143-151.	0.2	6
2528	Dietary soy isoflavones increase metastasis to lungs in an experimental model of breast cancer with bone micro-tumors. Clinical and Experimental Metastasis, 2015, 32, 323-333.	1.7	38
2529	Palliative therapy for esophageal cancer: laser therapy alone is associated with a better functional outcome. Updates in Surgery, 2015, 67, 61-67.	0.9	3
2530	Tag SNPs of CFI contributed to the susceptibility for non-small cell lung cancer in Chinese population. Tumor Biology, 2015, 36, 1955-1962.	0.8	2
2531	Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis. Journal of Ovarian Research, 2015, 8, 38.	1.3	28
2532	SATB1 Promotes Pancreatic Cancer Growth and Invasion Depending on MYC Activation. Digestive Diseases and Sciences, 2015, 60, 3304-3317.	1.1	17
2533	Esophageal Cancer Management: Preoperative CA19.9 and CEA Serum Levels May Identify Occult Advanced Adenocarcinoma. World Journal of Surgery, 2015, 39, 424-432.	0.8	23
2534	A pseudo-likelihood approach for estimating diagnostic accuracy of multiple binary medical tests. Computational Statistics and Data Analysis, 2015, 84, 85-98.	0.7	4
2535	PET-Based Radiation Therapy Planning. PET Clinics, 2015, 10, 27-44.	1.5	14
2536	Dietary habits and esophageal cancer. Ecological Management and Restoration, 2015, 28, 59-67.	0.2	44
2537	The Factors Effecting Lymphovascular Invasion in Adenocarcinoma of the Colon and Rectum. Indian Journal of Surgery, 2015, 77, 314-318.	0.2	5
2538	Oct4 is a critical regulator of stemness in head and neck squamous carcinoma cells. Oncogene, 2015, 34, 2317-2324.	2.6	108
2539	Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort. Annals of Oncology, 2015, 26, 221-230.	0.6	43
2540	Biosynthesis and the conjugation of magnetite nanoparticles with luteinizing hormone releasing hormone (LHRH). Materials Science and Engineering C, 2015, 46, 482-496.	3.8	47

#	Article	IF	CITATIONS
2541	Caveolin-1 regulates metastatic behaviors of anoikis resistant lung cancer cells. Molecular and Cellular Biochemistry, 2015, 399, 291-302.	1.4	25
2542	Extranodal extension in N1-adenocarcinoma of the pancreas and papilla of Vater. European Journal of Gastroenterology and Hepatology, 2016, 28, 205-209.	0.8	42
2543	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget, 2016, 7, 67495-67506.	0.8	42
2544	Evaluation of iNOS Expression in Esophageal Cancer Patients. Gastrointestinal Tumors, 2016, 3, 44-58.	0.3	6
2545	Anti-Proliferative and Apoptotic Activities of Müllerian Inhibiting Substance Combined with Calcitriol in Ovarian Cancer Cell Lines. Yonsei Medical Journal, 2016, 57, 33.	0.9	13
2546	Significant Association of Catechol-O-Methyltransferase Val158Met Polymorphism with Bladder Cancer Instead of Prostate and Kidney Cancer. International Journal of Biological Markers, 2016, 31, 110-117.	0.7	6
2547	Geranylated 4-Phenylcoumarins Exhibit Anticancer Effects against Human Prostate Cancer Cells through Caspase-Independent Mechanism. PLoS ONE, 2016, 11, e0151472.	1.1	17
2548	Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer. Annals of Laboratory Medicine, 2016, 36, 223-229.	1.2	25
2549	The Fascinating Effects of Baicalein on Cancer: A Review. International Journal of Molecular Sciences, 2016, 17, 1681.	1.8	170
2550	Prognostic Significance of the Histologic Response of Perihilar Cholangiocarcinoma to Preoperative Neoadjuvant Chemoradiation in Liver Explants. American Journal of Surgical Pathology, 2016, 40, 510-518.	2.1	37
2551	Sexâ€specific and race/ethnicityâ€specific disparities in cholangiocarcinoma incidence and prevalence in the USA: An updated analysis of the 2000–2011 Surveillance, Epidemiology and End Results registry. Hepatology Research, 2016, 46, 669-677.	1.8	40
2552	Prognostic value of continued smoking on survival and recurrence rates in patients with head and neck cancer: A systematic review. Head and Neck, 2016, 38, E2214-20.	0.9	50
2553	RNAi-mediated HOXD3 knockdown inhibits growth in human RKO cells. Oncology Reports, 2016, 36, 1793-1798.	1.2	8
2554	Leucine zipper, down regulated in cancer-1 gene expression in prostate cancer. Oncology Letters, 2016, 12, 2796-2800.	0.8	3
2555	HPV vaccine acceptability in HIV-infected and HIV negative men who have sex with men (MSM) in Ireland. Human Vaccines and Immunotherapeutics, 2016, 12, 1536-1541.	1.4	18
2556	PLGA-based microparticles loaded with bacterial-synthesized prodigiosin for anticancer drug release: Effects of particle size on drug release kinetics and cell viability. Materials Science and Engineering C, 2016, 66, 51-65.	3.8	65
2557	Tagging staphylococcal enterotoxin B (SEB) with TGFaL3 for breast cancer therapy. Tumor Biology, 2016, 37, 5305-5316.	0.8	9
2558	Cáncer y embarazo: Experiencia de seis años en un centro de referencia en cáncer en un paÃs latinoamericano (2007–2013). Revista Colombiana De CancerologÃa, 2016, 20, 117-123.	0.0	0

#	Article	IF	CITATIONS
2559	Three indigenous plants used in anti-cancer remedies, Garcinia kola Heckel (stem bark), Uvaria chamae P. Beauv. (root) and Olax subscorpioideaÂOliv. (root) show analgesic and anti-inflammatory activities in animal models. Journal of Ethnopharmacology, 2016, 194, 440-449.	2.0	26
2560	Deguelin inhibits proliferation and migration of human pancreatic cancer cells in vitro targeting hedgehog pathway. Oncology Letters, 2016, 12, 2761-2765.	0.8	21
2561	Transforming growth factor Î <sup>2</sup> 1 enhances stemness of head and neck squamous cell carcinoma cells through activation of Wnt signaling. Oncology Letters, 2016, 12, 5315-5320.	0.8	24
2562	Androgen receptor (AR) signaling promotes RCC progression via increased endothelial cell proliferation and recruitment by modulating AKT → NF-κB → CXCL5 signaling. Scientific Repor	r <mark>1.6</mark> 2016,	6 <sup>2</sup> 937085.
2563	Expression, phosphorylation, localization, and microtubule binding of tau in colorectal cell lines. Applied Biological Chemistry, 2016, 59, 807-812.	0.7	12
2564	Life Priorities in Head and Neck Cancer Patients Between Ages of 45 to 65. Journal of Craniofacial Surgery, 2016, 27, e398-e401.	0.3	4
2565	Esophagectomy in elderly patients: which is the best prognostic score?. Ecological Management and Restoration, 2016, 29, 589-597.	0.2	17
2566	Enhancement of triptolide-loaded micelles on tumorigenicity inhibition of human ovarian cancer. Journal of Biomaterials Science, Polymer Edition, 2016, 27, 545-556.	1.9	11
2567	Preparation and In Vitro Evaluation of Antitumor Activity of TGFαL3-SEB as a Ligand-Targeted Superantigen. Technology in Cancer Research and Treatment, 2016, 15, 215-226.	0.8	15
2568	FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy. Annals of Nuclear Medicine, 2016, 30, 114-121.	1.2	18
2569	Saw Palmetto for Symptom Management During Radiation Therapy for Prostate Cancer. Journal of Pain and Symptom Management, 2016, 51, 1046-1054.	0.6	5
2570	AURKA promotes cell migration and invasion of head and neck squamous cell carcinoma through regulation of the AURKA/Akt/FAK signaling pathway. Oncology Letters, 2016, 11, 1889-1894.	0.8	28
2571	Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer. Cell Death and Disease, 2016, 7, e2111-e2111.	2.7	96
2572	lsorhapontigenin suppresses growth of patient-derived glioblastoma spheres through regulating miR-145/SOX2/cyclin D1 axis. Neuro-Oncology, 2016, 18, 830-839.	0.6	32
2573	PPM1D exerts its oncogenic properties in human pancreatic cancer through multiple mechanisms. Apoptosis: an International Journal on Programmed Cell Death, 2016, 21, 365-378.	2.2	17
2574	Peri-tumoral leakage during intra-tumoral convection-enhanced delivery has implications for efficacy of peri-tumoral infusion before removal of tumor. Drug Delivery, 2016, 23, 771-776.	2.5	14
2575	Low-residue versus clear liquid diet before colonoscopy: a meta-analysis of randomized, controlled trials. Gastrointestinal Endoscopy, 2016, 83, 499-507.e1.	0.5	72
2576	Feline Mammary Cancer. Veterinary Pathology, 2017, 54, 32-43.	0.8	28

#	Article	IF	CITATIONS
2577	An ovarian mass after breast cancer: Metachronous carcinoma or metastasis? A case report. International Journal of Surgery Case Reports, 2017, 31, 106-108.	0.2	4
2578	Expression and clinical significance of C14orf166 in esophageal squamous cell carcinoma. Molecular Medicine Reports, 2017, 15, 605-612.	1.1	4
2579	Impact of Urologist Density and County Rurality on the Practice of Retroperitoneal Lymph Node Dissection and Cancer-Specific Death in Patients with Nonseminomatous Germ Cell Tumors. Journal of Adolescent and Young Adult Oncology, 2017, 6, 83-90.	0.7	7
2580	Phase I trial of radiation therapy and sorafenib in unresectable liver metastases. Radiotherapy and Oncology, 2017, 123, 234-239.	0.3	20
2581	Stage-I small cell lung cancer: A new potential option for stereotactic ablative radiation therapy? A review of literature. Critical Reviews in Oncology/Hematology, 2017, 112, 67-71.	2.0	11
2582	Adhesion of ligand-conjugated biosynthesized magnetite nanoparticles to triple negative breast cancer cells. Journal of the Mechanical Behavior of Biomedical Materials, 2017, 68, 276-286.	1.5	14
2583	Vitis vinifera peel polyphenols stabilized gold nanoparticles induce cytotoxicity and apoptotic cell death in A431 skin cancer cell lines. Advanced Powder Technology, 2017, 28, 1170-1184.	2.0	38
2584	Development of a cylindrical diffusing optical fiber probe for pancreatic cancer therapy. Proceedings of SPIE, 2017, , .	0.8	0
2585	National Utilization of Partial Nephrectomy Pre- and Post- AUA Guidelines: Is This as Good as It Gets?. Clinical Genitourinary Cancer, 2017, 15, 591-597.e1.	0.9	9
2586	Risk factors for lymph node metastasis (LNM) in patients with papillary thyroid microcarcinoma (PTMC): role of preoperative ultrasound. Journal of International Medical Research, 2017, 45, 1221-1230.	0.4	19
2587	Long intragenic nonâ€coding <scp>RNA</scp> linc <scp>RNA</scp> â€p21 suppresses development of human prostate cancer. Cell Proliferation, 2017, 50, .	2.4	37
2588	Immunonutrition before esophagectomy: Impact on immune surveillance mechanisms. Tumor Biology, 2017, 39, 101042831772868.	0.8	8
2589	Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells. Journal of Visualized Experiments, 2017, , .	0.2	10
2590	Skeletal Muscle Metastases from Squamous Cell Carcinoma of the Cervix: Report of Two Cases With Literature Review. International Journal of Gynecological Pathology, 2017, 36, 95-100.	0.9	6
2591	Combined high-dose rate brachytherapy (HDR-BT) and whole pelvic radiation therapy (WPRT) in node negative, intermediate- to high-risk localised prostate cancer: clinical outcomes and patient behaviours across ethnicities. Journal of Radiotherapy in Practice, 2017, 16, 141-147.	0.2	0
2592	Anticancer effect of triterpenes from GanodermaÃ⁻Âį¼2lucidumÃ⁻Âį¼2in human prostate cancer cells. Oncology Letters, 2017, 14, 7467-7472.	0.8	21
2593	Prognostic value of postdiagnostic inflammation-based scores in short-term overall survival of advanced pancreatic ductal adenocarcinoma patients. Medicine (United States), 2017, 96, e9247.	0.4	14
2594	Gastrointestinal Malignancies. Primary Care - Clinics in Office Practice, 2017, 44, 721-732.	0.7	12

#	Article	IF	CITATIONS
2595	Tumor Hypoxia Regulates Forkhead Box C1 to Promote Lung Cancer Progression. Theranostics, 2017, 7, 1177-1191.	4.6	32
2596	Targeting macrophage anti-tumor activity to suppress melanoma progression. Oncotarget, 2017, 8, 18486-18496.	0.8	18
2597	MiR-146a polymorphism correlates with lung cancer risk in Chinese nonsmoking females. Oncotarget, 2017, 8, 2275-2283.	0.8	31
2598	Study of Vitamin D Receptor Gene Polymorphism (Fokl, Taql and Apal) Among Prostate Cancer Patients in North India. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, BC05-BC08.	0.8	5
2599	RXRα-enriched cancer stem cell-like properties triggered by CDDP in head and neck squamous cell carcinoma (HNSCC). Carcinogenesis, 2018, 39, 252-262.	1.3	16
2600	βArrestin2 Mediates Renal Cell Carcinoma Tumor Growth. Scientific Reports, 2018, 8, 4879.	1.6	18
2601	A comparison of the clinical outcomes of esophagectomy and chemoradiotherapy after noncurative endoscopic submucosal dissection for esophageal squamous cell carcinoma. Surgery Today, 2018, 48, 783-789.	0.7	33
2602	Rectal Cancer Surveillance—Recurrence Patterns and Survival Outcomes from a Cohort Followed up Beyond 10ÂYears. Journal of Gastrointestinal Cancer, 2018, 49, 422-428.	0.6	16
2603	Autoubiquitination of feline E3 ubiquitin ligase BCA2. Gene, 2018, 638, 1-6.	1.0	6
2604	Cytotoxicity and apoptotic cell death induced by Vitis vinifera peel and seed extracts in A431 skin cancer cells. Cytotechnology, 2018, 70, 537-554.	0.7	28
2605	A Novel Systems Pharmacology Method to Investigate Molecular Mechanisms of Scutellaria barbata D. Don for Non-small Cell Lung Cancer. Frontiers in Pharmacology, 2018, 9, 1473.	1.6	25
2606	Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates. Biomedicine and Pharmacotherapy, 2018, 107, 1318-1325.	2.5	21
2607	MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer. Molecular Genetics and Genomics, 2018, 293, 1159-1167.	1.0	21
2608	Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer, 2018, 123, 91-98.	0.9	35
2609	Prognostic utility of neutrophil-to-lymphocyte and platelets-to-lymphocyte ratio in predicting biochemical recurrence post robotic prostatectomy. Biomarkers in Medicine, 2018, 12, 841-848.	0.6	14
2610	Effects of laparoscopic surgery on survival, quality of care and utilization in patients with colon cancer: a population-based study. Current Medical Research and Opinion, 2018, 34, 1663-1671.	0.9	2
2611	Extraintestinal Endosonography. , 2019, , 517-531.e4.		2
2612	An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States. Scientific Reports, 2019, 9, 12070.	1.6	58

#	Article	IF	CITATIONS
2613	miR-486 Promotes Capan-2 Pancreatic Cancer Cell Proliferation by Targeting Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN). Frontiers in Genetics, 2019, 10, 541.	1.1	24
2614	Prospective Observational Comparative Study of Response and Toxicities in Early Glottic Cancer Using Telecobalt Versus 3D-CRT. Indian Journal of Otolaryngology and Head and Neck Surgery, 2019, , 1.	0.3	0
2615	Prevalence of patients hospitalised for male breast cancer in France using the French nationwide hospital administrative database. European Journal of Cancer Care, 2019, 28, e13117.	0.7	6
2616	Prophylactic Cervical Lymph Node Dissection in Thoracoscopic Esophagectomy for Esophageal Cancer Increases Postoperative Complications and Does Not Improve Survival. Annals of Surgical Oncology, 2019, 26, 2899-2904.	0.7	32
2617	How does Surgical Apgar Score predict the short-term complications and long-term prognosis after esophagectomy?. Journal of Thoracic Disease, 2019, 11, S268-S270.	0.6	2
2618	Routine placement of feeding jejunostomy tube during esophagectomy increases postoperative complications and does not improve postoperative malnutrition. Ecological Management and Restoration, 2020, 33, .	0.2	16
2619	Squamous cell carcinoma antigen 1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity. Cancer Science, 2019, 110, 1552-1563.	1.7	21
2620	Molecular dynamic simulations of oxidized skin lipid bilayer and permeability of reactive oxygen species. Scientific Reports, 2019, 9, 4496.	1.6	60
2621	Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for patients with high-risk non-muscle invasive bladder cancer. BMJ Open, 2019, 9, e028287.	0.8	7
2622	Diagnostic and prognostic value of 18F-FDG PET/CT imaging in suspected recurrence of male breast cancer. Nuclear Medicine Communications, 2019, 40, 63-72.	0.5	7
2623	The pro-tumorigenic host response to cancer therapies. Nature Reviews Cancer, 2019, 19, 667-685.	12.8	135
2624	Therapeutic potency of Wnt signaling antagonists in the pathogenesis of prostate cancer, current status and perspectives. Journal of Cellular Physiology, 2019, 234, 1237-1247.	2.0	3
2625	Preventive effect of D-carvone during DMBA induced mouse skin tumorigenesis by modulating xenobiotic metabolism and induction of apoptotic events. Biomedicine and Pharmacotherapy, 2019, 111, 178-187.	2.5	32
2626	Bioimprint Mediated Labelâ€Free Isolation of Pancreatic Tumor Cells from a Healthy Peripheral Blood Cell Population. Advanced Biology, 2020, 4, 2000054.	3.0	1
2627	Exploratory Analysis of Qualitative MR Imaging Features for the Differentiation of Glioblastoma and Brain Metastases. Frontiers in Oncology, 2020, 10, 581037.	1.3	6
2628	Recommendations on complementary and alternative medicine within S3 guidelines in oncology: systematic quality assessment of underlying methodology. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2419-2425.	1.2	2
2629	Comparison of Biochemical Recurrence After Robot-assisted Laparoscopic Radical Prostatectomy with Volatile and Total Intravenous Anesthesia. International Journal of Medical Sciences, 2020, 17, 449-456.	1.1	10
2630	Role of Crocus sativus L. in the Modern Green Anticancer Approach. , 2020, , 263-269.		0

#	Article	IF	CITATIONS
2631	Computational Modeling on Aquaporin-3 as Skin Cancer Target: A Virtual Screening Study. Frontiers in Chemistry, 2020, 8, 250.	1.8	21
2632	Neoplasms of the Gastrointestinal Tract. , 2021, , 517-526.e3.		0
2633	A Novel Fuzzy Frequent Itemsets Mining Approach for the Detection of Breast Cancer. International Journal of Information Retrieval Research, 2021, 11, 36-53.	0.6	3
2634	Predictive factors of drainage volume and drain duration after the inframammary approach to nipple-areolar-complex sparing mastectomy and implant-based breast reconstruction. Archives of Aesthetic Plastic Surgery, 2021, 27, 23-30.	0.1	3
2635	Is hypermethylation of SOX1 gene an independent prognostic marker in surgically resected non-small cell lung cancer?. Journal of Cancer Research and Therapeutics, 2022, 18, 1692.	0.3	2
2636	Intraoperative hypotension is not associated with adverse short-term postoperative outcomes after esophagectomy in esophageal cancer patients. BMC Surgery, 2021, 21, 1.	0.6	28
2637	Cytotoxic and apoptosis-inducing effects of novel 8-amido isocoumarin derivatives against breast cancer cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 1437-1449.	1.4	9
2638	Role of ARK5 in cancer and other diseases (Review). Experimental and Therapeutic Medicine, 2021, 22, 697.	0.8	9
2639	Detection of Breast Cancer Based on Fuzzy Frequent Itemsets Mining. Irbm, 2021, 42, 198-206.	3.7	13
2640	Colorectal Cancer Risk in Women with Gynecologic Cancers—A Population Retrospective Cohort Study. Journal of Clinical Medicine, 2021, 10, 3127.	1.0	1
2641	Pancreatic cancer: A review of epidemiology, trend, and risk factors. World Journal of Gastroenterology, 2021, 27, 4298-4321.	1.4	180
2642	The young oral cancer patient: observations from the Hong Kong population. Faculty Dental Journal, 2021, 12, 120-125.	0.0	0
2643	Neoadjuvant Therapy for Resectable Pancreatic Cancer. Annals of Surgery, 2021, 274, 713-720.	2.1	48
2644	The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy. Acta Histochemica, 2021, 123, 151769.	0.9	13
2645	Androgens and Prostate Cancer Etiology: Sorting Through the Evidence. , 2005, , 183-196.		1
2647	Abnormalities of Nuclear Receptors in Thyroid Cancer. , 2004, 122, 165-178.		5
2648	Gliomas. , 2007, , 299-304.		1
2649	Anal Cancer. , 2007, , 482-500.		10

IF ARTICLE CITATIONS Laparoscopy., 2007,, 693-712. 2650 1 Ovarian Cancer: Linking Genomics to New Target Discovery and Molecular Markers — The Way Ahead. Advances in Experimental Medicine and Biology, 2008, 617, 23-40. 0.8 Supportive Care During Adjuvant Treatment. Cancer Treatment and Research, 2009, 151, 219-238. 0.2 2652 1 Diagnostic and Therapeutic Response Markers., 2010,, 675-701. Hematopoietic Growth Factors in Older Cancer Patients. Cancer Treatment and Research, 2010, 157, 2654 0.2 4 383-402. Estrogen Action and Breast Cancer., 2004, , 317-358. Strategies for the Chemoprevention of Prostate Cancer., 2004, , 71-106. 2656 3 The Role of Nanobacteria/Calcifying Nanoparticles in Prostate Disease., 2008, , 221-243. 2657 2658 Aberrant Crypt Foci in Colon Cancer Epidemiology. Methods in Molecular Biology, 2009, 472, 373-386. 0.4 35 Breast Cancer Gene Therapy., 2006, , 705-740. Future Health of Survivors of Adolescent and Young Adult Cancer., 2007, , 451-467. 2661 4 Fertility Issues and Options in Young Women with Cancer., 2008, 178, 203-224. 2662 Cannabinoids as Potential Antitumoral Agents in Pancreatic Cancer., 2009, , 39-49. 2663 1 The Breast as a Developing Organ., 2004, , 11-48. 2664 Head and Neck Cancers. , 2014, , 499-512. 2665 1 Axial Pattern Flaps. , 2005, , 345-364. Biology of Head and Neck Cancer., 2010, , 1015-1029. 5 2667 Epidemiology of Ovarian, Fallopian Tube, and Primary Peritoneal Cancers., 2004, , 326-340.

#	Article	IF	CITATIONS
2669	Radiation Therapy for Cancer Pain Management. , 2006, , 465-480.		1
2670	MRI of the Female Pelvis. , 2005, , 269-342.		4
2671	Epidemiology of Cancer Risk: Vitamin D and Calcium. , 2005, , 1617-1634.		3
2672	Vitamin D and Prostate Cancer. , 2005, , 1679-1707.		9
2673	Surgical treatment of small bowel cancer: a 20-year single institution experience. Journal of Gastrointestinal Surgery, 2003, 7, 925-930.	0.9	6
2674	Prostate cancer antigens and vaccines, preclinical developments. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 247-261.	0.5	11
2675	Systemic therapy for gynecological neoplasms: Ovary, cervix, and endometrium. Cancer Chemotherapy and Biological Response Modifiers, 2005, , 515-544.	0.5	11
2676	Chemotherapy, cytokines, and biochemotherapy for melanoma. Cancer Chemotherapy and Biological Response Modifiers, 2005, , 739-748.	0.5	3
2677	Butyrate inhibits pancreatic cancer invasion. Journal of Gastrointestinal Surgery, 2003, 7, 864-870.	0.9	1
2678	Effect of Vitamin D Supplementation in Prostate Cancer: A Systematic Review of Randomized Control Trials. International Journal for Vitamin and Nutrition Research, 2018, 88, 100-112.	0.6	11
2679	Advances in Alaryngeal Communication and the Art of Tracheoesophageal Voice Restoration. ASHA Leader, 2004, 9, 6-21.	0.2	2
2681	Cancer Incidence, Mortality, and Patient Survival in the United States. , 2006, , 139-173.		13
2683	Liver Cancer. , 2006, , 763-786.		63
2684	Cancers of the Colon and Rectum. , 2006, , 809-829.		63
2688	Keratinocyte Carcinomas (Basal and Squamous Cell Carcinomas of the Skin). , 2006, , 1230-1250.		38
2689	Cancers in Children. , 2006, , 1251-1268.		22
2690	Older Adults With Cancer. , 2006, , 7-18.		2
2691	Pancreatic Tumors in Patients with Lung Malignancies: A Spectrum of Clinicopathologic Considerations. Southern Medical Journal, 2004, 97, 811-815.	0.3	9

#	Article	IF	CITATIONS
2692	Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2006, 1, 417-424.	0.5	17
2693	Estrogen therapy and risk of breast cancer in postmenopausal women. Menopause, 2010, 17, 524-528.	0.8	9
2694	Molecularly Targeted Approaches to the Chemoprevention of Lung Cancer. Clinical Cancer Research, 2004, 10, 4249s-4253s.	3.2	33
2695	Standardized Uptake Value Variations of Normal Glandular Breast Tissue at Dual Time Point FDG-PET/CT Imaging. International Journal of Medical Imaging, 2013, 1, 56.	0.1	4
2696	Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. Journal of Clinical Investigation, 2004, 114, 1774-1781.	3.9	60
2697	Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. Journal of Clinical Investigation, 2004, 114, 1774-1781.	3.9	38
2698	Inactivating cholecystokinin-2 receptor inhibits progastrin-dependent colonic crypt fission, proliferation, and colorectal cancer in mice. Journal of Clinical Investigation, 2009, 119, 2691-701.	3.9	74
2699	Binding of pro-prion to filamin A disrupts cytoskeleton and correlates with poor prognosis in pancreatic cancer. Journal of Clinical Investigation, 2009, 119, 2725-2736.	3.9	83
2700	Surgical Management of Early-Stage Pancreatic Cancer. Cancer Control, 2004, 11, 23-31.	0.7	12
2701	Molecular-Targeted Agents in Pancreatic Cancer. Cancer Control, 2004, 11, 32-38.	0.7	7
2702	Palliative Care in Pancreatic Cancer. Cancer Control, 2004, 11, 39-45.	0.7	12
2703	Evidence-Based Practice: Recommendations for the Early Detection of Breast Cancer. Clinical Journal of Oncology Nursing, 2003, 7, 693-696.	0.3	4
2704	Improving Cancer Screening Among Lesbians Over 50: Results of a Pilot Study. Oncology Nursing Forum, 2003, 30, E71-E79.	0.5	13
2705	Behavioral Adjustment of Children and Adolescents With Cancer: Teacher, Parent, and Self-Report. Oncology Nursing Forum, 2003, 30, E84-E91.	0.5	38
2706	Uses of DNA Methylation in Cancer Diagnosis and Risk Assessment. , 2004, , 11-26.		5
2707	- Computational Regulomics: Information Theoretic Approaches toward Regulatory Network Inference. , 2013, , 248-267.		1
2708	Assessment of Reading Level and Content Adequacy of Oral Cancer Educational Materials from USAF Dental Clinics. Journal of Cancer Education, 2004, 19, 29-36.	0.6	7
2709	Claudin 4 Protein Expression in Primary and Metastatic Pancreatic Cancer Support for Use as a Therapeutic Target. American Journal of Clinical Pathology, 2004, 121, 226-230.	0.4	80

#	Article	IF	CITATIONS
2710	Kallikrein 4 Expression Is Up-Regulated in Epithelial Ovarian Carcinoma Cells in Effusions. American Journal of Clinical Pathology, 2005, 123, 360-368.	0.4	7
2711	Diffuse Optical Measurements of Tissue Blood Flow and Oxygenation during Interstitial Prostate PDT. , 2006, , .		1
2712	The WSB1 Gene Is Involved in Pancreatic Cancer Progression. PLoS ONE, 2008, 3, e2475.	1.1	31
2713	Genetic Heterogeneity of Oesophageal Cancer in High-Incidence Areas of Southern and Northern China. PLoS ONE, 2010, 5, e9668.	1.1	54
2714	The Loss of miR-26a-Mediated Post-Transcriptional Regulation of Cyclin E2 in Pancreatic Cancer Cell Proliferation and Decreased Patient Survival. PLoS ONE, 2013, 8, e76450.	1.1	52
2715	Dual Energy Spectral CT Imaging for Colorectal Cancer Grading: A Preliminary Study. PLoS ONE, 2016, 11, e0147756.	1.1	25
2718	CARCINOMA OF BREAST- A STUDY PROFILE. Journal of Evolution of Medical and Dental Sciences, 2018, 7, 4857-4861.	0.1	5
2719	Inhibition of STAT3 by RNA interference suppresses angiogenesis in colorectal carcinoma. Brazilian Journal of Medical and Biological Research, 2011, 44, 1222-1230.	0.7	21
2720	Avaliação de 496 laudos anatomopatológicos de melanoma diagnosticados no municÃpio de Florianópolis, Santa Catarina, Brasil. Anais Brasileiros De Dermatologia, 2007, 82, 227-232.	0.5	10
2721	Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor. Journal of Zhejiang University Science B, 2005, 6B, 4-10.	0.4	32
2722	Roles of SPARC in urothelial carcinogenesis, progression and metastasis. Oncotarget, 2016, 7, 67574-67585.	0.8	14
2723	FLNA is implicated in pulmonary neuroendocrine tumors aggressiveness and progression. Oncotarget, 2017, 8, 77330-77340.	0.8	34
2724	Survival rate variation with different histological subtypes of poor prognostic male anal squamous cell carcinoma: a population-based study. Oncotarget, 2017, 8, 84349-84359.	0.8	3
2725	Esophageal adenocarcinoma and obesity: peritumoral adipose tissue plays a role in lymph node invasion. Oncotarget, 2015, 6, 11203-11215.	0.8	39
2726	XB130 translocation to microfilamentous structures mediates NNK-induced migration of human bronchial epithelial cells. Oncotarget, 2015, 6, 18050-18065.	0.8	14
2727	Urine BLCA-4 exerts potential role in detecting patients with bladder cancers: a pooled analysis of individual studies. Oncotarget, 2015, 6, 37500-37510.	0.8	24
2728	Integrative bioinformatic analyses of an oncogenomic profile reveal the biology of endometrial cancer and guide drug discovery. Oncotarget, 2016, 7, 5909-5923.	0.8	6
2729	Quality of life assessment in esophagectomy patients. Annals of Translational Medicine, 2018, 6, 84-84.	0.7	20

#	Article	IF	CITATIONS
2730	Determinants of Mortality Following a Diagnosis of Prostate Cancer in Veterans Affairs and Private Sector Health Care Systems. American Journal of Public Health, 2003, 93, 1706-1712.	1.5	39
2731	Multiple Myeloma with a Pathologic Fracture During Pregnancy. Journal of Bone and Joint Surgery - Series A, 2004, 86, 1284-1288.	1.4	14
2732	Phantom-Limb Pain Due to Cervical Spinal Tuberculosis. Journal of Bone and Joint Surgery - Series A, 2004, 86, 1289-1291.	1.4	11
2733	Clinical and Translational Research Challenges in Biliary Tract Cancers. Current Medicinal Chemistry, 2020, 27, 4756-4777.	1.2	21
2734	Perceived Physical Strain at Work and Incidence of Prostate Cancer – a Case-Control Study in Sweden and Finland. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2331-2335.	0.5	3
2735	Radiation therapy for older cancer patients. Aging Health, 2006, 2, 919-930.	0.3	3
2736	The pituitary tumor transforming gene in thyroid cancer. Journal of Endocrinological Investigation, 2012, 35, 425-33.	1.8	7
2738	Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization. The Korean Journal of Hepatology, 2009, 15, 320.	1.5	20
2739	Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India. World Journal of Gastroenterology, 2009, 15, 1381.	1.4	22
2740	Gastric dysplasia may be an independent risk factor of anadvanced colorectal neoplasm. World Journal of Gastroenterology, 2009, 15, 5722.	1.4	29
2741	Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World Journal of Gastroenterology, 2004, 10, 1466.	1.4	148
2742	Gastric malignancies in Northern Jordan with special emphasis on descriptive epidemiology. World Journal of Gastroenterology, 2004, 10, 2174.	1.4	24
2743	An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World Journal of Gastroenterology, 2004, 10, 3127.	1.4	72
2744	Levels of v5 and v6 CD44 splice variants in serum of patients with colorectal cancer are not correlated with pT stage, histopathological grade of malignancy and clinical features. World Journal of Gastroenterology, 2004, 10, 583.	1.4	18
2745	Colorectal cancer in geriatric patients: Endoscopic diagnosis and surgical treatment. World Journal of Gastroenterology, 2005, 11, 315.	1.4	17
2746	Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice. World Journal of Gastroenterology, 2004, 11, 447.	1.4	25
2747	Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. World Journal of Gastroenterology, 2005, 11, 5266.	1.4	49
2748	Detection of CK20mRNA in peripheral blood of pancreatic cancer and its clinical significance. World Journal of Gastroenterology, 2005, 11, 1023.	1.4	11

#	Article	IF	CITATIONS
2749	Risk of colon cancer in hereditary non-polyposis colorectal cancer patients as predicted by fuzzy modeling: Influence of smoking. World Journal of Gastroenterology, 2006, 12, 4485.	1.4	23
2750	Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater. World Journal of Gastroenterology, 2006, 12, 437.	1.4	9
2751	Chemokine expression in hepatocellular carcinoma versus colorectal liver metastases. World Journal of Gastroenterology, 2006, 12, 6627.	1.4	39
2752	Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients. World Journal of Gastroenterology, 2007, 13, 257.	1.4	62
2753	Genetic alterations in pancreatic cancer. World Journal of Gastroenterology, 2007, 13, 4423.	1.4	36
2754	Systematic review of health-related quality of life after esophagectomy for esophageal cancer. World Journal of Gastroenterology, 2011, 17, 4660.	1.4	140
2755	Gastrojejunostomy in patients with unresectable pancreatic head cancer - the use of Roux loop significantly shortens the hospital length of stay. World Journal of Gastroenterology, 2013, 19, 8321.	1.4	13
2756	In vitro Anticancer Agent I-Tissue Culture Study of Human Lung Cancer Cells A549 II-Tissue Culture Study of Mice Leukemia Cells L1210. International Journal of Cancer Research, 2006, 2, 330-344.	0.2	20
2757	p53 Expression in MCF7, T47D and MDA-MB 468 Breast Cancer Cell Lines Treated with Adriamycin Using RT-PCR and Immunocytochemistry. Journal of Biological Sciences, 2008, 8, 380-385.	0.1	17
2758	Chemopreventive and Antilipidperoxidative Potential of Clerodendron inerme (L) Gaertn in 7,12-dimethylbenz(a)anthracene Indcued Skin Carcinogenesis in Swiss Albino Mic. Pakistan Journal of Biological Sciences, 2007, 10, 1465-1470.	0.2	19
2759	Specificity of Serum Tumor Markers (CA125, CEA, AFP, Beta HCG) in Ovarian Malignancies. Trends in Medical Research, 2007, 2, 128-134.	0.2	8
2760	Intracellular calcium excess as one of the main factors in the etiology of prostate cancer. AIMS Molecular Science, 2016, 3, 635-647.	0.3	16
2761	Impact of jejunostomy during esophagectomy for cancer on health related quality of life. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 678-84.	0.7	7
2762	The Clinical and Histopathological Characteristics of Male Breast Cancer Patients. Journal of Breast Cancer, 2007, 10, 211.	0.8	6
2763	Detection rate of prostate cancer using prostate specific antigen in patients presenting with lower urinary tract symptoms. Journal of Postgraduate Medicine, 2009, 55, 17-21.	0.2	27
2764	Desmoplasia influenced recurrence of disease and mortality in stage III colorectal cancer within five years after surgery and adjuvant therapy. Saudi Journal of Gastroenterology, 2017, 23, 39.	0.5	20
2765	Colorectal carcinoma: Clinico-pathological pattern and outcome of surgical management. Saudi Journal of Gastroenterology, 2006, 12, 83.	0.5	8
2766	Clinical evaluation of BIOXTRA in relieving signs and symptoms of dry mouth after head and neck radiotherapy of cancer patients at Seyed-al-Shohada Hospital, Isfahan, Iran. Advanced Biomedical Research, 2012, 1, 72.	0.2	10

#	ARTICLE Methylation pattern of SFRP1 promoter in stool sample is a potential marker for early detection of	IF	CITATIONS
2767	colorectal cancer. Advanced Biomedical Research, 2012, 1, 87.	0.2	21
2768	Lung Cancer Prevalence in Iran by Histologic Subtypes. Advanced Biomedical Research, 2017, 6, 111.	0.2	6
2769	Barriers related to fecal occult blood test for colorectal cancer screening in moderate risk individuals. Journal of Education and Health Promotion, 2014, 3, 120.	0.3	17
2770	Efficacy and safety of electromagnetic navigation bronchoscopy with or without radial endobronchial ultrasound for peripheral lung lesions. Endoscopic Ultrasound, 2016, 5, 189.	0.6	39
2771	Neoadjuvant Chemotherapy for Larynx Preservation: Has it Lost Importance?. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 227-233.	0.1	1
2772	Epidemiology of Gastrointestinal Malignancies in Nigeria:Port Harcourt Cancer Registry Study. Oncology Journal of India, 2020, 4, 1.	0.1	1
2773	Mouse Orthotopic Lung Cancer Model Induced by PC14PE6. Cancer Research and Treatment, 2006, 38, 234.	1.3	18
2774	Novel Nanosized Gd3+-ALGD-G2-C595: In vivo Dual Selective MUC-1 Positive Tumor Molecular MR Imaging and Therapeutic Agent. Journal of Nanomedicine & Nanotechnology, 2012, 03, .	1.1	11
2775	The Cooperative Anticancer Effect of Dual Styrenemaleic Acid Nano- Miceller System against Pancreatic Cancer. Journal of Nanomedicine & Nanotechnology, 0, s4, .	1.1	3
2776	Tumor-Dependent and -Independent Serum/Plasma Biomarkers for Early Diagnosis of Lung Cancer. Translational Medicine (Sunnyvale, Calif ), 2016, 06, .	0.4	5
2777	Dosimetric Impact of Inter-Fraction Variation in Interstitial HDR Brachytherapy. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 2013, 02, 111-116.	0.3	3
2778	Melanoma Immunotherapy: Overcoming Obstacles to Augment Anti-Tumor Immune Responses. Journal of Cosmetics Dermatological Sciences and Applications, 2013, 03, 7-27.	0.1	1
2779	Sexual Function in Men with Castrate Levels of Testosterone: Observations of a Subgroup of Sexually Active Men with Prostate Cancer Undergoing Androgen Deprivation Therapy. Open Journal of Urology, 2014, 04, 98-103.	0.0	9
2780	Small bowel carcinoid: Location isn't everything!. World Journal of Gastrointestinal Surgery, 2013, 5, 239.	0.8	8
2781	Role of the preoperative usefulness of the pathological diagnosis of pancreatic diseases. World Journal of Gastrointestinal Oncology, 2016, 8, 656.	0.8	13
2782	Hepatic metastatic disease in pediatric and adolescent solid tumors. World Journal of Hepatology, 2015, 7, 1807.	0.8	17
2783	High expression of nuclear factor of activated T cells in Chinese primary non-small cell lung cancer tissues. International Journal of Biological Markers, 2007, 22, 221-225.	0.7	9
2784	Mechanism of Anti-Invasive Action of Docosahexaenoic Acid in SW480 Human Colon Cancer Cell. Journal of Life Science, 2010, 20, 561-571.	0.2	2

#	Article	IF	CITATIONS
2785	Methylation Profiles of Multiple CpG Island Loci in Extrahepatic Cholangiocarcinoma Versus Those of Intrahepatic Cholangiocarcinomas. Archives of Pathology and Laboratory Medicine, 2007, 131, 923-930.	1.2	42
2786	Intracellular Zinc Excess as One of the Main Factors in the Etiology of Prostate Cancer. Journal of Analytical Oncology, 2016, 5, 124-131.	0.1	17
2787	Differences between 66 Chemical Element Contents in Normal and Cancerous Prostate. Journal of Analytical Oncology, 2017, 6, 37-56.	0.1	10
2788	Mature Results of a Prospective Randomized Trial Comparing 5-Flourouracil with Leucovorin to 5-Flourouracil with Levamisole as Adjuvant Therapy of Stage II and III Colorectal Cancer- The Israel Cooperative Oncology Group (ICOG) Study. Journal of Cancer, 2011, 2, 177-185.	1.2	5
2789	Haptoglobin Levels in Turkish Patients with Bladder Cancer and its Association with Clinicopathological Features. Asian Pacific Journal of Cancer Prevention, 2012, 13, 6063-6066.	0.5	12
2790	Accuracy of Frozen Sections for Intraoperative Diagnosis of Complex Atypical Endometrial Hyperplasia. Asian Pacific Journal of Cancer Prevention, 2012, 13, 1953-1956.	0.5	14
2791	Chemopreventive Potential of Annona Muricata L Leaves on Chemically-Induced Skin Papillomagenesis in Mice. Asian Pacific Journal of Cancer Prevention, 2012, 13, 2533-2539.	0.5	54
2792	FBW7 Upregulation Enhances Cisplatin Cytotoxicity in Non-small Cell Lung Cancer Cells. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6321-6326.	0.5	33
2793	Synergistic Anticancer Activity of 5-Aminolevulinic Acid Photodynamic Therapy in Combination with Low-dose Cisplatin on Hela Cells. Asian Pacific Journal of Cancer Prevention, 2013, 14, 3023-3028.	0.5	26
2794	Evaluation of Quality of Life in Turkish Patients with Head and Neck Cancer. Asian Pacific Journal of Cancer Prevention, 2013, 14, 4805-4809.	0.5	9
2795	Dickkopf-1 Levels in Turkish Patients with Bladder Cancer and its Association with Clinicopathological Features. Asian Pacific Journal of Cancer Prevention, 2014, 15, 381-384.	0.5	8
2796	SIRT7 Exhibits Oncogenic Potential in Human Ovarian Cancer Cells. Asian Pacific Journal of Cancer Prevention, 2015, 16, 3573-3577.	0.5	55
2797	Cultivated Orostachys japonicus Induces Apoptosis in Human Colon Cancer Cells. Korean Journal of Food Science and Technology, 2012, 44, 317-323.	0.0	15
2798	The impact of G protein-coupled oestrogen receptor 1 on male breast cancer: aÂretrospective analysis. Wspolczesna Onkologia, 2021, 25, 204-212.	0.7	1
2799	Optimization of Parameters for Accessory Cholera Enterotoxin (Ace) Protein Expression. Journal of Medical Sciences (Faisalabad, Pakistan), 2002, 2, 74-76.	0.0	4
2800	Androgen Signaling in Prostatic Neoplasia and Hyperplasia. , 2003, , 157-189.		0
2801	Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 565-584.	0.5	4
2802	The Contemporary Management of Laryngeal Cancer. Koutou (the LARYNX JAPAN), 2003, 15, 49-61.	0.1	0

IF ARTICLE CITATIONS Cancer Screening. , 2004, , 693-702. 2803 1 Visualization, Planning, and Monitoring Software for MRI-Guided Prostate Intervention Robot. Lecture Notes in Computer Science, 2004, , 73-80. 2804 1.0 2805 Serum Tumor Marker Test Profile in Testicular Germ-Cell Tumors., 2004, , 129-168. 0 Clinical Modalities for the Diagnosis, Characterization and Detection of Bone Metastases. Cancer 0.1 Metastasis - Biology and Treatment, 2004, , 49-69. When to Refer a Patient With Prostate Cancer to a Medical Oncologist., 2004, , 553-560. 2807 0 2808 PET in Bladder, Renal, and Prostate Cancer., 2004, , 243-249. Epidemiological Considerations in Breast Cancer., 2004, , 1-9. 2809 0 Melanoma, Myeloma, and Sarcoma., 2004, , 357-371. 2810 2811 Management of Newly Diagnosed Metastatic Disease., 2004, , 561-578. 0 Head and Neck Tumors. , 2004, , 247-261. Aging and the Lower Urogenital System., 2004, , 602-614. 2814 0 When Is Observation Appropriate?., 2004, , 195-215. 2816 Defining an Optimum PSA-Based Screening Strategy for Young Men., 2004, , 37-56. 2817 0 Epidemiology of Cervical, Vulvar, and Vaginal Cancers., 2004, , 3-30. Management of the Patient With Androgen-Independent Metastatic Prostate Cancer., 2004, , 579-587. 2819 0 Emotional and Informational Support for the Patient Undergoing Radical Prostatectomy., 2004,, 501-512. Human Tumor Screening., 2004, , 63-76. 2821 1 Genetics and Prevention of Pancreatic Cancer. Cancer Control, 2004, 11, 6-14.

#	Article	IF	CITATIONS
2823	Jaundice Secondary to Isolated Porta Hepatis Metastasis in Colorectal Cancer: Case Report and Review of the Literature. Southern Medical Journal, 2004, 97, 287-290.	0.3	0
2825	SENTINEL LYMPH NODE MAPPING IN BREAST CANCER. , 2004, , 153-180.		0
2826	Management of Dysplastic Nevi and Melanomas. , 2005, , 821-839.		1
2827	Diagnosis and Staging of Renal Cell Carcinoma. , 2005, , 173-194.		0
2828	TREATMENT OF COLORECTAL ADENOMAS: SCREENING, FOLLOW-UP, AND SURVEILLANCE. , 2005, , 331-342.		0
2829	Progressive Bone Loss due to Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2005, 31, 203-210.	0.0	0
2830	Cancers of the large bowel and hepatobiliary tract. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 443-469.	0.5	0
2831	Prevention of Cancers of the Esophagus and Stomach. , 2005, , 25-54.		1
2832	Tumor Ablation for Patients with Lung Cancer: The Thoracic Oncologist's Perspective. , 2005, , 459-465.		1
2833	Male Breast Cancer. , 2005, , 209-213.		0
2834	Office-Based Testing for Fecal Occult Blood. Annals of Internal Medicine, 2005, 143, 235.	2.0	0
2835	Resveratrol as an Inhibitor of Carcinogenesis. Oxidative Stress and Disease, 2005, , 233-383.	0.3	0
2836	Male Osteoporosis and Prostate Cancer. Seminars in Preventive and Alternative Medicine, 2005, 1, 18-22.	0.1	0
2837	Epidemiology, staging and clinical characteristics. , 2005, , 1-37.		0
2839	Neoplasms of the gastrointestinal tract and liver. , 2006, , 809-823.		0
2840	Identification of Leukemia Surface Proteins Using a Proteomic Technique. The Korean Journal of Hematology, 2006, 41, 272.	0.7	0
2842	New Advances in the Chemotherapy of Metastatic Colorectal Cancer. Oncology & Hematology Review, 2006, 00, 1.	0.2	0
2843	Treatment of special breast cancer patients. , 2006, , 375-393.		0

#	Article	IF	CITATIONS
2844	Diseases of the Blood. , 2006, , 745-779.	_	0
2845	Diseases of the Blood. , 2006, , 745-779.		0
2846	Tratamiento del paciente con melanoma. , 2006, , 265-273.		0
2847	Molecular Genetic Applications to the Diagnosis of Lymphoma. , 2006, , 393-413.		0
2848	Ureter, Bladder, Penis, and Urethra. , 2006, , 813-832.		0
2849	Male Breast Cancer. , 2006, , 903-923.		0
2850	The changing face of cancer in the elderly—Only a demographic change?. Journal of Clinical Oncology, 2006, 24, 18597-18597.	0.8	0
2851	Soft Tissue Sarcoma. , 2006, , 959-974.		0
2852	What Antisense Oligonucleotides Have Promise in Prostate Cancer. Translational Medicine Series, 2006, , 143-161.	0.0	0
2853	In-vitro maturation for fertility preservation. , 2006, , 382-389.		0
2854	Clinical course and surgical long-term outcome in geriatric patients with non-small cell carcinoma. Thoracic and Cardiovascular Surgeon, 2007, 55, .	0.4	0
2856	Serum ghrelin and leptin concentrations in children with cancer : comparisons with normal children. Korean Journal of Pediatrics, 2007, 50, 905.	1.9	4
2858	Chronic Pain Associated with Urological Malignancy. , 2007, , 397-406.		0
2859	A Mathematical Model for Prediction of Recurrence in Bladder Cancer Patients. Mathematics in Industry, 2008, , 868-872.	0.1	0
2861	Imaging of Renal Cell Carcinoma. , 2008, , 9-42.		0
2862	Cancer of the Head and Neck. , 2008, , 1177-1228.		1
2863	Usual Lung Cancers. , 2008, , 544-562.		1
2864	Mullerian Inhibiting Substance: A Potential Nontoxic, Naturally Occurring Therapeutic Agent for Certain Human Cancers. , 2008, , 333-353.		2

#	Article	IF	CITATIONS
2866	Detection of Cancer-Related Proteins in Fresh-Frozen Ovarian Cancer Samples Using Laser Capture Microdissection. , 2008, 414, 35-45.		9
2867	Psychological Characteristics of Patients with Depressive Symptoms At The Initial Diagnosis of Breast Cancer: Preliminary Results. Journal of Breast Cancer, 2008, 11, 83.	0.8	1
2868	Aerosolized Chemotherapy. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, .	1.2	0
2869	Cliomas. , 2009, , 131-136.		0
2870	Idiopathic Pulmonary Fibrosis and Associated Pulmonary Hypertension: Genetics, Pathobiology, Diagnosis, and Management. , 2009, , 51-69.		0
2871	Epidemiology of Gastric Cancer and Helicobacter pylori. , 2009, , 25-57.		0
2872	Carbonic Anhydrase IX Shedding Through Exosomes in Renal Carcinoma Cells. Glycobiology Insights, 0, 1, 3-12.	4.5	0
2873	Mammograms in Cosmetic Breast Surgery. , 2009, , 37-40.		1
2874	Fertility Preservation in Female Cancer Patients: A Review. Journal of SAFOG, 2009, 1, 5-11.	0.1	0
2875	Reversal of Immune Suppression in Sentinel Lymph Nodes. , 2009, , 407-423.		0
2876	Ligand-Independent Androgen Receptor Activity. , 2009, , 427-449.		0
2877	Editorial Comment. Journal of Endourology, 2009, , 1-6.	1.1	0
2878	Head and Neck Squamous Cell Carcinoma: Therapy with Fusaric Acid/Paclitaxel. , 2010, , 229-235.		0
2880	Cardio-Toxicity during chemotherapy: feasibility of new diagnostic approaches. Health, 2010, 02, 376-380.	0.1	0
2881	Chronic Myelogenous Leukemia. , 2010, , 260-263.		0
2882	Integrated Imaging in Genitourinary Oncology: PET/CT Imaging. , 2010, , 183-189.		0
2883	Cancer of the Oral Cavity. , 2010, , 588-612.		0
2884	Molecular Proteomics in Early Detection of Head and Neck Cancer. , 2010, , 19-30.		0

		15	Cizizionia
#	Article	IF	CITATIONS
2885	Miscellaneous Non-Pancreatic Non-Endocrine Tumors. , 2010, , 255-283.		0
2886	Mouse Xenograft Models for Drug Discovery in Pancreatic Cancer. , 2010, , 29-49.		Ο
2887	Vitamin D and Colon Cancer. , 2010, , 311-323.		0
2888	Tumors of Bone and Soft Tissue. , 2010, , 1324-1358.		0
2890	Vitamin D: Synthesis and Catabolism $\hat{a} \in$ "Considerations for Cancer Causation and Therapy. , 2011, , 1-24.		0
2891	Pulmonary Complications of Chronic Lymphocytic Leukemia. , 2011, , 715-723.		0
2892	Cancer of the Esophagus and the Gastroesophageal Junction: Two-cavity Approach. , 2011, , 125-136.		0
2894	6 Imaging of Lung Cancer. , 2011, , 89-107.		0
2895	Risk Factors of Urinary Bladder Cancer in Islamabad, Federal Area of Pakistan. British Journal of Medicine and Medical Research, 2011, 1, 96-104.	0.2	0
2896	The Mechanisms and Impact of Obesity and Insulin Resistance on Breast Cancer Incidence. Energy Balance and Cancer, 2011, , 77-99.	0.2	0
2897	Laparoscopy in the Elderly. , 2011, , 97-106.		0
2899	Computational Infrastructures for Large-Scale Data Access and Analysis in Post-Genomic Clinical Trials. , 2012, , 363-392.		0
2900	Extraintestinal Endosonography (including Celiac Block). , 2012, , 400-416.		0
2901	A review of transplantation for tumors other than hepatocellular carcinoma. International Journal of Hepatobiliary and Pancreatic Diseases, 2012, 2, 24.	0.2	0
2903	Elderly Lung Cancer Patients and Radiochemotherapy: A Review. Journal of Cancer Therapy, 2012, 03, 359-363.	0.1	0
2904	Trends and distributions of common types of cancer in Bangladesh: Results from the cancer registry data of 2008-10. Annals of Cancer Research and Therapy, 2012, 20, 32-38.	0.1	1
2905	Quality of Life of Women Undergoing Chemotherapy for a Gynaecological Oncological Disease in Turkey. Asian Pacific Journal of Cancer Prevention, 2012, 13, 1277-1280.	0.5	10
2906	Epidemiology of Prostate Cancer. , 2013, , 285-299.		0

	CITATION RE	CITATION REPORT		
#	Article	IF	CITATIONS	
2907	Palliative Surgical Approaches for Older Patients with Colorectal Cancer. , 2013, , 65-80.		0	
2908	The Role of MicroRNA in Head and Neck Cancer. , 2013, , 1019-1048.		0	
2909	Behavior of circulating epithelial tumor cells (CETC) and FISH (fluorescence <i>in situ</i> ) Tj ETQq0 0 ( during the course of therapy. Advances in Lung Cancer (Irvine), 2013, 02, 1-8.	) rgBT /Ov 0.2	erlock 10 Tf 5 0	
2910	Role of Mitochondria in Head and Neck Cancer. , 2013, , 949-975.		0	
2911	Focal Therapy of Prostate Cancer by Radiofrequency and Photodynamic Therapy. , 2013, , 727-751.		0	
2914	Prostatakarzinom. , 2014, , 513-676.		Ο	
2915	Gynecologic Considerations for Women with Breast Cancer. , 2014, , 355-370.		0	
2916	Sarcomas of Soft Tissueâ~†. , 2014, , .		Ο	
2917	Apoptotic Effect of ARTEMISIAE CAPILLARIS HERBA and COPTIDIS RHIZOMA Extracts on MIA PaCa-2 Cells. The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology, 2014, 27, 158-176.	0.0	1	
2918	Diagnostic Strategy for Malignant Bone Tumors. The Journal of the Korean Orthopaedic Association, 2015, 50, 429.	0.0	2	
2919	Human papillomavirus (HPV) Human Papillomavirus (HPV) Biomarker Biomarkers in Head and Neck: Squamous Cell Carcinoma (HNSCC). Biomarkers in Disease, 2015, , 709-728.	0.0	0	
2920	A 7-Years Retrospective Study of Gastrointestinal Cancers Incidence in the Western Iran. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, EC01-5.	0.8	2	
2921	Dealing with Complications of Rectal Surgery. , 2015, , 583-606.		0	
2922	EPIDEMIOLOGICAL PROFILE OF HEAD AND NECK CANCERS AT A TERTIARY CARE HOSPITAL. Journal of Evolution of Medical and Dental Sciences, 2015, 4, 14285-14293.	0.1	1	
2923	Roles of Steroid Receptor Coactivator-3 and TTF-1 in Lung Development and Lung Cancer. Journal of Life Science, 2015, 25, 1439-1444.	0.2	0	
2925	The Windows of Susceptibility to Breast Cancer. , 2016, , 1-20.		3	
2926	How to Design Clinical Trials?. , 2016, , 79-93.		1	
2927	Gliomas. , 2016, , 507-514.		0	

#	Article	IF	CITATIONS
2928	What Antisense Oligonucleotides Have Promise in Prostate Cancer. , 2016, , 161-180.		0
2929	Variations in Concentration and Distribution of Several Androgen-Dependent and Independent Trace Elements in Nonhyperplastic Prostate Gland Tissue throughout Adulthood. Journal of Andrology and Gynaecology, 2016, 4, .	0.5	4
2930	CLINICOPATHOLOGICAL CHARACTERISTICS OF CA OESOPHAGUS – EXPERIENCE FROM A TERTIARY CARE CENTRE IN NORTH-EAST INDIA. Journal of Evolution of Medical and Dental Sciences, 2016, 5, 7260-7262.	0.1	0
2931	Evaluation of the efficacy of post prostatic massage urine cytology in diagnosis of various prostatic lesions with cytohistological and clinical correlation. Journal of Cytology, 2017, 34, 212.	0.2	0
2932	STUDY OF GASTROINTESTINAL CANCERS IN A TERTIARY CARE HOSPITAL. Journal of Evidence Based Medicine and Healthcare, 2017, 4, 5537-5542.	0.0	0
2933	Cytogenetic damage from hyperthermia,6 MV X-rays, and topotecan in glioblastoma spheroids, simultaneously, and separately. Journal of Cancer Research and Therapeutics, 2018, 14, 1273-1278.	0.3	1
2935	TRANSHIATAL OESOPHAGECTOMY IN LOW AND MID OESOPHAGEAL CANCERS - A PROSPECTIVE STUDY. Journal of Evidence Based Medicine and Healthcare, 2018, 5, 3218-3222.	0.0	0
2936	Abdominosacral resection versus abdominoperineal resection in patients with low rectal carcinoma in terms of exposure/operating time/bleeding. World Journal of Colorectal Surgery, 2019, 8, 89.	0.0	0
2937	Age-Dependence of Some Trace Element Concentrations and their Ratios in Human Prostatic Fluid. Journal of Ageing Research and Healthcare, 2019, 2, 11-20.	0.3	1
2938	Epidemiology of Bone Lesions. , 2020, , 3-9.		1
2939	Assessment of Treatment Response and Survival in Patients Diagnosed with Locally Advanced Head and Neck Cancer and Treated with Chemoradiotherapy As Part of An Organ-Preservation Treatment Protocol. Sakarya Medical Journal, 0, , .	0.1	0
2940	Anal human papillomavirus infection among men who have sex with men and transgender women living with and without HIV in Pakistan: findings from a cross-sectional study. BMJ Open, 2021, 11, e052176.	0.8	2
2941	Split-dose vs same-day bowel preparation for afternoon colonoscopies: A meta-analysis of randomized controlled trials. World Journal of Meta-analysis, 2020, 8, 462-471.	0.1	0
2942	Split-dose <i>vs</i> same-day bowel preparation for afternoon colonoscopies: A meta-analysis of randomized controlled trials. World Journal of Meta-analysis, 2020, 8, 461-470.	0.1	0
2943	Karaciğer, safra kesesi ve safra yolu kanserlerinde epidemiyoloji ve sağ kalım özellikleri. Ege Tıp Dergisi, 0, , 78-87.	0.1	0
2948	Acute Lymphoblastic Leukemia. , 2006, , 1182-1209.		1
2950	Aetiology and pathogenesis of biliary cancer. , 0, , 23-35.		0
2951	Oncology—Lymphoma. , 2005, , 205-225.		1

#	Article	IF	CITATIONS
2952	Oncology—Lungs. , 2005, , 117-136.		1
2957	T-Cell Non-Hogdkin's Lymphoma. , 2006, , 161-220.		3
2958	Prostate Cancer: 16β-[18F] Fluoro-5α-Dihydrotesterone (FDHT) Whole-Body Positron Emission Tomography. , 2008, , 521-530.		1
2959	Cyclooxygenase 2 and its Metabolites: Implications for Lung Cancer Therapy. , 2009, , 251-272.		0
2960	Antimetastatic Gene Therapy. , 2005, , 299-319.		0
2961	Diagnosis and Surveillance of Upper Tract Tumors. , 2006, , 71-84.		0
2962	Melanoma and Nevi. , 2006, , 1004-1010.		1
2965	Open Radical Nephrectomy for Localized Renal Cell Carcinoma. , 2008, , 175-188.		2
2968	Prevention of Breast Cancer. , 2006, , 63-94.		0
2969	FDG-PET and PET/CT in Pancreatic Cancer. , 2008, , 97-105.		0
2971	Mammograms in Cosmetic Breast Surgery. , 2009, , 69-72.		0
2972	Prostatakarzinom. , 2014, , 513-676.		0
2973	Identification of Novel Cancer Target Antigens Utilizing EST and Genome Sequence Databases. , 2005, , 31-42.		1
2974	Robotic prostatectomy - a review. MedGenMed: Medscape General Medicine, 2004, 6, 20.	0.2	7
2975	Docetaxel for the treatment of hormone-refractory prostate cancer. Reviews in Urology, 2003, 5 Suppl 2, S14-21.	0.9	8
2976	The role of the urologist in treating patients with hormone-refractory prostate cancer. Reviews in Urology, 2003, 5 Suppl 2, S48-52.	0.9	4
2977	A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomy. Reviews in Urology, 2003, 5 Suppl 2, S42-7.	0.9	0
2978	Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014. Reviews in Urology, 2003, 5 Suppl 2, S28-34.	0.9	0

#	Article	IF	CITATIONS
2979	A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomy. Reviews in Urology, 2003, 5 Suppl 3, S59-64.	0.9	1
2980	Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer. Reviews in Urology, 2003, 5 Suppl 3, S65-70.	0.9	4
2981	A new paradigm for the treatment of high-risk prostate cancer: radiosensitization with docetaxel. Reviews in Urology, 2003, 5 Suppl 3, S71-7.	0.9	11
2982	Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014. Reviews in Urology, 2003, 5 Suppl 3, S45-51.	0.9	0
2983	Docetaxel for the treatment of hormone-refractory prostate cancer. Reviews in Urology, 2003, 5 Suppl 3, S14-21.	0.9	5
2984	Complementary medicine, chemoprevention, and staging of prostate cancer. Reviews in Urology, 2003, 5 Suppl 6, S23-32.	0.9	0
2985	Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. Transactions of the American Clinical and Climatological Association, 2004, 115, 233-47; discussion 247-8.	0.9	28
2986	The prospects for the control of cancer through screening-1976-today-the future. Transactions of the American Clinical and Climatological Association, 2004, 115, 221-32; discussion 232.	0.9	0
2988	Identification of a Specific Vimentin Isoform That Induces an Antibody Response in Pancreatic Cancer. Biomarker Insights, 2006, 1, 175-183.	1.0	18
2989	Prognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate cancer. Journal of the National Medical Association, 2004, 96, 1587-93.	0.6	17
2990	The management of painful bone metastases with an emphasis on radionuclide therapy. Journal of the National Medical Association, 2007, 99, 785-94.	0.6	30
2991	Multimodality Treatment With Helical Tomotherapy Intensity Modulated Radiotherapy, Capecitabine, and Photodynamic Therapy is Feasible and Well Tolerated in Patients With Hilar Cholangiocarcinoma. Gastrointestinal Cancer Research: GCR, 2008, 2, 219-24.	0.8	13
2992	Serum ferritin levels and transferrin saturation in men with prostate cancer. Journal of the National Medical Association, 2004, 96, 641-9.	0.6	23
2993	Identification and characterization of renal cell carcinoma gene markers. Cancer Informatics, 2007, 3, 65-92.	0.9	24
2994	Induction of Proteases in Peritoneal Carcinomatosis, the Role of ICAM-1/CD43 Interaction. Biomarker Insights, 2007, 2, 377-84.	1.0	4
2995	Body mass index affects the diagnosis and progression of prostate cancer in Hispanics. Ethnicity and Disease, 2010, 20, S1-168-72.	1.0	5
2996	Burden of human papillomavirus infection and related comorbidities in men: implications for research, disease prevention and health promotion among Hispanic men. Puerto Rico Health Sciences Journal, 2010, 29, 232-40.	0.2	36
2997	Squamous cell cancer of the esophagus: the forgotten one. Gastrointestinal Cancer Research: GCR, 2011, 4, 22-3.	0.8	3

		CITATION REPORT		
#	Article		IF	CITATIONS
2998	The epidemiology, prevention, and detection of melanoma. Ochsner Journal, 2010, 10,	56-65.	0.5	33
2999	The frequency of self-skin examination and full body skin examination in dermatologist Clinical and Aesthetic Dermatology, 2011, 4, 20-4.	s. Journal of	0.1	0
3001	Molecular analysis of MEN1 expression in MCF7, T47D and MDA-MB 468 breast cancer with adriamycin using RT-PCR and immunocytochemistry. DARU, Journal of Pharmaceu 2010, 18, 17-22.		0.9	9
3002	Patent foramen ovale as a preferential mechanism for increasing the likelihood of brain metastasis. American Journal of Cardiovascular Disease, 2012, 2, 29-33.	tumor	0.5	2
3003	Effects of cognitive behavioral counseling on body Image following mastectomy. Journ in Medical Sciences, 2011, 16, 1047-54.	al of Research	0.4	18
3004	Validity and reproducibility of a food frequency questionnaire for assessment of fruit a intake in Iranian adults(*). Journal of Research in Medical Sciences, 2011, 16, 1286-97.	nd vegetable	0.4	15
3005	Incidence of childhood cancers in golestan province of iran. Iranian Journal of Pediatrics 335-42.	s, 2010, 20,	0.1	9
3006	Evaluation of the Combined Effect of 2ME2 and (60)Co on the Inducement of DNA Da Spheroid Model of the U87MG Glioblastoma Cancer Cell Line Using Alkaline Comet As 2011, 13, 83-90.		0.2	11
3008	KAT5 and KAT6B are in positive regulation on cell proliferation of prostate cancer throu signaling. International Journal of Clinical and Experimental Pathology, 2013, 6, 2864-7	ıgh PI3K-AKT '1.	0.5	17
3009	Distinct breast cancer subtypes in women with early-onset disease across races. Ameri Cancer Research, 2014, 4, 337-52.	can Journal of	1.4	15
3011	Environmental tobacco smoke and pancreatic cancer: a case-control study. Internation Clinical and Experimental Medicine, 2015, 8, 16729-32.	al Journal of	1.3	3
3012	Technical considerations in percutaneous hepatic perfusiona multi-center experience. Extra-Corporeal Technology, 2011, 43, 30-3.	Journal of	0.2	2
3013	The antitumor activity study of ginsenosides and metabolites in lung cancer cell. Ameri Translational Research (discontinued), 2016, 8, 1708-18.	can Journal of	0.0	27
3014	Inhibition of AMPK-related kinase 5 (ARK5) enhances cisplatin cytotoxicity in non-small cancer cells through regulation of epithelial-mesenchymal transition. American Journal Translational Research (discontinued), 2017, 9, 1708-1719.		0.0	13
3017	Kindlin-2-mediated upregulation of ZEB2 facilitates migration and invasion of oral squa carcinoma in a miR-200b-dependent manner. American Journal of Translational Researc (discontinued), 2018, 10, 2529-2541.		0.0	6
3018	Therapeutical Attitude and Analysis of Results in Brain Metastases. Current Health Scie 2016, 42, 372-384.	nces Journal,	0.2	1
3019	Increased incidence of carcinoma of the tongue in patients with systemic sclerosis. Jou Rheumatology, 2005, 32, 637-41.	rnal of	1.0	45
3020	Human papillomavirus-associated anal squamous intraepithelial lesions in men who hav and transgender women living with and without HIV in Karachi Pakistan: implications for and prevention. BMC Infectious Diseases, 2021, 21, 1163.		1.3	3

#	Article	IF	CITATIONS
3021	Endoplasmic reticulum stress-induced release and binding of calreticulin from human ovarian cancer cells. Cancer Immunology, Immunotherapy, 2022, 71, 1655-1669.	2.0	10
3022	Log-Rank-Type Tests for Equality of Distributions in High-Dimensional Spaces. Journal of Computational and Graphical Statistics, 2022, 31, 1384-1396.	0.9	2
3023	RNA 5-Methylcytosine Regulators Contribute to Metabolism Heterogeneity and Predict Prognosis in Ovarian Cancer. Frontiers in Cell and Developmental Biology, 2022, 10, 807786.	1.8	7
3024	Design, Synthesis, and Biological Evaluation of [1,2,4]triazolo[4,3-a] Pyrazine Derivatives as Novel Dual c-Met/VEGFR-2 Inhibitors. Frontiers in Chemistry, 2022, 10, 815534.	1.8	4
3025	Prostate Cancer Screening. Comprehensive Therapy, 2005, 31, 119-123.	0.2	0
3035	Emerging drugs for head and neck cancer. Expert Opinion on Emerging Drugs, 2004, 9, 91-104.	1.0	1
3038	Effect of Mono-2-ethyhexyl Phthalate on DNA Methylation in Human Prostate Cancer LNCaP Cells. Biomedical and Environmental Sciences, 2017, 30, 641-648.	0.2	2
3039	Mapping of Lymph Node Metastasis From Thoracic Esophageal Cancer: A Retrospective Study. Annals of Surgical Oncology, 2022, 29, 5681-5688.	0.7	9
3041	Diosgenin, a Steroid Saponin of <i>Trigonella foenum graecum</i> (Fenugreek), Inhibits Azoxymethane-Induced Aberrant Crypt Foci Formation in F344 Rats and Induces Apoptosis in HT-29 Human Colon Cancer Cells. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 1392-1398.	1.1	219
3042	Aberrantly Methylated <i>CDKN2A</i> , <i>MGMT</i> , and <i>MLH1</i> in Colon Polyps and in Fecal DNA from Patients with Colorectal Polyps. Clinical Cancer Research, 2005, 11, 1203-1209.	3.2	130
3043	Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL [(â^')-gossypol] against diffuse large cell lymphoma. Molecular Cancer Therapeutics, 2005, 4, 13-21.	1.9	58
3044	Palliative Care Research: Issues and Opportunities. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 337-339.	1.1	34
3045	The mitotic serine threonine kinase, <i>Aurora-2</i> , is a potential target for drug development in human pancreatic cancer. Molecular Cancer Therapeutics, 2004, 3, 451-457.	1.9	66
3046	Colorectal Cancer Screening Adherence in a General Population. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 654-657.	1.1	29
3047	Increased Plasma Levels of Insulin-Like Growth Factor 2 and Insulin-Like Growth Factor Binding Protein 3 Are Associated with Endometrial Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 748-752.	1.1	36
3048	A Novel Anticancer Agent, Decursin, Induces G1 Arrest and Apoptosis in Human Prostate Carcinoma Cells. Cancer Research, 2005, 65, 1035-1044.	0.4	132
3049	A Fiber-Modified, Secretory Leukoprotease Inhibitor Promoter-Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer. Clinical Cancer Research, 2005, 11, 1327-1335.	3.2	34
3050	Down-regulation of RAB6KIFL/KIF20A, a Kinesin Involved with Membrane Trafficking of Discs Large Homologue 5, Can Attenuate Growth of Pancreatic Cancer Cell. Cancer Research, 2005, 65, 105-112.	0.4	97

#	Article	IF	CITATIONS
3051	Adherence to the AICR Cancer Prevention Recommendations and Subsequent Morbidity and Mortality in the Iowa Women's Health Study Cohort. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 1114-1120.	1.1	78
3052	TAS-108, a Novel Oral Steroidal Antiestrogenic Agent, Is a Pure Antagonist on Estrogen Receptor α and a Partial Agonist on Estrogen Receptor β with Low Uterotrophic Effect. Clinical Cancer Research, 2005, 11, 315-322.	3.2	26
3053	Overexpression of Tropomysin-Related Kinase B in Metastatic Human Pancreatic Cancer Cells. Clinical Cancer Research, 2005, 11, 440-449.	3.2	108
3054	Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Molecular Cancer Therapeutics, 2004, 3, 1271-1279.	1.9	92
3055	8-Amino-adenosine is a potential therapeutic agent for multiple myeloma. Molecular Cancer Therapeutics, 2004, 3, 1411-1420.	1.9	25
3056	X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Molecular Cancer Therapeutics, 2004, 3, 699-707.	1.9	121
3057	SB-431542, a small molecule transforming growth factor-Î <sup>2</sup> -receptor antagonist, inhibits human glioma cell line proliferation and motility. Molecular Cancer Therapeutics, 2004, 3, 737-745.	1.9	150
3058	Diet and Melanoma in a Case-Control Study. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 1042-1051.	1.1	135
3059	Cyclooxygenase-2 and p53 Expressions in Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 1538-1542.	1.1	36
3060	Novel peptide ligands for integrin α4β1 overexpressed in cancer cells. Molecular Cancer Therapeutics, 2004, 3, 1329-1334.	1.9	21
3061	A Comparison of Urinary Biomarkers of Tobacco and Carcinogen Exposure in Smokers. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 1617-1623.	1.1	41
3062	Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: Novel strategies for colon cancer prevention and treatment. Molecular Cancer Therapeutics, 2004, 3, 215-221.	1.9	61
3064	Oral Cancer Management. , 2022, , 1009-1055.		0
3065	A Novel Fuzzy Frequent Itemsets Mining Approach for the Detection of Breast Cancer. , 2022, , 511-531.		0
3066	SHMT2 Induces Stemness and Progression of Head and Neck Cancer. International Journal of Molecular Sciences, 2022, 23, 9714.	1.8	4
3069	Neoadjuvant Therapy and Biliary Decompression Lower Biliary and Pancreatic Juice Vascular Endothelial Growth Factor Levels in Patients with Periampullary Adenocarcinoma. American Surgeon, 2004, 70, 169-174.	0.4	0
3070	The Metastatic/Examined Lymph Node Ratio is an Important Prognostic Factor after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma. American Surgeon, 2004, 70, 235-240.	0.4	176
3071	Incurable Colorectal Carcinoma: The Role of Surgical Palliation. American Surgeon, 2004, 70, 433-437.	0.4	38

#	Article	IF	CITATIONS
3072	Use of Percutaneous Drainage to Treat Hepatic Abscess after Radiofrequency Ablation of Metastatic Pancreatic Adenocarcinoma. American Surgeon, 2004, 70, 496-499.	0.4	11
3073	Contralateral Portal Vein Embolization for Hepatectomy in the Setting of Hepatic Steatosis. American Surgeon, 2004, 70, 609-612.	0.4	6
3074	Extensive Stage Small Cell Lung Cancer Presenting as an Acute Perforated Appendix: Case Report and Review of the Literature. American Surgeon, 2004, 70, 706-709.	0.4	18
3075	The fundamental role of the exploration of the upper abdomen in ovarian cancer surgery. Obstetrics & Gynecology International Journal, 2021, 12, 337-342.	0.0	1
3076	Clinicopathological Profile of Non-small Cell Lung Cancer and the Changing Trends in Its Histopathology: Experience From a Tertiary Care Cancer Center in Kashmir, India. Cureus, 2023, , .	0.2	1
3078	Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario. Pharmaceutics, 2023, 15, 664.	2.0	2
3079	Surveillance strategies following curative resection and non-operative approach of rectal cancer: How and how long? Review of current recommendations. World Journal of Gastrointestinal Surgery, 0, 15, 177-192.	0.8	2
3080	The Influence of Ethnicity on Survival from Malignant Primary Brain Tumours in England: A Population-Based Cohort Study. Cancers, 2023, 15, 1464.	1.7	0
3082	Definitive chemoradiotherapy in elderly patients with esophageal cancer: Safety and outcome. Precision Radiation Oncology, 2023, 7, 51-58.	0.4	1
3083	ClinicoPathological Overview of Ovarian Tumors and Diagnostic Utility of Imprint Cytology. Asian Journal of Pharmaceutical Research and Health Care, 2023, 15, 11.	0.0	0
3086	HPV-associated cancers: insights into the mechanistic scenario and latest updates. , 2023, 40, .		1

3086 HPV-associated cancers: insights into the mechanistic scenario and latest updates. , 2023, 40, .